AU2005272848A2

AU2005272848A2 - Tie complex binding proteins

Info

Publication number: AU2005272848A2
Application number: AU2005272848A
Authority: AU
Inventors: Daniel T. Dransfield; Rene Hoet; Simon E. Hufton; Henk Pieters; Clive R. Wood
Original assignee: Dyax Corp
Current assignee: Dyax Corp
Priority date: 2004-08-12
Filing date: 2005-08-09
Publication date: 2006-02-23
Also published as: AU2005272848A1; CA2576886A1; JP2008532476A; EP1789451A2; EP1789451A4; WO2006020706A3; WO2006020706A2

Description

WO 2006/020706 PCT/US2005/028413 TIE COMPLEX BINDING PROTEINS CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of U.S. Application Serial No. 11/049,536, filed February 2, 2005, which is a continuation-in-part of U.S.

Application Serial No. 10/916,840, filed August 12, 2004, which claims priority to U.S. Application Serial No. 60/494,713, filed on August 12, 2003. This application is also a continuation-in-part ofPCT/US2004/ 026116, filed August 12, 2004, which claims priority to U.S. Application Serial No. 60/494,713, filed on August 12, 2003.

The contents of each of the foregoing applications are hereby incorporated by reference in their entirety.

BACKGROUND

[0002] The oxygen and nutrients supplied by the blood vessels are crucial for tissue development and function. Indeed, the cardiovascular system is the first organ system to develop in embryos. During organogenesis and the development of tissues or tumors, the proximity of the growing cells to the circulatory system is ensured by the coordinated growth of blood vessels and organ parenchyma. It may be possible to prevent or treat diseases by modulating blood vessel development or angiogenesis.

[0003] Blood vessels are composed of an inner layer of endothelial cells and an outer layer ofpericytes or smooth muscle cells. The first tubular structures are formed by endothelial cells that subsequently recruit pericytes and smooth muscle cells to ensheath them. The de novo formation of blood vessels from a dispersed population of mesodermally derived endothelial precursor cells is termed vasculogenesis. This primitive network undergoes successive morphogenctic events including sprouting, splitting, and remodeling to generate the hierarchical vascular network from large to branched small vessels. These successive morphogenetic events are collectively called angiogenesis. Previous studies have identified a number of endothelial cell specific receptor tyrosine kinases (RTKs) and their cognate ligands, which mediate the vasculogenic and angiogenic development of blood vessels.

Members of the vascular endothelial growth factor (VEGF) family and their receptors function during the formation of the initial embryonic vascular plexus, whereas angiopoietins (Angs) and their receptor, Tie2, as well as ephrins and their Eph WO 2006/020706 PCT/US2005/028413 receptors are implicated in the subsequent remodeling processes. See, Jones et al. (2001) Nat. Rev. Molec. Cell Biol. 2:257 for a review of receptors involved in angiogenic and lymphangiogenic responses.

[0004] Tiel and Tie2 are RTKs that are expressed almost exclusively in endothelial cells and hematopoietic precursor cells. These two receptors are required for the normal development of vascular structures during embryogenesis. The two Tie receptors form a RTK subfamily since, unlike other RTK family members, they include extracellular EGF-homology domains. See, Partanen (1992) Mol. Cell Biol. 12:1698 and WO 93/14124. Targeted disruption of the Tiel gene in mice results in a lethal phenotype characterized by extensive hemorrhage and defective microvessel integrity. See, Purl et al. (1995) EMBOJ. 14:5884. Tie2 null embryos have defects in vascular remodeling and maturation, resulting from improper recruitment of periendothelial supporting cells. Angiopoietins (Ang, Angl, Ang2, Ang3, and Ang4) are proteins that interact with Tie2.

SUMMARY

[0005] In one aspect, the invention features a method of modulating Tie complex formation, or interactions between Tie complex components, in a subject.

The method includes administering, to a subject, an agent that binds to Tiel. For example, the agent promotes Tiel self-association homodimerization) or antagonizes an association between at least two of the following: Tiel, Tie2, and an angiopoietin (Ang; such as Angl, Ang2, Ang3, or Ang4). In one embodiment, the agent antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang. In another embodiment, the binding of the agent can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang.

[0006] In one embodiment, the agent binds to Tiel. In one embodiment, the agent antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang. In another embodiment, the binding of the agent can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang. In another embodiment, the agent enhances Tiel self-association, homodimerization, and thereby associates Tiel with Tiel and prevents association of Tiel with Tie2 and/or Ang. The agent can include at least two valencies for binding to Tiel. In one embodiment, the agent increases phosphorylation of Tiel, Tiel WO 2006/020706 PCT/US2005/028413 "au~iphosphorylation. This mcrease can, but need not, depend on Tiel selfassociation.

[0007] In one embodiment, the agent includes a protein, such as an antibody, that binds to the extracellular domain of human Tiel. For example, the antibody can be one or more of the following: human, humanized, non-immunogenic, isolated, monoclonal, and recombinant. In one embodiment, the antibody can bind to the first Ig-like C2-type domain (Ig 1) or to the second Ig-like C2-type domain (Ig 2) of Tiel.

In one embodiment, the antibody binds to an EGF-like domain of Tiel first, second, or third EGF-like domain). In one embodiment, the antibody binds to the fibronectin type III repeats region of Tiel. In one embodiment, the antibody binds to amino acid residues 24-124, 74-174, 124-224, 174-274, 224-324, 274-374, 324-424, 374-474, 424-524, 474-574, 524-624, 574-674, 624-724, 674-759, or 724-759 of SEQ ID NO:2.

[0008] In one embodiment, the agent includes a protein that binds to a Tiel ectodomain and includes a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence. The protein can further include one or more of the following properties: at least one of the variable domain sequences includes at least one CDR of the E3 or E3b antibody one, two, or three CDRs of the E3 or E3b antibody); at least one of the variable domain sequences includes CDR sequences at least 85% identical, in sum, to the CDRs of the corresponding variable domain of the E3 or E3b antibody, at least one of the variable domains is at least 85% identical to the corresponding immunoglobulin variable domains of the E3 or E3b antibody, and the protein competes with E3 or E3b for binding to Tiel or binds to an epitope that overlaps the epitope bound by E3 or E3b on Tiel. Example of antibodies that include an antigen binding site that competes with E3 for binding to Tiel include M0044B08, M0056G08, M0045B03, M0053F04, M0055E10, M0060H01, M0054H10, M0058F03, and related antibodies.

[0009] In one embodiment, the agent includes the HC and/or LC variable domain of the E3 or E3b antibody, or a sequence at least 70, 80, 85, 90, 95, 98, 99% identical to the HC and/or LC variable domains of the E3 or E3b antibody. In one embodiment, the amino acid sequences of the HC variable domain sequence include CDR1, CDR2, and CDR3 sequences from the E3 or E3b clone and the LC variable WO 2006/020706 PCT/US2005/028413 domain sequence includes CDR1, CDR2, and CDR3 sequences from the E3 or E3b clone. In one embodiment, the agent comprises the E3 or E3b antibody. The LC variable domain sequence can include SEQ ID NO:116. The HC variable domain sequence can include SEQ ID NO:114. In one embodiment, the HC and LC framework regions are human. In one embodiment, that agent includes SEQ ID NO:723 and SEQ ID NO:724.

[0010] In one embodiment, the agent binds to Tie2. In one embodiment, the agent antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang. In another embodiment, the binding of the agent can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang. In another embodiment, the agent enhances Tie2 self-association, homodimerization, and, thereby associates Tie2 with Tie2 and prevents association of Tie2 with Tiel and/or Ang. In one embodiment, the agent includes a protein, an antibody that binds to the extracellular domain of human Tie2. For example, the antibody can be one or more of the following: human, humanized, non-immunogenic, isolated, monoclonal, and recombinant. In one embodiment, the antibody can bind to the first Ig-like C2type domain (Ig 1) or to the second Ig-like C2-type domain (Ig 2) of Tie2. In one embodiment, the antibody binds to an EGF-like domain of Tie2 first, second, or third EGF-like domain). In one embodiment, the antibody binds to the fibronectin type III repeats region of Tie2. In one embodiment, the antibody binds to amino acid residues 19-119, 69-169, 119-229, 169-269, 229-329, 269-369, 329-429, 369-469, 429-529, 469-569, 529-629, 569-669, 629-729, 669-745, 729-745 of SEQ ID NO:162.

[0011] In one embodiment, the agent binds to Ang Angl, Ang2, Ang3, or Ang4). In one embodiment, the agent antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang. In another embodiment, the binding of the agent can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang. In one embodiment, the agent includes a protein, an antibody that binds to Ang. For example, the antibody can be one or more of the following: human, humanized, non-immunogenic, isolated, monoclonal, and recombinant. In one embodiment, the antibody binds to the N-terminal domain of Angl the Nterminal 50 amino acids of Angl). In one embodiment, the antibody binds to the coiled-coil domain ofAngl. In one embodiment, the antibody binds to the fibrinogen-like domain ofAngl. In one embodiment, the antibody binds to amino WO 2006/020706 PCT/US2005/028413 acid residues 1-100, 50-150, 100-200, 150-250, 200-300, 250-350, 300-400, 350-450, 400-497, or 450-497 of SEQ ID NO:163.

[0012] In one embodiment, the agent includes a protein that contains a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence. In one embodiment, the HC and LC framework regions are human. In one embodiment, the agent also includes an Fe domain. In one embodiment, the agent includes the constant domains of a human IgG1, IgG2, IgG3, or IgG4. In one embodiment, the constant domains of the heavy chain are fallotype, allotype, or any other allotype.

[0013] In one embodiment, the agent is administered in an amount effective to decrease vascular development or angiogenesis. In one embodiment, the subject has an angiogenesis-related disorder. In other embodiments, the subject has for example: a neoplastic disorder, metastatic cancer, an angiogenesis-dependent cancer or tumor, an inflammatory disorder, rheumatoid arthritis, or psoriasis. In one embodiment, the protein is delivered systemically.

[0014] In another embodiment, the protein is administered in an amount effective to reduce one or more of the following activities: sprouting, splitting, remodeling of blood vessels, vasculogenesis, and tubule formation. The method can include other features described herein.

[0015] In one aspect, the invention includes a method of decreasing or inhibiting endothelial cell activity in the subject, the method includes administering an agent that decreases or inhibits Tie complex formation in an amount effective to decrease or inhibit endothelial cell activity in the subject. The method can include other features described herein.

[0016] In one aspect, the invention includes a method of decreasing endothelial cell activity by administering an agent that causes Tiel phosphorylation.

In one embodiment, the phosphorylation decreases endothelial cell differentiation, sprouting, splitting, and tube formation.

[0017] In another aspect, the invention includes a method of decreasing endothelial cell activity, the method by administering an agent that activates a signaling pathway. In one embodiment, the signaling pathway decreases endothelial cell differentiation, sprouting, splitting, and tube formation. For example, the WO 2006/020706 PCT/US2005/028413 agent increases Tiel autophosphorylation. The method can include other features described herein.

[0018] In one aspect, the invention includes an antibody for modulating Tie complex formation in a subject, wherein the antibody antagonizes an association between at least two of the following: Tiel, Tie2, and an angiopoietin (Ang). In one embodiment, the antibody binds to a Tie complex component or to one or more of Tiel, Tie2, and an Ang. In one embodiment, the antibody antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang. In another embodiment, the antibody can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang.

[0019] In one embodiment, the antibody binds to Tiel. In one embodiment, the antibody antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang.

In another embodiment, the binding of the antibody can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang. In another embodiment, the antibody enhances Tiel self-association, homodimerization, and thereby associates Tiel with Tiel and prevents association of Tiel with Tie2 or Ang. In another embodiment, the antibody increases Tiel phosphorylation and/or prevents association of Tie 1 with Tie2 or Ang. In one embodiment, the antibody includes an antibody that binds to the extracellular domain of human Tiel. For example, the antibody can be one or more of the following: human, humanized, nonimmunogenic, isolated, monoclonal, and recombinant. In one embodiment, the antibody can bind to the first Ig-like C2-type domain (Ig 1) or to the second Ig-like C2-type domain (Ig 2) of Tiel. In one embodiment, the antibody binds to an EGFlike domain of Tiel first, second, or third EGF-like domain). In one embodiment, the antibody binds to the fibronectin type III repeats region of Tiel. In one embodiment, the antibody binds to amino acid residues 24-124, 74-174, 124-224, 174-274, 224-324, 274-374, 324-424, 374-474, 424-524, 474-574, 524-624, 574-674, 624-724, 674-759, or 724-759 of SEQ ID NO:2.

[0020] In one embodiment, the antibody binds to a Tiel ectodomain and includes a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, the protein further includes one or more of the following properties: at least one of the variable domain sequences includes at least one CDR of the E3 or E3b antibody; at least one of the WO 2006/020706 PCT/US2005/028413 variable domain sequences includes CDR sequences at least 85% identical, in sum, to the CDRs of the corresponding variable domain of the E3 or E3b antibody; at least one of the variable domains is at least 85% identical to the corresponding immunoglobulin variable domains of the E3 or E3b antibody, and the protein competes with E3 or E3b for binding to Tiel or binds to an epitope that overlaps the epitope bound by E3 or E3b on Tiel. For example, the antibody is at least bivalent, with at least two antigen binding sites that bind to Tiel. In one embodiment, the antibody comprises the E3, E3b DX-2220), or DX-2240.

[0021] In one embodiment, the antibody includes one or more variable domains from the E3 or E3b antibody or a variable domain sequence that is at least 75, 80, 85, 90, 95, 98, or 995 identical to such a variable domain. In one embodiment, the amino acid sequences of the HC variable domain sequence include CDR1, CDR2, and CDR3 sequences from the E3 or E3b clone, and the LC variable domain sequence includes CDR1, CDR2, and CDR3 sequences from the E3 or E3b clone. In one embodiment, the LC variable domain sequence includes SEQ ID NO:116. In one embodiment, the HC variable domain sequence includes SEQ ID NO: 114. In one embodiment, the HC and LC framework regions are human.

[0022] In one embodiment, the antibody binds to Tie2. In one embodiment, the antibody antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang.

In another embodiment, the binding of the antibody can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang. In another embodiment, the antibody enhances Tie2 self-association, homodimerization, and thereby associates Tie2 with Tie2 and prevents association of Tie2 with Tiel or Ang. In one embodiment, the antibody causes Tiel phosphorylation. In one embodiment, the antibody prevents association of Tiel with Tie2 or Ang. In one embodiment, the antibody includes an antibody that binds to the extracellular domain of human Tie2. The antibody may have one or more of these properties, the antibody may cause Tiel phosphorylation and prevent association of Tiel with Tie2 or Ang, etc.

[0023] For example, the antibody can be one or more of the following: human, humanized, non-immunogenic, isolated, monoclonal, and recombinant. In one embodiment, the antibody can bind to the first Ig-like C2-type domain (Ig 1) or to the second Ig-like C2-type domain (Ig 2) of Tie2. In one embodiment, the antibody binds WO 2006/020706 PCT/US2005/028413 to an EGF-like domain of Tie2 first, second, or third EGF-like domain). In one embodiment, the antibody binds to the fibronectin type III repeats region of Tie2. In one embodiment, the antibody binds to amino acid residues 19-119, 69-169, 119-229, 169-269, 229-329, 269-369, 329-429, 369-469, 429-529, 469-569, 529-629, 569-669, 629-729, 669-745, 729-745 of SEQ ID NO:162.

[0024] In one embodiment, the antibody binds to Ang. In one embodiment, the antibody antagonizes formation of a heteromeric complex of Tiel, Tie2, and Ang.

In another embodiment, the binding of the antibody can antagonize the association between Tiel and Tie2, between Tiel and Ang, or between Tie2 and Ang. For example, the antibody can be one or more of the following: human, humanized, nonimmunogenic, isolated, monoclonal, and recombinant. In one embodiment, the antibody binds to the N-terminal domain of Angl the N-terminal 50 amino acids of Angl). In one embodiment, the antibody binds to the coiled-coil domain of Angl.

In one embodiment, the antibody binds to the fibrinogen-like domain of Angl. In one embodiment, the antibody binds to amino acid residues 1-100, 50-150, 100-200, 150- 250, 200-300, 250-350, 300-400, 350-450, 400-497, or 450-497 of SEQ ID NO:163.

[0025] In one embodiment, the antibody includes a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence.

[0026] In one embodiment, the HC and LC framework regions are human. In one embodiment, the antibody also includes an Fc domain. In one embodiment, the antibody includes the constant domains of a human IgG1, IgG2, IgG3, or IgG4.

[0027] In one embodiment, the antibody is administered in an amount effective to decrease vascular development and angiogenesis. In one embodiment, the antibody is delivered systemically. In one embodiment, antibody is administered in an amount effective to reduce one or more of the following activities: sprouting, splitting, remodeling of blood vessels, vasculogenesis, and tubule formation.

[0028] In one aspect, the invention includes an isolated protein that includes one or more variable domains of an antibody described herein.

[0029] In one aspect, the invention includes a nucleic acid that includes a coding sequence that encodes a polypeptide that includes a variable domain of an antibody described herein.

WO 2006/020706 PCT/US2005/028413 [0030] In one aspect, the invention includes a pharmaceutical composition that includes an antibody described herein. The composition and antibody can include other features described herein.

[0031] In one aspect, the invention includes an antibody described herein for treatment of an angiogenesis-related disorder. The antibody and treatment can include other features described herein.

[0032] In one aspect, the invention includes an antibody described herein for the manufacture of a medicament for treating an angiogenesis-related disorder. The medicament and antibody can include other features described herein.

[0033] In one aspect, the invention includes a method of providing a first therapy that includes administering a first agent in combination with a second therapy, an anti-cancer therapy. The first agent is an agent that decreases Tie complex formation or an agent that increases Tiel homodimerization. For example, the first agent is a Tiel binding protein. In one embodiment, the second therapy includes radiation therapy or surgery. In one embodiment, the second therapy includes administering a second agent. For example, the second agent antagonizes or decreases Tie complex formation or increases Tiel homodimerization. In one embodiment, the second agent is an agent that antagonizes signaling through a VEGF pathway, a VEGF antagonist antibody, bevacizumab; VEGF-Receptor tyrosine kinase inhibitor, or another agent that antagonizes VEGF pathway signalling.

See also "Combination Therapies" below.

[0034] In another aspect, the invention includes a composition that includes an agent that decreases Tie complex formation and an anti-cancer agent. For example, the anti-cancer agent can be a second agent that antagonizes Tie complex formation or a second agent that antagonizes a VEGF pathway.

[0035] In one aspect, the invention features an antibody that decreases endothelial cell activity by causing Tiel phosphorylation. For example, the antibody may decrease endothelial cell differentiation, sprouting, splitting, and tube formation.

[0036] In one aspect, the invention features a protein an isolated protein) that includes a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence and binds to Tiel ectodomain. The WO 2006/020706 WO 206/00706PCT/US20051028413 binding protein binds to Tiel ectodomain. For example, the protein binds with an affinity KD of less than 10O8 M, 5-10- 9 M, 10- 9 M, 10"0 M, 1011 M, or 10-2 M [00371 In one embodiment, one or more of the CDRs of the heavy and/or light chain variable domain sequence are human, primate, non-rodent non-mouse or non-rat), or synthetic. In one embodiment, one or more of the framework regions of the heavy andlor light chain variable domain sequence are human, primate, or nonrodent non-mouse or non-rat).

[0038] In one embodiment, the heavy chain variable domain sequence includes one or more of the following properties: i) a HC CDR1 that includes an amino acid sequence as follows: (AGSR)-Y-(GVK)-M-(GS VP), (SEQ ID NO: 117) (AGSIIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ IOD NO: 118), or (AGSTNRNI)-Y-(AGTVMKPQ)-M-(AGSTVMYWFKI{) (SEQ ID NO:1t19); ii) a HC CDR2 that includes an amino acid sequence as follows: X-I-Y-P-S-G-G-X-T-X-Y-A-D--VK-G (SEQ ID NO: 120), wherein X is any amino acid, (SEQ ID NO: 12 1), (SEQ ID NO: 160) (GS WQ)-T-(GY)-Y-A-D-S-V-K-G (SEQ ID NO: 122),

(GSVWV)-I-(SY)-P-S-G-G-(AGVMY)WQH)-T-(AGSTLVMYFKI{)

(SEQ ID NO: 123), or X-I-Y-P-S-G-G-(WPS)-T-(YVH)-Y-A-D (SEQ ID NO: 72 wherein X is any amino acid; iii) a H4C CDR3 that includes an amino acid sequence as follows: V-(four or five residues)-F-D-(I/Y (SEQ lID NO: 124), G-Y-G-P-1-A-P-G-L-D-Y (SEQ ID NO: 125), (SEQ ID NO: 126),

(GVD)-(AGLN)-(LYR)-(GSTLYMH)-(GYD)-(AGSYFP)-(SFD)-(AGYD).

(SEQ ID NO: 127), A-P-R-G-Y-S-Y-G-Y-Y-Y (SEQ ID NO:727), VNYYDSSGYGPIAPGLDY (SEQ ID NO: 128), or (SEQ ID NO:705), wherein X is any amino acid.

WO 2006/020706 WO 206/00706PCT/US20051028413 [0039] In one embodiment, the light chain variable domain sequence Includes one or more of the following properties: i) a LC CDR1 that includes an amino acid sequence as follows: R-A-S-Q-S-(WV)-S-(SR)-X1-Y-L-(A1N) (SEQ ID NO: 129), (SEQ ID NO:706), (SEQ ID NO:707), (SEQ ID NO:708), R-A-S-Q-S-V-S-S-X-L (SEQ ID NO:130), (SEQ ID NO: 13 or R-A-S-(RQy(GSTRN)-(V)-(GST)(STn1I)-Xl(SYvNHIy(Ly)- (ASN) (SEQ ID NO: 132), wherein X1 can be serine or absent; ii) a LC CDR2 that includes an amino acid sequence as follows: X-A-S-X-R-A-T (SEQ I) NO: 133), wherein X can be any amino acid, (AGD)-A-S-(STN)-R-A-T (SEQ ID NO: 134), (SEQ ID NO:709), (SEQ ID NO: 135), or (AGTKDEH)-A-S-(STN)-(LR)-(AVEQ)-(sT) (SEQ H) NO:136); and iii) a LC CDR3 that includes an amino acid sequence as follows: Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)-(LWRH>-(T1Y) (SEQ ID NO: 16 1), Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)-(LWR)(TLY)T (SEQ ID NO: 137), (LQ)-Q-(SYFR)-(GSYN)(SKN)-(STYW)-(RP)(Lw R}(TwY) (SEQ ID NO:138), (SEQ ID NO:7 10), wherein X is any amino acid, (SEQ ID NO:71 wherein X is any amino acid, -T (SEQ ID NO: 139), wherein X1 is any amino acid or absent, Q-Q-F-N-S-Y-P-H (SEQ ID NO:728), (LQ)-(LQ)-(SYFRD)-(GSYN)-(STRKcN(STYWF)(RP).(ILMWR1)-(TIY).

(TI) (SEQ ID NO: 140), or (LQ)-(LRQ)-(SYFRD)-(GSYN)-(ASTRK )-(STYWr)-(SVPP)- (STILMWMI)-(T1Y)-(STJ) (SEQ ID NO: 141).

WO 2006/020706 PCT/US2005/028413 [0040] In one embodiment, the light chain variable domain sequence includes one or more of the following properties: i) a LC CDR1 that includes an amino acid sequence as follows: S-X-(ND)-(IV)-(AG)-X1-X2-X3 (SEQ ID NO:142), or T-(GR)-(ST)-S-X5-(ND)-(IV)-(AG)-X1-X2-X3-Y-X4-S (SEQ ID NO:143), wherein X1 is any amino acid G or X2 is any amino acid Y or X3 is any amino acid F, N, or X4 is any amino acid aliphatic, V or

A);

ii) a LC CDR2 that includes an amino acid sequence as follows: (DE)-V-N-N-R-P-S (SEQ ID NO:144) (DE)-(VD)-(STDN)-(YRDN)-R-P-S (SEQ ID NO:145); iii) a LC CDR3 that includes an amino acid sequence as follows: (SQ)-S-(SY)-(ASID)-(GSR)-(ST)-(STRN)-(STYR)-(ATLY)-(SVWQ)

(SEQ

ID NO:146).

[0041] In one embodiment, the HC CDR2 includes an amino acid sequence as follows: (GSVW)-I-(SY)-P-SG-G-(AGVMYWPQH)-T-(AGSTLVMYFKH)-Y-(AT)- D-S-V-K-G (SEQ ID NO: 147) or V-K-G (SEQ ID NO:148).

[0042] In one embodiment, the protein includes HC CDR1 and HC CDR2 sequences that are related to the corresponding CDR sequences of p-F3, E3 or E3b.

For example, the protein includes the sequence MYGM (SEQ ID NO:149), at a position corresponding to HC CDR1. The sequence can be followed by a small amino acid, glycine, alanine, valine, or serine. In another example, the protein the sequence VISPSGGXITX 2 YADSAVKG (SEQ ID NO:150), at a position corresponding to HC CDR2. For example, X 1 can be a hydrophilic amino acid, e.g., glutamine or asparagine. For example, X 2 can be a small amino acid, glycine, alanine, valine, or serine.

[0043] In one embodiment, the heavy chain variable domain sequence can have one or more of the following features: the amino acid residue at Kabat position 31 is A, H, K, N, Q, R, S, or T, H, N, R, or S; the amino acid residue at Kabat position 32 is Y; the amino acid residue at Kabat position 33 is G, K, P, R, or V, K or V; the amino acid residue at Kabat position 34 is M; the amino acid residue at Kabat position 35 is A, G, H, I, L, M, S, or V, G, H, M, or V; the WO 2006/020706 PCT/US2005/028413 amino acid residue at Kabat position 50 is G, R, S, or V, S or V; the amino acid residue at Kabat position 51 is I; the amino acid residue at Kabat position 52 is S or Y, Y; the amino acid residue at Kabat position 52a is P or S, P; the amino acid residue at Kabat position 53 is S; the amino acid residue at Kabat position 54 is G; the amino acid residue at Kabat position 55 is G; the amino acid residue at Kabat position 56 is A, F, H, 1, Q, W, or Y, A, W or Y; the amino acid residue at Kabat position 57 is T; the amino acid residue at Kabat position 58 is R, S, T, or Y, Y.

In one embodiment, the length of CDR3 is between 8-18 amino acids, between 8-12, 8-10, or 15-17 amino acids.

[0044] In one embodiment, two or three of the CDRs of the HC variable domain sequence match motifs that also match a HC variable domain of an antibody described herein. Similarly, in one embodiment, two or three of the CDRs of the LC variable domain sequence match motifs that also match a LC variable domain of an antibody described herein. In still another embodiment, the matched motifs for the CDRs are based on a HC and a LC that are paired in an antibody described herein.

[0045] In one embodiment, the H1 and H2 hypervariable loops have the same canonical structure as an antibody described herein. In one embodiment, the L1 and L2 hypervariable loops have the same canonical structure as an antibody described herein.

[0046] In one embodiment, the HC CDR1 amino acid sequences have a length of at least 5 amino acids of which at least 3, 4, or 5 amino acids are identical to the CDR1 sequence of the HC of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p- D12, p-F3, p-F4, p-G3, s-A10, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s- El11, s-GO0, s-H4, or another antibody described herein. In one embodiment, the HC CDR2 amino acid sequences have a length of at least 15, 16, or 17 amino acids of which at least 10, 12, 14, 15, 16, or 17 amino acids are identical to the CDR2 sequence of the HC of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p- F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, ss-H4, or another antibody described herein. In one embodiment, the HC CDR2 amino acid sequences have a length of at least 17 amino acids of which at least 14, 16, or 17 amino acids are identical to the CDR2 sequence of the HC of clone E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s- B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody WO 2006/020706 PCT/US2005/028413 described herein. In one embodiment, the HC CDR3 amino acid sequences have a length of at least of at least 7 or 8 amino acids of which at least 5, 6, 7, or 8 amino acids are identical to the CDR3 sequence of the HC of clone E3, E3b, G2, p-Al, pp-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AIO, s-H1, s-A2, s-B2, s-B9, ss-C2, s-C7, s-D11, s-E11, s-G10, s-H4, or another antibody described herein.

[0047] In one embodiment, two or three of the CDRs of the HC variable domain sequence match motifs described herein such that the motifs are a set of motifs that match a HC variable domain of a clone described herein, E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-H1, s-A2, s- B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein. For example, the protein may include SEQ ID NO:118 and SEQ ID NO:160, motifs that match the E3 HC variable domain.

[0048] In one embodiment, the LC CDR1 amino acid sequences have a length of at least 10, 11, or 12 amino acids of which at least 7, 8, 9, 10, or 11 amino acids are identical to the CDR1 sequence of the LC of clone E3, E3b, G2, p-Al, p-A10, p-BI, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s- C7, s-D11, s-El11, s-G10, s-H4, or another antibody described herein. In one embodiment, the LC CDR2 amino acid sequences have a length of at least 6 or 7 amino acids of which at least 5, 6, or 7 amino acids are identical to the CDR2 sequence of the LC of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p- F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-El 1, ss-H4, or another antibody described herein. In one embodiment, the LC CDR3 amino acid sequences have a length of at least of at least 8, 9, or 10 amino acids of which at least 7, 8, 9, or 10 amino acids are identical to the CDR3 sequence of the LC of clone E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, ss-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein.

[0049] In one embodiment, two or three of the CDRs of the LC variable domain sequence match motifs described herein such that the motifs are a set of motifs that match a LC variable domain of a clone described herein, E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-HI, s-A2, s-B2, s- B9, s-C10, s-C2, s-C7, s-D1l, s-Ell, s-G10, s-H4, or another antibody described WO 2006/020706 PCT/US2005/028413 herein. For example, the protein may include SEQ ID NO:132, SEQ ID NO:136, and SEQ ID NO:161, motifs that match the E3 LC variable domain.

[0050] In one embodiment, the amino acid sequence of the HC variable domain sequence is at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to the amino acid sequence of the HC variable domain of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s- C2, s-C7, s-D11, s-El11, s-G10, s-H4, or another antibody described herein.

[0051] In one embodiment, the amino acid sequence of the LC variable domain sequence is at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to the amino acid sequence of the LC variable domain of clone E3, E3b, G2, p-Al, p-A1O, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s- C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein.

[0052] In one embodiment, the amino acid sequences of the HC and LC variable domain sequences are at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to the amino acid sequences of the HC and LC variable domains of a clone selected from the group consisting of E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p- D12, p-F3, p-F4, p-G3, s-A10, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s- Ell, s-G10, s-H4, and any other antibody described herein.

[0053] In one embodiment, the amino acid sequences of one or more framework regions FR1, FR2, FR3, and/or FR4) of the HC and/or LC variable domain are at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to corresponding framework regions of the HC and LC variable domains of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s- A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-E11, s-G10, s-H4, or another antibody described herein.

[0054] In one embodiment, the amino acid sequences of the HC and LC variable domain sequences comprise a sequence encoded by a nucleic acid that hybridizes under high stringency) to a nucleic acid encoding a variable domain of E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s- Hl, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein.

WO 2006/020706 PCT/US2005/028413 [0055] In one embodiment, the light chain variable domain sequence is human or non-immunogenic in a human. In one embodiment, the heavy chain variable domain sequence is human or non-immunogenic in a human.

[0056] The protein can bind to cells that express Tiel, endothelial cells.

In one embodiment, the protein does not substantially bind does not detectably bind) to platelets resting and/or activated platelets).

[0057] In one embodiment, the protein inhibits tube formation by HUVECs in vitro. For example, the E3 antibody inhibits tube formation by HUVECs in vitro under conditions described in Example 18). In one embodiment, the protein inhibits angiogenesis in an in vivo MATRIGELTM plug assay. For example, the E3 antibody can inhibit angiogenesis in an exemplary assay (see, an exemplary assay described in Example 21).

[0058] In one embodiment, the protein recognizes melanoma-associated structures in a histological section, not only melanoma tissue, but antigen in surrounding structures. In one embodiment, the protein does not stain blood vessels in normal skin in a histological section.

[0059] In one embodiment, the protein specifically binds to Tiel, it binds with at least a 10, 50, 100, 10 3 or 104 fold preference for Tiel relative to another human protein, Tie2, a natural protein other than Tiel that has a Ig-like domain, an EGF-like domain, or fibronectin Type III repeat, or human serum albumin. In one embodiment, the protein binds to a domain of Tiel described herein.

[0060] In another aspect, the invention features a protein an isolated protein) that modulates activity of Tiel, the Tiel receptor. For example, the protein is not naturally occurring. In one embodiment, the protein includes a HC and LC immunoglobulin variable domain sequence. In one embodiment, one or more of the CDRs of the heavy and/or light chain variable domain sequence are human, primate, non-rodent non-mouse or non-rat), or synthetic. In one embodiment, one or more of the framework regions of the heavy and/or light chain variable domain sequence are human, primate, or non-rodent non-mouse or non-rat). In another embodiment, the protein is substantially free of an immunoglobulin variable domain, the protein includes a peptide that independently interacts with Tiel or a polypeptide that does not include a immunoglobulin variable domain.

WO 2006/020706 PCT/US2005/028413 [0061] In one embodiment, the protein activates an activity of the Tiel protein, an activity in the Tiel/EpoR chimeric BaF3 cell assay described in Example 2. A protein that activates in this assay can behave as antagonists in other conditions, for example, in vivo.

[0062] In one embodiment, the protein includes the HC and LC immunoglobulin variable domains of the E3, E3b, or other antibody, HC and/or LC immunoglobulin variable domain sequences that are at least 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical in the CDR regions to the respective CDRs of the E3, E3b or other antibody described herein. In one embodiment, the protein competes with E3, E3b, or other antibody described herein for binding to Tiel or binds to an epitope that overlaps an epitope that is recognized by E3, E3b, or other antibody described herein, or that has at least one, two or three residues in common with an epitope that is recognized by E3, E3b, or other antibody described herein.

[0063] In one embodiment, the activating protein enables IL-3 dependent cells that express a chimeric receptor including the Tiel extracellular domain and the EpoR intracellular domain to survive in the absence of IL-3.

[0064] In one embodiment, the protein can cause dimerization of Tiel. In one embodiment, the protein can cause auto-phosphorylation of the RTK domain of Tiel.

[0065] In one embodiment, the protein synergizes with the E3 or E3b antibody to activate an activity of Tie, in the Ticl/EpoR chimeric BaF3 cell assay. In one embodiment, the protein includes the HC and LC immunoglobulin variable domains of the G2 or C7 antibody or domains that are at least 70, 80, 85, 90, 91, 92, 93, 94, 96, 97, 98, 99, or 100% identical in the CDR regions. In one embodiment, the protein competes with G2 or C7 for binding to Tiel or binds to an epitope that overlaps an epitope that is recognized by G2 or C7 or that has at least one, two or three residues in common with an epitope that is recognized by G2 or C7.

[0066] In another embodiment, the protein antagonizes an activity of the Tiel protein. For example, the protein can at least partially inhibit the ability of the E3 or E3b antibody to agonize the Tie protein. In one embodiment, the protein can at least partially inhibit the ability of the E3 or E3b antibody to enable IL-3 dependent cells that express a chimeric receptor including the Tiel extracellular domain and the EpoR intracellular domain to survive in the absence of IL-3.

WO 2006/020706 PCT/US2005/028413 [0067] In one embodiment, the HC and LC immunoglobulin variable domain sequences of the protein include the amino acid sequences that are at least 70, 80, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical to the amino acid sequences of respective immunoglobulin variable domains of B2 or D I.

[0068] In one embodiment, the Tiel binding protein includes the HC and LC immunoglobulin variable domains of an antibody selected from the group consisting of: B2, D11, A2, A10, P-B1, P-B3, and P-C6 or immunoglobulin domains that are at least 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical in the CDR regions to the CDR regions of the respective antibodies. For example, the protein binds with an affinity KD of less than 10-' M, 5-10 9 M, 10 9 M, 10-" M, 10-' M, or 12

M.

[0069] In one embodiment, the protein can at least partially inhibit the ability of a naturally occurring Tiel binding protein from interacting with the Tie protein.

[0070] The protein can include other features described herein.

[0071] In another aspect, the invention features an antibody an isolated antibody) that binds to the Tiel ectodomain, but does not substantially bind to platelets, as detected by fluorescence activated cell sorting. For example, the antibody does not substantially bind to activated platelets and/or resting platelets. In one embodiment, the antibody binds to endothelial cells. In one embodiment, the protein is a monoclonal antibody. The antibody can be provided in a preparation that is free of other Tiel-binding antibodies that have other specificities, free of Tiel binding antibodies that bind to platelets. The antibody can include other features described herein.

[0072] In another aspect, the invention features a protein an isolated protein) that preferentially binds to a Tiel protein in a conformation stabilized by the E3 or E3b antibody relative to an endogenous Tiel protein in an unstimulated state.

In one embodiment, the protein includes immunoglobulin HC and LC domains. In another embodiment, the protein includes a peptide of length less than 30, 28, 22, 20, 18, 16, or 14 amino acids) that independently binds to Tiel. For example, the peptide can include one, two, or three disulfide bonds. The protein can include other features described herein.

WO 2006/020706 PCT/US2005/028413 [0073] In another aspect, the invention features a protein an isolated protein) that preferentially binds to a Tiel protein in a dimeric conformation relative to a monomeric Tiel protein. In one embodiment, the protein includes immunoglobulin HC and LC domains. In another embodiment, the protein includes a peptide of length less than 30, 28, 25, 22, 20, 18, 16, or 14 amino acids) that independently binds to Tiel. For example, the peptide can include one, two, or three disulfide bonds. The protein can include other features described herein.

[0074] In another aspect, the invention features a protein an isolated protein) that preferentially binds to a Tie2 protein in a conformation that is biased against interaction with Ang or Tiel. In one embodiment, the protein includes immunoglobulin HC and LC domains. In another embodiment, the protein includes a peptide of length less than 30, 28, 25, 22, 20, 18, 16, or 14 amino acids) that independently binds to Tie2. For example, the peptide can include one, two, or three disulfide bonds. The protein can include other features described herein. The invention also features nucleic acid aptamers that have one or more of these properties.

[0075] In another aspect, the invention features a protein an isolated protein) that preferentially binds to an Ang protein, and modulates inhibits) interaction with Tiel and Tie2. In one embodiment, the protein includes immunoglobulin HC and LC domains. In another embodiment, the protein includes a peptide of length less than 30, 28, 25, 22, 20, 18, 16, or 14 amino acids) that independently binds to Ang. For example, the peptide can include one, two, or three disulfide bonds. The protein can include other features described herein. The invention also features nucleic acid aptamers that have one or more of these properties.

[0076] In another aspect, the invention features a protein an isolated protein) that binds to an epitope of Tiel ectodomain with a KD of less than 2 X M. The epitope overlaps, is within, or includes an epitope bound by E3, E3b, G2, p- Al, p-Al0, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-H1, s-A2, s-B2, s- B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein or that includes at least one, two, or three residues in common. For example, the protein binds with an affinity KD of less than 10 8 M, 5-10- 9 M, 10 9 M, 10 10 M, 11 M, or 10 12 M. In one embodiment, the protein includes immunoglobulin HC WO 2006/020706 PCT/US2005/028413 and LC domains. In another embodiment, the protein includes a peptide of length less than 30, 28, 25, 22, 20, 18, 16, or 14 amino acids) that independently binds to Tiel. For example, the peptide can include one, two, or three disulfide bonds. The protein can include other features described herein. The invention also features nucleic acid aptamers that have one or more of these properties.

[0077] In another aspect, the invention features a protein an isolated protein) that competitively inhibits binding of E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s- D11, s-E11, s-G10, s-H4, or another antibody described herein to a Tiel ectodomain.

[0078] In another aspect, the invention features a protein an isolated protein) that includes a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence and that antagonizes an activity of the Tiel ectodomain. In one embodiment, CDR1 of the light chain variable domain sequence includes: Q-S-X-S-S (SEQ ID NO:151) or R-A-S-Q-S-X- S-S-Y-L-A (SEQ ID NO:152), wherein X is any amino acid or optionally aliphatic, isoleucine or valine. In one embodiment, CDR2 of the light chain variable domain sequence includes: A-S-XI-R-X 2 -T (SEQ ID NO:153) or D-A-S-Xi-R-X 2

-T

(SEQ ID NO:154), wherein X 1 is any amino acid or optionally a hydrophilic amino acid, serine or asparagine, and X 2 is any amino acid or optionally aliphatic or small aliphatic, alanine or valine. In one embodiment, CDR3 of the light chain variable domain sequence includes: Q-R-S-X 2 -W-P-R (SEQ ID NO:155) or X 1

-Q-R-

S-X

2 -W-P-R-T (SEQ ID NO:156), wherein X 1 is any amino acid or optionally leucine or glutamine, and X 2 is any amino acid or optionally lysine or serine.

[0079] In one embodiment, the protein competes with the B2 and/or D11 antibody for binding to Tiel or competitively inhibits binding of B2 and/or D 1 to Tiel.

WO 2006/020706 PCT/US2005/028413 [0080] In one embodiment, the protein antagonizes a Tiel activity that is stimulated by the E3 or E3b antibody. In one embodiment, the protein inhibits dimerization of Tiel. The protein can include other features described herein.

[0081] In another aspect, the invention features an isolated, mono-specific protein including a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence, wherein the protein binds to Tiel ectodomain and includes a human or non-mouse constant domain a human IgG, lgG2, IgG3, or IgG4 constant domain). The protein can include other features described herein.

[0082] In another aspect, the invention features an isolated, human antibody that binds to a Tiel ectodomain. The protein can include other features described herein.

[0083] In another aspect, the invention features an isolated antibody an isolated antibody) that binds to a Tiel ectodomain and contains less than 5, 4, 3, or 2 peptides (of between 6-9 amino acid length) that are non-human in origin or less than 4, 3, or 2 peptides that are potential human T cell epitopes. In one embodiment, the antibody contains no peptide (of 6-9 amino acid length) that is non-human in origin or that is a potential human T cell epitope.

[0084] In one embodiment, the antibody is obtained by a method that includes deimmunization. For example, the antibody is deimmunized, completely deimmunized. The protein can include other features described herein.

[0085] In another aspect, the invention features an isolated antibody that binds to a Tiel ectodomain and that includes a modified Fe domain, a modified human Fc domain. For example, antibodies may include modifications, that alter Fe function. For example, the human IgG1 constant region can be mutated at one or more residues, one or more of residues 234 and 237, according to the number in US 5,648,260. Other exemplary modifications include those described in US 5,648,260. The protein can include other features described herein.

[0086] In another aspect, the invention features an isolated protein that binds to the Tiel receptor with an affinity KD of less than 10 7 M, 10 8 M, 5-10 9 M, 109 M, 10 M, 1011 M, or 10 1 2 M. The protein can include other features described herein.

WO 2006/020706 PCT/US2005/028413 [0087] In another aspect, the invention features an isolated protein including a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence, wherein the protein binds to Tiel ectodomain and, for example, includes at least one or more CDRs that are a nonprimate CDR a non-mouse or non-rabbit CDR) or a synthetic CDR. The protein can include other features described herein.

[0088] In another aspect, the invention features an isolated nucleic acid including a coding sequence that encodes a polypeptide including an immunoglobulin HC variable domain of an antigen binding protein that binds to Tiel. The nucleic acid or polypeptide can include one or more other features described herein. The nucleic acid can include one or more altered codons. In one embodiment, the nucleic acid includes SEQ ID NOs:725 and/or 726. Also featured is a mammalian expression vector that includes SEQ ID NOs:725 and/or 726.

[0089] In one embodiment, the nucleic acid further includes a second coding sequence that encodes a polypeptide including an immunoglobulin HC variable domain, an HC domain described herein. In one embodiment, the nucleic acid further includes a promoter operably linked to the coding sequence.

[0090] In another aspect, the invention features a nucleic acid that includes one or more coding sequence that encodes one or more polypeptide chains that collectively include an immunoglobulin HC or LC variable domain of an antigen binding protein that binds to Tiel. In one embodiment, the nucleic acid segment encoding at least one of the variable domains hybridizes to a nucleic acid described herein, under stringent conditions high stringency conditions), it hybridizes to a region encoding a variable domain and is at least 80, 85, 90, 95, or 98% of the length of such a region. The nucleic acid can include other features described herein.

[0091] In another aspect, the invention features a host cell that contains a first nucleic acid sequence encoding a polypeptide including a HC variable domain of an antigen binding protein and a second nucleic acid sequence encoding a polypeptide including a LC variable domain of the antigen binding protein, wherein the antigen binding protein binds to Tiel with a KD of less than 2 x 10 7 M. In one embodiment, WO 2006/020706 PCT/US2005/028413 the HC or LC variable domain includes at least one human CDR. The antigen binding protein can include other features described herein.

[0092] In another aspect, the invention features a host cell that contains a first nucleic acid encoding a polypeptide including a HC variable region and a second nucleic acid encoding a polypeptide including a LC variable region, wherein the HC and the LC variable regions each include at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to respective amino acid sequences of the HC and LC variable domains of a clone selected from the group consisting of E3, E3b, G2, p-Al, p-A1O, p-Bl, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-HI, s-A2, s-B2, s-B9, s-C10, s- C2, s-C7, s-D11, s-El1, s-G10, and s-H4. The antigen binding protein can include other features described herein.

[0093] In another aspect, the invention features a pharmaceutical composition including a protein described herein that interacts with Tiel and a pharmaceutically acceptable carrier.

[0094] In another aspect, the invention features a therapeutic composition including a protein described herein that interacts with Tiel wherein the composition is sterile and suitable for administration to a subject.

[0095] In another aspect, the invention features a method that includes: providing a signal-dependent or signal-responsive cell that expresses a chimeric receptor including the Tiel extracellular domain and a heterologous intracellular sequence that can produce a signal; contacting a candidate compound to the cell; and evaluating a property of the cell that is dependent on the signal. In one embodiment, the intracellular sequence includes at least a region of an intracellular sequence of the EpoR protein. The method can be used, to evaluate activity of a candidate compound, or a plurality of compounds.

[0096] In another aspect, the invention features a method that includes: providing an IL-3 dependent cell that expresses a chimeric receptor including the Tiel extracellular domain and the EpoR intracellular domain; contacting a candidate compound to the cell under conditions in which the concentration of IL-3 is not sufficient to sustain viability of the cell; and evaluating a property of the cell. The method can be used, to evaluate activity of a candidate compound, or a plurality of compounds. In one embodiment, the property is viability. In one embodiment, the WO 2006/020706 PCT/US2005/028413 evaluating includes an MTT assay. In one embodiment, the method further includes administering the candidate compound to a subject. For example, the candidate compound includes a protein, a protein that includes an immunoglobulin variable domain.

[0097] In another aspect, the invention features method of identifying a compound that modulates Tiel activity. The method includes: providing a plurality of candidate compounds; and evaluating each compound of the plurality using a method described herein.

[0098] In another aspect, the invention features a culture cell that expresses a chimeric transmembrane protein including a region of the Tiel extracellular domain and a heterologous intracellular sequence. In one embodiment, the intracellular sequence includes a region of the EpoR intracellular domain. In one embodiment, the cell requires IL-3 or Tiel for viability. For example, the cell is IL-3 dependent in the absence of the chimeric transmembrane protein, but is viable in the presence of the E3 or E3b antibody and the absence of IL-3.

[0099] In another aspect, the invention features a preparation that includes the isolated mammalian cells cells that expresses a chimeric transmembrane protein including a region of the Tiel extracellular domain and a heterologous intracellular sequence) and a Tiel-binding protein, wherein the Tiel-binding protein is necessary to sustain viability of the cells.

[0100] In another aspect, the invention features a kit including: a Tiel-binding protein and a culture cell that expresses a chimeric transmembrane protein including a region of the Tiel extracellular domain and a heterologous intracellular sequence.

[0101] In another aspect, the invention features a method of evaluating a candidate compound. The method includes: providing a preparation that includes a cell or membrane fraction that contains an insoluble protein that includes a region of the Tiel extracellular domain and a kinase domain and ATP; (ii) a ligand that alters activity of the kinase domain; and (iii) the candidate compound; and evaluating the phosphorylation state of the insoluble protein.

[0102] In another aspect, the invention features a method of evaluating a candidate compound. The method includes: providing a preparation that includes a cell or membrane fraction that includes a Tiel protein or a transmembrane protein that WO 2006/020706 PCT/US2005/028413 includes at least a region of the Tiel extracellular domain and ATP; (ii) a ligand that causes autophosphorylation of Tiel or the transmembrane protein; and (iii) the candidate compound; and evaluating phosphorylation state of the Tiel protein.

[0103] In one embodiment, the ligand is an antibody. In one embodiment, the ligand includes the HC and LC immunoglobulin variable domains of the E3 or E3b antibody or domains that are at least 90% identical in the CDR regions. In one embodiment, the method further includes administering the candidate compound to a subject.

[0104] In another aspect, the invention features a method that includes: providing a preparation that includes a cell or membrane fraction that includes a transmembrane protein that includes at least a region of the Tiel extracellular domain and ATP; and (ii) a ligand that causes autophosphorylation of Tiel or the transmembrane protein; and evaluating phosphorylation state of the transmembrane protein.

[0105] In another aspect, the invention features a method that includes: contacting a mammalian cell with a ligand that can agonize Tiel autophosphorylation and/or (ii) can enable an IL-3 dependent cell that expresses a chimeric receptor including the Tiel extracellular domain and the EpoR intracellular domain to remain viable under conditions in which the concentration of IL-3 is not sufficient to sustain viability of the cell; and evaluating the mammalian cell. In one embodiment, the cell expresses an endogenous Tiel protein. In one embodiment, the cell is an endothelial cell. In one embodiment, the method further includes contacting the mammalian cell with a test compound, other than the ligand. For example, the ligand is an antibody. For example, the ligand includes the HC and LC immunoglobulin variable domains of the E3 or E3b antibody or domains that are at least 90% identical in the CDR regions.

[0106] In another aspect, the invention features a method that includes: contacting a mammalian cell or fraction thereof with an agent that can modulate the activity of Tiel; and evaluating the mammalian cell or fraction thereof. In one embodiment, the agent is contacted to the cell while the cell is living, and the evaluating includes isolating a fraction of the cell. In one embodiment, the agent is a protein, an antibody or a peptide. In one embodiment, the agent includes the HC WO 2006/020706 PCT/US2005/028413 and LC immunoglobulin variable domains of the E3 or E3b antibody or domains that are at least 90% identical in the CDR regions to the E3 or E3b antibody. In one embodiment, the agent includes the HC and LC immunoglobulin variable domains of the B2 or D11 antibody or domains that are at least 90% identical in the CDR regions to the B2 or D11 antibody. In one embodiment, the agent includes the HC and LC immunoglobulin variable domains of the A2, A10, P-B1, P-B3, or P-C6 antibody or domains that are at least 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical% identical in the CDR regions to the A2, Al0, P-B1, P-B3, or P-C6 antibody. In one embodiment, the agent includes the HC and LC immunoglobulin variable domains of the G2 or C7 antibody or domains that are at least 90% identical in the CDR regions to the G2, or C7 antibody. The agent can include other features described herein.

[0107] In another aspect, the invention features a method of evaluating a test compound. The method includes evaluating interaction between an agent that can modulate the activity of Tiel and a protein that includes at least a region of the Tiel extracellular domain in the presence of the test compound. In one embodiment, the agent is a test compound is a small organic compound with molecular weight less than 8000, 7000, 6000, 5000, or 3000 Daltons. For example, the evaluating includes contacting cells that include the protein that includes at least a region of the Tiel extracellular domain with the agent in the presence of the test compound. In another example, the evaluating includes forming a cell-free preparation that includes the protein that includes at least a region of the Tiel extracellular domain, the agent, and the test compound.

[0108] In another aspect, the invention features an artificial protein complex that includes a protein that includes a Tiel extracellular domain and (ii) a Tiel binding protein that can modulate agonize or antagonize) an activity of Tiel. In one embodiment, the ligand is an antibody an antibody described herein). For example, the ligand includes the HC and LC immunoglobulin variable domains of an antibody selected from the group consisting of: E3, E3b, B2, Dll, A2, A10, P-B1, P- B3, P-C6, G2 and C7, or immunoglobulin domains that are at least 90% identical in the CDR regions to the CDR regions of the respective antibody. In one embodiment, the complex is present in a membrane fraction, on a mammalian cell, and/or in a subject.

WO 2006/020706 PCT/US2005/028413 [0109] In another aspect the invention features a method that includes: administering a composition that includes a protein that interacts with Tiel, Tie2, or Ang a protein described herein) to a subject in an amount effective to reduce angiogenesis in the subject or otherwise treat or prevent a disorder in a subject. For example, the protein binds to Tiel, Tie2, or Ang with an affinity KD of less than 10 8 M, 5-10'9 M, 10- 9 M, 10-10 M, 10- 1 M, or 10 12

M.

[0110] In one embodiment, the protein is a Tiel binding protein. The protein can have at least two valencies, each of which binds to Tiel. For example, at least one, two, or all of the valencies can be binding sites that competes with E3 for binding to Tiel. In one embodiment, the protein competes with E3 for binding to Tiel or binds to an epitope that overlaps the epitope bound by E3 on Tiel.

[0111] In one embodiment, the protein comprises a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence. The protein further includes one or more of the following properties: at least one of the variable domain sequences comprising at least one CDR of the E3 antibody; at least one of the variable domain sequences comprising CDR sequences at least 85% identical, in sum, to the CDRs of the corresponding variable domain of the E3 antibody; at least one of the variable domains is at least identical to the corresponding immunoglobulin variable domains of the E3 antibody, and the protein competes with E3 for binding to Tiel or binds to an epitope that overlaps the epitope bound by E3 on Tiel.

[0112] In one embodiment, one or more of the CDRs of the heavy and/or light chain variable domain sequence are human, primate, non-rodent non-mouse or non-rat), or synthetic. In one embodiment, one or more of the framework regions of the heavy and/or light chain variable domain sequence are human, primate, or nonrodent non-mouse or non-rat).

[0113] In one embodiment, the heavy chain includes one or more of the following properties: i) a HC CDR1 that includes an amino acid sequence as follows: (AGSR)-Y-(GVK)-M-(GSVF), (SEQ ID NO:117) (AGSIMRH)-Y-(GVMK)-M-M-SVMFH) (SEQ ID NO:118), or WO 2006/020706 WO 206/00706PCTII§S2005/028413 (AGSIMR]S1T)Y-(AGTVMKPQ)-M-(AGSTVMr~YWV'KI) (SEQ ID NO:119); ii) a HC CDR2 that includes an amino acid sequence as follows: X-I-Y-P-S-G-G-X-T-X-Y-A-D-S-V-K-G (SEQ ID NO: 120), wherein X is any amino acid, (SEQ ID NO: 121), (SEQ ID NO: 122), (GSVW)-I-(SY)-P-S-G-G-(AGVMYWVPQHI)-T-(AGSTLVMYFKI{) (SEQ ID INO: 123); or X-I-Y-P-S-G-G-(WPS)-T-(YVH)-Y-A-D (SEQ ID NO:704), wherein X is any amino acid; iii) a HG CDR3 that includes an amino acid sequence as follows: V-(four or five residues)-F-D-(I/Y) (SEQ ID NO: 124), G-Y-G-P-I-A-P-G-L-D-Y (SEQ ID NO: 125), (SEQ ID NO: 126),

(GVD)-(AGLN)-(LYR)-(GSTLYH)-(GYD)-(AGSYFP)-(SFD)-(AGYD)-

(SEQ ID NO: 127), VNYYDSSGYGPJAPGLDY (SEQ ID NO: 128), or G-X-X-G-(AY)-IF-D-(YI) (SEQ ID NO:705), wherein X is any amino acid.

[01141 In one embodiment, the light chain includes one or more of the following properties: i) a light chain cdrl that includes an amino acid sequence as follows: R-A-S-Q-S-(IV)-S-(SR)-X1 (SEQ ID NO: 129), R-A-S-Q-S-(IIV)-S-S-(YS)-L-(ALN) (SEQ ID NO:706), (SEQ ID NO:707), (SEQ ID NO:708), (SEQ ID NO: 130), (SEQ ID NO: 13 OR (ASN) (SEQ ID NO: 132), wherein Xl can be serine or absent; ii) a LC CDR2 that includes an amino acid sequence as follows: X-A-S-X-R-A-T (SEQ ID NO: 13 wherein X can be any amino acid, (AGD)-A-S-(STN)-R-A-T (SEQ ID NO: 134), WO 2006/020706 WO 206/00706PCTII§S2005/028413 (SEQ ID NO:709), (SEQ ID NO: 13 OR (AGTKDEH)-A-S-(STN)-(LR)-(AVEQ)-(ST) (SEQ ID NO: 136); AND iii) a LC CDR3 that includes an amino acid sequence as follows: Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)-(LWR)-(T1Y)-T (SEQ ID NO: 137), (LQ)-Q-(SYFR)-(GSYN)-(SKN)-(STYW)-{RP)-(LWR.)-(TIY)-T (SEQ ID NO: 138), (SEQ ED NO:710), wherein x is any amino acid, (SEQ ID NO:71 wherein x is any amino acid, (SEQ ID NO: 139), wherein X1 is any amino acid or absent, (L)(Q-SFD-GY)(TK)(TW)(P-IM

R)(I)

(TI) (SEQ lID NO: 140), or

(LQ)-(LRQ)-(SYFRD)-(GSY-N)-(ASTRKN)M-(STYWF)-(SVR-P)-

(ST1LMWRH)-(T1y)-(STI) (SEQ ID NO: 141).

[0115] In one embodiment, the heavy chain includes one or more of the following properties: i) a HC CDRl that includes an amino acid sequence as follows: (AGSIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ ID NO: 118), or (AGSIMRMI)-Y-(AGTVMKPQ)-M-(AGSTVMYWFKH) (SEQ ID NO: 119); ii) a HG CDR2 that includes an amino acid sequence as follows: (SEQ ID NO: 160), (SEQ ID NO:122), or (GV )I(Y-----AVYPH--ASLMFH (SEQ ID) NO:123)-) iii) a HG CDR3 that includes an amino acid sequence as follows: APRGYSYGYYY (SEQ lID NO:712).

[0116] In one embodiment, the light chain includes one or more of the following properties: i) a LC CDRI that includes an amino acid sequence as follows: WO 2006/020706 WO 206/00706PCTII§S2005/028413 R,-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN-(STIRH)-XI -(SYWNH)-(LV)-(ASN) (SEQ ID NO: 132), wherein XI can be serine or absent; ii) a LC CDR2 that includes an amino acid sequence as follows: (TAGD)-A-S-(STN)-(LR)-(AEQ)-(ST) (SEQ ID NO:71 or (AGTKDEH)-A-S-(STN)-(LR)-(AVEQ)-(ST) (SEQ ID NO: 136); and iii) a LC CDR3 that includes an amino acid sequence as follows: Q-Q-(SYFR)- (GSYN)-S-(STYW)-(RP)-(LHW R)-(TlY (SEQ ID NO:714), (LQ)-Q-(SYFR)- (GSYN)-(SK1N)-(STYW)-(RP)-(LHWR)-(TIY (SEQ ID NO:71 or (SYFRD)-(GSYN)-(STRK1')-(STYWF)-(RP)-(ILMWVR1)-(TIY) (SEQ ID NO:71 6).

[0117] In one embodiment, the light chain includes one or more of the following properties: i) a LC CDRl that includes an amino acid sequence as follows: -X2-X3 (SEQ ID NO: 142), or (TV)-(AG)-X1 -X2-X3-Y-X4-S (SEQ ID NO: 143), wherein Xl is any amino acid G or X2 is any amino acid Y or X3 is any amino acid F, N, or X4 is any amino acid aliphatic, V or iii) a LC CDR2 that includes an amino acid sequence as follows: (DE)-V-N-N-R-P-S (SEQ ID NO: 144); (DE)- (VD)-(STDN)-(YRDN)-R-P-S (SEQ lID NO: 145); v) a LC CDR3 that includes an amino acid sequence as follows: (SQ)-S-(SY)-(ASID)-(GSR)-(ST)-(STRN)-(STYRY- (ATLY)-(SVWQ) (SEQ ID NO: 146).

[0118] In one embodiment, the HO CDR2 includes an amino acid sequence as follows: (GV )I(Y--GG(GMWQ)T(GTVIFH--A) D-S-V-K-G (SEQ ID NO: 147)or V-K-G (SEQ lID NO: 148).

[0119] In one embodiment, the HG CDRi amino acid sequences have a length of at least 5 amino acids of which at least 3, 4, or 5 amino acids are identical to the CDRi sequence of the HC of clone E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p- DI12, p-F3, p-174, p-G3, s-AiO0, s-Hi, s-A2, s-B2, s-1B9, s-CIO0, s-C2, s-C7, s-Dl 1, s- Eli, s-G1O, s-H4, or another antibody described herein. In one embodiment, the HC CDR2 amino acid sequences have a length of at least 15, 16, or 17 amino acids of which at least 10, 12, 14, 15, 16, or 17 amino acids are identical to the CDR2 sequence of the HC of clone E3, E3b, G2, p-Al, p-AiO, p-BI, p-B3, p-C 6 p-D12, p- F3, p-F4, p-G3, s-AIO, s-Hi, s-A2, s-B2, s-B9, s-CiO, s-C2, s-C7, s-Dl1, s-Eu s- Gi 0, s-H4, or another antibody described herein. In one embodiment, the HC CDR2 amino acid sequences have a length of at least 17 amino acids of which at least 14, WO 2006/020706 PCT/US2005/028413 16, or 17 amino acids are identical to the CDR2 sequence of the HC of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AO1, s-H1, s-A2, s- B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein. In one embodiment, the HC CDR3 amino acid sequences have a length of at least of at least 7 or 8 amino acids of which at least 5, 6, 7, or 8 amino acids are identical to the CDR3 sequence of the HC of clone E3, E3b, G2, p-Al, pp-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, ss-C2, s-C7, s-D11, s-E11, s-G10, s-H4, or another antibody described herein.

[0120] In one embodiment, the LC CDR1 amino acid sequences have a length of at least 10, 11, or 12 amino acids of which at least 7, 8, 9, 10, or 11 amino acids are identical to the CDR1 sequence of the LC of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s- C7, s-D11, s-E11, s-G10, s-H4, or another antibody described herein. In one embodiment, the LC CDR2 amino acid sequences have a length of at least 6 or 7 amino acids of which at least 5, 6, or 7 amino acids are identical to the CDR2 sequence of the LC of clone E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p- F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D1, s-Ell, ss-H4, or another antibody described herein. In one embodiment, the LC CDR3 amino acid sequences have a length of at least of at least 8, 9, or 10 amino acids of which at least 7, 8, 9, or 10 amino acids are identical to the CDR3 sequence of the LC of clone E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, ss-Hi, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-DIl, s-Ell, s-GO0, s-H4, or another antibody described herein.

[0121] In one embodiment, the amino acid sequence of the HC variable domain sequence is at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to the amino acid sequence of the HC variable domain of clone E3, E3b, G2, p-Al, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s- C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein.

[0122] In one embodiment, the amino acid sequence of the LC variable domain sequence is at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to the amino acid sequence of the LC variable domain of clone E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-Al0, s-H1, s-A2, s-B2, s-B9, s-CO1, s- C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein.

WO 2006/020706 PCT/US2005/028413 [0123] In one embodiment, the amino acid sequences of the HC and LC variable domain sequences are at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to the amino acid sequences of the HC and LC variable domains of a clone selected from the group consisting of E3, E3b, G2, p-Al, p-AlO, p-B1, p-B3, p-C6, p- D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-Dll, s- Ell, s-G10, and s-H4.

[0124] In one embodiment, the amino acid sequences of one or more framework regions FR1, FR2, FR3, and/or FR4) of the HC and/or LC variable domain are at least 70, 80, 85, 90, 92, 95, 97, 98, 99, or 100% identical to corresponding framework regions of the HC and LC variable domains of clone E3, E3b, G2, p-Al, p-AlO, p-Bl, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-H1, s- A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein.

[0125] In one embodiment, the light chain variable domain sequence is human or non-immunogenic in a human. In one embodiment, the heavy chain variable domain sequence is human or non-immunogenic in a human.

[0126] The protein can bind to cells that express Tiel, endothelial cells.

In one embodiment, the protein does not substantially bind does not detectably bind) to platelets.

[0127] In one embodiment, the protein specifically binds to Tiel, it binds with at least a 10, 50, 100, 10 3 or 10 4 fold preference for Tiel relative to another human protein, Tie2, a natural protein other than Tiel that has a Ig-like domain, an EGF-like domain, or fibronectin Type III repeat, or human serum albumin. In one embodiment, the protein binds to a domain of Tiel described herein.

[0128] In one embodiment, the protein is delivered locally. In one embodiment, the protein is delivered systemically.

[0129] In one embodiment, the subject is in need of reduced angiogenesis, or identified as such. For example, the subject has an angiogenesis-related disorder. In another example, the subject has a neoplastic disorder, a metastatic cancer. For example, the subject has an angiogenesis-dependcnt cancer or tumor. The tumor can be a solid tumor, a tumor at least 1, 2, 3, 5, 8 or 10 mm in diameter. In one embodiment, the solid tumor has a hypoxic core. The method can further include WO 2006/020706 PCT/US2005/028413 administering an anti-metabolite 5-FU, with leucovorin), irinotecan, (or other topoisomerase inhibitor), doxorubicin, bevacizumab, or all of these agents. The method can include, prior to administering the antagonist, evaluating the subject and detecting a solid tumor in the subject.

[0130] In another embodiment, the subject has an inflammatory disorder, e.g., rheumatoid arthritis, psoriasis, rheumatoid or rheumatic inflammatory disease, or other chronic inflammatory disorders, such as chronic asthma, arterial or posttransplantational atherosclerosis, and endometriosis.. Other disorders that can be treated include those that have deregulated or undesired angiogenesis, such as ocular neovascularization, retinopathies (including diabetic retinopathy and age-related macular degeneration) hemangioblastoma, hemangioma, and arteriosclerosis.

[0131] In one embodiment, the protein is administered in an amount effective to reduce one or more of the following activities: sprouting, splitting and remodeling of blood vessels. In one embodiment, the protein is administered in an amount effective to reduce vasculogenesis or tubule formation.

[0132] In one embodiment, the method further includes, prior to the administering, identifying the subject as a subject in need of reduced angiogenesis. In one embodiment, the method further includes administering the protein continuously or in separate boluses. In one embodiment, the method further includes monitoring the subject during the course of administration. For example, the monitoring includes imaging blood vessels (locally or throughout) the subject. In another example, the monitoring include evaluating tumor size or tumor load in the subject.

[0133] In another aspect the invention features a method that includes: administering a composition that includes a protein described herein a protein that reduces a Tiel activity) to a subject in an amount effective to reduce a Tiel activity in the subject. The method can include other features described herein.

[0134] In another aspect the invention features a method that includes: administering a composition that includes a protein described herein a protein that can modulate an activity of Tiel) to a subject in an amount effective to modulate endothelial cell activity in the subject. In one embodiment, the protein is delivered into the circulation.

WO 2006/020706 PCT/US2005/028413 [0135] In one embodiment, the composition is effective for sensitizing endothelial cells to a treatment, and providing a treatment to the subject that inhibits, kills, ablates, or otherwise arrests the sensitized endothelial cells.

[0136] In another aspect the invention features a method that includes: (i) contacting the sample (and optionally, a reference, control, sample) with a protein that binds to Tiel, a protein described herein, under conditions that allow interaction of the Tiel-binding protein and the Tiel protein to occur; and (ii) detecting formation of a complex between the Tiel-binding protein, and the sample (and optionally, the reference, control, sample).

[0137] In another aspect the invention features a method that includes: (i) administering to a subject (and optionally a control subject) a Tiel-binding protein an antibody or antigen binding fragment thereof), under conditions that allow interaction of the Tiel-binding protein and the Tiel protein to occur; and (ii) detecting formation of a complex between the Tiel-binding protein and a Tiel molecule of the subject or detecting distribution of Tiel-binding protein or at least one location of the Tiel-binding protein in the subject. In one embodiment, the Tiel-binding protein does not modulate the activity of Tiel. The Tiel-binding protein can be a protein described herein. In one embodiment, the ligand detects activated Tiel.

[0138] An antibody that binds to Tiel is preferably monospecific, a monoclonal antibody, or antigen-binding fragment thereof. For example, the antibody can recognize Tiel on a living cell, an endogenous Tiel molecule or a Tiel molecule that is expressed from a heterologous nucleic acid. In one embodiment, the Tiel-binding protein interacts with primary endothelial cells. The term "monospecific antibody" refers to an antibody that displays a single binding specificity and affinity for a particular target, epitope. This term includes a "monoclonal antibody" which refers to an antibody that is produced as a single molecular species, from a population of homogenous isolated cells. A "monoclonal antibody composition" refers to a preparation of antibodies or fragments thereof of in a composition that includes a single molecular species of antibody. In one embodiment, a monoclonal antibody is produced by a mammalian cell. One or more monoclonal antibody species may be combined.

WO 2006/020706 PCT/US2005/028413 [0139] The Tiel-binding antibodies can be full-length an IgG an IgG1, IgG2, IgG3, IgG4), IgM, IgA IgA1, IgA2), IgD, and IgE) or can include only an antigen-binding fragment a Fab, F(ab') 2 or scFv fragment), it does not include an Fc domain or a CH2, CH3, or CH4 sequence. The antibody can include two heavy chain immunoglobulins and two light chain immunoglobulins, or can be a single chain antibody. The antibodies can, optionally, include a constant region chosen from a kappa, lambda, alpha, gamma, delta, epsilon or a mu constant region gene. A Tiel-binding antibody can include a heavy and light chain constant region substantially from a human antibody, a human IgG1 constant region or a portion thereof.

[0140] In one embodiment, the antibody (or fragment thereof) is a recombinant or modified antibody, a chimeric, a humanized, a deimmunized, or an in vitro generated antibody. The term "recombinant" or "modified" human antibody, as used herein, is intended to include all antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial antibody library, antibodies isolated from an animal a mouse) that is transgenic for human immunoglobulin genes or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant antibodies include humanized, CDR grafted, chimeric, deimmunized, in vitro generated antibodies, and may optionally include constant regions derived from human germline immunoglobulin sequences.

[0141] In one embodiment, the antibody binds to an epitope distinct from an epitope bound by known monoclonal antibodies that bind to Tiel, an antibody described in WO 95/26364, 3C4C7G6 and 10F11G6. In other embodiments, the antibody does not compete with known monoclonal antibodies that bind to Tiel, e.g., 3C4C7G6 and 10F11G6. In still other embodiments, the antibody does not compete with ligand described herein, the E3 antibody.

[0142] Also within the scope of the invention are antibodies or other agents protein or non-protein agents) that bind overlapping epitopes of, or competitively inhibit the binding of the proteins disclosed herein, proteins that bind to Tiel, Tie2, or Ang. For example, the antibodies or other agents bind WO 2006/020706 PCT/US2005/028413 overlapping epitopes of or competitively inhibit the binding of monospecific antibodies, E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p- G3, s-Al0, s-HI, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-Ell, s-G10, s-H4, or another antibody described herein to Tiel, or vice versa the monospecific antibodies competitively inhibiting binding of the ligands). Overlapping epitopes can include at least one amino acid in common. Agents that competitively inhibit binding of one another do not necessarily bind to overlapping epitopes. For example, they may inhibit binding by steric interference or by altering the conformation of Tiel.

[0143] Any combination of binding proteins is within the scope of the invention, two or more antibodies that bind to different regions ofTiel, Tie2, or Ang, antibodies that bind to two different epitopes on the extracellular domain of Tiel, Tie2, or Ang, a bispecific antibody.

[0144] In one embodiment, the Tiel-binding antibody or antigen-binding fragment thereof includes at least one light or heavy chain immunoglobulin (or preferably, at least one light chain immunoglobulin and at least one heavy chain immunoglobulin). Preferably, each immunoglobulin includes a light or a heavy chain variable region having at least one, two and, preferably, three complementarity determining regions (CDRs) substantially identical to a CDR from an anti-Tiel light or heavy chain variable region, respectively, from a variable region of an antibody described herein, E3, E3b, G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-H1, s-A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D 1, s-El 1, ss-H4, or another antibody described herein.

[0145] In one aspect, the invention features an agent an antibody) that decreases endothelial cell activity by increasing Tiel phosphorylation. In one embodiment, the agent decreases endothelial cell differentiation, sprouting, splitting, and tube formation.

[0146] In one aspect, the invention features an agent an antibody) that decreases endothelial cell activity by activating a signaling pathway. In one embodiment, the antibody decreases endothelial cell differentiation, sprouting, splitting, and tube formation. This agent-induced effect can be independent or dependent of Tiel self-association.

WO 2006/020706 WO 206/00706PCTII§S2005/028413 [0147] In one aspect, the invention features an isolated protein that includes a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence, wherein the protein binds to TielI ectodomain and the heavy chain immunoglobulin variable domain sequence includes one or miore of the following properties: i) a HG CDR1 that includes an amino acid sequence of a clone from the group consisting of: M0044-A06; M0044-Al 1; M0044- B04; M0044-1305; M0044-1108; M0044-1309; M0044-131O; M0044-1312; M0044-C07; M0044-D01; M0044-1303; M0044-1703; M0044-F06; M0044-F09; M0044-G06;- M0044-G07; M0044-GI 1; M0044-1-03; M0044-H05; M0044-H07; M0044-H09; M0045-A02; M0045-A04; M0045-1301; M0045-1303; M0045-B11; M0045-C02; M0045-C 11; M0045-C 12; M0045-1301; M0045-D07; M0045-GO1; M0045-G1 0; M0046-Al1; M0046-1306; M0046-1310; M0046-G12; M0046-1103; M0046-H10; M0046-Hl11; M0047-1B03; M0047-DO 1; M0047-D03; M0047-EI10; M0047-G09; M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-13 11; M0053-D03; M0053-D06; M0053-D 12; M0053-E03; M0053-E04; M0053-E08; M0053-1704; M0053-F05; M0053-F06; M0053-F08; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-1308; M0054-C03; M0054-C07; M0054-E04; M0054-GOl; M0054-G05; M0054-Hl10; M0055-A09; M0055-BI 1; M0055-B12; M0055-C05; M0055-C07; M0055-D03; M0055-D06; M0055-D 12; M0055-E04; M0055-E06; M0055-ElO; M0055-E12; M0055-FlO; M0055-G02; M0055-G03; M0055-H04; M0056-AO 1; M0056-A06; M0056-BOS; M0056-1309; M0056-C03; M0056-C04; M0056-EO8; M0056-F01; M0056-F02; M0056-10; M005 6-Fl 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; M0056-H04; M0056-1112; M0057-B05; M0057-H07; M0058-A09; M0058-D04; M0058-E09; M0058-F03; M0058-G03; M0058-1101; M0059-A02; M0059-A06; M0060-1302; M0060-HO 01; M0061 -A03; M006 1-C05; M0061 -C06; M0061-1307; M006 1-G12; M0061 -1109; M0062-A12; M0062-B05;, M0062-B07; M0062-C03;- M0062-D04;- M0062-E02;- M0062-E03; M0062-El 1; M0062-FlO; M0062-G06; and M0062-1101, or a sequence that is at least 70, 75, 80, 85, or 90% identical to such a sequence; ii) a HIC CDR2 that includes an amino acid sequence of a clone from. the group consisting of:. M0044- A06; M0044-Al 1; M0044-B04; M0044-1305; M0044-1308; M0044-1309; M0044-1310; M0044-1312; M0044-C07; M0044-DOl; M0044-E03; M0044-F03; M0044-F06; M0044-1709; M0044-G06; M0044-G07; M0044-GI 1; M0044-H03; M0044-HOS; M0044-H07; M0044-1109; M0045-A02; M0045-A04; M0045-BOI;- M0045-B03; WO 2006/020706 WO 206/00706PCTII§S2005/028413 M0045-BI 1; M0045-C02; M0045-Cl 1; M0045-C12; M0045-DOI; M0045-D07; M0045-G01; M0045-G10; M0046-A11; M0046-B06; M0046-B1O; M0046-G12; M0046-H03; M0046-HI0; M0046-HI1; M0047-B03; M0047-D01; M0047-D03; M0047-E1 0; M0047-G09; M0053-A02; M0053-A03; M0053-AOS; M0053-A09; M0053-B09; M0053-I 1; M0053-D03; M0053-D06; M0053-D12; M0053-E03; M0053-E04; M0053-E08; M0053-F04; M0053-F05; M0053-F06; M0053-F08; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-BO8; M0054-C03; M0054-C07; M0054-E04; M0054-G01; M0054-G05; M0054-H10; M0055-A09; M0055-B 1; M0055-1312; M0055-C05; M0055-C07; M0055-D03; M0055-D06; M0055-D12; M0055-E04; M0055-E06; M0055-E1O; M0055-E12; M0055-F1O; M0055-G02; M005S-G03; M0055-1104- M0056-AOI; M0056-A06; M0056-B08; M0056-B09; M0056-C03; M0056-C04; M0056-E08; M0056-F01; M0056-F02; M0056-F 10; M0056-Fl 1; M0056-G03; M0056-G04; M0056-G08; M0056-G1 2; M0056-J{04; M0056-1112; M0057-1305; M0057-H07; M0058-A09; M0058-D04; M005 8-E09; M0058-1703; MOOS 8-G03; MOOS 8-HOl; M0059-A02; M0059-A06; M0060-B02; M0060-HO1; M0061-A03; M0061-C05; M0061-C06; M0061-F07; M0061-G12; M0061-H09; M0062-A12; M0062-B05; M0062-1307; M0062-C08; M0062-D04; M0062-E02; M0062-E03; M0062-E 11; M0062-F 10; M0062-G06; and M0062-11O1, or a sequence that is at least 70, 75, 80, 85, or 90% identical to such a sequence; iii) a HC CDR3 that includes an amnino, acid sequence of a clone from the group consisting of: M0044-A06; M0044-Al 1; M0044-1304; M0044-B05; M0044- B08; M0044-B09; M0044-B310; M0044-1312; M0044-C07; M0044-DO1; M0044-1103; M0044-F03; M0044-F06; M0044-F09; M0044-G06; M0044-G07; M0044-G 11; M0044-H03; M0044-H05; M0044-H07; M0044-H09; M0045-A02; M0045-A04; M0045-BOl; M0045-B03; M0045-B 11; M0045-C02; M0045-C1 1; M0045-C12; M0045-DO 1; M0045-D07; M0045-GO 1; M0045-G1 0; M0046-Al 1; M0046-1B06; M0046-B 10; M0046-G12; M0046-H03; M0046-HIO; M0046-HI 1; M0047-1303; M0047-DO 1; M0047-D03; M0047-EI 0; M0047-G09; M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-B 11; M0053-D03; M0053-D06; M0053-D12; M0053-E03; M0053-E04; M0053-E08; M0053-F04; M0053-F05; M0053-F06; M0053-FO8; M0053-G04; M0053-G05; M0054-AO8; M0054-B06; M0054-BO8; M0054-C03; M0054-C07; M0054-E04; M0054-GO 1; M0054-G05; M0054-H1O; M0055-A09; M0055-Bl1I; M0055-B12; M0055-G05; M0055-G07; M0055-D03; M0055-D06; M0055-1312; M0055-E04; M0055-E06; M0055-E1O; WO 2006/020706 WO 206/00706PCTII§S2005/028413 M0O55-EI2;- M0055-F1O; M0055-GO2; M0055-G03; M0055-H04; M0056-AO1; M0O56-A06; M0056-1308; M0056-B09; M0056-C03; M0056-C04; M0056-E08; M0056-FOI; M0056-F02; M0056-F1O; M0056-Fl 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; MO056-H04; M0056-Hl 2; M0057-B05; M0057-H07; M0058-A09; M0058-D04; MO058-E09; M0058-F03; M0O58-G03; M0058-H0l; M0O59-A02; M0059-A06; MOO60-B02; M0060-HO1; M0061-A03; M0061-C05; M0061-C06; M0061-1F07; MOO61-G12; M0061-H09; M0062-A12; M0062-B05; M0062-B07; M0062-C08; M0062-D 04; M0062-E02; M0062-E03; M0062-El 1; M0O62-F1O; M0062-G06; and M0062-HOl, or a sequence that is at least 70, 75, or 90% identical to such a sequence.

[0148] In one embodiment, the protein also includes the light chain immunoglobulin variable domain sequence which includes one or more of the following properties: i) a LC CDRl that includes an amino acid sequence of a clone from the group consisting of: M0044-A06; M0044-Al 1; M0044-B04; M0044-B05; M0044-B08; M0044-1B09; M0044-BIO; M0044-B12; M0044-C07; M0044-DO1; M0044-E03; M0044-F03; M0044-F06; M0044-1F09; M0044-G06; M0044-G07; M0044-GI 1; M0044-H13; M0044-H05; M0044-H07; M0044-H09; M0045-A02; M0045-A04; M0045-BO 1; M0045-B03; M0045-B 1; M0045-C02; M0045-C 1; M0045-C12; M0045-DOI; M0045-DO7; M0045-GOI; M0045-G1O; M0046-Al I; M0046-B06; M0046-BIO; M0046-G12; M0046-H03; M0046-H1O; M0046-H1I; M0047-B03; M0047-DOI1; M0047-D03; M0047-E 10; M0047-G09; M005 3-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-B 1 1; M0053-D03; M0053-D06; M0053-D12; M0053-E03; M0053-E04; M0053-E08; M0053-F04; M0053-F05; M0053-F06; M0053-F08; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-1B08; M0054-C03; M0054-C07; M0054-E04; M0054-GO 1; M0054-G05; M0054-H{l M0055-A09; M0055-Bl 1; M0055-B 12; M0055-C05; M005 5-C07; MOOSS -D03; MOOS 5-D06; M0055-D12; M0055-E04; M0055-E06; M0055-E1O; M0055-E12; MOOSS-FlO; M0055-G02; M0055-603; M0055-H04; M005 6-AOl; M0056-A06; M0056-B08; M0056-B09; M0056-C03; M0056-C04; M0056-E08; M0056-FO 1; M0056-F02; M0056-Fl 0; M0056-Fl 1; M0056-G03; M0056-G04; MOOS 6-G08; M0056-G1 2; M0056-H04; MOOS 6-Hi 2; M0057-BOS; M0057-HO7; M0058-A09; MOO58-D04; M0058-E09; M005 8-F03; M005 8-603; M005 8-HO 1; M005 9-A02; M0059-A06; M0060-B02; M0060-HO1; M006 1-A03; WO 2006/020706 WO 206/00706PCTII§S2005/028413 M0061I-CO5; M0061-C06; M006 1-F07; M006 1-Gi 2; M0061 -H09; M0062-A1 2; M0062-B05; M0062-B07; M0062-C08; M0062-D04; M0062-E02; M0062-E03; M0062-El11; M0062-F1O; M0062-G06; and M0062-HOl, or a sequence that is at least 75, 80, 85, or 90% identical to such a sequence; ii) a LC CDR2 that includes an amino acid sequence of a clone from the group consisting of: M0044-A06; M0044- All M0044-B04; M0044-B05; M0044-B08; M0044-B09; M0044-B 10; M0044-B 12; M0044-C07; M0044-DOl; M0044-E03; M0044-F03; M0044-F06; M0044-1F09; M0044-G06; M0044-G07; M0044-GI 1; M0044-H03; M0044-1105; M0044-L{07; M0044-H09; M0045-A02; M0045-A04; M0045-13O1; M0045-B03; M0045-Bl 1; M0045-C02; M0045-C 1I; M0045-CI 2; M0045-DO 1; M0045-D07; M0045-GO1; M0045-GlO0; M0046-Al 1; M0046-B06; M0046-B 10; M0046-GI12; M0046-1103; M0046-HlO0; M0046-HI11; M0047-B03; M0047-DOl; M0047-D03; M0047-ELO; M0047-G09; M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-Bl 1; M0053-D03; M0053-D06; M0053-1312; M0053-E03; M0053-E04; M0053-E08; M0053-F04; M0053-F05; M0053-F06; M0053-F08; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-B08; M0054-C03; M0054-C07; M0054-E04; M0054-GOl; M0054-G05; M0054-HlO; M0055-A09; M0055-Bl1 M0055-B12; M0055-C05; M0055-C07; M0055-D03; M0055-D06; M0055-D12; M0055-E04; M0055-E06; M0055-ElO; M0055-E12; M0OSS-FlO; M0055-G02; MOOS 5-G03; M0055-H04; M0056-AO 1; M0056-A06; M0056-B08; M0056-B09; M0056-C03; M0056-C04; M0056-E08; M0056-FO1; M0056-F02; M0056-FI 0; M0056-Fl 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; M0056-1104; M0056-1 2; M0057-B05; M0057-1107; MOOS 8-A09; MOOS 8-D04; M0058-E09; M0058-F03; M005 8-G03; M0058-HO1; M0059-A02; M0059-A06; M0060-B02; M0060-HOl; M006 1-A03; M0061 -C05; M0061 -C06; M0061-1707; M006 1-G 12; M0061-1109; M0062-A12; M0062-B05; M0062-B07; M0062-COS; M0062-D04; M0062-E02; M0062-E03; M0062-E11; M0062-FlO; M0062-G06; and M0062-I, or a sequence that is at least 70, 75, 80, 85, or 90% identical to such a sequence; iii) a LC CDR3 that includes an amino acid sequence of a clone from the group consisting of: M0044-A06; M0044-Al 1; M0044-1304; M0044-13O5; M0044-B08; M0044-B09; M0044-11; M0044-B12; M0044-C07; M0044-DOl; M0044-E03; M0044-F03; M0044-1706; M0044-F09; M0044-G06; M0044-G07; M0044-GI 1; M0044-1103; M0044-1-05; M0044-H07; M0044-H09; M0045-A02; M0045-A04; M0045-BOl; M0045-1303; M0045-BI 1; M0045-C02; M0045-C1 1; M0045-C12; M0045-DO1; WO 2006/020706 WO 206/00706PCTII§S2005/028413 M0045-D07; M0045-GO1; M0045-G1O; M0046-A1I; M0046-B06; M0046-1310; M0046-G12; M0046-1103; M0046-H1O; M0046-HI1; M0047-1303; M0047-DO1; M0047-D03; M0047-ElO; M0047-G09; M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-B 11; M0053-D03; M0053-D06; M0053-D 12; M0053-E03; M0053-E04; M0053-E08; M0053-FO4; M0053-F05; M0053-F06; M0053-F08; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-1308; M0054-C03; M0054-C07; M0054-E04; M0054-GO1; M0054-G05; M0054-HIO; M0055-A09; M0055-B 11; M0055-B 12; MOOSS-CO5; M0055-C07; M0055-D03; M0055-D06; M0055-D 12; M005 5-E04; M0055-E06; MOOSS-El 0; M0055-E1 2; M0055-FIO; M0055-G02; M0055-G03; M0055-H04; M0056-AO1; M0056-A06; M0056-B08; M0056-B09; M0056-C03; M0056-C04; M0056-E08; M0056-FOI; M0056-F02; M0056-F 10; M0056-Fl 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; M0056-1104; M0056-H12; M0057-B05; M0057-H07; M0058-A09; M0058-D04; M0058-E09; M0058-1703; M0058-G03; M0058-HO 1; M0059-A02; M0059-A06; M0060-1302; M0060-HO1; M0061-A03; M0061-C05; M0061-C06; M0061-F07; M006 l-G12; M006 1-H09; M0062-A12; M0062-1305; M0062-B07; M0062-C08; M0062-D04; M0062-E02; M0062-E03; M0062-El 1; M0062-F M0062-G06; and M0062-1101, or a sequence that is at least 70, 75, 80, 85, or identical to such a sequence.

[0149] In one- embodiment, the protein includes the amino acid sequence of the HC variable domain sequence which is at least 85, 90, 95, 98, or 99% identical to the amino acid sequence of the HC variable domain of clone M0044-A06; M0044- All1; M0044-1304; M0044-B05S; M0044-1B08; M0044-B09; M0044-BIO; M0044-B 12; M0044-C07; M0044-DOlI; M0044-E03;- M0044-F03; M0044-F06; M0044-F09; M0044-G06; M0044-G07; M0044-Gl 1; M0044-H03; M0044-H05; M0044-H07; M0044-H09; M0045-A02; M0045-A04; M0045-BOl; M0045-B03; M0045-Bl11; M0045-C02; M0045-C 11; M0045-Cl 2; M0045-13O1; M0045-D07; M0045-GO1; M0045-G1O; M0046-AI1; M0046-B06; M0046-1310; M0046-G12; M0046-H03; M0046-11; M0046-Hl11; M0047-1B03; M0047-DO1; M0047-D03; M0047-El10; M0047-G09; M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-P09; M0053-BI 1; M0053-D03; M0053-D06; M0053-1312; M0053-1E03; M0053-E04;7 M0053-E08; M0053-F04; M0053-F05; M0053-F06; M0053-FOS; M0053-G04; M0053-G05; M0054-A08; M0054-1306; M0054-B08; M0054-C03; M0054-C07; WO 2006/020706 WO 206/00706PCTII§S2005/028413 M0054-E04;. M0054-GO 1; M0054-G05; M0054-H1 0; M0055-A09; MOOSS-Bi 1; M005 5-B 12; M0055-C05; M0055-C07; M0055-D03; M0055-D06; M0055-Dl2; M0055-E04; M0055-E06; M0055-E1O; MOOS 5-E12; M0055-F1O; M0055-G02; M0055-G03; M0055-H04; M0056-AO1; M0056-A06; M0056-B08; M0O56-BO9; M0056-C03; M0056-C04; M0056-EO8; M0056-FOl; M0056-F02; M0056-F1O; M0056-F1 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; M0056-H04; M0056-H12; M0057-B05; M0057-H07; M0058-A09; M0058-D04; M0058-E09; M0058-F03; M0058-G03; M0058-HO1; M0059-A02; M0059-A06; M0060-B02; M0060-HO1; M0061I-A03; M0061 -CO5; M0061 -C06; M006 1-F07; M0061 -G12; M0061-1109; M0062-A12; M0062-B05; M0062-B07; M0062-C08; M0062-D04; M0062-E02; M0062-E03; M0062-E1 1; M0062-F1O; M0062-G06; or M0062-HO1.

[0150] In one embodiment, the protein includes the amino acid sequence of the LC variable domain sequence which is at least 85, 90, 95, 98, or 99% identical to the amino acid sequence of the LC variable domain of clone M0044-A06; M0O44- All; M0044-B04; M0044-B05; M0044-BOS; M0044-B09; M0044-BI10; M0044-B 12; M0044-C07; M0044-DO 1; M0044-E03; M0044-F03; M0044-F06; M0044-F09; M0044-G06; M0044-G07; M0044-Gl M0044-H03; M0044-1105; M0044-1107; M0044-H09; M0045-A02; M0045-A04; M0045-BOI; M0045-B03; M0045-B 11; M0045-C02; M0045-Cl 1; M0045-C12; M0045-DOl; M0045-D07; M0045-GO1; M0045-G1O; M0046-Al1; M0046-1B06; M0046-B1O; M0046-G12; M0046-1103; M0046-Hl 0; M0046-Hl 1; M0047-B03; M0047-DOl; M0047-D03; M0047-ElO; M0047-609; M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-B 11; M0053-D03; M0053-D06; M0053-D12; M0053-E03; M0053-E04; M0053-EO8; M0053-F04; M0053-F05; M0053-F06; M0053-FO8; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-BO8; M0054-C03; M0054-C07; M0054-E04; M0054-GOl; M0054-G05; M0054-H10; M0055-A09; M0055-B 11; M0055-B 12; MOOSS-CO5; M0055-C07; M0055-D03; M0055-D06; M0055-D12; M0055-E04; M0055-E06; MOOSS-EIO; M0055-E12; M0055-F1O; M0055-G02; M0055-G03; M0055-H04; M0056-AO1; M0056-A06; M0056-B08; M0056-B09; M0056-C03; M0056-C04; M0056-E08; M0056-FO1; M0056-F02; MOOS 6-Fl 0; M0056-F 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; M0056-H04; M0056-H12; M0057-BO5; M0057-H07; MOOS 8-A09; MOOS 8-D04; MOOS 8-E09; M0058-F03; M0058-G03; M0058-HO1; M0059-A02; M0059-A06; M0060-B02; WO 2006/020706 PCT/US2005/028413 M0060-II01; M0061-A03; M0061-C05; M0061-C06; M0061-F07; M0061-G12; M0061-H09; M0062-A12; M0062-B05; M0062-B07; M0062-C08; M0062-D04; M0062-E02; M0062-E03; M0062-E11; M0062-F10; M0062-G06; or M0062-H01.

[0151] An antibody or other binding protein a Tiel-binding protein, Tie2-binding protein, or Ang binding protein) described herein can be administered to a subject or used in vitro in non-derivatized or unconjugated forms. In other embodiments, the binding protein can be derivatized, modified or linked to another functional molecule, another protein HSA, an Fc domain, etc.), a polymer PEG) isotope, cell, or insoluble support. For example, the binding protein can be functionally linked by chemical coupling, genetic fusion, non-covalent association or otherwise) to one or more other molecular entities, such as an antibody if the protein is an antibody to form a bispecific or a multi-specific antibody), a toxin, a radioisotope, a therapeutic a cytotoxic or cytostatic) agent or moiety, among others. For example, the binding protein can be coupled to a radioactive ion an or p-emitter), iodine (1311 or 1251), yttrium 90 lutetium 1 77 Lu), actinium 22 5 Ac), rhenium (1' 6 Re), or bismuth 212 Bi or 21 3 Bi).

[0152] In another aspect, the invention features a nucleic acid that includes a coding sequence that encodes a polypeptide comprising an immunoglobulin heavy or light chain variable domain that binds to Tiel, an immunoglobulin heavy or light chain variable domain described herein. For example, the nucleic acid can include a particular nucleic acid sequence described herein, a nucleic acid that is at least 75, 90, 95, 96, 97, 98, or 99% identical to a nucleic acid sequence described herein a particular nucleic acid sequence), or a nucleic acid that specifically hybridizes under conditions described herein, high stringency conditions) to a nucleic acid sequence described herein a particular nucleic acid sequence, a nucleic acid encoding one or more variable domains of M0044-A06; M0044-A11; M0044- B04; M0044-B05; M0044-B08; M0044-B09; M0044-B10; M0044-B12; M0044-C07; M0044-D01; M0044-E03; M0044-F03; M0044-F06; M0044-F09; M0044-G06; M0044-G07; M0044-G11; M0044-H03; M0044-H05; M0044-H07; M0044-H09; M0045-A02; M0045-A04; M0045-B01; M0045-B03; M0045-B11; M0045-C02; M0045-C11; M0045-C12; M0045-D01; M0045-D07; M0045-G01; M0045-G10; M0046-A11; M0046-B06; M0046-B10; M0046-G12; M0046-H03; M0046-H10; M0046-H11; M0047-B03; M0047-D01; M0047-D03; M0047-E10; M0047-G09; WO 2006/020706 WO 206/00706PCTII§S2005/028413 M0053-A02; M0053-A03; M0053-A05; M0053-A09; M0053-B09; M0053-Bl 1; M0053-D03; M0053-D06; M0053-D12; M0053-E03; M0053-E04; M0053-E08; M0053-F04; M0053-F05; M0053-P06; M0053-F08; M0053-G04; M0053-G05; M0054-A08; M0054-B06; M0054-B08; M0054-C03; M0054-C07; M0054-E04; M0054-G0 1; M0054-G05; M0054-Hl 0; MOOS 5-A09; M0055-Bl I1; MOOS 5-Bi 2; M0055-C05; M0055-C07; M005 5-D03; M0055-D06; M0055-D 12; M005 5-E04; M0055-E06; M0055-E1O; M0055-E12; MOOSS-FlO; M0055-G02; M0055-G03; MOOS 5-HO4; M0056-AOI; M0056-A06; M0056-B08; M0056-B09; M0056-G03; M0056-C04; M0056-E08; M0056-FO1; M0056-F02; M0056-F1 0; M0056-F 1; M0056-G03; M0056-G04; M0056-G08; M0056-G12; M0056-1104; M0056-H1 2; M0057-B05; M0057-1{07; M005 8-A09; M005 8-D04; MOOS 8-E09; M0058-F03; M0058-G03; MO058-HO1; 1V0059-A02; M0059-A06; M0060-B02; M0060-HO1; M006 1-A03; M006 1-C05; M0061 -C06; M0061 -F07; M006 1-012; M0061 -119; M0062-A12; M0062-B05; M0062-BO7; M0062-C08; M0062-D04; M0062-EO2; M0062-E03; M0062-El 1; M0062-F1O; M0062-G06; or M0062-1101), or fragments thereof CDR-coding fragments).

[01531 A nucleic acid described herein can farther include a promoter operably linked to the coding sequence. A nucleic acid can include a first and second coding sequence, wherein the first coding sequence encodes a polypeptide that includes an inumunoglobulin heavy chain variable domain and the second coding sequence encodes a polypeptide that includes an imimunoglobulin light chain variable domain.

[0154] In another aspect, the invention features a host cell that contains a first nucleic, acid encoding a polypeptide comprising a heavy chain variable region and a second nucleic acid encoding a polypeptide comprising a light chain variable region.

The heavy chain variable region and the light chain variable region can associate to form a Tiel binding protein. These variable regions can have one or more properties described herein, at least 75, 80, 85, 90, 95, 96, 97, 98, or 99% identity to a sequence described herein. The invention also includes a method of providing a Tielbinding antibody. The method can include providing a host cell described herein; and expressing said first and second nucleic acids in the host cell under conditions that allow assembly of said light and heavy chain variable regions to form an antigen binding protein that interacts with Tiel.

WO 2006/020706 PCT/US2005/028413 [0155] In another aspect, the invention provides compositions, e.g., pharmaceutical compositions, which include a pharmaceutically acceptable carrier, excipient or stabilizer, and at least one of the Tiel-binding proteins antibodies or fragments thereof) described herein. In one embodiment, the compositions, the pharmaceutical compositions, include a combination of two or more of the aforesaid Tiel-binding proteins.

[0156] In another aspect, the invention features a kit that includes a Tielbinding antibody (or fragment thereof), a Tiel-binding antibody (or fragment thereof) as described herein, for use alone or in combination with other therapeutic modalities, a cytotoxic or labeling agent, a cytotoxic or labeling agent as described herein, along with instructions on how to use the Tiel antibody or the combination of such agents to treat, prevent or detect a Tiel-related disorder, an endothelial cell related disorder, rheumatoid arthritis or metastatic cancer.

[0157] In another aspect, the binding protein that binds to Tiel is a polypeptide that is not an immunoglobulin. For example, the polypeptide can be of variable length, 4 to 100 amino acid residues in length, preferably 5 to 75, 6 to or 7 to 40 amino acid residues in length, or more preferably 8 to 30 or 10 to amino acid residues in length. In some embodiments, the polypeptide includes nonstandard or synthetic amino acid residues, norleucine, selenocysteine, pyrrolysine, etc. In some embodiments, the polypeptide includes cross-linking groups, two cysteine residues that can form a disulfide bond or some other type of chemical cross-linking moieties that can be used to cyclize the peptide. In other preferred embodiments, the polypeptide can be modified, using polyethylene glycol or fusion to a soluble protein, to increase the solubility or circulatory halflife of the polypeptide.

[0158] The target-binding protein can be physically associated with fused to) another protein, a protein that does not bind to the target, to the amino or carboxy terminus. For example, the target-binding protein can be associated with fused to) a protein that increases serum residence or alters stability, an albumin, a serum albumin, HSA (human serum albumin). In another example, the target binding protein is physically associated with fused to) a moiety that facilitates purification, a purification tag such as His, PEG, or to a functional moiety, Fc.

WO 2006/020706 PCT/US2005/028413 [0159] In another aspect, the invention features a method of identifying a protein that specifically binds to Tiel. In preferred embodiments, the invention includes: providing a Tiel antigen; providing a display library a phage display library member); identifying a member present in the library, wherein the member expresses a protein that specifically binds to the Tiel antigen. The term "Tiel antigen" refers to any antigenic fragment of Tiel that is at least 8 amino acids in length. For example, a Tiel antigen can include a fragment of the Tiel ectodomain, a fragment that includes a folded protein domain such as a fragment described herein. In some embodiments, the Tiel antigen is of human origin and includes, e.g., the extracellular domain of human Tiel or a fragment thereof a fragment described herein. The Tiel antigen can be a recombinant polypeptide optionally fused to another polypeptide, a Fc domain, or it can be a cell that expresses Tiel on its surface an endothelial cell). In other preferred embodiments, the Tiel antigen has an activated conformation, the Tiel antigen is a dimeric conformation or a conformation stabilized by the E3 or E3b antibody described herein.

[0160] The methods described here are, for example, applicable to libraries that are based on bacteriophage with a substantially complete genome including a modified gene III) and to libraries that are based on bacteriophage particles that include a phagemid nucleic acid. The terms "bacteriophage library member" and "phage" encompass members of both types of libraries. The term "bacteriophage particle" refers to a particle formed of bacteriophage coat proteins that packages a nucleic acid. The packaged nucleic acid can be a modified bacteriophage genome or a phagemid, a nucleic acid that includes a bacteriophage origin of replication but lacks essential phage genes and cannot propagate in E. coli without help from "helper phage" or phage genes supplied in trans.

[0161] In other embodiments, the invention features a method of identifying a protein that specifically binds to Tiel. The method includes: providing a Tiel antigen an region of the Tiel ectodomain); immunizing a non-human animal with the Tiel antigen; and isolating a cell that produces a imnnnunoglobulin that interacts with Tiel. For example, the method can include producing hybridoma cells from the spleen of the animal an immunized mouse); and identifying individual WO 2006/020706 PCT/US2005/028413 hybridoma cell lines expressing an antibody that specifically binds to the Tiel antigen. For example, the [0162] In preferred embodiments, the Tiel antigen is of human origin and includes, the extracellular domain of human Tiel or some fragment thereof, e.g., the HA binding domain of Tiel. The Tiel antigen can be a recombinant polypeptide optionally fused to another polypeptide, a purification handle, or it can be a cell that expresses Tiel an endothelial cell) on its surface. In other preferred embodiments, the Tiel antigen has an activated conformation, dimerized.

[0163] In preferred embodiments, the methods further include isolating a nucleic acid molecule from the identified phage or hybridoma, wherein the nucleic acid molecule encodes the polypeptide or antibody that specifically binds to the Tiel antigen. The isolated nucleic acid molecules can be used to produce therapeutic agents, as described herein.

[0164] In another aspect, the invention features nucleic acids that encode proteins identified by the methods described herein. In preferred embodiments, the nucleic acids include sequences encoding a heavy and light chain immunoglobulin or immunoglobulin fragment described herein. For example, the invention features, a first and second nucleic acid encoding a heavy and light chain variable region, respectively, of a Tiel-binding antibody molecule as described herein. Sequences encoding a heavy and light chain that function together can be present on separate nucleic acid molecules or on the same nucleic acid molecule. In another aspect, the invention features host cells and vectors containing a nucleic acid described herein.

[0165] In yet another aspect, the invention features a method of producing a Tiel-binding antibody, or antigen-binding fragment thereof. The method includes: providing a host cell that contains a first nucleic acid encoding a polypeptide comprising a heavy chain variable region, a heavy chain variable region as described herein; providing a second nucleic acid encoding a polypeptide comprising a light chain variable region, a light chain variable region as described herein; and expressing said first and second nucleic acids in the host cell under conditions that allow assembly of said light and heavy chain variable regions to form an antigen binding protein that interacts with Tiel. The first and second nucleic acids can be linked or unlinked, expressed on the same or different vector, respectively. The WO 2006/020706 PCT/US2005/028413 nrst ani second nucleic acids can be components of the same molecule or can reside on different molecules different chromosomes or plasmids).

[0166] The host cell can be a eukaryotic cell, a mammalian cell, an insect cell, a yeast cell, or a prokaryotic cell, E. coli. For example, the mammalian cell can be a cultured cell or a cell line. Exemplary mammalian cells include lymphocytic cell lines NSO), Chinese hamster ovary cells (CHO), COS cells, HEK294, oocyte cells, and cells from a transgenic animal, mammary epithelial cell. For example, nucleic acids encoding the antibodies described herein can be expressed in a transgenic animal. In one embodiment, the nucleic acids are placed under the control of a tissue-specific promoter a mammary specific promoter) and the antibody is produced in the transgenic animal. For example, the antibody molecule is secreted into the milk of the transgenic animal, such as a transgenic cow, pig, horse, sheep, goat or rodent. To produce a single chain antibody, the nucleic acid is configured to encode a single polypeptide that comprises both the heavy and light chain variable domains.

[0167] Tiel has been found to be overexpressed in association with a wide range of cancers. Targeting Tiel on the tumor vasculature with Tiel-binding proteins antibodies) can be used to inhibit, destroy, or otherwise antagonize the vasculature so that tumor growth and metastasis is reduced. The proteins can be, for example, associated with a toxic payload or can mediate direct functional inhibition.

Proteins proteins that have an Fc domain) that can cause ADCC can also be used.

[0168] In another aspect, the invention features a method of inhibiting an activity of a cell, an endothelial cell, proliferation, adhesion, growth or survival of a cell, an endothelial cell, an endothelial cell in the vicinity of a cancer, a tumor. Exemplary methods include contacting the cell with a Tiel binding protein, in an amount sufficient to inhibit the adhesion, migration, growth or proliferation of the cell. Methods of administering a Tiel binding protein can be used, for example, to treat or prevent a disorder, an inflammatory disorder rheumatoid arthritis, lupus, restenosis, psoriasis, graft v. host response, or multiple sclerosis), or a cancerous disorder a malignant or metastatic disorder), by administering to a subject an experimental animal or a human patient) a Tielbinding protein in an amount effective to treat or prevent such disorder.

WO 2006/020706 PCT/US2005/028413 [0169] A Tie 1-binding protein can be used to treat or prevent angiogenesisrelated disorders, particularly angiogenesis-dependent cancers and tumors.

Angiogenesis-related disorders include, but are not limited to, solid tumors; tumor metastasis; benign tumors hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; rheumatoid arthritis); psoriasis; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy ofprematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis; Osler-Webber Syndrome; myocardial angiogenesis; plaque neovascularization; telangiectasia; hemophiliac joints; angiofibroma; and wound granulation.

[0170] "Angiogenesis-dependent cancers and tumors" are cancers tumors that require, for their growth (expansion in volume and/or mass), an increase in the number and density of the blood vessels supplying then with blood. In one embodiment a Tiel-binding protein causes regression of such cancers and tumors.

"Regression" refers to the reduction of tumor mass and size, a reduction of at least 2, 5, 10, or [0171] In addition, Tiel and Tie2 are also expressed in hematopoietic cells.

(Kukk et al (1997) Br. J Haematol. 98: 195; Iwama et al (1993) Biochem. Biophys.

Res. Commun. 195: 301). Accordingly, in another embodiment, a Tiel-binding protein is used to treat hematopoietic conditions, hematopoietic cancers.

Examples of hematopoietic cancers include: cancers derived from hyperplastic/neoplastic cells of hematopoietic origin, cells arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Exemplary cancers include acute promyeloid leukemia (APML), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia non-Hodgkin's lymphoma, peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma (ATL), cutaneous Tcell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), B cell chronic lymphocytic leukemia, myelodysplastic syndrome, and Hodgkin's disease.

[0172] In another aspect, the invention features a method of contacting a cell (in vitro, ex vivo, or in vivo), an endothelial cell, an endothelial cell in the vicinity of a cancer, a tumor. The method can include providing an agent a WO 2006/020706 PCT/US2005/028413 protein) that interacts with Tiel, a protein described herein, and contacting the cell with the protein, in an amount sufficient to form at least one detectable ligand-cell complex. The protein can include, for example, a label or cytotoxic entity, an immunoglobulin Fc domain or a cytotoxic drug.

[0173] In another aspect, the invention features administering the agent described herein as an adjuvant therapy, to a subject. The adjuvant therapy can be a post-operative therapy that is administered to the subject after the subject has undergone surgery to remove all or part of a tumor after surgery to treat glioblastoma or colorectal, breast, or lung cancer). For example, the agent is a protein that inhibits Tie complex formation, promotes Tiel homodimerization, or increases Tiel phosphorylation. For example, the agent is a protein that binds Tiel an anti-Tiel antibody). In one embodiment, the agent is administered within 6, 12, 24, 48, or 100 hours of surgery. The agent can be administered before as well as after surgery.

[0174] An exemplary agent is a Tiel binding agent that includes a heavy chain variable domain sequence that is at least 85, 90, 95, 98, 99%, or 100% identical to the heavy chain variable domain of the E3 antibody and a light chain variable domain sequence that is at least 85, 90, 95, 98, 99%, or 100% identical to the light chain variable domain of the E3 antibody; a heavy chain variable domain sequence and a light chain variable domain sequence that form an antigen binding site that competes with E3 for binding to Tiel; or one, two, or three, of the CDRs of the heavy chain variable domain of the E3 antibody, and one, two, or three of the CDRs of the light chain variable domain of the E3 antibody. Other Tiel binding agents described herein can also be used, a Tiel binding agent that includes a heavy chain variable domain sequence that is at least 85, 90, 95, 98, 99%, or 100% identical to the heavy chain variable domain ofM0059A02, M0045A02*, M0054G05, M0053F05, M0053G05, M0061C06, M0045B01, M0046G12, M0046H11, M0053A02, M0053A05, M0046B06, M0044B10, M0044B08, M0056G08, M0045B03, M0053F04, M0055E10, M0060H01, M0054H10, or M0058F03, and a light chain variable domain sequence that is at least 85, 90, 95, 98, 99%, or 100% identical to the light chain variable domain of M0059A02, M0045A02*, M0054G05, M0053F05, M0053G05, M0061C06, M0045B01, M0046G12, M0046H 11, M0053A02, M0053A05, M0046B06, M0044B10, WO 2006/020706 PCT/US2005/028413 M0044B08, M0056G08, M0045B03, M0053F04, M0055E10, M0060H01, M0054H10, or M0058F03.

[0175] In another aspect, the invention features a method of treating, e.g., inhibiting, ablating or killing, a cell or impairing at least one activity of the cell. The method includes providing a Tiel-binding protein, e.g. a ligand described herein, and contacting the cell with the protein, in an amount sufficient to impair at least one activity of the cell, inhibit, ablate or kill the cell. The contacting can be in vitro or in vivo. For example, the cell can be, an endothelial cell, an endothelial cell in the vicinity of a cancer, a tumor. The protein can include a cytotoxic entity.

Methods of administering a Tiel binding protein or other agent described herein can be used, for example, to treat or prevent a disorder, a endothelial cell-based disorder, a blood vessel disorder, wound healing, or a cancerous disorder a malignant or metastatic disorder), by administering to a subject an experimental animal or a human patient) a Tiel-binding protein in an amount effective to treat or prevent such disorder.

[0176] A Tiel binding protein or other agent described herein can be used on cells in culture, e.g. in vitro or ex vivo. For example, an endothelial cell, an endothelial cell in cancer biopsy, can be cultured in vitro in culture medium and the contacting step can be effected by adding the Tiel-binding protein to the culture medium. The method can be performed on cells cancerous or metastatic cells) present in a subject, as part of an in vivo therapeutic or prophylactic) protocol.

For in vivo embodiments, the contacting step is effected in a subject and includes administering the Tiel-binding protein to the subject under conditions effective to permit both binding of the protein to the cell, and the inhibition of adhesion, migration, growth or proliferation of the cell.

[0177] A Tiel binding protein or other agent described herein can be used to treat or prevent cancerous disorders, including hematopoietic cancers, solid tumors, soft tissue tumors, and metastatic lesions, particularly tumors that require a blood supply or angiogenesis. Examples of solid tumors include malignancies, e.g., sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal colon), and genitourinary tract renal, urothelial cells), pharynx, as well as adenocarcinomas which include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver WO 2006/020706 PCT/US2005/028413 cancer, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus. The subject can be a mammal, a primate, preferably a higher primate, a human a patient having, or at risk of, a disorder described herein, an endothelial cell-based disorder, cancer).

[0178] The Tiel-binding antibody or fragment thereof, a Tiel-binding antibody or fragment thereof as described herein, can be administered to the subject systemically orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intranasally, transdermally, or by inhalation), topically, or by application to mucous membranes, such as the nose, throat and bronchial tubes.

[0179] The methods can further include the step of monitoring the subject, for a reduction in one or more of: a reduction in tumor size; reduction in cancer markers, levels of cancer specific antigen; reduction in the appearance of new lesions, in a bone scan; a reduction in the appearance of new disease-related symptoms; or decreased or stabilization of size of soft tissue mass; or any parameter related to improvement in clinical outcome. The subject can be monitored in one or more of the following periods: prior to beginning of treatment; during the treatment; or after one or more elements of the treatment have been administered. Monitoring can be used to evaluate the need for further treatment with the same Tiel-binding protein or for additional treatment with additional agents. Generally, a decrease in one or more of the parameters described above is indicative of the improved condition of the subject. Information about the monitoring can be recorded, in electronic or digital form.

[0180] The Tiel-binding protein can be used alone in unconjugated form to thereby inhibit adhesion, migration, or extravasation or the Tiel-expressing cells, or ablate or kill the Tiel-expressing cells. If the Tiel-binding protein is an antibody, the ablation or killing can be mediated, by an antibody-dependent cell killing mechanisms such as complement-mediated cell lysis and/or effector cell-mediated cell killing. In other embodiments, the Tiel-binding protein can be bound physically associated, either directly or indirectly, covalently or non-covalently) to a substance, a cytotoxic agent or moiety, effective to kill or ablate the Tielexpressing cells. For example, the Tiel-binding protein can be coupled to a WO 2006/020706 PCT/US2005/028413 radioactive ion an or p-emitter), iodine 1I or 1251), yttrium 90

Y),

lutetium 7 actinium 225 Ac), or bismuth 21 2 Bi or 213 Bi).

[0181] The methods and compositions described herein can be used in combination with other therapeutic modalities. In one embodiment, the methods include administering to the subject a Tiel-binding protein, a Tiel-binding antibody or fragment thereof, in combination with a cytotoxic agent, in an amount effective to treat or prevent the disorder. The Tiel-binding protein and the cytotoxic agent can be administered simultaneously or sequentially. In other embodiments, a Tiel binding protein or other agent described herein is used in combination with surgical and/or radiation procedures.

[0182] In another aspect, the invention features methods for detecting the presence of a Tiel protein or a cell expressing Tiel an endothelial cell) in a sample, in vitro a biological sample, a tissue biopsy, a cancerous lesion).

The subject method can be used to evaluate, diagnose or stage a disorder described herein, a cancerous disorder. The method includes: contacting the sample (and optionally, a reference, control sample) with a Tiel-binding protein, as described herein, under conditions that allow interaction of the Tiel-binding protein and the Tiel protein to occur; and (ii) detecting formation of a complex between the Tiel-binding protein, and the sample (and optionally, the reference, e.g., control, sample). Formation of the complex is indicative of the presence of Tiel protein activated Tiel protein), and can indicate the suitability or need for a treatment described herein. For example, a statistically significant change in the formation of the complex in the sample relative to the reference sample, the control sample, is indicative of the presence of Tiel activated Tiel) in the sample.

[0183] In yet another aspect, the invention provides a method for detecting the presence of Tiel activated Tiel) in vivo in vivo imaging in a subject). The subject method can be used to evaluate, diagnose, localize, or stage a disorder described herein, a cancerous disorder. The method includes: administering to a subject (and optionally a control subject) a Tiel-binding protein an antibody or antigen binding fragment thereof), under conditions that allow interaction of the Tiel-binding protein and the Tiel protein to occur; and (ii) detecting formation of a complex between the Tiel-binding protein and Tiel, wherein a statistically significant WO 2006/020706 PCT/US2005/028413 change in the formation of the complex in the subject relative to the reference, e.g., the control subject or subject's baseline, is indicative of the presence of the Tiel. The presence of Tiel in particular locations within a subject can be indicative of an endothelial-cell related disorder, an angiogenesis-related disorder, a cancer, metastatic cancer, or other angiogenesis-related disorder described herein.

[0184] Tumor cells can express Tiel. In one aspect, the invention features a method of providing a sample from a subject and evaluating the Tiel expression in cells in the sample. In one embodiment, the result of evaluating Tiel expression levels is compared to a reference, a reference value or reference quality. For example, the Tiel expression on the evaluated sample may have the same, less than, or greater than the reference value. A reference value or quality can be determined using a control sample, a statistical value an average, median, etc.) or an arbitrary value. For example, the control sample can be a normal sample, a sample devoid of tumor cells from the same or different subject. A change an increase) relative to the reference can indicate that the sample includes tumor cells, the subject may be indicated as having a tumor.

[0185] In other embodiments, a method of diagnosing or staging a disorder as described herein an inflammatory or cancerous disorder), is provided. The method includes: identifying a subject having, or at risk of having, the disorder; (ii) obtaining a sample of a tissue or cell affected with the disorder; (iii) contacting said sample or a control sample with a Tiel-binding protein, under conditions that allow interaction of the binding agent and the Tiel protein to occur, and (iv) detecting formation of a complex. A statistically significant increase in the formation of the complex between the Tiel-binding protein with respect to a reference sample, a control sample, is indicative of the disorder or the stage of the disorder. For example, the finding of activated Tiel on tumor cells located in a solid tumor can indicate that the tumor is progressing into a metastatic tumor.

[0186] Preferably, the Tiel-binding protein used in the in vivo and in vitro diagnostic methods is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound binding agent. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. In one embodiment, the Tielbinding protein is coupled to a radioactive ion, indium (11 In), iodine (31'I or 125), WO 2006/020706 PCT/US2005/028413 yttrium 9 actinium (ZZmAc), bismuth 2 12 Bi or 213 Bi), sulfur 35 carbon 4

C),

tritium 3 rhodium 18 Rh), or phosphorous 3 2 In another embodiment, the Tiel-binding protein is labeled with an NMR contrast agent.

[0187] In one aspect, the invention features a method of imaging tumor vasculature, the method includes: providing a protein that binds to Tiel, Tie2, or Ang, a protein described herein, wherein the protein is physically associated to an imaging agent; administering the protein to a patient, with a tumor; and imaging the patient, to detect tumor vasculature.

[0188] In one aspect, the invention features a method of treating a subject with a blood born neoplastic disorder, the method includes administering a protein that binds to Tiel, Tie2, or Ang, a protein described herein, to a subject with a blood born neoplastic disorder a proliferative disorder ofhematopoietic cells, e.g., leukemia), thereby treating the disorder.

[0189] In one aspect, the invention features a method of diagnosing and treating a subject, the method includes evaluating a parameter associated with Tiel, Tie2, or Ang in a subject; and, if the parameter is altered relative to a reference, administering a protein described herein to the subject, thereby treating the subject.

In one embodiment, the parameter includes a value indicative of protein or mRNA levels, in a tissue of a subject. In one embodiment, the reference includes a value determined for a reference subject, an age/gender matched subject, a control or normal subject.

[0190] In one aspect, the invention features a method of treating a subject, the method includes: administering a protein described herein to a subject that has elevated Tiel, Tie2, or Ang biomolecules or activity relative to a reference. The method can include evaluating the subject, to determine if the subject has elevated Tiel, Tie2, or Ang biomolecules or activity relative to a reference. In one embodiment, the subject has elevated Tiel protein or mRNA levels.

[0191] The invention also provides polypeptides and nucleic acids that encompass a range of amino acid and nucleic acid sequences, sequences described herein or sequences related to those described herein. For example, the invention features nucleic acids that encodes each of the polypeptides described herein. The nucleic acid can include the cognate codons or any set of codons that can WO 2006/020706 PCT/US2005/028413 be translated to produce the respective polypeptide. Such polypeptides include individual subunits of a multi-chain protein, an antibody that includes a plurality of different polypeptide chains. The nucleic acid may also be a nucleic acid fragment or vector that is not expressed, but includes a sequence encoding at least a part of an immunoglobulin variable region including a CDR described herein) or a complement thereof. Such nucleic acids can be used to prepare useful constructs, cells, and proteins. In addition, the invention features a host cell that includes a nucleic acid described herein. The cell can express a protein described herein, on its surface. The invention also includes are proteins that include an amino acid sequence encoded by a nucleic acid described herein or that hybridize to a nucleic acid described herein.

[0192] As used herein, the term "antibody" refers to a protein that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence. For example, an antibody can include a heavy chain variable region (abbreviated herein as VI), and a light chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy chain variable regions and two light chain variable regions. The term "antibody" encompasses antigen-binding fragments of antibodies single chain antibodies, Fab fragments, F(ab')2, a Fd fragment, a Fv fragments, and dAb fragments) as well as complete antibodies.

[0193] The VH and VL regions can be further subdivided into regions of hypervariability, termed "complementarity determining regions" (CDR), interspersed with regions that are more conserved, termed "framework regions" The extent of the framework region and CDRs has been precisely defined (see, Kabat, et al.

(1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S.

Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917). Kabat definitions are used herein. Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0194] An "immunoglobulin domain" refers to a domain from the variable or constant domain of immunoglobulin molecules. Immunoglobulin domains typically contain two p-sheets formed of about seven P-strands, and a conserved disulphide WO 2006/020706 PCT/US2005/028413 bond (see, A. F. Williams and A. N. Barclay 1988 Ann. Rev Immunol. 6:381- 405). The canonical structures of hypervariable loops of an immunoglobulin variable can be inferred from its sequence, as described in Chothia et al. (1992) J Mol. Biol.

227:799-817; Tomlinson et al. (1992) J. Mol. Biol. 227:776-798); and Tomlinson et al. (1995) EMBO J. 14(18):4628-38.

[0195] As used herein, an "immunoglobulin variable domain sequence" refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may omit one, two or more N- or C-terminal amino acids, internal amino acids, may include one or more insertions or additional terminal amino acids, or may include other alterations. In one embodiment, a polypeptide that includes immunoglobulin variable domain sequence can associate with another immunoglobulin variable domain sequence to form a target binding structure (or "antigen binding site"), a structure that interacts with Tiel, binds to or inhibits Tiel.

[0196] The VH or VL chain of the antibody can further include all or part of a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are inter-connected by, disulfide bonds. The heavy chain constant region includes three domains, CH1, CH2 and CH3. The light chain constant region includes a CL domain. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system effector cells) and the first component (Clq) of the classical complement system. The term "antibody" includes intact immunoglobulins of types IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof). The light chains of the immunoglobulin may be of types kappa or lambda.

In one embodiment, the antibody is glycosylated. An antibody can be functional for antibody-dependent cytotoxicity and/or complement-mediated cytotoxicity.

[0197] One or more regions of an antibody can be human or effectively human. For example, one or more of the variable regions can be human or effectively human. For example, one or more of the CDRs can be human, HC CDR1, HC WO 2006/020706 PCT/US2005/028413 CDR2, HC CDR3, LC CUDR1, LC CDR2, and LC CDR3. Each of the light chain CDRs can be human. HC CDR3 can be human. One or more of the framework regions can be human, FR1, FR2, FR3, and FR4 of the HC or LC. In one embodiment, all the framework regions are human, derived from a human somatic cell, a hematopoietic cell that produces immunoglobulins or a nonhematopoietic cell. In one embodiment, the human sequences are germline sequences, encoded by a germline nucleic acid. One or more of the constant regions can be human or effectively human. In another embodiment, at least 70, 85, 90, 92, 95, or 98% of the framework regions FR1, FR2, and FR3, collectively, or FR1, FR2, FR3, and FR4, collectively) or the entire antibody can be human or effectively human. For example, FR1, FR2, and FR3 collectively can be at least 70, 75, 80, 85, 90, 92, 95, 98, or 99% identical to a human sequence encoded by a human germline V segment of a locus encoding a light or heavy chain sequence.

[0198] All or part of an antibody can be encoded by an immunoglobulin gene or a segment thereof. Exemplary hunan immunoglobulin genes include the kappa, lambda, alpha (IgAl and IgA2), gamma (IgG1, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin light chains (about 25 Kd or 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH--terminus. Full-length immunoglobulin heavy chains (about 50 Kd or 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, gamma (encoding about 330 amino acids). A light chain refers to any polypeptide that includes a light chain variable domain. A heavy chain refers to any polypeptide that a heavy chain variable domain.

[0199] The term "antigen-binding fragment" of a full-length antibody (or simply "antibody portion," or "fragment"), as used herein, refers to one or more fragments of a full-length antibody that retain the ability to specifically bind to a target of interest. Examples of binding fragments encompassed within the term "antigen-binding fragment" of a full length antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment including two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CH1 domains; WO 2006/020706 PCT/US2005/028413 (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, a dAb fragment (Ward et al., (1989) Nature 341:544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR) that retains functionality. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules known as single chain Fv (scFv). See Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883.

[0200] Antibody fragments can be obtained using any appropriate technique including conventional techniques known to those with skill in the art. The term "monospecific antibody" refers to an antibody that displays a single binding specificity and affinity for a particular target, epitope. This term includes a "monoclonal antibody" or "monoclonal antibody composition," which as used herein refer to a preparation of antibodies or fragments thereof of single molecular composition. As used herein, "isotype" refers to the antibody class IgM or IgG) that is encoded by heavy chain constant region genes.

[0201] In one embodiment, the HC or LC of an antibody includes sequences that correspond to an amino acid sequence encoded by a human germline sequence, the framework regions and/or in the CDRs. For example, the antibody can include sequences from the human DP47 antibody. In one embodiment, one or more codons for the antibody are altered relative to the germline nucleic acid sequence, but are chosen to encode the same amino acid sequence. Codons can be selected, to optimize expression in a particular system, create restriction enzyme sites, create a silent fingerprint, etc.

[0202] In one embodiment, CDR2 of the antibody HC includes at least 11, 12, 13, 14, or 15 amino acid positions that are identical to the amino acids found in CDR2 of DP47.

[0203] A "humanized" immunoglobulin variable region is an immunoglobulin variable region that includes sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an WO 2006/020706 PCT/US2005/028413 immunogenic response in a normal human. Descriptions of "humanizcd" immunoglobulins include, for example, US 6,407,213 and US 5,693,762.

[0204] An "effectively human" immunoglobulin variable region is an immunoglobulin variable region that includes a sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response in a normal human. An "effectively human" antibody is an antibody that includes a sufficient number of human amino acid positions such that the antibody does not elicit an immunogenic response in a normal human.

[0205] As used herein, "Tie complex" refers to a heteromeric complex that includes Tiel, Tie2, and an angiopoietin (Ang). The Tie complex is formed in part by association of the extracellular domains of Tiel and Tie2 and also includes Ang. As used herein, "complex members" refers to the proteins that are included in a heteromeric Tie complex. Accordingly, Tiel, Tie2, and Ang are all complex members. The term "Ang" includes all angiopoietins, such as Angl, Ang2, Ang3, and Ang4. The heteromeric Tie complex can include other proteins in addition to Tiel, Tie2, and Ang. A protein or ligand that antagonizes complex formation inhibits or decreases the association of Tiel, Tie2, or Ang with at least one other member of the complex and thereby decreases Tie2 signaling and downstream effects such as angiogenesis. Angiogenesis includes all stages of vessel development blood or lymphatic vessel development), including initial vessel formation and later vessel remodeling and morphological changes.

[0206] As used herein, the terms "agonist" and "antagonist" describe properties in context of a particular activity or effect. For example, the E3 or E3b antibody can be an agonist in the context of promoting Tiel self-association homodimerization), yet an antagonist in the context of decreasing or inhibiting Tie complex formation and tube formation by HUVECs. Likewise, an agent that is an agonist in the context of a Tiel signaling pathway can be an antagonist in the context of endothelial cell sprouting, splitting, and tube formation.

[0207] The term "Tiel ectodomain" refers to an extracellular region of a Tiel protein, a region that includes about amino acids 25-759 of SEQ ID NO:2. Other exemplary regions are regions that include one or more EGF-like domains 214- WO 2006/020706 PCT/US2005/028413 256, 258-303, 303-345, 214-303, 258-345, or 214-345 of SEQ ID NO:2); one or more Ig-Like C2-type domains 43-105, 43-426, 372-426); one or more Fibronectin Type III repeats 446-540, 543-639, 643-744, 446-639, 543-744, or 446-744 of SEQ ID NO:2); and combinations thereof. The terms "first Ig-like C2-type domain" and "Ig 1" refer to the immunoglobulin-like domain in Tiel or Tie2 that is located closest to the amino terminus of the protein relative to the other Ig-like C2-type domain (the second such domain). For example, for Tiel, the first Immunoglobulinlike C2-type domain is located at about residue 43 to about residue 105 and the second Ig-like C2-type domain is located at about residue 372 to about residue 426.

[0208] As used herein, "binding affinity" refers to the apparent association constant or Ka. The Ka is the reciprocal of the dissociation constant A ligand may, for example, have a binding affinity of at least 105, 106, 107 or 108 M 1 for a particular target molecule. Higher affinity binding of a ligand to a first target relative to a second target can be indicated by a higher Ka (or a smaller numerical value Kd) for binding the first target than the Ka (or numerical value Kd) for binding the second target. In such cases the ligand has specificity for the first target relative to the second target. Differences in binding affinity for specificity or other comparisons) can be at least 1.5, 2, 5, 10, 50, 100, or 1000-fold. For example, a Tiel-binding protein may preferentially bind to Tiel at least 1.5, 2, 5, 10, 50, 100, or 1000-fold better than to another antigen, Tie2, EGF, fibronectin, or human serum albumin. A Tielbinding protein may also be species-specific or species-general can bind to a Tiel protein from more than one species).

[0209] Binding affinity can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy using a fluorescence assay). These techniques can be used to measure the concentration of bound and free ligand as a function of ligand (or target) concentration. The concentration of bound ligand ([Bound]) is related to the concentration of free ligand ([Free]) and the concentration of binding sites for the ligand on the target where is the number of binding sites per target molecule by the following equation: [Bound] N [Free]/((1/Ka) [Free]) WO 2006/020706 PCT/US2005/028413 [0210] Although quantitative measurements of Ka are routine, it is not always necessary to make an exact determination of Ka, though, since sometimes it is sufficient to obtain a qualitative measurement of affinity, determined using a method such as ELISA or FACS analysis, is proportional to Ka, and thus can be used for comparisons, such as determining whether a higher affinity is, 2, 5, 10, 20, or fold higher than a reference. Binding affinity is typically evaluated in 0.01 M HEPES pH 7.4, 0.15 M NaCI, 3 mM EDTA and 0.005 surfactant [0211] An "isolated composition" refers to a composition that is removed from at least 90% of at least one component of a natural sample from which the isolated composition can be obtained. Compositions produced artificially or naturally can be "compositions of at least" a certain degree of purity if the species or population of species of interests is at least 5, 10, 25, 50, 75, 80, 90, 95, 98, or 99% pure on a weight-weight basis.

[0212] An "epitope" refers to the site on a target compound that is bound by a ligand, an antigen-binding protein a Fab or antibody). In the case where the target compound is a protein, for example, an epitope may refer to the amino acids that are bound by the ligand. Overlapping epitopes include at least one common amino acid residue.

[0213] As used herein, the term "substantially identical" (or "substantially homologous") is used herein to refer to a first amino acid or nucleotide sequence that contains a sufficient number of identical or equivalent with a similar side chain, conserved amino acid substitutions) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have similar activities. In the case of antibodies, the second antibody has the same specificity and has at least 50% of the affinity of the same.

[0214] Sequences similar or homologous at least about 85% sequence identity) to the sequences disclosed herein are also part of this application. In some embodiment, the sequence identity can be about 85%, 90%, 91%, 92%, 93%, 94%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity exists when the nucleic acid segments will hybridize under selective hybridization conditions highly stringent hybridization conditions), to the complement of the strand. The WO 2006/020706 PCT/US2005/028413 nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.

[0215] Calculations of "homology" or "sequence identity" between two sequences (the terms are used interchangeably herein) are performed as follows. The sequences are aligned for optimal comparison purposes gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least even more preferably at least 60%, and even more preferably at least 70%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0216] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6 or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. A particularly preferred set of parameters (and the one that should be used if the practitioner is uncertain about what parameters should be applied to determine if a molecule is within a sequence identity or homology WO 2006/020706 PCT/US2005/028413 limitation described herein) are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of [0217] As used herein, the term "homologous" is synonymous with "similarity" and means that a sequence of interest differs from a reference sequence by the presence of one or more amino acid substitutions (although modest amino acid insertions or deletions) may also be present. Presently preferred means of calculating degrees ofhomology or similarity to a reference sequence are through the use of BLAST algorithms (available from the National Center of Biotechnology Information (NCBI), National Institutes of Health, Bethesda MD), in each case, using the algorithm default or recommended parameters for determining significance of calculated sequence relatedness. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm ofE. Meyers and W.

Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

[0218] As used herein, the term "hybridizes under low stringency, medium stringency, high stringency, or very high stringency conditions" describes conditions for hybridization and washing. Guidance for performing hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley Sons, N.Y.

(1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. Specific hybridization conditions referred to herein are as follows: 1) low stringency hybridization conditions in 6X sodium chloride/sodium citrate (SSC) at about 45 0 C, followed by two washes in 0.2X SSC, 0.1% SDS at least at 50 0 C (the temperature of the washes can be increased to 55 0 C for low stringency conditions); 2) medium stringency hybridization conditions in 6X SSC at about 45 0

C,

followed by one or more washes in 0.2X SSC, 0.1% SDS at 60 0 C; 3) high stringency hybridization conditions in 6X SSC at about 45 0 C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65 0 C; and 4) very high stringency hybridization conditions are 0.5M sodium phosphate, 7% SDS at 65 0 C, followed by one or more washes at 0.2X SSC, 1% SDS at 65 0

C.

[0219] It is understood that the proteins described herein may have mutations relative to a particular protein described herein a conservative or non-essential WO 2006/020706 PCT/US2005/028413 ammo acid substitutions), which do not have a substantial effect on finction.

Whether or not a particular substitution will be tolerated, will not adversely affect desired biological properties, such as binding activity can be determined as described in Bowie, et al. (1990) Science 247:1306-1310. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains lysine, arginine, histidine), acidic side chains aspartic acid, glutamic acid), uncharged polar side chains glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains threonine, valine, isoleucine) and aromatic side chains tyrosine, phenylalanine, tryptophan, histidine). It is possible, for example, for framework and CDR amino acid residues to include one or more conservative substitutions.

[0220] A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of the binding agent, the antibody, without abolishing or more preferably, without substantially altering a biological activity, whereas an "essential" amino acid residue results in such a change.

[0221] Generally, where is used to represent an amino acid residue, any amino acid any of the twenty naturally occurring amino acids) can be used at that position, or at least a subset thereof any of the nineteen non-cysteine amino acids).

[0222] The terms "polypeptide" or "peptide" (which may be used interchangeably) refer to a polymer of three or more amino acids linked by a peptide bond, between 3 and 30, 12 and 60, or 30 and 300, or over 300 amino acids in length. The polypeptide may include one or more unnatural amino acids. Typically, the polypeptide includes only natural amino acids. A "protein" can include one or more polypeptide chains. Accordingly, the term "protein" encompasses polypeptides.

A protein or polypeptide can also include one or more modifications, a glycosylation, amidation, phosphorylation, and so forth. The term "small peptide" can be used to describe a polypeptide that is between 3 and 30 amino acids in length, between 8 and 24 amino acids in length.

[0223] Statistical significance can be determined by any art known method.

C Exemplary statistical tests include: the Students T-test, Mann Whitney U nonparametric test, and Wilcoxon non-parametric statistical test. Some statistically significant relationships have a P value of less than 0.05, or 0.02. Particular ligands may show a difference, in specificity or binding, that are statistically significant P value 0.05 or 0.02).

00 ,I [0223a] Definitions of the specific embodiments of the invention as claimed herein follow.

Nn According to a first embodiment of the invention, there is provided a method of 0inhibiting vascular development in a subject, the method comprising administering, to a subject having or at risk for a disorder requiring inhibition of vascular development, an isolated protein comprising a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence wherein the protein binds to Tiel ectodomain and the heavy chain immunoglobulin variable domain sequence comprises one or more of the following properties: i) a HC CDRI that includes (AGSIMRH)-Y-(GVMK)-M-(GSVMFH)

(SEQ

ID NO: 118); ii) a HC CDR2 that includes

(SEQ

ID NO:160); and iii) a HC CDR3 that includes A-P-R-G-Y-S-Y-G-Y-Y-Y (SEQ ID NO:727); and/or the light chain immunoglobulin variable domain sequence comprises one or more of the following properties: i) a LC CDRI that includes R-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN)- (STIRH)-X1-(SYWNH)-(LV)-(ASN) (SEQ ID NO:132), wherein Xl can be serine or absent; ii) a LC CDR2 that includes Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)- (LWRH)-(TIY) (SEQ ID NO:161); and iii) a LC CDR3 that includes Q-Q-F-N-S-Y-P-H (SEQ ID NO:728), the method further comprising providing a second therapy that is an anticancer therapy.

[0223b] According to a second embodiment of the invention, there is provided 0a method of providing a post-operative adjuvant therapy to a subject who has had surgery to remove a tumor, the method comprising administering to the subject an isolated protein comprising a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence wherein the protein binds to Tiel ectodomain and 0 0 the heavy chain immunoglobulin variable domain sequence comprises one 0 or more of the following properties: i) a HC CDR1 that includes (AGSIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ ID NO:118); i ii) a HC CDR2 that includes (GSV)-I-(SY)-P-S-G-G-(WNQ)-T-(GY) (SEQ ID NO:160); and iii) a HC CDR3 that includes A-P-R-G-Y-S-Y-G-Y-Y-Y (SEQ ID NO:727); and/or the light chain immunoglobulin variable domain sequence comprises one or more of the following properties: i) a LC CDR1 that includes R-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN)- (STIRH)-XI-(SYWNH)-(LV)-(ASN) (SEQ ID NO:132), wherein Xl can be serine or absent; ii) a LC CDR2 that includes Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)- (LWRH)-(TIY) (SEQ ID NO:161); and iii) a LC CDR3 that includes Q-Q-F-N-S-Y-P-H (SEQ ID NO:728).

[0224] Other features and advantages of the instant invention will become more apparent from the following detailed description and claims. Embodiments of the invention can include any combination of features described herein. In no case does the term "embodiment" necessarily exclude one or more other features disclosed herein, in another embodiment. The contents of all references, patent applications and patents, cited throughout this application are hereby expressly incorporated by reference.

BRIEF DESCRIPTION OF THE FIGURES [02251 FIG. 1 illustrates a bivariant FACS plot showing labelling with the O platelet specific marker CD42 with Tiel and labelling with the E3 antibody. Only a background number of CD42 positive cells are labeled by the E3 antibody.

[0226] FIGs. 2A, 2B, 2C, and 2D are plots of the number of branching points Sversus antibody concentration comparing germlined E3 (2C and 2D) with parental E3 (2A and 2B).

oO [0227] FIG. 3 depicts a graph of blood vessel density in matrigels that were o stained with fluorescein-lectin from an in vivo assay using MATRIGEL T M and evaluating the germlined E3 antibody.

[0228] FIG. 4 depicts results of tube formation in HUVECs using the parental N1 E3 and E3b (germlined) proteins.

[0229] FIG. 5 depicts graphically the results from animal studies in which nu/nu mice were implanted with SW-480 colorectal cancer cells and treated with DX- 2220 (10 mg/kg), cisplatin (4 mg/kg), or a control. Control conditions were: no treatment, PBS vehicle alone, or a non-specific, isotype-matched IgG1 antibody (A2- SV) (10 mg/kg). Tumor weight is plotted on the y axis; days after tumor cell injection is plotted on the x axis.

66b WO 2006/020706 PCT/US2005/028413 [0230] FIG. 6 depicts graphically the results from animal studies in which nu/nu mice were implanted with LNM35 lung cancer cells and treated with DX-2220 mg/kg) or a non-specific, isotype-matched IgG1 antibody (A2-SV) (20 mg/kg).

Tumor volume (mm 3 is plotted on the y axis; days after tumor cell injection is plotted on the x axis.

[0231] FIG 7A and 7B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-Al, respectively.

[0232] FIG 8A and 8B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-A5, respectively.

[0233] FIG 9A and 9B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-A6, respectively.

[0234] FIG 10A and 10B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-A10, respectively.

[0235] FIG 11A and 11B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-B1, respectively.

[0236] FIG 12A and 12B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-B3, respectively.

[0237] FIG 13A and 13B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-C6, respectively.

[0238] FIG 14A and 14B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-D6, respectively.

[0239] FIG 15A and 15B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-D10, respectively.

[0240] FIG 16A and 16B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-D12, respectively.

[0241] FIG 17A and 17B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-F3, respectively.

[0242] FIG 18A and 18B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-F4, respectively.

WO 2006/020706 PCT/US2005/028413 luZ4.J F1H 19A and 19B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-G3, respectively.

[0244] FIG 20A and 20B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-A2, respectively.

[0245] FIG 21A and 21B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-A10, respectively.

[0246] FIG 22A and 22B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-B2, respectively.

[0247] FIG 23A and 23B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-B9, respectively.

[0248] FIG 24A and 24B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-C2, respectively.

[0249] FIG 25A and 25B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-C7, respectively.

[0250] FIG 26A and 26B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-C10, respectively.

[0251] FIG 27A and 27B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-D11, respectively.

[0252] FIG 28A and 28B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-E11, respectively.

[0253] FIG 29A and 29B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-G4, respectively.

[0254] FIG 30 lists the amino acid sequence of the light chain variable domain of clone s-G9.

[0255] FIG 31A and 31B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-G10, respectively.

[0256] FIG 32A and 32B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-H1, respectively.

WO 2006/020706 PCT/US2005/028413 [0257] FIG 33A and 33B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone s-H4, respectively.

[02581 FIG 34A and 34B list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone G2, respectively.

[0259] FIG 35 and 36 list the amino acid sequence of the heavy chain variable domain and the light chain variable domain of clone p-Al, respectively.

[0260] FIG 37 provides Table 5, a summary of heavy chain sequences.

[0261] FIG 38 provides Table 6, a summary of light chain sequences.

[0262] FIG 39 provides Table 9, characteristics of some exemplary Tiel binding antibodies.

DETAILED DESCRIPTION [0263] This disclosure provides, inter alia, agents (also referred to as binding proteins and ligands) that bind to components of a Tie complex, e.g.,Tiel, Tie2, and Ang. Examples of such agents include proteins, for example, a small peptide a cyclic or linear peptide, of between 7 and 25 amino acids), a polypeptide a polypeptide of at least 20 amino acids), or a multi-chain protein including at least two peptides or polypeptides). An example of a multi-chain protein is an IgG full-length antibody that has separate heavy and light chains. An example of a polypeptide is a single chain antibody.

[0264] Agents can be selected that have particular properties, ability to antagonize Tiel/Tie2/Ang complex formation, ability to promote Tiel homodimerization, and ability to promote Tiel phosphorylation. For example, agents that bind to Tiel, Tie2, or Ang can be tested for their ability to antagonize formation ofheteromeric Tie complexes. Antagonism of this complex decreases Tie2 signaling and its downstream effects, such as promoting angiogenesis.

[0265] Tiel is a receptor tyrosine kinase protein that includes a transmembrane domain. Tiel is present almost exclusively on endothelial cells.

Accordingly, a Tiel-binding protein can be used, to specifically recognize or target an endothelial cell. Some Tiel-binding proteins can also be used to agonize or WO 2006/020706 PCT/US2005/028413 antagomze encotnelial cells. In some embodiments, these Tiel-binding proteins have an affinity for particular structural features a feature listed below), a combination of features listed below, and/or an epitope that includes at least one amino acid in a structural feature listed below (The sequence is relative to the amino acid sequence provided in SEQ ID NO:2, Example 1, below): Key From To LengthDescription SIGNAL 1 24 24 POTENTIAL.

CHAIN 25 1138 1114 TYROSINE-PROTEIN KINASE RECEPTOR TIE1.

DOMAIN 25 759 735 EXTRACELLULAR (POTENTIAL).

TRANSMEM 760 784 25 POTENTIAL.

DOMAIN 785 1138 354 CYTOPLASMIC (POTENTIAL).

DOMAIN 43 105 63 IG-LIKE C2-TYPE 1.

DOMAIN 214 256 43 EGF-LIKE 1.

DOMAIN 258 303 46 EGF-LIKE 2.

DOMAIN 305 345 41 EGF-LIKE 3.

DOMAIN 372 426 55 IG-LIKE C2-TYPE 2.

DOMAIN 446 540 95 FIBRONECTIN TYPE-III 1.

DOMAIN 543 639 97 FIBRONECTIN TYPE-III 2.

DOMAIN 643 744 102 FIBRONECTIN TYPE-III 3.

DOMAIN 839 1118 280 PROTEIN KINASE.

NP_BIND 845 853 9 ATP (BY SIMILARITY).

BINDING 870 870 ATP (BY SIMILARITY).

ACTSITE 979 979 BY SIMILARITY.

CARBOHYD 83 83 N-LINKED (GLCNAC...) (POTENTIAL).

CARBOHYD 161 161 N-LINKED (GLCNAC...) (POTENTIAL).

CARBOHYD 503 503 N-LINKED (GLCNAC...) (POTENTIAL).

CARBOHYD 596 596 N-LINKED (GLCNAC...) (POTENTIAL).

CARBOHYD 709 709 N-LINKED (GLCNAC...) (POTENTIAL).

MOD_RES 1007 1007 PHOSPHORYLATION (AUTO-) (BY

SIMILARITY).

[0266] Tie2 is a receptor tyrosine kinase protein that includes a transmembrane domain. Tie2 is present almost exclusively on endothelial cells.

Accordingly, a Tie2-binding protein can be used, to specifically recognize or target an endothelial cell. Some Tie2-binding proteins can also be used to modulate agonize or antagonize) an activity of an endothelial cell. In some embodiments, these Tie2-binding proteins have an affinity for particular structural features, a WO 2006/020706 PCT/US2005/028413 combination of features, and/or an epitope that includes at least one amino acid in a structural feature. Exemplary structural features of Tie2 include: two Ig-like domains, three EGF-like domains, and three fibronectin type III domains.

[0267] The angiopoietins are a family of ligands that bind to Tie2. Some Ang-binding proteins antibodies or artificial Ang-binding proteins) can be used to agonize or antagonize endothelial cells. In some embodiments, these Ang-binding proteins have an affinity for particular structural features, a combination of features, and/or an epitope that includes at least one amino acid in a structural feature.

Exemplary structural features include: the N-terminal region of about 50 amino acids, the coiled-coil domain, or the fibrinogen-like domain.

[0268] Examples of Ang-binding proteins include proteins that inhibit Ang multimerization ability of Ang proteins to form tetramers), proteins that inhibit Ang-Tie2 interactions, and proteins that inhibit a ternary complex of Tiel-Tie2-Ang.

Inhibitory proteins can function by disrupting existing interactions or by preventing interactions from occurring.

[0269] Tiel and Tie2 can associate through their extracellular domains and form a heteromeric complex with an angiopoietin (Ang), such as Angl, Ang2, Ang3, and Ang4. This heteromeric complex activates the intracellular signaling cascade mediated by Tie2. Thus, antagonizing formation of this heteromeric complex provides a novel approach to inhibiting Tie2 signaling and its downstream effects, such as angiogenesis. Complex formation can be antagonized by proteins that bind to the extracellular domains of Tiel or Tie2 or that bind to Ang so as to prevent its recruitment into the complex or to prevent its multimerization.

[0270] One method for identifying proteins that bind to Tiel includes: providing a library and selecting from the library one or more members that encode a protein that binds to the Tiel antigen or a fragment thereof the extracellular domain, an EGF domain, a fibronectin repeat, or an Ig-superfamily domain a Iglike C2-type 2 domain)). The selection can be performed in a number of ways. For example, the library can be a display library. The Tiel can be tagged and recombinantly expressed. The Tiel is purified and attached to a support, to affinity beads, or paramagnetic beads or other magnetically responsive particles. The Tiel can also be expressed on the surface of a cell. Members of the display library WO 2006/020706 PCT/US2005/028413 that specifically bind to the cell, only if the Tiel is activated, can be selected.

Analogous procedures can be performed to identify proteins that bind to Tie2 or a fragment thereof the extracellular domain, an EGF domain, a fibronectin repeat, or an Ig-superfamily domain a Ig-like C2-type 2 domain)). Analogous procedures can also be performed to identify proteins that bind to Ang or a fragment thereof the N-terminal domain, the coiled-coil domain, or the fibrinogen-like domain).

[0271] Proteins identified as being capable of binding a Tie complex member can be tested for their ability to antagonize heteromeric complex formation, ability to promote Tiel phosphorylatoin, and/or ability to promote Tiel homodimerization, as described in the examples below. Proteins identified as antagonizing formation of the heteromeric complex can be used in pharmaceutical compositions to treat a subject in need of such treatment, for example, a subject with an angiogenesis-dependent cancer or tumor or other angiogenesis-related disorders.

[0272] Exemplary Tiel Modulators [0273] In one embodiment, a Tiel-binding protein can modulate a Tiel activity. For example, a Tiel-binding protein can function as a Tiel agonist or antagonist in the Tiel/EpoR chimeric BaF3 cell assay described in Example 2. Tiel agonists in this Tiel/EpoR chimeric BaF3 cell assay can stimulate certain activity of an endothelial cell under particular conditions, the conditions of the Tiel/EpoR chimeric BaF3 cell assay.

[0274] Some Tiel binding proteins increase phosphatidyl inositol 3-kinase (PI3 kinase) activity in an endothelial cell and/or Akt kinase activity. Kontos et al.

suggest that the cytoplasmic domain of Tiel can associate with the p85 subunit of PI3 kinase and activate PI3 kinase activity. Kontos et al. (2002) Mol. Cell Biol. 22:1704- 1713. The Tiel cytoplasmic domain may also associate with a protein tyrosine phosphatase Shp2. See, Marron et al. (2000) Adv. Exp. Med. Biol. 476:35-46.

[0275] Some Tie binding proteins may increase dimerization, and/or tyrosine phosphorylation as a result of auto-phosphorylation) of the Tiel cytoplasmic domain, the tyrosine in the motif YVN at about amino acid 1117.

WO 2006/020706 PCT/US2005/028413 [0276] Tiel-binding protein can be evaluated in a cell assay in the Tiel/EpoR chimeric BaF3 cell assay as described below in Example An exemplary cell assay uses a growth factor dependent cell in which a chimeric receptor that includes the Tiel ectodomain fused to the intracellular domain of the growth factor receptor is expressed. Cells are evaluated for ability to grow in the absence of the essential growth factor, but in the presence of a test compound, a Tielbinding protein. If the Tiel-binding protein agonizes Tiel in the Tiel/EpoR chimeric BaF3 cell assay, a signalling activity of the Tiel chimera can substitute for stimulation by the required growth factor thorough its cognate receptor. Thus, survival of the cell in the absence of the required growth factor can be used as an indication that the Tiel-binding protein interacts with the Tiel ectodomain.

[0277] Tiel agonists in the Tiel/EpoR chimeric BaF3 cell assay may behave as inhibitors of Tiel activity under other conditions, in vivo, and, irrespective of in vitro properties, may be useful as inhibitors of angiogenesis in vivo.

[0278] Tiel binding proteins can be used, to reduce an activity of an endothelial cell. For example, some Tiel binding proteins can be used to decrease phosphatidyl inositol 3-kinase (PI3 kinase) activity in an endothelial cell, Shp2 activity, and/or Akt kinase activity. Some Tiel binding proteins may also reduce dimerization, and/or tyrosine phosphorylation as a result of autophosphorylation) of the Tiel cytoplasmic domain, the tyrosine in the motif YVN at about amino acid 1117.

[0279] Tiel-binding protein can be evaluated for activity in a cell assay. For example, the binding protein can be assayed for ability to prevent another ligand, e.g., the E3 antibody, from modulating a Tiel activity in a cell assay described herein the Tiel/EpoR chimeric BaF3 cell assay as described below in Example 2).

[02801 Display Libraries [0281] A number of methods can be used to identify proteins that bind to Tiel, Tie2, Ang, fragments thereof, complexes that include one or more of these proteins or fragments thereof. In one embodiment, a display library is used to identify such proteins. A display library is a collection of entities; each entity includes an accessible protein component and a recoverable component that encodes or identifies the protein component. The protein component can be of any length, e.g.

WO 2006/020706 PCT/US2005/028413 from three amino acids to over 300 amino acids. In a selection, the protein component of each member of the library is probed with a target, Tiel protein, and if the protein component binds to the target, the display library member is identified, by retention on a support. The method can be adapted for other targets, such as Tie2, Ang, fragments thereof, complexes that include one or more of these proteins or fragments thereof.

[0282] Retained display library members are recovered from the support and analyzed. The analysis can include amplification and a subsequent selection under similar or dissimilar conditions. For example, positive and negative selections can be alternated. The analysis can also include determining the amino acid sequence of the protein component and purification of the protein component for detailed characterization. A variety of formats can be used for display libraries. Examples include the following.

[0283] Phage Display. One format utilizes viruses, particularly bacteriophages. This format is termed "phage display." The protein component is typically covalently linked to a bacteriophage coat protein. The linkage results form translation of a nucleic acid encoding the protein component fused to the coat protein.

The linkage can include a flexible peptide linker, a protease site, or an amino acid incorporated as a result of suppression of a stop codon. Phage display is described, for example, in Ladner et al., U.S. Patent No. 5,223,409; Smith (1985) Science 228:1315-1317; WO 92/18619; WO 91/17271; WO 92/20791; WO 92/15679; WO 93/01288; WO 92/01047; WO 92/09690; WO 90/02809; de Haard et al. (1999) J. Biol. Chem 274:18218-30; Hoogenboom et al. (1998) Immunotechnology 4:1-20; Hoogenboom et al. (2000) Immunol Today 2:371-8; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum Antibod Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J 12:725- 734; Hawkins et al. (1992) JMol Biol 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) PNAS 89:3576-3580; Garrard et al. (1991) Bio/Technology 9:1373-1377; Rebar et al. (1996) Methods Enzymol. 267:129-49; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) PNAS 88:7978-7982.

[0284] Phage display systems have been developed for filamentous phage (phage fl, fd, and M13) as well as other bacteriophage T7 bacteriophage and WO 2006/020706 PCT/US2005/028413 lambdoid phages; see, Santini (1998) J Mol. Biol. 282:125-135; Rosenberg et al.

(1996) Innovations 6:1-6; Houshmet al. (1999) Anal Biochem 268:363-370). The filamentous phage display systems typically use fusions to a minor coat protein, such as gene III protein, and gene VIII protein, a major coat protein, but fusions to other coat proteins such as gene VI protein, gene VII protein, gene IX protein, or domains thereof can also been used (see, WO 00/71694). In one embodiment, the fusion is to a domain of the gene III protein, the anchor domain or "stump," (see, e.g., U.S. Patent No. 5,658,727 for a description of the gene III protein anchor domain). It is also possible to physically associate the protein being displayed to the coat using a non-peptide linkage, a non-covalent bond or a non-peptide covalent bond. For example, a disulfide bond and/or c-fos and c-jun coiled-coils can be used for physical associations (see, Crameri et al. (1993) Gene 137:69 and WO 01/05950).

[0285] Bacteriophage displaying the protein component can be grown and harvested using standard phage preparatory methods, PEG precipitation from growth media. After selection of individual display phages, the nucleic acid encoding the selected protein components, by infecting cells using the selected phages.

Individual colonies or plaques can be picked, the nucleic acid isolated and sequenced.

[0286] Cell-based Display. In still another format the library is a cell-display library. Proteins are displayed on the surface of a cell, a eukaryotic or prokaryotic cell. Exemplary prokaryotic cells include E. coli cells, B. subtilis cells, and spores (see, Lu et al. (1995) Biotechnology 13:366). Exemplary eukaryotic cells include yeast Saccharomyces cerevisiae, Schizosaccharomyces pombe, Hanseula, or Pichiapastoris). Yeast surface display is described, in Boder and Wittrup (1997) Nat. Biotechnol. 15:553-557 and WO 03/029456, which describes a yeast display system that can be used to display immunoglobulin proteins such as Fab fragments and the use of mating to generate combinations of heavy and light chains.

[0287] Ribosome Display. RNA and the polypeptide encoded by the RNA can be physically associated by stabilizing ribosomes that are translating the RNA and have the nascent polypeptide still attached. Typically, high divalent Mg 2 concentrations and low temperature are used. See, Mattheakis et al. (1994) Proc.

Nail. Acad. Sci. USA 91:9022 and Hanes et al. (2000) Nat Biotechnol. 18:1287-92; Hanes et al. (2000) Methods Enzymol. 328:404-30; and Schaffitzel et al. (1999) J Imunol Methods. 231(1-2):119-35.

WO 2006/020706 PCT/US2005/028413 [0288] Polypeptide-Nucleic Acid Fusions. Another format utilizes polypeptide-nucleic acid fusions. Polypeptide-nucleic acid fusions can be generated by the in vitro translation of mRNA that include a covalently attached puromycin group, as described in Roberts and Szostak (1997) Proc. Natl. Acad. Sci. USA 94:12297-12302, and U.S. Patent No. 6,207,446. The mRNA can then be reverse transcribed into DNA and crosslinked to the polypeptide.

[0289] Other Display Formats. Yet another display format is a nonbiological display in which the protein component is attached to a non-nucleic acid tag that identifies the polypeptide. For example, the tag can be a chemical tag attached to a bead that displays the polypeptide or a radiofrequency tag (see, U.S.

Patent No. 5,874,214).

[0290] Display technology can also be used to obtain binding proteins, e.g., antibodies that interact with particular epitopes of a target. This can be done, for example, by using competing non-target molecules that lack the particular epitope or are mutated within the epitope, with alanine. Such non-target molecules can be used in a negative selection procedure as described below, as competing molecules when binding a display library to the target, or as a pre-elution agent, to capture in a wash solution dissociating display library members that are not specific to the target.

[0291] Iterative Selection. In one preferred embodiment, display library technology is used in an iterative mode. A first display library is used to identify one or more binding proteins for a target. These proteins are then varied, using a mutagenesis method, to form a second display library. Higher affinity binding proteins are then selected from the second library, by using higher stringency or more competitive binding and washing conditions.

[0292] In some implementations, the mutagenesis is targeted to regions known or likely to be at the binding interface. If, for example, the identified binding proteins are antibodies, then mutagenesis can be directed to the CDR regions of the heavy or light chains as described herein. Further, mutagenesis can be directed to framework regions near or adjacent to the CDRs, framework regions, particular within ten, five, or three amino acids of a CDR junction. In the case of antibodies, mutagenesis WO 2006/020706 PCT/US2005/028413 can also be limited to one or a few of the CDRs, to make precise step-wise improvements.

[0293] Some exemplary mutagenesis techniques include: error-prone PCR (Leung et al. (1989) Technique 1:11-15), recombination (see, USSN 10/279,633), DNA shuffling using random cleavage (Stemmer (1994) Nature 389- 391; termed "nucleic acid shuffling"), RACHITTTM (Coco et al. (2001) Nature Biotech. 19:354), site-directed mutagenesis (Zoller et al. (1987) Nucl Acids Res 10:6487-6504), cassette mutagenesis (Reidhaar-Olson (1991) Methods Enzymol.

208:564-586) and incorporation of degenerate oligonucleotides (Griffiths et al. (1994) EMBO J 13:3245).

[0294] In one example of iterative selection, the methods described herein are used to first identify a binding protein from a display library that binds a Tiel with at least a minimal binding specificity for a target or a minimal activity, an equilibrium dissociation constant for binding of greater than 1 nM, 10 nM, or 100 nM.

The nucleic acid sequence encoding the initial identified binding protein is used as a template nucleic acid for the introduction of variations, to identify a second binding protein that has enhanced properties binding affinity, kinetics, or stability) relative to the initial binding protein.

[0295] Off-Rate Selection. Since a slow dissociation rate can be predictive of high affinity, particularly with respect to interactions between polypeptides and their targets, the methods described herein can be used to isolate binding proteins with a desired kinetic dissociation rate reduced) for a binding interaction to a target.

[0296] To select for slow dissociating binding proteins from a display library, the library is contacted to an immobilized target. The immobilized target is then washed with a first solution that removes non-specifically or weakly bound biomolecules. Then the immobilized target is eluted with a second solution that includes a saturation amount of free target, replicates of the target that are not attached to the particle. The free target binds to biomolecules that dissociate from the target. Rebinding is effectively prevented by the saturating amount of free target relative to the much lower concentration of immobilized target.

[0297] The second solution can have solution conditions that are substantially physiological or that are stringent. Typically, the solution conditions of the second WO 2006/020706 PCT/US2005/028413 solution are identical to the solution conditions of the first solution. Fractions of the second solution are collected in temporal order to distinguish early from late fractions.

Later fractions include biomolecules that dissociate at a slower rate from the target than biomolecules in the early fractions. It is also possible to recover display library members that remain bound to the target even after extended incubation. These can either be dissociated using chaotropic conditions or can be amplified while attached to the target. For example, phage bound to the target can be contacted to bacterial cells.

[0298] Selecting and Screening for Specificity. "Selection" refers to a process in which many members of a display library are allowed to contact the target and those that bind are recovered and propagated. The selection can be from a library having numerous members, more than 10 10 members. "Screening" refers to a process in which isolated members of the library are tested singly for binding to the target. Through automation, thousands of candidates may be screened in a highly parallel process. The display library selection methods described herein can include a selection process that discards display library members that bind to a non-target molecule. Examples of non-target molecules include, extracellular domains of molecules that include an immunoglobulin super-family domain or an EGF domain and receptor tyrosine kinases other than Tiel, Tie2, or other than Tie2, Tiel, or other than Tiel and Tie2. In one implementation, a so-called "negative selection" step is used to discriminate between the target and related non-target molecule and a related, but distinct non-target molecules. The display library or a pool thereof is contacted to the non-target molecule. Members of the sample that do not bind the non-target are collected and used in subsequent selections for binding to the target molecule or even for subsequent negative selections. The negative selection step can be prior to or after selecting library members that bind to the target molecule.

[0299] In another implementation, a screening step is used. After display library members are isolated for binding to the target molecule, each isolated library member is tested for its ability to bind to a non-target molecule a non-target listed above). For example, a high-throughput ELISA screen can be used to obtain this data. The ELISA screen can also be used to obtain quantitative data for binding of each library member to the target. The non-target and target binding data are compared using a computer and software) to identify library members that WO 2006/020706 PCT/US2005/028413 specifically bind to Tiel, Tie2, Ang, fragments thereof, or a complex comprising one or more such components.

[0300] The display library selection and screening methods described herein can include a selection or screening process that selects for display library members that bind to specific sites on the target molecule. For example, elution with high concentration of an antibody described herein can be used to select for phage that bind to an epitope that is near or overlaps with the epitope bound by the antibody used for elution. Accordingly, one can screen for a phage that binds to the E3-binding site of Tiel by performing ELISAs with and without E3 antibody in the buffer.

[0301] The following description provides one exemplary method for identifying antibodies that bind to Tiel using a phagemid Fab library. For example, three rounds of selection can be performed with decreasing amounts of target protein 100, 50 and 50 jig for first, second, and third rounds, respectively). The target is immobilized on streptavidin coated magnetic beads (Dynal). The library is depleted against streptavidin coated magnetic beads prior to each round of selection and optionally against an unrelated protein which may include a common purification handle. For example, if the target is produced as a fusion to a Fe domain, the library can be depleted against soluble Trail-Fc (a commercially available Fe fusion protein).

The depletion process removes Fc binders.

[0302] Each round of selection can include, two cycles of streptavidin magnetic bead depletion, a cycle of binding of phage to Tiel-coated beads, ten cycles of washes, elution of bound phage, and propagation of enriched phage for the next round. Phage bound to Tiel-coated beads after ten washes can be directly amplified or eluted before amplification. After three rounds of selection, individual clones may be grown in 96-well microtiter plates and individually screened for Tiel binding activity by phage ELISA. ELISAs can include evaluations of binding to Tiel, specificity controls, and unrelated controls. Isolates can be DNA fingerprinted to determine the diversity emerging from the selection process. For example, positive isolates can be PCR amplified with the oligonucleotide primers M13-reverse and geneIII-forward (see, Marks et al. (1991), J. Mol. Biol. 222:581). The products can be analyzed by BstNI fingerprinting.

WO 2006/020706 PCT/US2005/028413 [0303] An exemplary method for performing ELISA's with phage that display a binding protein is as follows. Individual clones can be grown and rescued as described previously (Marks et al. (1991), J. Mol. Biol. 222:581). For ELISAs, 96well Immulon 2 HB plates (Thermo Labsystems) are coated with 1 [tg/well ImmunoPureTM streptavidin (Pierce) in PBS and incubated overnight at 4°C. After three washes with PBS, 100 jtL ofbiotinylated Tiel protein is allowed to bind to the immobilized streptavidin for 30-60 minutes at room temperature. Then, Tiel-coated wells are blocked with 300 pL of 2% milk/lx PBS/0.05% Tween MPBST) for two hours at 37°C. The wells are incubated with 100 IL of phage culture supernatant that had been blocked with 2% MPBST for one hour at room temperature. The wells are washed five times with IxPBS/Tween 0.1% (PBST), and incubated with 100 tL of anti-M13-HRP secondary antibody at a 1:5,000 dilution for one hour at room temperature. The wells are washed five times with PBST before developing with TMB-solution and read at 630 nm.

[0304] For the cell ELISAs, cells are washed once in PBS and resuspended at a concentration of 1 x 106 to 2 x 106 cells/mL ofPBS. A final concentration of 1-2 x s cells per well of a 96-well tissue culture plate (Falcon, VWR) can be used. The cells are fixed by adding an equal volume of 0.2% glutaraldehyde (Sigma-Aldrich) and incubating at 37°C for 12 minutes. They are then washed three times with PBS using an automated plate washer (Bio-Tek Instruments, Inc.) and blocked with 200 iL of 2% MPBST for one hour at room temperature. The rest of the ELISA procedure can be performed as described above except that IxPBS/Tween 0.05% is used for the washes and incubations.

[0305] Germlining Antibodies [0306] It is possible to modify an antibody that binds Tiel, Tie2, or Ang, e.g., an antibody described herein, in order to make the variable regions of the antibody more similar to one or more germline sequences. For example, an antibody can include one, two, three or more amino acid substitutions, in a framework or CDR region, to make it more similar to a reference germline sequence. One exemplary germlining method can include: identifying one or more germline sequences that are similar most similar in a particular database) to the sequence of the isolated antibody. Then mutations (at the amino acid level) can be made in the isolated WO 2006/020706 PCT/US2005/028413 antibody, either incrementally, in combination, or both. For example, a nucleic acid library that includes sequences encoding some or all possible germline mutations is made. The mutated antibodies are then evaluated, to identify an antibody that has one or more additional germline residues relative to the isolated antibody and that is still useful has a functional activity). In one embodiment, as many germline residues are introduced into an isolated antibody as possible.

[0307] In one embodiment, mutagenesis is used to substitute or insert one or more germline residues into a CDR region. For example, the germline CDR residue can be from a germline sequence that is similar most similar) to the variable region being modified. After mutagenesis, activity binding or other functional activity) of the antibody can be evaluated to determine if the germline residue or residues are tolerated. Similar mutagenesis can be performed in the framework regions.

[0308] Selecting a germline sequence can be performed in different ways. For example, a germline sequence can be selected if it meets a predetermined criteria for selectivity or similarity, at least a certain percentage identity, at least 75, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 99.5% identity. The selection can be performed using at least 2, 3, 5, or 10 germline sequences. In the case of CDR1 and CDR2, identifying a similar germline sequence can include selecting one such sequence. In the case of CDR3, identifying a similar germline sequence can include selecting one such sequence, but may including using two germline sequences that separately contribute to the amino-terminal portion and the carboxy-terminal portion.

In other implementations more than one or two germline sequences are used, to form a consensus sequence.

[0309] In one embodiment, with respect to a particular reference variable domain sequence, a sequence described herein, a related variable domain sequence has at at least 30, 40, 50, 60, 70, 80, 90, 95 or 100% of the CDR amino acid positions that are not identical to residues in the reference CDR sequences, residues that are identical to residues at corresponding positions in a human germline sequence an amino acid sequence encoded by a human germline nucleic acid).

[0310] In one embodiment, with respect to a particular reference variable domain sequence, a sequence described herein, a related variable domain WO 2006/020706 PCT/US2005/028413 sequence has at at least 30, 50, 60, 70, 80, 90 or 100% of the FR regions are identical to FR sequence from a human germline sequence, a germline sequence related to the reference variable domain sequence.

[0311] Accordingly, it is possible to isolate an antibody which has similar activity to a given antibody of interest, but is more similar to one or more germline sequences, particularly one or more human germline sequences. For example, an antibody can be at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5% identical to a germline sequence in a region outside the CDRs framework regions). Further an antibody can include at least 1, 2, 3, 4, or 5 germline residues in a CDR region, the germline residue being from a germline sequence of similar most similar) to the variable region being modified. Germline sequences of primary interest are human germline sequences. The activity of the antibody the binding activity) can be within a factor or 100, 10, 5, 2, 0.5, 0.1, and 0.001 of the original antibody.

[0312] Exemplary germline reference sequences for Vkappa include: 012/02, 018/08, A20, A30, L14, LI, L15, L4/18a, L5/L19, L8, L23, L9 ,L24, L11, L12, 011/01, A17, Al, A18, A2, A19/A3, A23, A27, All, L2/L16, L6, L20, B3, B2, A26/A10, and A14. See, Tomlinson et al. (1995) EMBO J. 14(18):4628- 3.

[0313] A germline reference sequence for the HC variable domain can be based on a sequence that has particular canonical structures, 1-3 structures in the H1 and H2 hypervariable loops. The canonical structures ofhypervariable loops of an immunoglobulin variable domain can be inferred from its sequence, as described in Chothia et al. (1992) J. Mol. Biol. 227:799-817; Tomlinson et al. (1992) J. Mol. Biol.

227:776-798); and Tomlinson et al. (1995) EMBO J. 14(18):4628-38. Exemplary sequences with a 1-3 structure include: DP-1, DP-8, DP-12, DP-2, DP-25, DP-15, DP- 7, DP-4, DP-31, DP-32, DP-33, DP-35, DP-40, 7-2, hv3005, hv3005f3, DP-46, DP- 47, DP-58, DP-49, DP-50, DP-51, DP-53, and DP-54.

[0314] Diversity [0315] Display libraries and other libraries include variation at one or more positions in the displayed polypeptide. The variation at a given position can be synthetic or natural. For some libraries, both synthetic and natural diversity are included.

WO 2006/020706 PCT/US2005/028413 [0316] Synthetic Diversity. Libraries can include regions of diverse nucleic acid sequence that originate from artificially synthesized sequences. Typically, these are formed from degenerate oligonucleotide populations that include a distribution of nucleotides at each given position. The inclusion of a given sequence is random with respect to the distribution. One example of a degenerate source of synthetic diversity is an oligonucleotide that includes NNN wherein N is any of the four nucleotides in equal proportion.

[0317] Synthetic diversity can also be more constrained, to limit the number of codons in a nucleic acid sequence at a given trinucleotide to a distribution that is smaller than NNN. For example, such a distribution can be constructed using less than four nucleotides at some positions of the codon. In addition, trinucleotide addition technology can be used to further constrain the distribution. So-called "trinucleotide addition technology" is described, in Wells et al. (1985) Gene 34:315-323, US 4,760,025 and US 5,869,644.

[0318] Natural Diversity. Libraries can include regions of diverse nucleic acid sequence that originate (or are synthesized based on) from different naturallyoccurring sequences. An example of natural diversity that can be included in a display library is the sequence diversity present in immune cells (see also below).

Nucleic acids are prepared from these immune cells and are manipulated into a format for polypeptide display.

[03191 Antibody Display Libraries [0320] In one embodiment, the display library presents a diverse pool of proteins, each of which includes an immunoglobulin domain, an immunoglobulin variable domain. Display libraries are particular useful, for example for identifying human or "humanized" antibodies that recognize human antigens. Such antibodies can be used as therapeutics to treat human disorders such as endothelial-related disorders, metastatic cancer. Since the constant and framework regions of the antibody are human, these therapeutic antibodies may avoid themselves being recognized and targeted as antigens. The constant regions are also optimized to recruit effector functions of the human immune system. The in vitro display selection process surmounts the inability of a normal human immune system to generate antibodies against self-antigens.

WO 2006/020706 PCT/US2005/028413 [0321] A typical antibody display library displays a polypeptide that includes a VH domain and a VL domain. An "immunoglobulin domain" refers to a domain from the variable or constant domain of immunoglobulin molecules. Immunoglobulin domains typically contain two P-sheets formed of about seven P-strands, and a conserved disulphide bond (see, A. F. Williams and A. N. Barclay 1988 Ann. Rev Immunol. 6:381-405). The canonical structures of hypervariable loops of an immunoglobulin variable can be inferred from its sequence, as described in Chothia et al. (1992) J. Mol. Biol. 227:799-817; Tomlinson et al. (1992) Mol. Biol. 227:776- 798); and Tomlinson et al. (1995) EMBO J. 14(18):4628-38. The display library can display the antibody as a Fab fragment using two polypeptide chains) or a single chain Fv using a single polypeptide chain). Other formats can also be used.

[0322] As in the case of the Fab and other formats, the displayed antibody can include a constant region as part of a light or heavy chain. In one embodiment, each chain includes one constant region, as in the case of a Fab. In other embodiments, additional constant regions are displayed.

[0323] Antibody libraries can be constructed by a number of processes (see, de Haard et al. (1999) J. Biol. Chem 274:18218-30; Hoogenboom et al. (1998) Immunotechnology 4:1-20. and Hoogenboom et al. (2000) Immunol Today 21:371-8).

Further, elements of each process can be combined with those of other processes. The processes can be used such that variation is introduced into a single immunoglobulin domain VH or VL) or into multiple immunoglobulin domains VH and VL). The variation can be introduced into an immunoglobulin variable domain, e.g., in the region of one or more of CDR1, CDR2, CDR3, FR1, FR2, FR3, and FR4, referring to such regions of either and both of heavy and light chain variable domains.

In one embodiment, variation is introduced into all three CDRs of a given variable domain. In another preferred embodiment, the variation is introduced into CDR1 and CDR2, of a heavy chain variable domain. Any combination is feasible. [0324] In one process, antibody libraries are constructed by inserting diverse oligonucleotides that encode CDRs into the corresponding regions of the nucleic acid.

The oligonucleotides can be synthesized using monomeric nucleotides or trinucleotides. For example, Knappik et al. (2000) J. Mol. Biol. 296:57-86 describe a method for constructing CDR encoding oligonucleotides using trinucleotide synthesis and a template with engineered restriction sites for accepting the oligonucleotides.

WO 2006/020706 PCT/US2005/028413 [0325] In another process, an animal, a non-human animal, a rodent, is immunized with the Tiel. The animal is optionally boosted with the antigen to further stimulate the response. Then spleen cells are isolated from the animal, and nucleic acid encoding VH and/or VL domains is amplified and cloned for expression in the display library. The non-human animal can include one or more human immunoglobulin gene sequences. For example, the animal can include a complete human immunoglobulin locus. The animal may also have an inactivated endogenous immunoglobulin locus.

[0326] In yet another process, antibody libraries are constructed from nucleic acid amplified from naive germline immunoglobulin genes human genes). The amplified nucleic acid includes nucleic acid encoding the VH and/or VL domain.

Sources ofimmunoglobulin-encoding nucleic acids are described below.

Amplification can include PCR, with primers that anneal to the conserved constant region, or another amplification method.

[0327] Nucleic acid encoding immunoglobulin domains or fragments thereof can be obtained from the immune cells of, a human, a primate, mouse, rabbit, camel, or rodent. In one example, the cells are selected for a particular property. B cells at various stages of maturity can be selected. In another example, the B cells are naive.

[0328] In one embodiment, fluorescent-activated cell sorting (FACS) is used to sort B cells that express surface-bound IgM, IgD, or IgG molecules. Further, B cells expressing different isotypes of IgG can be isolated. In another preferred embodiment, the B or T cell is cultured in vitro. The cells can be stimulated in vitro, by culturing with feeder cells or by adding mitogens or other modulatory reagents, such as antibodies to CD40, CD40 ligand or CD20, phorbol myristate acetate, bacterial lipopolysaccharide, concanavalin A, phytohemagglutinin or pokeweed mitogen.

[0329] In still another embodiment, the cells are isolated from a subject that has an immunological disorder, systemic lupus erythematosus (SLE), rheumatoid arthritis, vasculitis, Sjogren syndrome, systemic sclerosis, or anti-phospholipid syndrome. The subject can be a human, or an animal, an animal model for the human disease, or an animal having an analogous disorder. In yet another WO 2006/020706 PCT/US2005/028413 emooalment, me cells are isolated from a transgenic non-human animal that includes a human immunoglobulin locus.

[0330] In one preferred embodiment, the cells have activated a program of somatic hypermutation. Cells can be stimulated to undergo somatic mutagenesis of immunoglobulin genes, for example, by treatment with anti-immunoglobulin, antiand anti-CD38 antibodies (see, Bergthorsdottir et al. (2001) Jlmmunol.

166:2228). In another embodiment, the cells are naive.

[0331] The nucleic acid encoding an immunoglobulin variable domain can be isolated from a natural repertoire by the following exemplary method. First, RNA is isolated from the immune cell. Full length capped) mRNAs are separated (e.g.

by dephosphorylating uncapped RNAs with calf intestinal phosphatase). The cap is then removed with tobacco acid pyrophosphatase and reverse transcription is used to produce the cDNAs.

[0332] The reverse transcription of the first (antisense) strand can be done in any manner with any suitable primer. See, de Haard et al. (1999) J. Biol. Chem 274:18218-30. The primer binding region can be constant among different immunoglobulins, in order to reverse transcribe different isotypes of immunoglobulin. The primer binding region can also be specific to a particular isotype ofimmunoglobulin. Typically, the primer is specific for a region that is 3' to a sequence encoding at least one CDR. In another embodiment, poly-dT primers may be used (and may be preferred for the heavy-chain genes).

[0333] A synthetic sequence can be ligated to the 3' end of the reverse transcribed strand. The synthetic sequence can be used as a primer binding site for binding of the forward primer during PCR amplification after reverse transcription.

The use of the synthetic sequence can obviate the need to use a pool of different forward primers to fully capture the available diversity.

[0334] The variable domain-encoding gene is then amplified, using one or more rounds. If multiple rounds are used, nested primers can be used for increased fidelity. The amplified nucleic acid is then cloned into a display library vector.

[0335] Any method for amplifying nucleic acid sequences may be used for amplification. Methods that maximize and do not bias diversity are preferred. A variety of techniques can be used for nucleic acid amplification. The polymerase WO 2006/020706 PCT/US2005/028413 chain reaction (PCR; U.S. Patent Nos. 4,683,195 and 4,683,202, Saiki, et al. (1985) Science 230, 1350-1354) utilizes cycles of varying temperature to drive rounds of nucleic acid synthesis. Transcription-based methods utilize RNA synthesis by RNA polymerases to amplify nucleic acid Pat. No 6,066,457; U.S. Pat. No 6,132,997; U.S. Pat. No 5,716,785; Sarkar et. al., Science (1989) 244: 331-34; Stofler et al., Science (1988) 239: 491). NASBA Patent Nos. 5,130,238; 5,409,818; and 5,554,517) utilizes cycles of transcription, reverse-transcription, and RNaseH-based degradation to amplify a DNA sample. Still other amplification methods include rolling circle amplification (RCA; U.S. Patent Nos. 5,854,033 and 6,143,495) and strand displacement amplification (SDA; U.S. Patent Nos. 5,455,166 and 5,624,825).

[03361 Secondary Screening Methods [0337] After selecting candidate display library members that bind to a target, each candidate display library member can be further analyzed, to further characterize its binding properties for the target. Similarly candidate binding proteins by immunization, etc.) obtained by other methods can also be analyzed. Each candidate binding protein can be subjected to one or more secondary screening assays. The assay can be for a binding property, a catalytic property, a physiological property cytotoxicity, renal clearance, immunogenicity), a structural property stability, conformation, oligomerization state) or another functional property.

The same assay can be used repeatedly, but with varying conditions, to determine pH, ionic, or thermal sensitivities.

[0338] As appropriate, the assays can use the display library member directly, a recombinant polypeptide produced from the nucleic acid encoding a displayed polypeptide, or a synthetic peptide synthesized based on the sequence of a displayed polypeptide. Exemplary assays for binding properties include the following.

[0339] ELISA. Proteins encoded by a display library can also be screened for a binding property using an ELISA assay. For example, each protein is contacted to a microtitre plate whose bottom surface has been coated with the target, a limiting amount of the target. The plate is washed with buffer to remove non-specifically bound polypeptides. Then the amount of the protein bound to the plate is determined by probing the plate with an antibody that can recognize the polypeptide, a tag or WO 2006/020706 PCT/US2005/028413 constant portion of the polypcptide. The antibody is linked to an enzyme such as alkaline phosphatase, which produces a colorimetric product when appropriate substrates are provided. The protein can be purified from cells or assayed in a display library format, as a fusion to a filamentous bacteriophage coat. Alternatively, cells live or fixed) that express the target molecule, Tiel, Tie2, or Ang, can be plated in a microtitre plate and used to test the affinity of the peptides/antibodies present in the display library or obtained by selection from the display library.

[0340] Cell Binding Assays. Binding proteins Tiel, Tie2, or Ang binding proteins) can be evaluated for their ability to interact with one or more cell types, endothelial cells or platelets. Fluorescent activated cell sorting (FACS) is one exemplary method for testing an interaction between a protein and a cell. The binding protein is labeled directly or indirectly with a fluorophore, before or after, binding to the cells, and then cells are counted in a FACS sorter.

[0341] For example, the following method can be used to evaluate whether a Tiel binding protein interacts with platelets or other cell types.

[0342] Isolation of Platelets. Human blood can be obtained from informed healthy volunteers. For example, venous blood is collected into one-sixth volume of ACD (2.5 g of sodium citrate, 1.5 g citric acid, and 2.5 g glucose in 100 ml dH 2 0).

The blood is centrifuged at 800 X g for 15 min at room temperature and the plateletrich plasma is removed and incubated for 60 min at 37°C. in the presence of 1 mM acetylsalicylic acid followed by centrifugation at 1000 x g for 10 min at room temperature. The platelet pellet can be resuspended at a density of 2 x 10 s cells/ml with HEPES-buffered Tyrode's solution (137 mM NaC1, 2.7 mM KCI, 1 mM MgC1 2 3 mM NaH 2

PO

4 5 mM glucose, 10 mM HEPES pH 7.4, 0.2% bovine serum albumin, and 0.05 U/mL apyrase). See also, Kornecki et al. (1990) J Biol Chem.

265:10,042-10,048 and Naik et al. (1995) Biochem J. 310:155-162).

[0343] FACS. For example, for FACS analysis of platelets, cells can be resuspended in 0.1% BSA/PBS (4 x 105 cells/sample) in the presence of PGE1 (1 mg/mL) and incubated with a candidate Tiel binding protein at about gg/mL) or with a control. After a 1-hour incubation at 22 0 C, the cells are washed with 0.1% BSA/PBS, treated with 50 giL 1/100 diluted FITC-labeled secondary antibody, incubated for 30 minutes on ice, washed, and resuspended in 0.1% BSA/PBS. The WO 2006/020706 PCT/US2005/028413 samples are analyzed using an Immunocytometry Systems flow cytometer

(FACSORT

T M Becton Dickinson, San Jose, CA). See also, Malgorzata et al.

(2000) Blood, Vol. 95 No. 8 (April 15 pp. 2600-2609.

[0344] In addition, it is possible to evaluate platelets by Westerns analysis of SDS-page separated proteins from isolated platelets and by immunoprecipitation.

Still other methods involve binding cells to surfaces to which the Tiel-binding protein is attached coated to).

[0345] Other cell types can be prepared for FACS by methods known in the art.

[0346] Homogeneous Binding Assays. The binding interaction of candidate polypeptide with a target can be analyzed using a homogenous assay, after all components of the assay are added, additional fluid manipulations are not required.

For example, fluorescence resonance energy transfer (FRET) can be used as a homogenous assay (see, for example, Lakowicz et al., U.S. Patent No. 5,631,169; Stavrianopoulos, et al., U.S. Patent No. 4,868,103). A fluorophore label on the first molecule the molecule identified in the fraction) is selected such that its emitted fluorescent energy can be absorbed by a fluorescent label on a second molecule the target) if the second molecule is in proximity to the first molecule. The fluorescent label on the second molecule fluoresces when it absorbs to the transferred energy. Since the efficiency of energy transfer between the labels is related to the distance separating the molecules, the spatial relationship between the molecules can be assessed. In a situation in which binding occurs between the molecules, the fluorescent emission of the 'acceptor' molecule label in the assay should be maximal.

A binding event that is configured for monitoring by FRET can be conveniently measured through standard fluorometric detection means well known in the art using a fluorimeter). By titrating the amount of the first or second binding molecule, a binding curve can be generated to estimate the equilibrium binding constant.

[0347] Surface Plasmon Resonance (SPR). The binding interaction of a molecule isolated from a display library and a target can be analyzed using SPR. SPR or Biomolecular Interaction Analysis (BIA) detects biospecific interactions in real time, without labeling any of the interactants. Changes in the mass at the binding surface (indicative of a binding event) of the BIA chip result in alterations of the WO 2006/020706 PCT/US2005/028413 refractive index of light near the surface (the optical phenomenon of surface plasmon resonance The changes in the refractivity generate a detectable signal, which are measured as an indication of real-time reactions between biological molecules.

Methods for using SPR are described, for example, in U.S. Patent No. 5,641,640; Raether (1988) Surface Plasmons Springer Verlag; Sjolander and Urbaniczky (1991) Anal. Chem. 63:2338-2345; Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699-705 and on-line resources provide by BIAcore International AB (Uppsala, Sweden).

[0348] Information from SPR can be used to provide an accurate and quantitative measure of the equilibrium dissociation constant and kinetic parameters, including Kon and Koff, for the binding of a biomolecule to a target. Such data can be used to compare different biomolecules. For example, different proteins can be compared to identify individuals that have high affinity for the target or that have a slow Koff. This information can also be used to develop structure-activity relationships (SAR). For example, the kinetic and equilibrium binding parameters of matured versions of a parent protein can be compared to the parameters of the parent protein. Variant amino acids at given positions can be identified that correlate with particular binding parameters, high affinity and slow Koff. This information can be combined with structural modeling using homology modeling, energy minimization, or structure determination by crystallography or NMR). As a result, an understanding of the physical interaction between the protein and its target can be formulated and used to guide other design processes.

[0349] Protein Arrays. Proteins identified from the display library can be immobilized on a solid support, for example, on a bead or an array. For a protein array, each of the polypeptides is immobilized at a unique address on a support.

Typically, the address is a two-dimensional address. Protein arrays are described below (see, Diagnostics). It is also possible to use a protein array to evaluate any plurality of proteins, for interaction with Tiel, Tie2, or Aug.

[0350] Cellular Assays. Candidate proteins can be selected from a library by transforming the library into a host cell; the library could have been previously identified from a display library. For example, the library can include vector nucleic acid sequences that include segments that encode the polypeptides and that direct expression, such that the proteins are produced within the cell, secreted from the cell, or attached to the cell surface. The cells can be screened or selected for proteins WO 2006/020706 PCT/US2005/028413 that bind to the Tiel, Tie2, or Ang, as detected by a change in a cellular phenotype or a cell-mediated activity. For example, in the case of an antibody that binds to Tiel, the activity may be autophosphorylation, activation ofPI3 Kinase, activation of AKT, or a change in endothelial cell activity proliferation).

[0351] In another embodiment, the library of cells is in the form of a cellular array. The cellular array can likewise be screened for any appropriate detectable activity. In other embodiments, competition binding assays are used to identify proteins that are compete with a reference protein for binding to Tiel. Similarly, epitope mapping can be used to identify proteins that bind to a particular epitope of Tie. Fragments and mutants of Tiel can be also be used in the binding proteinidentification process, in one or more of characterization, screening, or immunization.

[03521 Methods for Obtaining Target-Binding Antibodies [0353] In addition to the use of display libraries, other methods can be used to obtain a target-binding antibody or in combination with the use of display libraries.

For example, the Tiel ectodomain or a region thereof can be used as an antigen in a non-human animal, a rodent. Similarly, Tie2 or Ang, or a region thereof can be used as an antigen in a non-human animal, a rodent.

[0354] In one embodiment, the non-human animal includes at least a part of a human immunoglobulin gene. For example, it is possible to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci.

Using the hybridoma technology, antigen-specific Mabs derived from the genes with the desired specificity may be produced and selected. See, XenoMouseTM, Green et al. Nature Genetics 7:13-21 (1994), U.S. 20030070185, WO 96/34096, published Oct. 31, 1996, and PCT Application No. PCT/US96/05928, filed Apr. 29, 1996.

[0355] In another embodiment, a monoclonal antibody is obtained from the non-human animal, and then modified, humanized or deimmunized. Winter describes a CDR-grafting method that may be used to prepare the humanized antibodies (UK Patent Application GB 2188638A, filed on March 26, 1987; Winter US 5,225,539. All of the CDRs of a particular human antibody may be replaced with at least a portion of a non-human CDR or only some of the CDRs may be replaced WO 2006/020706 PCT/US2005/028413 witt non-numan UUKts. It is only necessary to replace the number of CDRs required for binding of the humanized antibody to a predetermined antigen.

[0356] Humanized antibodies can be generated by replacing sequences of the Fv variable region that are not directly involved in antigen binding with equivalent sequences from human Fv variable regions. General methods for generating humanized antibodies are provided by Morrison, S. 1985, Science 229:1202-1207, by Oi et al., 1986, BioTechniques 4:214, and by Queen et al. US 5,585,089, US 5,693,761 and US 5,693,762. Those methods include isolating, manipulating, and expressing the nucleic acid sequences that encode all or part of immunoglobulin Fv variable regions from at least one of a heavy or light chain. Sources of such nucleic acid are well known to those skilled in the art and, for example, may be obtained from a hybridoma producing an antibody against a predetermined target, as described above. The recombinant DNA encoding the humanized antibody, or fragment thereof, can then be cloned into an appropriate expression vector.

[0357] A target-binding antibody may also be modified by specific deletion of human T cell epitopes or "deimmunization" by the methods disclosed in WO 98/52976 and WO 00/34317, the contents of which are specifically incorporated by reference herein. Briefly, the heavy and light chain variable regions of an antibody can be analyzed for peptides that bind to MHC Class II; these peptides represent potential T-cell epitopes (as defined in WO 98/52976 and WO 00/34317). For detection of potential T-cell epitopes, a computer modeling approach termed "peptide threading" can be applied, and in addition a database of human MHC class II binding peptides can be searched for motifs present in the VH and VL sequences, as described in WO 98/52976 and WO 00/34317. These motifs bind to any of the 18 major MHC class II DR allotypes, and thus constitute potential T cell epitopes. Potential T-cell epitopes detected can be eliminated by substituting small numbers of amino acid residues in the variable regions, or preferably, by single amino acid substitutions. As far as possible conservative substitutions are made, often but not exclusively, an amino acid common at this position in human germline antibody sequences may be used. Human germline sequences are disclosed in Tomlinson, I.A. et al. (1992) J Mol. Biol. 227:776-798; Cook, G. P. et al. (1995) Immunol. Today Vol. 16 237- 242; Chothia, D. et al. (1992) J. Mol. Bio. 227:799-817. The V BASE directory provides a comprehensive directory of human immunoglobulin variable region WO 2006/020706 PCT/US2005/028413 sequences (compiled by Tomlinson, I.A. et al. MRC Centre for Protein Engineering, Cambridge, UK). After the deimmunizing changes are identified, nucleic acids encoding VH and VL can be constructed by mutagenesis or other synthetic methods de novo synthesis, cassette replacement, and so forth). Mutagenized variable sequence can, optionally, be fused to a human constant region, human IgG1 or K constant regions.

[0358] In some cases a potential T cell epitope will include residues which are known or predicted to be important for antibody function. For example, potential T cell epitopes are usually biased towards the CDRs. In addition, potential T cell epitopes can occur in framework residues important for antibody structure and binding. Changes to eliminate these potential epitopes will in some cases require more scrutiny, by making and testing chains with and without the change.

Where possible, potential T cell epitopes that overlap the CDRs were eliminated by substitutions outside the CDRs. In some cases, an alteration within a CDR is the only option, and thus variants with and without this substitution should be tested. In other cases, the substitution required to remove a potential T cell epitope is at a residue position within the framework that might be critical for antibody binding. In these cases, variants with and without this substitution should be tested. Thus, in some cases several variant deimmunized heavy and light chain variable regions were designed and various heavy/light chain combinations tested in order to identify the optimal deimmunized antibody. The choice of the final deimmunized antibody can then be made by considering the binding affinity of the different variants in conjunction with the extent of deimmunization, the number of potential T cell epitopes remaining in the variable region. Deimmunization can be used to modify an antibody that includes a non-human sequence, a murine antibody or other nonhuman monoclonal antibody. Deimmunization can be used to modify an antibody isolated from a display library.

[03591 Endothelial Cell Assays [0360] A target-binding protein or a candidate binding protein can be characterized using a cellular assay, to evaluate a change in a cellular phenotype or other activity when the binding protein is contacted to the cell. Typically the cell is expresses a protein that includes at least part of the ectodomain of Tie. In some WO 2006/020706 PCT/US2005/028413 embodiments, the cell expresses 'liel, a full-length, mature Tiel protein, Tie2, and/or is contacted with Ang..

[0361] Endothelial cell proliferation. A candidate target-binding protein can be tested for endothelial proliferation inhibiting activity using a biological activity assay such as the bovine capillary endothelial cell proliferation assay, the chick CAM assay, the mouse coreal assay, and evaluating the effect of the binding protein on implanted tumors. The chick CAM assay is described, by O'Reilly, et al. in "Angiogenic Regulation of Metastatic Growth" Cell, vol. 79 Oct. 21, 1994, pp.

315-328. Briefly, three day old chicken embryos with intact yolks are separated from the egg and placed in a petri dish. After three days of incubation a methylcellulose disc containing the protein to be tested is applied to the CAM of individual embryos.

After 48 hours of incubation, the embryos and CAMs are observed to determine whether endothelial growth has been inhibited. The mouse corneal assay involves implanting a growth factor-containing pellet, along with another pellet containing the suspected endothelial growth inhibitor, in the cornea of a mouse and observing the pattern of capillaries that are elaborated in the cornea.

[0362] Angiogenesis. Angiogenesis may be assayed, using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FLUOROBLOCKTM cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on MATRIGELTM (Becton Dickinson) or collagen I.

[0363] Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins or adhesion of cells to each other, in presence or absence of candidate target-binding proteins. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5 g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2 x final test concentration and added to the blocked, coated wells. Cells WO 2006/020706 PCT/US2005/028413 are then added to the wells, and the unbound cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

[0364] Cell-cell adhesion assays can be used to measure the ability of candidate target-binding proteins to modulate binding of cells to each other. These assays can use cells that naturally or recombinantly express an adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate together with other cells (either more of the same cell type, or another type of cell to which the cells adhere). The cells that can adhere are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate binding proteins. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

High-throughput cell adhesion assays have also been described. See, Falsey J R et al., Bioconjug Chem. May-June 2001;12(3):346-53.

[0365] Tubulogenesis. Tubulogenesis assays can be used to monitor the ability of cultured cells, generally endothelial cells, to form tubular structures on a matrix substrate, which generally simulates the environment of the extracellular matrix.

Exemplary substrates include MATRIGELTM (Becton Dickinson), an extract of basement membrane proteins containing laminin, collagen IV, and heparin sulfate proteoglycan, which is liquid at 4 0 C. and forms a solid gel at 37 0 C. Other suitable matrices comprise extracellular components such as collagen, fibronectin, and/or fibrin. Cells are stimulated with a pro-angiogenic stimulant, and their ability to form tubules is detected by imaging. Tubules can generally be detected after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Tube formation assays are well known in the art Jones M K et al., 1999, Nature Medicine 5:1418-1423). These assays have traditionally involved stimulation with serum or with the growth factors FGF or VEGF. In one embodiment, the assay is performed with cells cultured in serum free medium. In one embodiment, the assay is performed in the presence of one or more pro-angiogenic agents, inflammatory angiogenic factors such as TNF-a, or FGF, VEGF, phorbol myristate acetate (PMA), TNF-alpha, ephrin, etc.

[0366] Cell Migration. An exemplary assay for endothelial cell migration is the human microvascular endothelial (HMVEC) migration assay. See, Tolsma et WO 2006/020706 PCT/US2005/028413 al. (1993) J. Cell Biol 122, 497-511. Migration assays are known in the art Paik J H et al., 2001, J Biol Chem 276:11830-11837). In one example, cultured endothelial cells are seeded onto a matrix-coated porous lamina, with pore sizes generally smaller than typical cell size. The lamina is typically a membrane, such as the transwell polycarbonate membrane (Coming Costar Corporation, Cambridge, Mass.), and is generally part of an upper chamber that is in fluid contact with a lower chamber containing pro-angiogenic stimuli. Migration is generally assayed after an overnight incubation with stimuli, but longer or shorter time frames may also be used. Migration is assessed as the number of cells that crossed the lamina, and may be detected by staining cells with hemotoxylin solution (VWR Scientific.), or by any other method for determining cell number. In another exemplary set up, cells are fluorescently labeled and migration is detected using fluorescent readings, for instance using the Falcon HTS FLUOROBLOKTM (Becton Dickinson). While some migration is observed in the absence of stimulus, migration is greatly increased in response to proangiogenic factors. The assay can be used to test the effect of a target-binding protein on endothelial cell migration.

[0367] Sprouting assay. An exemplary sprouting assay is a three-dimensional in vitro angiogenesis assay that uses a cell-number defined spheroid aggregation of endothelial cells ("spheroid"), embedded in a collagen gel-based matrix. The spheroid can serve as a starting point for the sprouting of capillary-like structures by invasion into the extracellular matrix (termed "cell sprouting") and the subsequent formation of complex anastomosing networks (Korff and Augustin, 1999, J Cell Sci 112:3249-58).

In an exemplary experimental set-up, spheroids are prepared by pipetting 400 human umbilical vein endothelial cells into individual wells of a nonadhesive 96-well plates to allow overnight spheroidal aggregation (Korff and Augustin: J Cell Biol 143: 1341- 52, 1998). Spheroids are harvested and seeded in 900 pl of methocel-collagen solution and pipetted into individual wells of a 24 well plate to allow collagen gel polymerization. Test agents are added after 30 min by pipetting 100 p.1 of concentrated working dilution of the test substances on top of the gel. Plates are incubated at 37°C for 24 h. Dishes are fixed at the end of the experimental incubation period by addition of paraformaldehyde. Sprouting intensity of endothelial cells can be quantitated by an automated image analysis system to determine the cumulative sprout length per spheroid.

WO 2006/020706 PCT/US2005/028413 [0368] In some embodiments, a target-binding protein has a statistically significant effect on an assay described herein, a cellular assay desribed herein.

[03691 Protein Production [0370] Standard recombinant nucleic acid methods can be used to express a binding proteinthat binds to Tiel, Tie2, or Ang. See, for example, the techniques described in Sambrook Russell, Molecular Cloning: A Laboratory Manual, 3 rd Edition, Cold Spring Harbor Laboratory, N.Y. (2001) and Ausubel et al., Current Protocols in Molecular Biology (Greene Publishing Associates and Wiley Interscience, N.Y. (1989). Generally, a nucleic acid sequence encoding the binding proteinis cloned into a nucleic acid expression vector. If the protein includes multiple polypeptide chains, each chain can be cloned into an expression vector, the same or different vectors, that are expressed in the same or different cells. Methods for producing antibodies are also provided below.

[0371] Antibody Production. Some antibodies, Fabs, can be produced in bacterial cells, E. coli cells. For example, if the Fab is encoded by sequences in a phage display vector that includes a suppressible stop codon between the display entity and a bacteriophage protein (or fragment thereof), the vector nucleic acid can be shuffled into a bacterial cell that cannot suppress a stop codon. In this case, the Fab is not fused to the gene III protein and is secreted into the media.

[0372] Antibodies can also be produced in eukaryotic cells. In one embodiment, the antibodies scFv's) are expressed in a yeast cell such as Pichia (see, Powers et al. (2001) JImmunol Methods. 251:123-35), Hanseula, or Saccharomyces.

[0373] In one embodiment, antibodies are produced in mammalian cells.

Preferred mammalian host cells for expressing the clone antibodies or antigen-binding fragments thereof include Chinese Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216- 4220, used with a DHFR selectable marker, as described in Kaufman and Sharp (1982) Mol. Biol. 159:601-621), lymphocytic cell lines, NSO myeloma cells, SP2 cells, COS cells, HEK 293T cells, and a cell from a transgenic animal, a transgenic mammal. For example, the cell is a mammary epithelial cell.

WO 2006/020706 PCT/US2005/028413 [0374] In addition to the nucleic acid sequence encoding the immunoglobulin domain, the recombinant expression vectors may carry additional sequences, such as sequences that regulate replication of the vector in host cells origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see U.S. Patents Nos. 4,399,216, 4,634,665 and 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin or methotrexate, on a host cell into which the vector has been introduced. Preferred selectable marker genes include the dihydrofolate reductase (DHFR) gene (for use in dhfr host cells with methotrexate selection/amplification) and the neo gene (for G418 selection).

Another exemplary expression system is the glutamine synthase (GS) vector system available from Lonza Group Ltd. CH (see, Clark et al. (2004) BioProcess International 2(4):48-52; Barnes et al. (2002) Biotech Bioeng. 81(6):631-639).

[0375] In an exemplary system for recombinant expression of an antibody, or antigen-binding portion thereof, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr- CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to enhancer/promoter regulatory elements derived from SV40, CMV, adenovirus and the like, such as a CMV enhancer/AdMLP promoter regulatory element or an enhancer/AdMLP promoter regulatory element) to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification. The selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium. For example, some antibodies can be isolated by affinity chromatography with a Protein A or Protein G.

[0376] The codon usage can adapted to the codon bias of the host cell, for CHO cells it can be adapted for the codon bias Cricetulus griseus genes. In addition, regions of very high 80%) or very low 30%) GC content can be avoid avoided WO 2006/020706 PCT/US2005/028413 where possible. During the optimization process following cis-acting sequence motifs were avoided: internal TATA-boxes; chi-sites and ribosomal entry sites; AT-rich or GC-rich sequence stretches; ARE, INS, CRS sequence elements; repeat sequences and RNA secondary structures; and (cryptic) splice donor and acceptor sites, branch points. Two STOP codons can be used to ensure efficient termination. The codon optimization of the sequence can be evaluated according to Sharp, Li, W.H., Nucleic Acids Res. 15 1987). The standard codon adaptation index (CAI) can be used. Rare codons include those with a quality class between 0-40.

[0377] The invention features isolated nucleic acid molecules that are altered relative to a sequence described herein, to include improved codons or sequence features, include an isolated nucleic acid molecule that comprises a heavy or light chain coding sequence. For example, at least 30, 40, 45, 50, 60, 65, 70, 75, or 80% of the codons in the heavy or light chain coding sequence are non-rare or frequent codons in a mammalian cell or the heavy or light chain coding sequence includes fewer than 50, 45, 40, 35, 30, 25, 20, 15, 10% rare codons in a mammalian cell, a Chinese hamster cell (Cricetulus griseus). In one embodiment, the codon adaptation index is greater than 0.6, 0.7, 0.8, 0.85, 0.90, 0.92, 0.94, 0.95, 0.96, 0.97, or 0.98.

[0378] In one embodiment, the heavy chain coding sequence encodes a polypeptide comprising an antibody heavy chain described herein an E3 heavy chain as set forth in SEQ ID NO:723), (ii) a polypeptide at least 85, 90, 95, 96, 97, 98, or 99% identical to an antibody heavy chain coding sequence described herein SEQ ID NO:723), or (iii) a polypeptide that comprises a heavy chain variable domain sequence having the CDRs of an antibody heavy chain variable domain described herein an E3 heavy chain variable domain). In one embodiment, the heavy chain coding sequence differs from SEQ ID NO:703 at at least 2, 3, 5, 6, 8, 9, 10, or codons.

[0379] In one embodiment, the light chain coding sequence encodes a polypeptide comprising an antibody light chain described herein an E3 light chain as set forth in SEQ ID NO:724), (ii) a polypeptide at least 85, 90, 95, 96, 97, 98, or 99% identical to an antibody light chain coding sequence described herein SEQ ID NO:724), or (iii) a polypeptide that comprises a light chain variable domain sequence having the CDRs of an antibody light chain variable domain described herein an E3 light chain variable domain). In one embodiment, the light chain WO 2006/020706 PCT/US2005/028413 coding sequence differs from SEQ ID NO:702 at at least 3, 5, 6, 8, 9, 10, or codons.

[0380] In one embodiment, for example, one or more of the ala-GCG codons can be changed to GCC; one or more of the arg-CGT codons are changed to CGC; one or more of the pro-CCG codons are changed to CCC, CCT, or CCA; one or more of the ser-TCG codons are changed to TCC; and/or one or more of the thr-ACG codons are changed to ACC.

[0381] Codon-altered codon-optimized) sequences can be used to produce an antibody. An exemplary method includes providing a mammalian cell that includes an antibody-coding nucleic acid and expressing the nucleic acid in the cell, maintaining the cell under conditions in which the protein is expressed. The antibody-coding nucleic acid can be providing in a mammalian expression vector, a vector that is introduced into the cell. The cell can be a non-human mammalian cell, a CHO cell.

[0382] For antibodies that include an Fc domain, the antibody production system preferably synthesizes antibodies in which the Fc region is glycosylated. For example, the Fc domain of IgG molecules is glycosylated at asparagine 297 in the CH2 domain. This asparagine is the site for modification with biantennary-type oligosaccharides. It has been demonstrated that this glycosylation is required for effector functions mediated by Fcy receptors and complement Clq (Burton and Woof (1992) Adv. Inmunol. 51:1-84; Jefferis et al. (1998) hnmunol. Rev. 163:59-76). In a preferred embodiment, the Fe domain is produced in a mammalian expression system that appropriately glycosylates the residue corresponding to asparagine 297. The Fe domain can also include other eukaryotic post-translational modifications.

[0383] Antibodies can also be produced by a transgenic animal. For example, U.S 5,849,992 describes a method of expressing an antibody in the mammary gland of a transgenic mammal. A transgene is constructed that includes a milk-specific promoter and nucleic acids encoding the antibody of interest and a signal sequence for secretion. The milk produced by females of such transgenic mammals includes, secreted-therein, the antibody of interest. The antibody can be purified from the milk, or for some applications, used directly.

WO 2006/020706 PCT/US2005/028413 [0384] It is also possible to produce antibodies that bind to Tiel, Tie2, or Ang by immunization, using an animal, with natural, human, or partially human immunoglobulin loci. Such an antibody can be of any allotype, a,z allotype, f allotype, or non-A allotype. Non-human antibodies can also be modified to include substitutions for human immunoglobulin sequences, consensus human amino acid residues at particular positions, at one or more of the following positions (preferably at least five, ten, twelve, or all): (in the FR of the variable domain of the light chain) 4L, 35L, 36L, 38L, 43L, 44L, 58L, 46L, 62L, 63L, 64L, 65L, 66L, 67L, 68L, 69L, 70L, 71L, 73L, 85L, 87L, 98L, and/or (in the FR of the variable domain of the heavy chain) 2H, 4H, 24H, 36H, 37H, 39H, 43H, 45H, 49H, 58H, 60H, 67H, 68H, 69H, 70H, 73H, 74H, 75H, 78H, 91H, 92H, 93H, and/or 103H (according to the Kabat numbering). See, U.S. 6,407,213.

[0385] Tiel production. Methods for producing Tiel ectodomain protein, Tiel protein, or Tiel liposomes are known in the art. See, WO 93/14124.

Methods for producing Tie2 and Ang are similarly known. See U.S. Patent Nos.

6,521,424, 6,376,653; WO 96/11269; WO 96/31598.

[0386] Biotinylation Methods. A variety of methods are available to biotinylate proteins, an immunoglobulin protein or a target protein. For example, the protein can be incubated with a 5-fold molar excess of sulfo-NHS-SS-biotin in mM HEPES, pH 8.0, 100 mM NaC1 overnight at 4 0 C. Free biotin is removed by buffer exchange into PBS, 0.01% Tween 20, using a BIOMAX® device with a kDa molecular weight cut-off membrane or by dialysis. The number of biotin molecules incorporated per mole of protein can be determined using the HABA assay as described by the manufacturer (Pierce).

[03871 Pharmaceutical Compositions [0388] In another aspect, the invention provides compositions, e.g., pharmaceutically acceptable compositions, which include an agent that binds to Tiel, Tie2, or Ang, an antibody molecule, other polypeptide or peptide identified as binding to Tiel, Tie2, or Ang, or described herein, formulated with a phamnaceutically acceptable carrier. Pharmaceutical compositions encompass labeled binding proteins for in vivo imaging) as well as therapeutic compositions.

WO 2006/020706 PCT/US2005/028413 [0389] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.

Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration by injection or infusion).

Depending on the route of administration, the binding protein, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

[0390] A "pharmaceutically acceptable salt" refers to a salt that retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see Berge, et al. (1977) J. Pharm. Sci. 66:1-19).

Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.

[0391] Compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for administration of humans with antibodies. The preferred mode of administration is parenteral intravenous, subcutaneous, intraperitoneal, intramuscular). In a preferred embodiment, the target-binding protein is administered by intravenous infusion or injection. In another preferred embodiment, the target-binding protein is administered by intramuscular or subcutaneous injection.

WO 2006/020706 PCT/US2005/028413 [0392] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasteral injection and infusion.

[0393] The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.

Sterile injectable solutions can be prepared by incorporating the binding protein in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

[0394] The binding proteins described herein can be administered by a variety of methods known in the art, although for many applications, the preferred route/mode of administration is intravenous injection or infusion. For example, for therapeutic applications, the target-binding protein can be administered by intravenous infusion, at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m 2 or 7 to 25 mg/m 2 The route and/or mode of administration will vary depending upon the desired results. In certain embodiments, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be WO 2006/020706 PCT/US2005/028413 used, such as ethylene viyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known. See, Sustained and Controlled Release Drug Delivery Systems, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[0395] In certain embodiments, the binding protein may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The compound (and other ingredients, if desired) may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer a compound described herein by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation.

[0396] Pharmaceutical compositions can be administered with medical devices known in the art. For example, in a preferred embodiment, a pharmaceutical can be administered with a needleless hypodermic injection device, such as the devices disclosed in U.S. Patent Nos. 5,399,163, 5,383,851, 5,312,335, 5,064,413, 4,941,880, 4,790,824, or 4,596,556. Examples of implants and modules include: U.S. Patent No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4.,486,194, which discloses a therapeutic device for administering medicants through the skin; U.S. Patent No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Patent No. 4,439,196, which discloses an osmotic drug delivery system having multichamber compartments; and U.S. Patent No. 4,475,196, which discloses an osmotic drug delivery system. Of course, many other such implants, delivery systems, and modules are also known.

[0397] In certain embodiments, a binding protein described herein can be formulated to ensure proper distribution in vivo. For example, the blood-brain barrier (BBB) excludes many highly hydrophilic compounds. To ensure that the therapeutic WO 2006/020706 PCT/US2005/028413 protein crosses the BBB (if desired), it can be formulated, for example, in liposomes.

For methods of manufacturing liposomes, see, U.S. Patents 4,522,811; 5,374,548; and 5,399,331. The liposomes may include one or more moieties which are selectively transported into specific cells or organs, thus enhance targeted drug delivery (see, V.V. Ranade (1989) J. Clin. Pharmacol. 29:685).

[0398] Dosage regimens are adjusted to provide the optimum desired response a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms can be dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

[0399] An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody described herein is 0.1-20 mg/kg, more preferably 1-10 mg/kg. The target-binding antibody can be administered by intravenous infusion at a rate of less than 30, 20, 10, 5, or 1 mg/min to reach a dose of about 1 to 100 mg/m 2 or about 5 to 30 mg/m 2 For binding proteins smaller in molecular weight than an antibody, appropriate amounts can be proportionally less. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

WO 2006/020706 PCT/US2005/028413 [0400] The pharmaceutical compositions may be prepared using a "therapeutically effective amount" or a "prophylactically effective amount" of an target-binding protein described herein. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the binding protein to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects. A "therapeutically effective dosage" preferably inhibits a measurable parameter, inflammation or tumor growth rate by at least about more preferably by at least about 40%, even more preferably by at least about and still more preferably by at least about 80% relative to untreated subjects. The ability of a compound to inhibit a measurable parameter, cancer, can be evaluated in an animal model system predictive of efficacy in human tumors.

Alternatively, this property of a composition can be evaluated by examining the ability of the compound to inhibit, such inhibition in vitro by assays known to the skilled practitioner.

[0401] A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result.

Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0402] Also within the scope of the invention are kits including the binding protein that binds to Tiel, Tie2, or Ang and instructions for use, treatment, prophylactic, or diagnostic use. In one embodiment, the instructions for diagnostic applications include the use of the target-binding protein antibody or antigenbinding fragment thereof, or other polypeptide or peptide) to detect Tiel, Tie2, or Ang, in vitro, in a sample, a biopsy or cells from a patient having an inflammatory disorder or a cancer or neoplastic disorder, or in vivo. In another embodiment, the instructions for therapeutic applications include suggested dosages and/or modes of administration in a patient with a cancer or neoplastic disorder. The kit can further contain at least one additional reagent, such as a diagnostic or WO 2006/020706 PCT/US2005/028413 therapeutic agent, a diagnostic or therapeutic agent as described herein, and/or one or more additional target-binding proteins, formulated as appropriate, in one or more separate pharmaceutical preparations.

[0403] In one embodiment, target binding proteins (such as the Tiel antibodies described herein) can be produced from gene-based vectors, such as transgenes or via adenoviral delivery.

[04041 Stabilization and Retention [0405] In one embodiment, a target-binding agent a Tiel-binding protein, polypeptide, antibody, or aptamer described herein) is physically associated with a moiety that improves its stabilization and/or retention in circulation, in blood, serum, lymph, or other tissues.

[0406] For example, a target-binding agent can be associated with a polymer, a substantially non-antigenic polymers, such as polyalkylene oxides or polyethylene oxides. Suitable polymers will vary substantially by weight. Exemplary polymers include polymers having molecular number average weights ranging from about 200 to about 35,000, from about 1,000 to about 15,000, and 2,000 to about 12,500.

[0407] For example, an target-binding agent can be conjugated to a water soluble polymer, hydrophilic polyvinyl polymers, e.g. polyvinylalcohol and polyvinylpyrrolidone. A non-limiting list of such polymers include polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained. Additional useful polymers include polyoxyalkylenes such as polyoxyethylene, polyoxypropylene, and block copolymers of polyoxyethylene and polyoxypropylene (Pluronics); polymethacrylates; carbomers; branched or unbranched polysaccharides which comprise the saccharide monomers D-mannose, D- and L-galactose, fucose, fructose, D-xylose, L-arabinose, D-glucuronic acid, sialic acid, D-galacturonic acid, D-mannuronic acid polymannuronic acid, or alginic acid), D-glucosamine, Dgalactosamine, D-glucose and neuraminic acid including homopolysaccharides and heteropolysaccharides such as lactose, amylopectin, starch, hydroxyethyl starch, amylose, dextrane sulfate, dextran, dextrins, glycogen, or the polysaccharide subunit WO 2006/020706 PCT/US2005/028413 of acid mucopolysaccharides, e.g. hyaluronic acid; polymers of sugar alcohols such as polysorbitol and polymannitol; heparin or heparon.

[0408] Other compounds can also be attached to the same polymer, a cytotoxin, a label, or another targeting agent, another target-binding agent or an unrelated agent. Mono-activated, alkoxy-terminated polyalkylene oxides (PAO's), monomethoxy-terminated polyethylene glycols (mPEG's); C 1 -4 alkyl-terminated polymers; and bis-activated polyethylene oxides (glycols) can be used for crosslinking. See, U.S. 5,951,974.

[0409] In its most common form poly(ethylene glycol), PEG, is a linear or branched polyether terminated with hydroxyl groups and having the general structure:

HO-(CH

2

CH

2 0)-CH 2

CH

2

-OH

PEG can be synthesized by anionic ring opening polymerization of ethylene oxide initiated by nucleophilic attack of a hydroxide ion on the epoxide ring. Particularly useful for polypeptide modification is monomethoxy PEG, mPEG, having the general structure:

CH

3 0-(CH 2

CH

2 0),-CH 2

CH

2

-OH

For further description, see, Roberts et al. (2002) Advanced Drug Delivery Reviews 54:459-476.

[0410] In one embodiment, the polymer prior to cross-linking need not be, but preferably is, water soluble. Generally, after crosslinking, the product is water soluble, exhibits a water solubility of at least about 0.01 mg/ml, and more preferably at least about 0.1 mg/ml, and still more preferably at least about 1 mg/ml.

In addition, the polymer should not be highly immunogenic in the conjugate form, nor should it possess viscosity that is incompatible with intravenous infusion or injection if the conjugate is intended to be administered by such routes.

[0411] In one embodiment, the polymer contains only a single group which is reactive. This helps to avoid cross-linking of protein molecules. However, it is within the scope herein to maximize reaction conditions to reduce cross-linking, or to purify the reaction products through gel filtration or ion exchange chromatography to recover substantially homogenous derivatives. In other embodiments, the polymer contains two or more reactive groups for the purpose of linking multiple agents to the polymer backbone. Again, gel filtration or ion exchange chromatography can be used to recover the desired derivative in substantially homogeneous form.

WO 2006/020706 PCT/US2005/028413 [0412] The molecular weight of the polymer can range up to about 500,000 D, and preferably is at least about 20,000 D, or at least about 30,000 D, or at least about 40,000 D. The molecular weight chosen can depend upon the effective size of the conjugate to be achieved, the nature structure, such as linear or branched) of the polymer, and the degree of derivatization.

[0413] The covalent crosslink can be used to attach a target-binding agent a protein) to a polymer, for example, crosslinking to the N-terminal amino group and epsilon amino groups found on lysine residues, as well as other amino, imino, carboxyl, sulfhydryl, hydroxyl or other hydrophilic groups. The polymer may be covalently bonded directly to the target-binding protein without the use of a multifunctional (ordinarily bifunctional) crosslinking agent. Covalent binding to amino groups is accomplished by known chemistries based upon cyanuric chloride, carbonyl diimidazole, aldehyde reactive groups (PEG alkoxide plus diethyl acetal of bromoacetaldehyde; PEG plus DMSO and acetic anhydride, or PEG chloride plus the phenoxide of 4-hydroxybenzaldehyde, activated succinimidyl esters, activated dithiocarbonate PEG, 2,4,5-trichlorophenylcloroformate or P-nitrophenylcloroformate activated PEG.) Carboxyl groups can be derivatized by coupling PEG-amine using carbodiimide. Sulfhydryl groups can be derivatized by coupling to maleimidosubstituted PEG alkoxy-PEG amine plus sulfosuccinimidyl 4-(Nmaleimidomethyl)cyclohexane-l-carboxylate) WO 97/10847 or PEG-maleimide commercially available from Shearwater Polymers, Inc., Huntsville, Ala.).

Alternatively, free amino groups on the binding protein epsilon amino groups on lysine residues) can be thiolated with 2-imino-thiolane (Traut's reagent) and then coupled to maleimide-containing derivatives of PEG, as described in Pedley et al., Br. J. Cancer, 70: 1126-1130 (1994).

[0414] Functionalized PEG polymers that can be attached to a target-binding agent protein) are available, from Shearwater Polymers, Inc. (Huntsville, Ala.). Such commercially available PEG derivatives include, amino-PEG, PEG amino acid esters, PEG-hydrazide, PEG-thiol, PEG-succinate, carboxymethylated PEG, PEG-propionic acid, PEG amino acids, PEG succinimidyl succinate, PEG succinimidyl propionate, succinimidyl ester of carboxymethylated PEG, succinimidyl carbonate of PEG, succinimidyl esters of amino acid PEGs, PEGoxycarbonylimidazole, PEG-nitrophenyl carbonate, PEG tresylate, PEG-glycidyl WO 2006/020706 PCT/US2005/028413 ether, PEG-aldehyde, PEG vinylsulfone, PEG-maleimide, PEG-orthopyridyldisulfide, heterofunctional PEGs, PEG vinyl derivatives, PEG silanes, and PEG phospholides. The reaction conditions for coupling these PEG derivatives may vary depending on the Tiel-binding protein, the desired degree of PEGylation, and the PEG derivative utilized. Some factors involved in the choice of PEG derivatives include: the desired point of attachment (such as lysine or cysteine R-groups), hydrolytic stability and reactivity of the derivatives, stability, toxicity and antigenicity of the linkage, suitability for analysis, etc. Specific instructions for the use of any particular derivative are available from the manufacturer.

[0415] The conjugates of an target-binding agent a Tiel binding protein) and a polymer can be separated from the unreacted starting materials, by gel filtration or ion exchange chromatography, HPLC. Heterologous species of the conjugates are purified from one another in the same fashion. Resolution of different species containing one or two PEG residues) is also possible, due to the difference in the ionic properties of unreacted amino acids. See, WO 96/34015.

[0416] A target binding protein can also be physically associated with a protein that provides a stabilizing or retention function, an albumin, human serum albumin. US 20040171794 describes exemplary methods for physically associating a protein with serum albumin. For exemplary, human albumin sequences or fragments thereof, see EP 201 239, EP 322 094 WO 97/24445, W095/23857 especially the mature form of human albumin as shown in SEQ ID NO:18 of US 20040171794 and WO 01/79480 or albumin from other vertebrates or fragments thereof, or analogs or variants of these molecules or fragments thereof. Other exemplary human serum albumin proteins can include one or both of the following sets of point mutations Leu-407 to Ala, Leu-408 to Val, Val-409 to Ala, and Arg-410 to Ala; or Arg-410 to Ala, Lys-413 to Gln, and Lys-414 to Gin (see, International Publication No. W095/23857, with reference to SEQ ID NO:18 of US 20040171794).

[04171 Aptamers [0418] In one embodiment, the invention also features target protein-binding agents such as aptamers. The term nucleic acid "aptamer," as used herein, refers to a nucleic acid molecule which has a conformation that includes an internal non-duplex nucleic acid structure of at least 5 nucleotides. An aptamer can be a single-stranded WO 2006/020706 PCT/US2005/028413 nucleic acid molecule which has regions of self-complementarity. Exemplary aptamers include nucleic acid molecules that bind to a target molecule other than a nucleic acid, to Tiel, Tie2, or Ang. Particular aptamers may also modulate formation of a Tie complex or have one or more properties of a target binding agent described herein and can be used in place of a target binding protein.

[0419] Aptamers can be screened in vitro since a selected aptamer can be recovered by standard nucleic acid amplification procedures. The method can be enhanced, in later rounds of selection, by splitting selected aptamers into pools and modifying each aptamer in the pool with a detectable label such as a fluorophore.

Pools having aptamers that functionally alter the properties of the label can be identified. Such pools can be repeatedly split and reanalyzed to identify the individual aptamers with the desired properties (see, Jhaveri et al. Nature Biotechnol. 18:1293).

[0420] In addition, aptamers can be screened for activity in vivo. For example, shuffled nucleic acids can be cloned into an expression vector that is introduced into cells. RNA aptamers resulting from the expressed shuffled nucleic acids can be screened for a biological activity. Cells having the activity can be isolated and the expression vector for the selected RNA aptamer recovered.

[0421] An important feature of therapeutic oligomers aptamers) is the design of the backbone of the administered oligomer. In some embodiments, the backbone contains intemucleoside linkages that are stable in vivo and is structured such that the oligomer is resistant to endogenous nucleases, such as nucleases that attack the phosphodiester linkage. At the same time, the oligomer retains its ability to hybridize to the target DNA or RNA (Agarwal, K. L. et al. (1979) Nucleic Acids Res.

6:3009; Agarwal, S. et al. (1988) Proc. Natl. Acad. Sci USA 85:7079). Modified oligonucleotides can be constructed using alternate intemucleoside linkages. Several of these exemplary linkages are described in Uhlmann, E. and Peyman, A. (1990) Chemical Reviews 90:543-584. Among these are methylphosphonates (wherein one of the phosphorus-linked oxygens has been replaced by methyl); phosphorothioates (wherein sulphur replaces one of these oxygens) and various amidates (wherein NH 2 or an organic amine derivative, such as morpholidates or piperazidates, replace an oxygen). These substitutions confer enhanced stability. WO 91/15500 teaches various oligonucleotide analogs in which one or more of the internucleotide linkages WO 2006/020706 PCT/US2005/028413 are replaced by a sulfur based linkage, typically sulfamate diesters, which are isosteric and isoelectric with the phosphodiester. WO 89/12060 similarly discloses linkages containing sulfides, sulfoxides, and sulfones. WO 86/05518 suggests a variant of stereoregular polymeric 3',5'linkages. U.S. Pat. No. 5,079,151 discloses a msDNA molecule of branched RNA linked to a single strand DNA via a phosphodiester linkage. U.S. Pat. No. 5,264,562 describes modified linkages of the formula Y'CX' 2 wherein Y' is independently O or S and wherein each X' is a stabilizing substituent and independently chosen. Morpholino-type intemucleotide linkages are described in U.S. Pat. No. 5,034,506 and in some cases give rise to an increased affinity of the oligomer for complementary target sequences. U.S. Pat. Nos.

5,264,562 5,596,086 disclose modified oligonucleotides having modified nucleoside linkages which are capable of strong hybridization to target RNA and DNA.

[04221 Treatments [0423] Binding agents that bind to Tiel, Tie2, or Ang have therapeutic and prophylactic utilities. For example, these binding agents can be administered to cells in culture, e.g. in vitro or ex vivo, or can be administered to a subject, in vivo, to treat, prevent, and/or diagnose a variety of disorders, such as endothelial cell disorders, blood vessel development disorders, wound healing, inflammatory diseases and cancers, particularly metastatic cancers. The term "treat" or "treatment" refers to the application or administration of an agent, alone or in combination with one or more other agents a second agent) to a subject, a patient, a patient who has a disorder a disorder as described herein), a symptom of a disorder or a predisposition for a disorder, to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder, the symptoms of the disorder or the predisposition toward the disorder. Treating a cell refers to a reduction in an activity of a cell, ability of an endothelial cell to form tubes or vessels. A reduction does not necessarily require a total elimination of activity, but a reduction, a statistically significant reduction, in the activity or the number of the cell.

[0424] As used herein, an amount of a target binding agent effective to treat a disorder, or a "therapeutically effective amount" refers to an amount of the binding agent which is effective, upon single or multiple-dose administration to a subject, in treating a cell, an endothelial cell a Tiel-expressing endothelial cell) or WO 2006/020706 PCT/US2005/028413 cancer cell (particularly a metastatic cell thereof), or in prolonging curing, alleviating, relieving or improving a subject with a disorder as described herein beyond that expected in the absence of such treatment. In some cases, a therapeutically effective amount can be ascertained by evaluating the ability of the binding agent to reduce tumor size of a xenograft in a nude mouse model relative to an untreated control mouse. As used herein, "inhibiting the growth" of a tumor or other neoplasm refers to slowing, interrupting, arresting or stopping its growth and metastases and does not necessarily indicate a total elimination of the neoplastic growth.

[0425] As used herein, an amount of an target-binding agent effective to prevent a disorder, or a "a prophylactically effective amount" of the binding agent refers to an amount of a target binding agent, a Tiel-binding protein, a Tielbinding antibody described herein, which is effective, upon single- or multiple-dose administration to the subject, for preventing or delaying the occurrence of the onset or recurrence of a disorder, an endothelial cell-related disorder, a blood vessel development disorder, an inflammatory disease or a cancer.

[0426] Subjects that can be treated include human and non-human animals.

For example, the human can be a human patient having a disorder characterized by abnormal cell proliferation or cell differentiation. The term "non-human animals" includes all vertebrates, non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, sheep, dog, cow, pig, etc.

[0427] A binding agent described herein can be used to reduce angiogenesis in a subject, to treat a cancer a solid tumor) or an angiogenesis-associated disorder. The method includes administering the binding to the subject, in an amount effective to modulate angiogenesis, a symptom of the disorder, or progression of the disorder. The agent a Tiel-binding protein, an anti-Tiel antibody, E3) may be administered multiple times at least two, three, five, or ten times) before a therapeutically effective amount is attained.

[0428] The binding agent, a Tiel binding protein, can be used to treat or prevent cancer. In one embodiment, reduction in Tiel activity by a Tiel-binding protein can reduce or prevent angiogenesis near and around the tumor, thereby reducing or preventing tumor growth. In another embodiment, the neoplasia includes endothelial or hematopoietic cells that are proliferating abnormally. A Tiel-binding WO 2006/020706 PCT/US2005/028413 protein can be used to modulate the cells of a cancer themselves, to kill or ablate a neoplastic cell that expresses Tiel. For example, the cell is a hematopoietic cell.

[0429] Examples of cancers that can be treated include, but are not limited to, solid tumors, soft tissue tumors, and metastatic lesions. Examples of solid tumors include malignancies, sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting lung, breast, lymphoid, gastrointestinal colon), and genitourinary tract renal, urothelial cells), pharynx, prostate, ovary as well as adenocarcinomas which include malignancies such as most colon cancers, rectal cancer, renal-cell carcinoma, liver cancer, non-small cell carcinoma of the lung, cancer of the small intestine and so forth. Metastatic lesions of the aforementioned cancers can also be treated or prevented using the Tiel binding proteins and other agents described herein.

[0430] Still further examples of solid tumors that can be treated include: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, gastrointestinal system carcinomas, colon carcinoma, pancreatic cancer, breast cancer, genitourinary system carcinomas, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, endocrine system carcinomas, testicular tumor, lung carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.

[0431] A Tiel-binding protein can also be used to inhibit the proliferation of hyperplastic/neoplastic cells of hematopoietic origin, cells arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof, particularly such cells that express Tiel. For instance, the binding proteins described herein can be used for the treatment of various myeloid disorders including, but not limited to, acute promyeloid WO 2006/020706 PCT/US2005/028413 leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) Crit Rev. in Oncol./Hemotol.

11:267-97). Lymphoid malignancies which may be treated include, but are not limited to acute lymphoblastic leukemia (ALL), which includes B-lineage ALL and T-lineage ALL, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM).

Additional forms of malignant lymphomas include non-Hodgkin's lymphoma and variants thereof, peripheral T-cell lymphomas, adult T-cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF) and Hodgkin's disease. As Tiel has been shown to be upregulated in acute myelogenous leukemia and myelodysplastic syndrome (Verstovsek et al., 2001, Leuk, Lymphoma), B cell chronic lymphocytic leukemia (Aguayo et al, 2001. Leukemia Research 25(4):279-85.), binding proteins that interact with Tiel can be used to detect, treat, or prevent these diseases.

[0432] Accordingly, a subject having or at risk for a hematopoietic disorder, a hematopoietic cancer, can be treated by administering a Tiel binding protein, e.g. a Tiel binding protein that increases Tiel homodimerization, or a binding protein that antagonizes Tie complex formation. For example, the Tiel binding protein can be an anti-Tiel antibody, an antibody described herein. The administration of the binding protein can include multiple administrations, to achieve a therapeutic concentration using more than one dose. For example, the administrations can be about once a week, every second or third day, etc.

[0433] Methods of administering Tiel-binding proteins and other agents are also described in "Pharmaceutical Compositions". Suitable dosages of the molecules used will depend on the age and weight of the subject and the particular drug used.

The binding proteins can be used as competitive agents to inhibit, reduce an undesirable interaction, between a natural or pathological agent and the Tiel.

[0434] In one embodiment, the Tiel-binding proteins are used to inhibit inhibit at least one activity of, reduce proliferation, migration, growth or viability) of a cell, an endothelial cell in vivo. The binding proteins can be used by themselves or conjugated to an agent, a cytotoxic drug, cytotoxin enzyme, or radioisotope.

This method includes: administering the binding protein alone or attached to a cytotoxic drug, to a subject requiring such treatment.

WO 2006/020706 PCT/US2005/028413 [0435] Since the Tiel-binding proteins recognize Tiel-expressing endothelial cells and can bind to endothelial cells that are associated with in proximity of or intermingled with) cancer cells, cancerous lung, liver, colon, breast, ovarian, epidermal, laryngeal, and cartilage cells, and particularly metastatic cells thereof, Tiel-binding proteins can be used to inhibit inhibit at least one activity, reduce growth and proliferation, or kill) any such cells and inhibit angiogenesis. Reducing endothelial cell activity near a cancer can indirectly inhibit inhibit at least one activity, reduce growth and proliferation, or kill) the cancer cells which may be dependent on the endothelial cells for nutrients, growth signals and so forth.

[0436] Alternatively, the binding proteins bind to cells in the vicinity of the cancerous cells, but are sufficiently close to the cancerous cells to directly or indirectly inhibit inhibit at least one activity, reduce growth and proliferation, or kill) the cancers cells. Thus, the Tiel-binding proteins modified with a toxin, a cytotoxin) can be used to selectively inhibit kill or ablate cells in cancerous tissue (including the cancerous cells themselves and endothelial cells associated with or invading the cancer).

[0437] The binding proteins may be used to deliver a variety of cytotoxic drugs including therapeutic drugs, a compound emitting radiation, molecules of plants, fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as toxins short-range radiation emitters, short-range, high-energy a-emitters.

[0438] To kill or ablate normal, benign hyperplastic, or cancerous cells, a first binding protein is conjugated with a prodrug which is activated only when in close proximity with a prodrug activator. The prodrug activator is conjugated with a second binding protein, preferably one which binds to a non-competing site on the target molecule. Whether two binding proteins bind to competing or non-competing binding sites can be determined by conventional competitive binding assays. Exemplary drug-prodrug pairs are described in Blakely et al., (1996) Cancer Research, 56:3287-3292.

[0439] The Tiel-binding proteins can be used directly in vivo to eliminate antigen-expressing cells via natural complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC). The binding proteins described WO 2006/020706 PCT/US2005/028413 herein can include complement binding effector domain, such as the Fc portions from IgG1, or -3 or corresponding portions of IgM which bind complement. In one embodiment, a population of target cells is ex vivo treated with a binding agent described herein and appropriate effector cells. The treatment can be supplemented by the addition of complement or serum containing complement. Further, phagocytosis of target cells coated with a binding protein described herein can be improved by binding of complement proteins. In another embodiment target, cells coated with the binding protein which includes a complement binding effector domain are lysed by complement.

[0440] Use of the therapeutic methods described herein to treat cancers has a number of benefits. Tiel expression may be induced in response to hypoxic signals that can arise within the interior of a tumor to stimulate changes in vasculature, including blood and lymphatic vessels so as to increase nutrient and oxygen supply to the tumor. Certain Tiel-binding antibodies E3 and related antibodies) maybe particularly effective because they can inhibit changes to tumor vasculature and may cause a decrease in intra-tumor pressure. These agents may also be well suited as therapeutics in situations in which conventional agents have difficulty in penetrating into a tumor. Furthermore, Tiel binding proteins may leave hematopoiesis unaffected. Treatment can be effectively monitored with clinical parameters.

Alternatively, these parameters can be used to indicate when such treatment should be employed.

[0441] A Tiel binding protein, e.g. a Tiel binding protein that increases Tiel homodimerization, or a binding protein that antagonizes Tie complex formation can be administered to a subject to treat or prevent an inflammatory disorder, e.g., psoriasis or rheumatoid arthritis.

[0442] Psoriasis. Psoriasis is a chronic skin disease, characterized by scaling and inflammation. When psoriasis develops, typically patches of skin thicken, redden, and become covered with silvery scales, referred to as plaques. Psoriasis most often occurs on the elbows, knees, scalp, lower back, face, palms, and soles of the feet. The disease also may affect the fingernails, toenails, and the soft tissues inside the mouth and genitalia. About 10 percent of people with psoriasis have joint inflammation that produces symptoms of arthritis. Patients can be evaluated using a static Physician Global Assessment (sPGA), and receive a category score ranging WO 2006/020706 PCT/US2005/028413 from six categories between clear and very severe. The score is based on plaque, scaling, and erythema. The therapeutic methods herein can be used to achieve an improvement for at least one of these indicia.

[0443] Rheumatoid arthritis is a chronic inflammatory disease that causes pain, swelling, stiffness, and loss of function, primarily the joints. RA frequently begins in the synovium, the membrane that surrounds a joint creating a protective sac. In many individuals suffering from RA, leukocytes infiltrate from the circulation into the synovium causing continuous abnormal inflammation synovitis). Consequently, the synovium becomes inflamed, causing warmth, redness, swelling, and pain. The collagen in the cartilage is gradually destroyed, narrowing the joint space and eventually damaging bone. The inflammation causes erosive bone damage in the affected area. During this process, the cells of the synovium grow and divide abnormally, making the normally thin synovium thick and resulting in a joint that is swollen and puffy to the touch. RA can be assessed by a variety of clinical measures. Some exemplary indicia include the total Sharp score (TSS), Sharp erosion score, and the HAQ disability index. The therapeutic methods herein can be used to achieve an improvement for at least one of these indicia.

[0444] A Tiel binding protein a Tiel binding protein that increases Tiel homodimerization) or a binding protein that antagonizes Tie complex formation can be administered to a subject to treat or prevent a retinal disorder, a proliferative retinopathy, such as diabetic retinopathy, ischemic retinopathy, or retinopathy of prematurity; choroidal neovascularization; lens neovasculation; corneal neovascularization; iridial neovascularization; or conjunctival neovascularization.

The binding protein can be used to reduce the risk of retinal detachment associated with pathological ocular neovascularization. In some cases, the binding protein is administered by subconjunctival administration.

[04451 Combination Therapies [0446] Binding proteins described herein can be administered in combination with one or more of the other therapies for treating cancers, including, but not limited to: surgery; radiation therapy, and chemotherapy. For example, proteins that antagonize Tie complex formation or that modulate Tie signalling activity (including, proteins that promote Tiel homodimerization and/or phosphorylation) can also WO 2006/020706 PCT/US2005/028413 be used in combination with other anti-cancer therapies, such as radiation therapy, chemotherapy, surgery, or administration of a second agent. For example, the second agent can be one that targets or negatively regulates the VEGF signaling pathway.

Examples of this latter class include VEGF antagonists anti-VEGF antibodies such as bevacizumab) and VEGF receptor antagonists anti-VEGF receptor antibodies). One particularly combination includes bevacizumab. The combination can further include 5-FU and leucovorin, and/or irinotecan.

[0447] The term "combination" refers to the use of the two or more agents or therapies to treat the same patient, wherein the use or action of the agents or therapies overlap in time. The agents or therapies can be administered at the same time as a single formulation that is administered to a patient or as two separate formulations administered concurrently) or sequentially in any order. Sequential administrations are administrations that are given at different times. The time between administration of the one agent and another agent can be minutes, hours, days, or weeks. The use of a Tiel binding protein described herein can also be used to reduce the dosage of another therapy, to reduce the side-effects associated with another agent that is being administered, to reduce the side-effects of an anti-VEGF antibody such as bevacizumab. Accordingly, a combination can include administering a second agent at a dosage at least 10, 20, 30, or 50% lower than would be used in the absence of the Tiel binding protein.

[0448] In addition, a subject can be treated for an angiogenesis-associated disorder by administering to the subject a first and second agent. For example, the first agent modulates early stage angiogenesis and the second agent modulates a subsequent stage of angiogenesis or also modulates early stage angiogenesis. The first and second agents can be administered using a single pharmaceutical composition or can be administered separately. In one embodiment, the first agent is a VEGF pathway antagonist an inhibitor of a VEGF VEGF-A, or -C) or a VEGF receptor KDR or VEGF receptor III (Flt4)) or a bFGF pathway antagonist an antibody that binds to bFGF or a bFGF receptor). Other VEGF pathway antagonists are also described, herein and elsewhere. In one embodiment, the second agent inhibits or decreases assembly and stabilization of the blood vessels, disrupts maintenance of blood or lymphatic vessels, or alters distribution of lymphatic vessels in tumors. For example, the second agent comprises inhibits a Tie complex WO 2006/020706 PCT/US2005/028413 formation or promotes Tiel homodimerization. For example, the second agent is a Tiel binding protein described herein.

[0449] Once a tumor reaches a certain size 1-2 mm), the tumor requires new vasculature prior to increasing its mass. An early stage of tumor angiogenesis can include a signal from the tumor, secretion of VEGF, to stimulate the growth of new blood vessels from the host and infiltration of the tumor by the vessels. VEGF can, for example, stimulate proliferation of endothelial cells that are then assembled into blood vessels. A late stage of tumor angiogenesis can include a signal that leads to the assembly and stabilization of the blood vessels. This assembly and stabilization may involve interaction between the endothelial cells and the pericytes that surround the endothelial cells of the vessels. Tiel, for example, may play a role in the assembly and stabilization of the vessels and in maintaining the association between the pericytes and endothelial cells. Thus, an effective therapy to treat angiogenesis-related disorders can involve a combination of an agent that modulates an early stage angiogenesis VEGF pathway antagonists, anti- VEGF bevacizumab) or anti-VEGF receptor anti-KDR) antibodies; or antagonists of other pro-angiogenic pathways, anti-bFGF antibodies or antibFGF receptor anti-bFGF receptor-1, antibodies) and an agent that modulates a late stage of tumor angiogenesis antagonists of Tiel anti-Tiel antibodies an antibody disclosed herein, an E3 antibody)), of Tie2 anti-Tie2 antibodies), or of Angs anti-Ang antibodies anti-Ang2 antibodies) or anti-Ang2 peptides inhibitory Ang2 peptides)). One or more of these agents can be used in combination. One or more of these agents may also be used in combination with other anti-cancer therapies, such as radiation therapy or chemotherapy.

[0450] Exemplary VEGF receptor antagonists include inhibitors of VEGF receptor tyrosine kinase activity. 4-[4-(1-Amino-l-methylethyl)phenyl]-2-[4-(2- (JNJ-17029259) is one of a structural class of 5-cyanopyrimidines that are orally available, selective, nanomolar inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).

Additional examples include: PTK-787/ZK222584(Astra-Zeneca), SU5416, SU11248 (Pfizer), and ZD6474 ([N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1methylpiperidin-4-yl)methoxy]quinazolin-4-amine]). Still other agents that can be WO 2006/020706 PCT/US2005028413 used in combination with Tiel-binding proteins are broad specificity tyrosine kinase inhibitors, SU6668. See, Bergers, B. et al. (2003) J. Clin. Invest. 111, 1287-1295.

[0451] The second agent or therapy can also be another anti-cancer agent or therapy. Nonlimiting examples of anti-cancer agents include, anti-microtubule agents, topoisomerase inhibitors, antimetabolites, mitotic inhibitors, alkylating agents, intercalating agents, agents capable of interfering with a signal transduction pathway, agents that promote apoptosis, radiation, and antibodies against other tumorassociated antigens (including naked antibodies, immunotoxins and radioconjugates).

Examples of the particular classes of anti-cancer agents are provided in detail as follows: antitubulin/antimicrotubule, paclitaxel, vincristine, vinblastine, vindesine, vinorelbin, taxotere; topoisomerase I inhibitors, irinotecan, topotecan, camptothecin, doxorubicin, etoposide, mitoxantrone, daunorubicin, idarubicin, teniposide, amsacrine, epirubicin, merbarone, piroxantrone hydrochloride; antimetabolites, 5-fluorouracil methotrexate, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, cytarabine/Ara-C, trimetrexate, gemncitabine, acivicin, alanosine, pyrazofurin, N-Phosphoracetyl-L-Asparate=PALA, pentostatin, 5-Aza 2'-deoxycytidine, ara-A, cladribine, 5 fluorouridine, FUDR, tiazofurin, N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-Nmethylamino]-2-thenoyl]-L-glutamic acid; alkylating agents, cisplatin, carboplatin, mitomycin C, BCNU=Carmustine, melphalan, thiotepa, busulfan, chlorambucil, plicamycin, dacarbazine, ifosfamide phosphate, cyclophosphamide, nitrogen mustard, uracil mustard, pipobroman, 4-ipomeanol; agents acting via other mechanisms of action, dihydrolenperone, spiromustine, and desipeptide; biological response modifiers, to enhance anti-tumor responses, such as interferon; apoptotic agents, such as actinomycin D; and anti-hormones, for example anti-estrogens such as tamoxifen or, for example antiandrogens such as 4'-cyano-3-( 4 fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl) propionanilide.

[0452] A combination therapy can include administering an agent that reduces the side effects of other therapies. The agent can be an agent that reduces the side effects of anti-cancer treatments. For example, the agent can be leucovorin.

[0453] Combination therapies that include administering a Tiel binding protein or other binding protein described herein can also be used to treat a subject WO 2006/020706 PCT/US2005/028413 having or at risk for another angiogenesis related disorder a disorder other than cancer, disorders that include undesired endothelial cell proliferation or undesirable inflammation, rheumatoid arthritis.

[04541 Diagnostic Uses [0455] Binding proteins that bind to Tiel antibodies, an antibody described herein) have in vitro and in vivo diagnostic, therapeutic and prophylactic utilities.

[0456] In one aspect, the invention provides a diagnostic method for detecting the presence of a Tiel, in vitro a biological sample, such as tissue, biopsy, a cancerous tissue) or in vivo in vivo imaging in a subject). The method includes: contacting a sample with Tiel-binding protein; and (ii) detecting formation of a complex between the Tiel-binding protein and the sample. The method can also include contacting a reference sample a control sample) with the binding protein, and determining the extent of formation of the complex between the binding protein and the sample relative to the same for the reference sample. A change, a statistically significant change, in the formation of the complex in the sample or subject relative to the control sample or subject can be indicative of the presence of Tiel in the sample. The Tiel-binding protein can be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody.

Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.

[0457] Complex formation between the Tiel-binding protein and Tiel can be detected by measuring or visualizing either the binding protein bound to the Tiel or unbound binding protein. Conventional detection assays can be used, an enzyme-linked immunosorbent assays (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. Further to labeling the Tiel-binding protein, the presence of Tiel can be assayed in a sample by a competition immunoassay utilizing standards labeled with a detectable substance and an unlabeled Tiel-binding protein. In one example of this assay, the biological sample, the labeled standards and the Tiel binding agent are combined and the amount of labeled standard bound to the unlabeled binding protein is determined. The amount of Tiel in the sample is WO 2006/020706 PCT/US2005/028413 inversely proportional to the amount of labeled standard bound to the Tiel binding agent.

[0458] Fluorophore and chromophore labeled binding proteins can be prepared. Since antibodies and other proteins absorb light having wavelengths up to about 310 nm, the fluorescent moieties should be selected to have substantial absorption at wavelengths above 310 nm and preferably above 400 nm. A variety of suitable fluorescers and chromophores are described by Stryer (1968) Science, 162:526 and Brand, L. et al. (1972) Annual Review ofBiochemistry, 41:843-868. The binding proteins can be labeled with fluorescent chromophore groups by conventional procedures such as those disclosed in U.S. Patent Nos. 3,940,475, 4,289,747, and 4,376,110. One group of fluorescers having a number of the desirable properties described above is the xanthene dyes, which include the fluoresceins and rhodamines.

Another group of fluorescent compounds are the naphthylamines. Once labeled with a fluorophore or chromophore, the binding protein can be used to detect the presence or localization of the Tiel in a sample, using fluorescent microscopy (such as confocal or deconvolution microscopy).

[0459] Histological Analysis. Immunohistochemistry can be performed using the binding proteins described herein. For example, in the case of an antibody, the antibody can synthesized with a label (such as a purification or epitope tag), or can be detectably labeled, by conjugating a label or label-binding group. For example, a chelator can be attached to the antibody. The antibody is then contacted to a histological preparation, a fixed section of tissue that is on a microscope slide.

After an incubation for binding, the preparation is washed to remove unbound antibody. The preparation is then analyzed, using microscopy, to identify if the antibody bound to the preparation. The method can be used to evaluate an endothelial cell or tissue formed by endothelial cells, blood vessels. The antibody (or other polypeptide or peptide) can be unlabeled at the time of binding. After binding and washing, the antibody is labeled in order to render it detectable.

[0460] Protein Arrays. The Tiel-binding protein can also be immobilized on a protein array. The protein array can be used as a diagnostic tool, to screen medical samples (such as isolated cells, blood, sera, biopsies, and the like). Of course, the protein array can also include other binding proteins, that bind to Tiel or to other target molecules, such as hyaluronic acid.

WO 2006/020706 PCT/US2005/028413 [0461] Methods of producing polypeptide arrays are described, in De Wildt et al. (2000) Nat. Biotechnol. 18:989-994; Lueking et al. (1999) Anal. Biochem.

270:103-111; Ge (2000) Nucleic Acids Res. 28, e3, I-VII; MacBeath and Schreiber (2000) Science 289:1760-1763; WO 01/40803 and WO 99/51773A1. Polypeptides for the array can be spotted at high speed, using commercially available robotic apparati. The array substrate can be, for example, nitrocellulose, plastic, glass, e.g., surface-modified glass. The array can also include a porous matrix, acrylamide, agarose, or another polymer.

[0462] For example, the array can be an array of antibodies, as described in De Wildt, supra. Cells that produce the binding proteins can be grown on a filter in an arrayed format. Polypeptide production is induced, and the expressed polypeptides are immobilized to the filter at the location of the cell. A protein array can be contacted with a labeled target to determine the extent of binding of the target to each immobilized polypeptide. If the target is unlabeled, a sandwich method can be used, using a labeled probed, to detect binding of the unlabeled target. Information about the extent of binding at each address of the array can be stored as a profile, e.g., in a computer database. The protein array can be produced in replicates and used to compare binding profiles, of a target and a non-target.

[0463] FACS. (Fluorescent Activated Cell Sorting). The target-binding protein can be used to label cells, cells in a sample a patient sample). The binding protein can also be attached (or attachable) to a fluorescent compound. The cells can then be sorted using fluorescent activated cell sorted using a sorter available from Becton Dickinson Immunocytometry Systems, San Jose CA; see also U.S. 5,627,037; 5,030,002; and 5,137,809). As cells pass through the sorter, a laser beam excites the fluorescent compound while a detector counts cells that pass through and determines whether a fluorescent compound is attached to the cell by detecting fluorescence. The amount of label bound to each cell can be quantified and analyzed to characterize the sample.

[0464] The sorter can also deflect the cell and separate cells bound by the binding protein from those cells not bound. The separated cells can be cultured and/or characterized.

WO 2006/020706 PCT/US2005/028413 [0465] In Vivo Imaging. In still another embodiment, the invention provides a method for detecting the presence of a Tiel-expressing cancerous tissues in vivo.

The method includes: administering the Tiel-binding protein to a subject; and detecting the Tiel-binding protein in the subject. The detecting can include determining location or time of formation of the complex. The method can include scanning or otherwise imaging the subject, a region of the subject's body.

Another method includes administering to a subject a patient having a cancer or neoplastic disorder) a Tiel-binding antibody, conjugated to a detectable marker; (ii) exposing the subject to a means for detecting said detectable marker to the Tielexpressing tissues or cells. For example, the method can be used visualize blood vessels or the location of endothelial cells, Tiel-expressing endothelial cells.

The subject can be imaged, by NMR or other tomographic means.

[0466] Examples of labels useful for diagnostic imaging include radiolabels such as 131I, In, 123, 99Te, 32p, 125, 3 H, 14 C, and 'Rh, fluorescent labels such as fluorescein and rhodamine, nuclear magnetic resonance active labels, positron emitting isotopes detectable by a positron emission tomography scanner, chemiluminescers such as luciferin, and enzymatic markers such as peroxidase or phosphatase. Short-range radiation emitters, such as isotopes detectable by short-range detector probes can also be employed. The binding protein can be labeled with such reagents using known techniques. For example, see Wensel and Meares (1983) Radioimmunoimaging and Radioimmunotherapy, Elsevier, New York for techniques relating to the radiolabeling of antibodies and D. Colcher et al. (1986) Meth. Enzymol. 121: 802-816.

[0467] A radiolabeled binding protein can also be used for in vitro diagnostic tests. The specific activity of an isotopically-labeled protein depends upon the half-life, the isotopic purity of the radioactive label, and how the label is incorporated into the protein.

[0468] Effective imaging agents for tumor-associated neo-vasculature are needed. Tiel is up regulated on tumor-associated vasculature. The binding proteins described herein can be used to image such vasculature.

The binding proteins described herein can be used for imaging in several ways. A binding protein can be physically associated, coupled to a chelator for imaging WO 2006/020706 PCT/US2005/028413 agents such as 99mTc, 16Re, or 99"Tc and 8Re emit gamma rays suitable for single photon emission computer tomography (SPECT) imaging. Radioactive fluorine (18F), indium iodine (123I, 1311), gallium 68 Ga, 67 Ga), carbon thallium (201Tl), and other elements may be used as imaging agents.

[0469] The binding proteins can also be attached, covalently or noncovalently, to a particle, a nano-particle, that includes a radionuclide or spin labels suitable for use as an imaging agent. The binding proteins can be linked to a spin label that would allow imaging through MRI. Botnar et al. (Circulation. (2004) 109:2023-2029.) describe MRI imaging using an exemplary gadolinium-labeled peptide. The binding proteins described herein can be similarly labeled for imaging.

[0470] Chen et al. Nucl. Med., (2004) 45:1776-1783) showed that coupling a small PEG molecule (average molecular weight 3.4 KDa) improved that pharmacodynamics of an ovfO 3 -binding peptide. Binding proteins Tiel, Tie2, or Ang binding proteins) can be coupled to PEG molecules to adjust the clearance rate and pathway.

[0471] Positron Emission Tomography (PET) can be used with imaging agents such as positron emitters such as 64Cu and 18F. These isotopes are becoming more readily available. 64C can be captured in the chelator DOTA. DOTA derivatives can be covalently linked to proteins. In one embodiment, one or more DOTA derivatives are attached to a binding protein a Fab) through a lysine side group.

[0472] Fabs are useful binding agents for imaging because they: a) clear from the system fairly raipdly, allowing imaging within a few hours of injection, and b) penetrate tumors efficiently.

[0473] Fabs that bind to Tiel, Tie2, or Ang can be produced, in E. coli or in eukaryotic cells. The Fabs can be purified by chromatography over protein A. Ion exchange chromatography can also be used. For use in imaging, covalent attachment of a chelating group suitable to the desired radionuclide or other imaging agent allows the Fab to be labeled at the time of use. The Fabs can also have spin labels attached to allow MRI imaging. Fabs can also be attached to particles nano-particles) that include a radionuclide or spin label suitable for imaging. In particular embodiments, Fabs may be coupled to PEG molecules to adjust the rate and pathway WO 2006/020706 PCT/US2005/028413 of clearance. In other embodiments, the Fabs are not coupled to PEG, to maintain their rapid clearance properties.

[0474] Procedures for labeling polypeptides with the radioactive isotopes (such as 14 3H, 35S, 125, 32 1311) are generally known. For example, tritium labeling procedures are described in U.S. Patent No. 4,302,438. Iodinating, tritium labeling, and 35 S labeling procedures, as adapted for murine monoclonal antibodies, are described, by Goding, J.W. (Monoclonal antibodies principles and practice :production and application ofmonoclonal antibodies in cell biology, biochemistry, and immunology 2nd ed. London; Orlando Academic Press, 1986.

pp 124-126) and the references cited therein. Other procedures for iodinating polypeptides, such as antibodies, are described by Hunter and Greenwood (1962) Nature 144:945, David et al. (1974) Biochemistry 13:1014-1021, and U.S. Patent Nos.

3,867,517 and 4,376,110. Radiolabeling elements which are useful in imaging include 123, 1311, 1 1 n, and 99mTc, for example. Procedures for iodinating antibodies are described by Greenwood, F. et al. (1963) Biochem. J 89:114-123; Marchalonis, J.

(1969) Biochem. J. 113:299-305; and Morrison, M. et al. (1971) Immunochemistry 289-297. Procedures for 99 mTc-labeling are described by Rhodes, B. et al. in Burchiel, S. et al. Tumor Imaging: The Radioimmunochemical Detection of Cancer, New York: Masson 111-123 (1982) and the references cited therein. Procedures suitable for "1'In-labeling antibodies are described by Hnatowich, D.J. et al. (1983) J Immul. Methods, 65:147-157, Hnatowich, D. et al. (1984) J. Applied Radiation, 35:554-557, and Buckley, R. G. et al. (1984) F.E.B.S. 166:202-204.

[0475] In the case of a radiolabeled binding protein, the binding protein is administered to the patient, is localized to the tumor bearing the antigen with which the binding protein reacts, and is detected or "imaged" in vivo using known techniques such as radionuclear scanning using a gamma camera or emission tomography. See A.R. Bradwell et al., "Developments in Antibody Imaging", Monoclonal Antibodies for Cancer Detection and Therapy, R.W. Baldwin et al., pp 65-85 (Academic Press 1985). Alternatively, a positron emission transaxial tomography scanner, such as designated Pet VI located at Brookhaven National Laboratory, can be used where the radiolabel emits positrons C, 18 F, 150, and 13N).

WO 2006/020706 PCT/US2005/028413 [0476] MRI Contrast Agents. Magnetic Resonance Imaging (MRI) uses NMR to visualize internal features of living subject, and is useful for prognosis, diagnosis, treatment, and surgery. MRI can be used without radioactive tracer compounds for obvious benefit. Some MRI techniques are summarized in EP-A-0 502 814. Generally, the differences related to relaxation time constants T1 and T2 of water protons in different environments are used to generate an image. However, these differences can be insufficient to provide sharp high resolution images.

[0477] The differences in these relaxation time constants can be enhanced by contrast agents. Examples of such contrast agents include a number of magnetic agents paramagnetic agents (which primarily alter T1) and ferromagnetic or superparamagnetic (which primarily alter T2 response). Chelates EDTA, DTPA and NTA chelates) can be used to attach (and reduce toxicity) of some paramagnetic substances Fe 3 Mn 2 Gd+3). Other agents can be in the form of particles, e.g., less than 10 mn to about 10 nM in diameter). Particles can have ferromagnetic, antiferromagnetic or superparamagnetic properties. Particles can include, e.g., magnetite (Fe 3 0 4 y-Fe 2 03, ferrites, and other magnetic mineral compounds of transition elements. Magnetic particles may include: one or more magnetic crystals with and without nonmagnetic material. The nonmagnetic material can include synthetic or natural polymers (such as sepharose, dextran, dextrin, starch and the like [0478] The target-binding proteins can also be labeled with an indicating group containing of the NMR-active 9F atom, or a plurality of such atoms inasmuch as substantially all of naturally abundant fluorine atoms are the 19 F isotope and, thus, substantially all fluorine-containing compounds are NMR-active; (ii) many chemically active polyfluorinated compounds such as trifluoracetic anhydride are commercially available at relatively low cost, and (iii) many fluorinated compounds have been found medically acceptable for use in humans such as the perfluorinated polyethers utilized to carry oxygen as hemoglobin replacements. After permitting such time for incubation, a whole body MRI is carried out using an apparatus such as one of those described by Pykett (1982) Scientific American, 246:78-88 to locate and image cancerous tissues.

[0479] Information obtained from evaluating an target-binding protein, a binding protein described herein, can be recorded on machine-compatible media, e.g., computer readable or computer accessible media. The information can be stored as a WO 2006/020706 PCT/US2005/028413 computer representation, in a database in the case of imaging using a binding protein, a database of images for one or a plurality of subjects). The term "computer representation" refers to information which is in a form that can be manipulated by a computer. The act of storing a computer representation refers to the act of placing the information in a form suitable for manipulation by a computer.

[0480] Also within the scope of the invention are kits including the binding protein that binds to Tiel and instructions for diagnostic use, the use of the target-binding protein antibody or antigen-binding fragment thereof, or other polypeptide or peptide) to detect Tiel, in vitro, in a sample, a biopsy or cells from a patient having a cancer or neoplastic disorder, or in vivo, by imaging a subject. The kit can further contain a least one additional reagent, such as a label or additional diagnostic agent. For in vivo use the binding protein can be formulated as a pharmaceutical composition.

[0481] The following examples are not to be construed as limiting.

WO 2006/020706 WO 206/00706PCT11JS2005/028413

EXAM'VPLES

Ifl4R~1 Example 1 Tiel Seauences 104821 [0483] An exemplary Tiel amino acid sequence (SEQ ID) NO:2) is as follows:

MVWRVPPFLLPILFLASHVGAAVDLTLLANLRLTDPQRFFLTCVSGEAGAGRGSDAWGPP

LLLEKDDRIVRTPPGPPLjRLARNGSHQVTLRGFSKPSDTLVGVFSCVGGAGARRTRVIYVH NSGHLrVHVKDAVSRHEKTVWSGYYLWEQGFT

QLPNVQPPSSGIYSATYLEASPLGSAFFRLIVRGICGAGRWGPGCTKECPGCLHCGVCHDH

DGECVCPPGFTGTRCEQACREGRFGQSCQEQCPGI SGCRGLTFCLPDPYGCSCGSGWRGS

QCQEACAPGHFGADCRLQCQCQNGGTCDRFSGCVCPSGWHGVHCEKSDRIPQILNMASEL

EFNLETMPRINCAAAGNPFPVRGSIELRKPDGTVLLSTKAIVEPEKTTAEFEVPRLVLAD

SGFWECRVSTSGGQDSRPRFKVNVKVPPVPLAAPRLLTKQSRQLVVSPLVSFSGDGPISTV

RLHYRPQDSTMDWSTIVVDPSENVTLMNLRPKTGYSVRVQLSRPGEGGEGAWGPPTLMTT

DCPEPLLQPWLEGWH-VEGTDRLRVSWSLPLVPGPLVGDGFLLRLWDGTRGQERRENVSSP

QARTALLTGLTPGTHYQLDVQLYHCTLLGPASPPAHVLLPPSGPPAPRHLHAQALSDSEI

QLTWKHPEALPGPISKYVVEVQVAGGAGDPLWIDVDRPEETSTIIRGLNASTRYLFRMRA

S IQGLGDWSNTVEESTLGNGLQAEGPVQESRAABEGLDQQLILAVVGSVSATCLTILAAL

LTLVCIRRSCLHRRRTFTYQSGSGEETILQFSSGTLTJTRRPKLQPEPLSYPVLEWEDIT

FEDLIGEGNFGQVIRAM'IKKDGLKNAAIKMLKEYASENDHRDFAGELEVLCKLGHHPNI

INLLGACKNRGYLYIAIEYAPYGNLLDFLRKSRVLETDPAFAREHGTASTLSSRQLLRFA

SDAAN~GMQYLSEKQFIHRDLA1ARNVLVGENLASKIAfFGLSRGEEVYVKKTMGRLPVRWM

AIESLNYSVYTTKSDVWSFGVLLWEIVSLGGTPYCGMTCAELYEKLPQGYRMEQPRNCDD

EVYELMRQCWRDRPYERPPFAQIALQLGRMLEARKAYVNMSLFENFTYAGIDATAEEA

[0484] An exemplary nucleic acid sequence (SEQ ID NO: 1) that encodes Tiel is as follows: atggtctggc gcggcggtgg ctgacttgcg ctgctgctg gcgcgcaacg ggcgtcttct aacaqccctg accgctgtac aacggatcct cagctcccaa agccccctg gggccaggct gacggcgaat 9agggccgtt CtCaCCttCt cagtgccaag tgtcagaatg ggagtgcact gagttcaact ytgCgYgyca attgtggagc agtgggttct gtcaatgtga CgCCagCttg cgcctgcact agtgagaacg ctgagccggc gactgtcctg gggt9CCCCC acctgacgct tgtctgggga agaaggacga gttcgcacca cctgcgtggg 9agcccacct tttctgcacg acttctacac atgtgcagcc gcagcgectt 9taccaagga gtgtatgccc ttgggcagag gCCtCCCaga aagcttgtgc gtggcacttg gtgagaagtc tagagacqat 9catagagct cagagaagac gggagtgccg aagtgccccc tggtCtCCCC accggcccca tgacgttaat caggggaagg agcctttgtt tttCttgCtc gctggccaac ggCCgyg9cg ccgtatcgtg ggtcacgctt cggtgctggg gcttccagac tgtgeacaag cctggactgg accatcgagc ctttCggCtC 9tgcccaggt CCCtggCttc ctgccaggag cccctatggc ccctggtcat tgaccggttc agaccggatc 9ccccgqatc dCgCaayCCa cacagctgag tgtgtccaca CgtgCCCCtg gctggtctcg ggacagtacc gaacctgagg aggagagggg gcagccgtgg cccatcctct CtgC9gctca gggaggggct CgCaccccgC cgcggcttct gcgcggcgca aaqqtcacac gagaagcaga catgaagccc ggcatctaca atcgtgcggg tgCCtaCatg actggcaccc cagtgcccag tgctc"-tgtg tttggggctg agtggttgtg ccccagatcc aactgtgcag gacggcact9 ttcgaggtgc tctggcggcc gctgcacctC ttctctgggg atggactggt ccaaagacag gcctgggggc ttggagggct tcttggcttc eggaCCCCCa cggacgcctg CCgggccacc ccaagccctc cgcgcgtcat acactgtgaa cagacgtgat aggatgggcg gtgccaetta gttgtggggc gaggtgtctg gctgtgaaca gcatatcagg gatctggctg attgccgact tCtgCCCCtC tcaacatggc ctgcagggaa tgctcctgtc cccgcttggt aagacagccg ggctcctgac atggacccat Cgaccattgt gatacagtgt CtCCCaCCCt yg9catgt9ga tcatgtgggc gcgcttcttc gcccgCCC cctgcgcctg ygacctcgtg ctacgtgcac caaaqgtgac ctggaagagc gttcctgctg CCtggaa9cc tgggcgctgg ccacgaccat ggcctgcaga ctgccggggc gagaggaagc ccagtgccag tgggtggcat ctcagaactg CCCCttCCCC caUcdaaggCC tcttgcggac gcgcttcaag caagcagagc CtCCaCtgtC ggtggaCCCC tcgtgtgcag catgaccaca aggcactgac 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1G20 1680 WO 2006/020706 WO 206/00706PCTII§S2005/028413 Cqgctgcgag tgagctggtc ctgctgcgcc tgtgggacgg caggcccgca ctgccctcct cagctctacc actgcaccct cccagtgc ctccagcccc cagctqacat ggaagcaccc qtgcaggtqg ctgggggtgc acaagcacca tcatccgtgg a9cattcagg qgctcgg9ga ctgcaggctg agqgcccagt CtgatCCtgg Cggtygtqgg ttaaccctgg tgtgcatccg tcaggctcgg gcgaggagac cggccaaaac tgcagcccga tttgaggacc tcatcgggga gacgggctga agatgaacgc catcgtgact ttgcgggaga atcaacctcc tgqggcctg ccctacga acctqctaga tttgctcgag agcatggqac agtgatgcgg ccaatggcat 9ctgcccgqa atgtgctqgt tctcggggag aggaggttta gccattgagt ccctgaacta gtctcttt gggagatagt gagctctatg aaaagctqcc gaagtgtacg agctgatgcg gcccagattq cqctacaqct tcgctgtttg agaactteac Cttgcccttg gtgCCC999C gacacggggg gacg9ggatc cctqgCeCg ccgacacctc gggctctg aggagaccca cctcaacgcc ctgqagcaac ccaagagag9c ctccgtgtct cagaagctgc catcctgcag gCCCCtgagc ggqqaacttC agccatcaaa aCtggaagtt taaqaaccga ttttCtqCgg agcctctacc gcagtacctq cggagagaac tgtgaagaaq cagtqtctat gaqccttgqa ccagqgctac tCagtgCtgg aggccgcatq ttaCgCqggC CaggagCggc aCgcctggca gCCtcgCCCC caCqcccaqq Cetgggccaa ctgtqqataq agcaCqgCgt acagtagaag cgggcagctg gCCacctgcc ctgcatcgga ttcagctcag tacccagtgc ggc~Caggtcea atgctqaaag ctgtgcaaat qqttaCttgt aaaagccgg cttagctccc agtqagaagc ctagcctcca acgatggggc accarccaaga ggtacaccct cqcatggagc cqgaccqtc ctqgaagcca a1 tgatgcca CdiCtqg9yg gggagaacgt cccactacca ctgcacacgt ccctctcaga tatccaagta acgtggacag acctc1ttccg agtccaccct dagayggCCt tcaccatcct gacgcacctt qgaccttgac tagagtggga tcgggerat aqtatgcctc tggggCatca atatcqctat tcCtagagac ggcagctgct agttcatcca agattgcaga gtCtCCCtgt gtgatgtCtg actgtggcat agcctcgaa~a cctatgagcq ggaaggccta cagctgagga CqaCggtttC atcatccccc gCtgqatqtg gCttCtgCCC ctccgaqatc cgttgtggag qcctgagqag catgCgcc gqgcaacgg 99atcagcaq ggCCgCCCtt cacctaccag acttacccgg qgacatcacc gatcaagaag tgaaaatgac ccccaacatc tgaatatgCC tgacccagct gcgtttcgcc caqggacctg cttzcggcctt gcgctggatq gt catttgga gacctgtgcc ctstgacgat accccccttt tgtgaacatg ggCCtga 1740 1800 1860 1920 1980 2040 2100 2160 2220 2280 2340 2400 2460 2520 2580 2640 2700 2760 2820 2880 2940 3000 3060 3120 3180 3240 3300 3360 3417 (04851 Example 2 :Selection and Primarv Screening [0486] We have used phage display to select Tiel-specific antibodies from a very large phage library that displays inmunLoglobulins as Fab fragments. To isolate antibodies specific to Tie 1, a phage displayed Fab antibody library was selected against the Tie 1 extracellular domain fused to human Fc or to a histidine purification tag.

[04871 Selection in solution was done using biotin labelled antigen which was captured on streptavidin coated magnetic beads (M-280-DYNALO). Selection on cells expressing Tiel was performed using a KINGFISHERTM automated magnetic bead capture device. Selection on immobilized antigen was performed using Tiel-Fc coated onto immunotubes. Several selection strategies were used: [0488] Strategy 1 Round I (500mM biotin labelled Tiel/magnetic beads), Round 2 (1 x 10 Tiel expressing cells/Kingfisher), Round 3 (1 X 1 Tiel expressing cells/Kingfisher) WO 2006/020706 PCT/US2005/028413 Strategy 2 Round 1 (500mM biotin labelled Tiel/magnetic beads), Round 2 (1 x 107 Tiel expressing cells/KINGFISHERTM), (300mM biotin labelled Tiel/magnetic beads) [0489] Strategy 3 Round 1 (Tiel Fc coated immunotubes at 5|tg/ml), Round 2 (Tiel-Fc coated immunotubes), Round 3 (Tiel Fc coated immunotubes plus depletion with human IgG).

[0490] Library members recovered from the selection strategies were tested for antigen binding in phage ELISA. Each isolate was tested for binding to coated Tiel Fc. Strategy 1 did not identify any binding clones whereas strategy 2 identified 13 positive clones (n 95). Strategy 3 identified 86 binding clones (n [0491] Sequence analysis of the selected clones were grouped on the basis of the CDR3 selected of the heavy chain and resulted in 23 different antibodies with unique VH-CDR3 sequences.

[0492] We reformatted the selected Fabs as completely human antibodies by recloning the VH and VL coding sequences from the display library vector into two vectors of a mammalian expression vector system. These vectors contain the human kappa constant domain and the human gamma-1 heavy chain constant region. The vectors were co-transfected into mammalian CHO-K1 cells for expression and production of the corresponding complete IgGs. These antibodies were characterized using several assays as described below, including: 1. Western blotting and immunoprecipitation of Tiel transfected cells and primary human endothelial cells; 2.

Immunofluorescence of Tiel transfected cells and primary human endothelial cells; 3.

Stimulation and inhibition of Tiel in BaF3 cells and primary human endothelial cells; and 4. Immunostaining of human tissues.

[0493] We identified 23 antibodies that interact with Tiel. See FIGs. 7-36.

After sequence confirmation of the reformatted clones they were used in a transient transfection of HEK293T cells. After growth the IgG was purified from culture supematants using a protein A column. The quality of purified IgGI was determined using SDS-PAGE.

[0494] The specificity of the Tiel specific IgG's can be determined in a whole cell ELISA on mouse lung microvascular endothelial cells (LEII) and LEII-Tiel cells transfected with a Tiel expression construct. Cells are seeded into 96 well plates at a WO 2006/020706 PCT/US2005/028413 density of 10,000 cells/well and were fixed using 4% paraformaldehyde. Staining and detection of binding of IgG1 to LEII cells are detected using standard labelling with a HRP conjugated rabbit anti human HRP and TMB staining. Binding of purified IgG1 to LEII-Tiel transfected cells can also be corrected for Tiel protein that is expressed endogenously. Alternatively cells that have little or no endogenous Tiel can be used for the analysis.

[0495] At least one of the binding antibodies E3 functions as a Tiel activating antibody in the BaF3 cell bioassay. We studied Tiel phosphorylation in response to E3 IgG treatment in transiently transfected COS 1 cells and human primary endothelial cells. Our results indicate that E3 IgG activates the Tiel receptor.

The BaF3 cell bioassay (also referred to as the "Tiel/EpoR chimericBAF cell assay" may provide an indication of a ligand's ability to cross-link the Tiel receptor.

Because the assay is artificial, crosslinking of the non-naturally occurring Tie-Epo fusion proteins may or may not be predictive of a ligand's ability to modulate in vivo function.

[0496] E3 can be used, instead of possible natural ligands to characterize several functions of Tiel in vitro and in vivo. The region of Tiel which interacts with E3 can be the target for small molecular weight compounds for Tiel activation or inhibition.

[0497] Although E3 functions in one particular Tiel activating assay, E3 and other positives in this assay may also have inhibitory effect as to other functions or in other contexts. For example, E3 can inhibit tube formation by HUVEC cells. See below.

[0498] In addition, we found two antibodies that inhibit the survival effect conferred by E3 in the BaF3 cell bioassay. These two antibodies may inhibit dimerization of Tiel induced by E3 in the BaF3 assay. Two antibodies, B2 and Dll, completely blocked the viability of Tiel/EpoR cells when used in combination with E3.

[04991 Methods [0500] Cell culture. COS1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), glutamine WO 2006/020706 PCT/US2005/028413 and antibiotics. The murine BaF3 pre-B lymphocytes were cultured in DMEM supplemented with 10% FCS, glutamine, antibiotics and 2 ng/ml interleukin-3 (Calbiochem). Human dermal microvascular endothclial cells (HDMVECs), obtained from PromoCell (Heidelberg, Germany) were cultured in endothelial cell medium provided by the supplier and used at passages 4-7.

[0501] Western blotting and immunoprecipitation. COS 1 cells were transfected with pcDNA3-Tiel-V5 (1 ptg DNA per 10 cm cell culture plate) using FUGENE 6 (Roche) according to manufacturer's instruction and incubated for 48 h before stimulation. For immunoprecipitation, Tiel transfected cells and HMVEC cells were lysed in DOC-RIPA lysis buffer (50mM Tris-HC1 pH 8.0, 150 mM NaC1, 1% Triton-X-100, 0.1% SDS, 1% DOC, 10mM EDTA) supplemented with aprotinin, leupeptin, PMSF and sodium vanadate. Immunoprecipitation was carried out from equal amount of cell lysates by incubating with polyclonal anti-human Tiel antibodies monoclonal anti-V5 antibodies (Invitrogen) or altogether 23 anti- Tiel antibodies (1 g/ml) for 1 to 2 h followed by incubation with protein G- Sepharose (Amersham Pharmacia Biotech AB) for 1 h. The immunoprecipitates were washed twice with PBS-T and twice with PBS, followed by elution with the Laemmli buffer and separation in 8% SDS-PAGE. The blots were probed with the 23 anti-Tiel antibodies (5 jLg/ml) and subsequently anti-human Fe antibodies conjugated with

HRP.

[0502] Immunofluorescence staining. COS1 cells on the glass coverslips were transiently transfected with pcDNA3-Tiel-V5 (the V5-epitope was added to the 3' terminus ofpcDNA3-Tiel) (1 pjg DNA per 10 cm cell culture plate) using FUGENETM 6 (Roche) according to manufacturer's instruction and incubated for 48 h before staining. Cells were fixed in 4% paraformaldehyde for 10 min at 4 0 C. If required, the cells were permeabilized with 0.2% Triton X-100 in PBS for 5 min.

Unspecific binding sites were blocked by incubation with 1% BSA in PBS for 30 min.

The cells were then stained with anti-Tiel antibodies (5 uig/ml) and antibodies for 1 h at room temperature, followed by incubation with FITC- conjugated anti-human antibodies (DAKO, 40 gg/ml) and TRITC-conjugated anti-mouse antibodies (DAKO, 15 [pg/ml) for 30 min. Hoechst 33258 fluorochrome (Sigma, pg/ml) was used for the staining of the nuclei.

WO 2006/020706 PCT/US2005/028413 [0503] BaF3 bioassay. To generate Tiel-EpoR expressing BaF3 cells for the bioassay, BaF3 pre-B cells were stably transfected with a nucleic acid that expresses chimeric receptor containing the extracellular domain of human Tiel fused with the transmembrane and cytoplasmic domains of the mouse erythropoietin receptor. The nucleic acid used was a Tiel-EpoR chimeric cDNA in a pEF-BOS expression vector.

The nucleic acid encoding the chimeric receptor was constructed by cloning the PCR amplified extracellular part of human Tiel (bp 37-2316 of X60975) as EcoRI-BglII fragment into mEpoR-pcDNA vector. The cDNA encoding for the chimeric receptor consisting of the extracellular part ofTiel fused with the transmembrane and intracellular domains of EpoR was subcloned into the pEF-BOS expression vector.

Vector was linearized and co-transfected into BaF3 cells with pcDNA3.1(+) Zeo vector (Invitrogen). Stable cell pools were generated by selection with 250 gg/ml Zeocin. The expression of Tiel/EpoR fusion protein in several clones was analyzed by Western blotting with an antibody against EpoR.

[0504] To perform the assays, BaF3 cells expressing the Tiel-EpoR chimera were split in 96-well microtiter plates at 50 000 cells/well in the presence of the indicated concentrations ofanti-Tiel antibodies. The E3 antibody used in this study was the germ-lined E3 antibody (DX-2220). As controls, Zeocin resistant pools not expressing the Tiel-EpoR were used. After 48 h, the viability of the cells was determined by adding MTT 3 4 ,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Sigma), 0.5 mg/ml), followed by further 2 h of culture, addition of an equal volume of cell lysis solution (10% SDS, 10 mM HC1) and incubation overnight at 37 0 C. Absorbance was measured at 540 nm.

[0505] Tiel phosphorylation assay. COS1 cells were transfected with After 24 h oftransfection, the cells were serum starved for 8 h and then treated with E3 IgG. For the Tiel phosphorylation assay, HDMVECs were cultured on 10 cm dishes to near confluence, starved (8-16 h) in serum free medium and stimulated as indicated. After the stimulations, the cells were lysed in lysis buffer (RIPA-DOC: 50 mM Tris-HC1 pH 8.0, 150 mM NaC1, 1% Triton-X-100, 0.1% SDS, DOC, 10 mM EDTA, supplemented with aprotinin, leupeptin, PMSF and sodium vanadate). Clarified lysates from transfected COS1 cells or HDMVECs were immunoprecipitated with anti-V5 or anti-Tiel B9, respectively. Proteins were WO 2006/020706 WO 206/00706PCTII§S2005/028413 separated by SDS-PAGE, transferred to nitrocellulose and imm-unoblotted using the anti-phosphotyrosine and anti-Tie 1 (R&D systems) antibodies.

[0506] hrnnunostaining of human tissues. To evaluate reactivity of anti-Tiel antibodies in inimunohistochemistry, 5 gim cryosections of human kidney and lung were dried at room temperature for 30 min and fixed with cold acetone for 10 min.

Slides were washed with PB3S and treated with 0.03 11202 in PBS for 15 min to reduce endogenous peroxidase activity. TNB (3 0 min at room temperature) was used to block non-specific binding and sections were incubated with Tiel antibodies at concentration of 10 jig/ml overnight at +I 4'C. After several washings with PBS, biotinylated anti human antibody (1:300, Zymed) was added to the tissues. Signal was amplified by using a TSA kit and detected with AEC staining.

r0507] Results [0508] Western blotting, immunoprecipitation and immunofluorescence of Tiel transfected cells and primary human endothelial cells (see Table 1).

Table 1: Assay Summary Clone WB:Tiel- WYB: TP: Tiel1- IP: IF: Tiel- IF: BaF3 transfected HDMEC transfected HDMEC transfected 1{DMEC assay E3 ND~ G2 A2 +H B2 B9 C2 C7 Clo D11 +i Eli +i GlO 4i- -I-i HI H14 -H +I P-Al -p+i P- +I P-B1 -weak P-B3 +i i P-C6 +i +i P- D12__ WO 2006/020706 PCT/US2005/028413 Clone WB: Tiel- WB: IP: Tiel- IP: IF: Tiel- IF: BaF3 transfected HDMEC transfected HDMEC tfansfected HDMEC assay P-F3 P-F4 cross P-G3 PH1 [0509] To confirm the binding ability of the 23 selected anti-Tiel antibodies, we first performed western blotting and immunoprecipitation using COS1 cells transfected with pcDNA3-Tiel-V5 (V5 tagged) and primary endothelial cells. Next, to find out if the anti-Tiel antibodies recognize Tiel in living cells, those cells were studied by immunofluorescence staining. All the antibodies analyzed recognized both transfected and endogenous Tiel, although differences were detected in the binding affinity as shown in Table 1.

[0510] Stimulation and inhibition of Tiel in Tiel-EpoR transfected BaF3 cells and himan primary endothelial cells. Although no ligand for Tiel has been identified, we used the following efficient scdrening method for Tiel-binding proteins. Interleakain-3 dependent pre B-lymphocyte (BaF3) cells were transfected with a construct that expresses a fiielEpoR fusion prY-tein. Since BaF3 cells are W-- 3 dependent, they die unless IL-3 is provided. However, Tie-EpoR receptor expressing BaF3 cells can survive and proliferate if the medium contains a Tiel-binding protein, either a natural ligand or an artificial mimetic. Cell survival can be quantitated, e.g., by colorimetric MTT-assay, which measures mitochondrial activity.

[0511] The results from the BaF3 cell assays indicated that, of the 23 different monoclonal antibodies tested, only E3 IgG was able to promote survival of Tiel- EpoR cells whereas the viability ofEpoR BaF3 cells used as a control was not affected by E3 IgG. The IgG part of the inamunoglobulin molecule was needed for the survival effect ofE3 IgG, as the E3 Fab fragment had no effect on the viability of Tiel-EpoR cells. A concentration of 50 ng/ml ofE3 IgG gave almost maximal viability in Tiel-EpoR cell survival assays and the viability was dose dependent.

[0512] To test if the E3 IgG binding to the extracellular region of Tiel induces autophosphorylation of Tiel, the Tiel receptor phosphorylation level in -esponse to E3 IgG treatment was studied in transiently transfected COS1 cells and human primary endothelial cells. COS1 cells were transfected with an expression vector containing a V5-tagged full length Tiel cDNA, and, after serum starvation, the cells WO 2006/020706 PCT/US2005/028413 were treated with E3 IgG (200 ng/ml). Cell lysates were extracted at several time points and Tiel was immunoprecipitated with anti-V5 followed by western blotting using anti-phosphotyrosine and anti-Tiel antibodies. The results indicated that Tiel is tyrosine phosphorylated after 10 to 30 min of E3 IgG stimulation. To determine if E3 IgG induces Tiel phosphorylation in primary endothelial cells, HDMVEC cells were serum starved and stimulated with several concentrations ofE3 for 60 min. Tiel was then immunoprecipitated from cell lysates and subjected to anti-phosphotyrosine blotting analysis, which showed receptor phosphorylation following E3 IgG stimulation at 50-200 ng/ml. Also higher concentrations ofE3 (500-1000 ng/ml) induced Tiel phosphorylation but the response was more rapid and was most prominent after 5 min of stimulation.

[0513] To study the kinetics of E3 IgG induced Tiel activation, cells were stimulated with E3 IgG (200 ng/ml) and receptor phosphorylation was studied at various time points. Tiel phosphorylation was highest 15-30 min after E3 IgG treatment but phosphorylation persisted for up to 1 h.

[0514] To determine if any of the other monoclonal antibodies tested inhibit the survival effect of E3 IgG in Tiel-EpoR BaF3 assay, antibodies'were studied in combination with E3 IgG. A concentration of 100 ng/ml of E3 IgG together with 100 or 500 ng/ml of the other antibodies were used and the viability of Tiel- EpoR cells was measured. The results from both combinations of E3 IgG and the test antibody (in 1:1 and 1:5 ratios) were similar and indicated that two of the 23 antibodies (B2 and D1 1) blocked completely the survival effect of E3 IgG. Several antibodies (A2, A10, P-B1, P-B3 and P-C6) inhibited the viability effect of E3 IgG to some extent and two of the antibodies (G2 and C7) promoted the survival of Tiel/EpoR BaF3 cells in combination with E3 IgG.

[0515] Immunostaining of human tissues. The anti-Tiel antibodies react with human Tiel in cultured cells. It is also possible to determine whether they could stain human tissue samples from lung and kidney as well as from tumors by using biotinylated anti-Tiel antibodies and detecting bound antibodies using labeled streptavidin or avidin.

WO 2006/020706 PCT/US2005/028413 [05161 Example 3 Exemplary Sequences [0517] Sequences of exemplary immunoglobulin variable domains are shown in FIGs. 7-36.

[05181 Example 4 Inhibition of Tube Formation by HUVEC Cells Using Anti Tiel E3-IgG [0519] To demonstrate the ability of E3 to inhibit angiogenesis in vitro, purified E3 was tested for its ability to inhibit tube formation by human umbilical cord endothelial cells (HUVECS). Human Umbilical vein endothelial cells (HUVEC) were obtained by treating fresh human umbilical cord veins with Trypsin-EDTA (Ix) (Gibco/Invitrogen) for 20-25 minutes at 37 0 C. The cells were cultured in a T-25 flask coated with attachment factor (Cascade Biologics) in RPMI 1640 medium supplemented with 10 FCS, 0.4 BBE, 1% 1-glutamin, 1% penicillin/streptomycin. Primary cultures were detached with warm Trypsin-EDTA and used when confluent at the second or third passage. The cells weremaintained in a proliferative state by culturing them in a split ratio 1:2 at an approximate density of the monolayer of about 60-80%. To dissociate the cells, HUVEC monolayers were treated with trypsin/EDTA (500 il/dish) at 37 0 C for 3 min. Trypsin activity was stopped by adding 3 volumes of complete RPMI medium. The cells were carefully scraped, separated by repeated pipetting, and finally washed with PBS.

[0520] After 2 passages HUVECs were seeded in their culture medium x 103/ 50 gl/well of a 96-well plate) on a collagen gel (50 Al of collagen I mg/ml) prepared by mixing 7.5 volumes of 2mg/ml collagen (Collagen R; Serva, Heidelberg, Germany), 1 volume of 10X MEM, 1.5 volume of NaHCO 3 (15.6 mg/ml) and 1 volume of NaOH to adjust the pH to 7.4. After 1.5h, the culture medium was then discarded and the cells were covered with a new layer of collagen (1.5 mg/ml, new preparation, 50 pl/well). After polymerization of the gel, culture medium was added to each well in presence or in absence of E3 antibody (1 ng/ml to 10 pg/ml).

The assay was performed with a streptavidin antibody used as a control (from 1 ng/ml to 10 tpg/ml). The total length of the tube network on the culture surface was quantified at 40 x magnification by the METAVUETM Software (Universal Imaging WO 2006/020706 PCT/US2005/028413 Corporation). Results from triplicate wells were expressed as mean vessel area per field SEM (relative units). Each assay was performed at least three times.

[0521] E3 is a potent inhibitor of tube formation by HUVECS even at a concentration of 10 ng/ml. The control anti-streptavidin has no effect on the ability of HUVECS to form tubes. This results indicates that E3 can inhibit at least one aspect of angiogenesis.

[05221 Example 5: Immunohistochemical Analysis of E3 Binding to Matched Tumor and Normal Tissue Sections [0523] To evaluate the binding of E3 to Tiel in primary tumor and normal tissue the antibody was produced as an IgG and biotin labeled. The E3 antibody and two other anti Tiel antibodies B2 and D11-were reformatted as full length IgG molecules. Nucleic acids encoding these IgGs were transiently transfected into HEK293T cells. Plasmid preparations for transient cell transfections were performed using the HP-GENELUTETM MIDI prep kit (Sigma, cat. no. NA0200). HEK293T cells (GenHunter Corp. cat. no. Q401) were seeded 24 hours before transfection; 6 x 106 cells were plated per 10-cm culture dish. Transfections were carried out using

LIPOFECTAMINE

T 2000 reagent (Invitrogen, cat. no. 11668019) following the manufacturer's instructions. Five micrograms ofplasmid DNA was used per dish. Cells were cultured in DMEM (Invitrogen, cat. no. 31966021) supplemented with 10 "ultra-low IgG" fetal calf serum (Invitrogen, cat. no. 16250078), at 37°C, COz, in a water saturated atmosphere. Conditioned media were harvested 72 hours and 144 hours after transfection, pooled and sterile filtered.

[0524] One hundred microliters of Protein A beads (rProtein A Sepharose 4 Fast Flow, Amersham Biosciences, cat. no. 17-1279-01) equilibrated in PBS were added to the cell culture supernatants, and these were rotated overnight at 4 0 C, in ml tubes. The beads were collected by centrifugation, transferred to a 96-well filter plate (UNI-FILTER 800 GF/B, Whatman, cat. no. 7700-2803) and washed extensively with PBS using a vacuum manifold (Macherey Nagel, cat. no. 760681).

Elution of the antibodies was achieved by resuspending the beads in 400 pl of 12.5 mM citric acid. After a 30 to 60 second incubation, the bead eluates were collected, using the vacuum manifold, into the wells of a 96-well collection plate (UNIPLATE WO 2006/020706 PCT/US2005/028413 750, Whatman, cat. no. 7701-5750). Each well of the collection plate contained 60 gl of 1 M HEPES pH 7.5 buffer to immediately neutralize the eluted fractions. The elution step was performed twice to maximize antibody recovery. The eluted samples were then dialyzed against PBS using dialysis cassettes (Slide-A-Lyser Dialysis Cassettes, MWCO 10,000, Pierce, cat. no. 66380) and protein concentration was determined from the absorbance at 280 nm assuming that a 1 mg/ml solution has an absorbance of 1.35. The quality of the preparations was analyzed by reducing and non-reducing SDS-PAGE.

[0525] The Tiel antibodies were biotinylated using the EZ-link Sulfo-NHS- SS-Biotin (Pierce, Cat. 21331). For Tiel/Fc and Tiel-His, the reaction was performed for 2 hours on ice in 50 mM sodium carbonate buffer, pH 9.6, in the presence of a fold molar excess ofbiotinylating agent. For the antibodies, the reaction was performed for 2 hours on ice in PBS, in the presence of a 15-fold molar excess of EZlink Sulfo-NHS-SS-Biotin. The reaction was stopped by the addition of Tris-HC1, pH (50 mM final concentration) followed by a 1-hour incubation on ice. Samples were then dialyzed against PBS.

[0526] Various normal and tumor tissue sections were stained with biotinylated antibodies. A mouse monoclonal anti-Tiel antibody (7e8) (Alitalo laboratory, University of Helsinki) was used as a positive control. Sections without primary antibody served as negative control. All samples were fresh frozen tissues and staining was performed with the TSA-kit (Perkin-Elmer Life Sciences). After acetone fixation (10-20 min, -20 0 C) the slides were treated with 0.73% H 2 0 2 for min to reduce endogenous peroxidase activity followed by blocking for 30 min with TNB buffer. Sections (5-10 mm thick) were incubated with primary antibodies jig/ml) overnight at 4 0 C. Sections with the mouse monoclonal anti-tiel antibody (7e8) were treated with biotinylated anti-mouse antibodies (VectaStain) before the addition of streptavidin-HRP. Signal was amplified by using a TSA kit and the visualized by AEC (235 ml NaAc,15 ml AEC (stock solution: 1600 mg 3-amino-9ethyl-carbazole and 480 ml N-dimethylformamide), 250 pl H 2 0 2 [0527] In general, Tiel expression was upregulated in tumor tissue when compared with matching normal tissue. However, in the tumor tissues the anti Tiel antibodies stained other structures in addition to the vessels. Furthermore, some tissue specificity in the expression of certain epitopes was observed. For example, the WO 2006/020706 PCT/US2005/028413 E3 antibody stained vessels in the lung and kidney but not in the skin while the B2 antibody stained vessels very faintly in other normal tissues than in the breast.

Shedding of the ectodomain of Tiel into the tumor tissues can explain observed differences.

[0528] In skin tissue, the E3, B2, and D11 antibodies stained blood vessels very faintly whereas the murine 7e8 control antibody gave a clear staining in the normal skin. In melanoma tissue, the 7e8 antibody stained vessels only but the E3, B2, and D11 antibodies also stained other surrounding structures. The staining pattern was similar with all three of the E3, B2, and D11 antibodies.

[0529] In lung tissue, we observed that the E3 antibody stained especially clearly the large veins in the lung, whereas D11 and 7e8 gave a faint staining. B2 did not stain the same veins. The expression of Tiel was dramatically upregulated in lung carcinoma and all the antibodies stained vessels more strongly in samples with lung carcinoma than in samples from normal lung. In the lung tumors, the E3, B2, and D11 antibodies stained structures other than vessels.

[0530] In kidney, the E3 and D11 antibodies stained kidney tubules in addition to the vessels. B2 gave only very faint staining of either tubules or vessels while 7e8 stained only vessels. In hypemephroma tissue, only the E3 antibody gave a clear staining.

[0531] In breast, E3 gave the brightest staining in the veins and capillaries of the mammary tissue, B2 and 7e8 gave a similar staining while D11 stained those structures rather faintly. In breast carcinoma the Tiel expression was substantially upregulated, and the E3, B2, and D11 antibodies stained also other structures in addition to vessels.

[0532] Example 6 Binding to Mouse Endothelial Cell Lines of Anti Tiel E3- IgG Using Flow Cytometry [0533] We evaluated if E3 cross reacts with mouse Tiel in situ and thus if we can evaluate E3 activity in mouse tumor xenograft models binding to mouse endothelial cells was tested and compared with human and transfected cell lines.

[0534] Specific binding of the Tiel antibodies and of control Mabs to mouse endothelial cells was measured by flow cytometry analysis (FACSscan, Becton WO 2006/020706 PCT/US2005/028413 Dickinson, Oxnard, Epics, Coulter). Mouse endothelial cell lines MS1, Le-2, Bend3, SVEC (ATCC, Rockville) and Tiel transfected Le-2 cells were stained. Cell staining was modified from existing protocols. About 200,000 cells were used in each experiment: after trypsinization, cells were washed one time in PBS and resuspended PBS, 10% heat inactivated human serum (incubation buffer). To test specificity, antibodies were incubated at different dilutions for 1 h at room temperature. Cells were spun down by centrifugation for 3 min at 611 g. Between incubations cells were washed twice with PBS. Then relevant biotinylated antibodies (A2 against streptavidin, E3 against Tiel, were added and incubated for 1 h at room temperature).

The E3 DX-2210 antibody, in which the light chain has been germlined, was used for these studies. This was followed by incubation with Strepatvidin- R-phycoerythrin (Dako, Glostrup, Denmark) for 1 hour at room temperature in incubation buffer.

After the final incubation step bound antibodies were detected by means of flow cytometry on a FACSCan and Epics Altra (Becton Dickinson, Oxnard, Coulter) and results analyzed.

[0535] Intracellular Tiel was measured as described above, except for the addition of Saponin to the incubation buffer to a final concentration of 0.1% during incubations. The anti-Tiel antibody E3 binds to mouse endothelial cell lines indicating a cross reactivity of E3 with mouse and human Tiel in situ. The binding pattern in mouse cell lines detected by flow cytometry is different from the binding pattern in HUVEC in that in mouse cells there is a greater cell surface staining than that compared to primary human endothelial cell lines. DX-2210 stained positively both mouse endothelial cell lines as well as the HUVEC control cells. There was a shift in the fluorescent signal when the cells were treated with saponin, indicating a significant intracellular pool of sequestered Tiel.

[05361 Example 7 Determination of anti Tiel E3-IgG Binding to Human Platelets Using Flow Cytometry [0537] Binding experiments with a purified polyclonal goat antiserum against Tiel (R&D systems) had showed binding to human platelets in a previous study (Tsiamis et al., (2000) J. Vasc. Res. 37:437-42). The conclusion form this study was that platelets represent a large pool of Tiel immunoreactivity which could present a WO 2006/020706 PCT/US2005/028413 problem for development of Tiel as a therapeutic target. To determine if the antibody E3 binds to platelets we performed flow cytometric analysis on both activated and inactivated platelets and compared the staining pattern with the purified anti Tiel polyclonal serum.

[0538] To avoid platelet activation, human platelets were isolated from plasma of healthy donors using the platelet GelSep kit (Biocytex, Marseille, France) kit according to the guidelines of the manufacturer. Platelets were activated by the addition of thrombin to a final concentration of 0.8 U/ml. To distinguish activated from non-activated platelets double staining was performed with Tiel antibodies/control antibodies and antibody CD42 (total platelets) or CD62 (activated platelets).

[0539] After preparation, platelets were resuspended in buffer 2 of the GelSep kit, 10% heat inactivated human serum (incubation buffer) and incubated for 1 hour.

To test specificity, biotinylated antibodies human anti-Tiel(E3), human antistreptavidin (A2-SV, an antibody that does not bind Tiel), human anti-FITC and goat anti-Tie (R&D systems) were incubated with 500 000 platelets per test for 1 hour at different dilutions (2 pg/ml, 10 pjg/ml) for 1 h at room temperature. Platelets were spun down by centrifugation for 10 min at 611 g. Between incubations platelets were washed twice with Buffer 1 of the GelSep kit. Then, Strepatvidin- R-phycoerythrin together with anti-CD42-PercP or anti-CD62-PercP were incubated for 30 minutes at room temperature in incubation buffer After the last incubation and washing detection of bound antibodies was performed by means of flow cytometry on a FACSscan and Epics Altra (Becton Dickinson, Oxnard, Coulter,) and results analyzed. Cells were gated on SSC and anti-CD42-PcrcP for the total platelets in case non-activated platelets were used and on SSC and anti-CD62-PercP for the activated platelets.

[0540] The polyclonal goat anti-Tiel antibody indeed binds to platelets under the conditions tested. This binding is lower when platelets are activated. In contrast, the human anti-Tiel antibody E3 shows no significant binding to total platelets, nor to activated platelets (FIG. 1).

[0541] Example 10 Assessment of Tiel Immunoreactivity in Human Platelets Using Immunoprecipitation with Anti Tiel E3-IgG WO 2006/020706 PCT/US2005/028413 [0542] A previous study with a purified polyclonal goat antiserum against Tiel (R&D Systems) had showed binding to human platelets (Tsiamis et al., 2000).

The conclusion from this study was that platelets represent a large pool of Tiel immunoreactivity which could present a problem for development of Tiel as a therapeutic target. To exclude the possibility that the antibody E3 binds to platelets immunoprecipitation of lysates prepared from platelets and HUVECS were performed. Both activated and inactivated platelets were tested.[0543] Anti-Tiel antibodies B2, D11, E3, the goat polyclonal AF619 and negative control antibodies anti-FITC and anti-Streptavidin were used. HUVECS were retrieved from culture dishes by trypsinization and platelets were prepared with the platelet GelSep kit (Biocytex, Marseille, France) kit according to the guidelines of the manufacturer. Per immunoprecipitation experiment 3-5 x 10 6 and 3 x 10 cells platelets were used for each antibody tested. Platelets and cells were washed with PBS and spun down at 1400 rpm for 4 minutes and supernatant was removed. Then cells were lysed in 1 ml lysis buffer containing 50mM Tris HCL pH 7.5, 150 mM NaCI, 0.5% Deoxycholic acid (DOC) and 0.5% NP-40 for 5 minutes. The lysed cells were spin down for 10 minutes at 14.000 rpm and 5 4tg/ml antibody was added to the supernatant and incubated at 4 0 C on a rotator. 100 Vl/sample protein A beads (Uppsala, Sweden) were washed 3 times with lysis buffer (centrifugation speed: seconds, 2000 rpm) then cell lysates incubated with antibody were added for minutes 4°C. Then beads were washed three times with washing buffer containing Tris HCL pH 7.5, 400 mM NaC1, 0.5% DOC, 0.5% NP-40. Finally, beads are spun down and the pellets was resuspended in an equal amount in sample buffer to perform SDS-page and Western blotting. In Western blotting Tiel was detected with the polyclonal goat anti-Tiel antibody. The conclusions of this study are that E3 is able to immunoprecipitate Tiel in HUVEC but not in platelets.

[05441 Example 8 Distribution of Tiel in HUVEC Cells Determined by Staining with Anti Tiel E3-Ig [0545] We analyzed the staining pattern of E3 in HUVECS using confocal microscopy. HUVEC were trypsinised, washed with PBS and spotted at a density of 000 cells on a gelatine coated microscope slide and incubated for 24 hours in a WO 2006/020706 PCT/US2005/028413 humidified incubator at 37 0 C. Cells were air dried and fixed with 4% paraformaldehyde for 20 minutes at room temperature. The slides were washed with PBS. The slides were incubated with 10% Heat inactivated human serum (incubation buffer).

[0546] For measuring specific binding to Tiel, biotinylated antibody E3 and biotinylated negative control antibody A2 were used at a concentration of 10 jtg/ml and incubated for 1 hour at room temperature. Slides were washed twice with PBS.

Then, Strepatvidin- R-phycoerythrin (Dako, Glostrup, Denmark) was added and incubated for 1 hour at room temperature. After the last incubation and washing detection of bound antibodies was performed by means of confocal microscopy.

[0547] E3 binds specifically to HUVEC as detected by confocal microscopy.

The staining is pre-dominantly located inside of the cell which suggests a large intracellular pool of Tiel relative to a smaller pool of cell surface localized Tiel. The localization of E3 was consistent with co-localization of Tiel with a cytoskeletal protein.

[0548] Example 9 Conversion of Somatic Mutations Positioned in the Framework Region of Anti Tiel E3 to Germline Residues [0549] To reduce potential immunogenicity of E3 in humans, all non germline amino acid residues in the LC framework regions were corrected back to germline.

An initial analysis was performed which aligned the LC of E3 with a database containing all kappa and lambda light chain germline genes. The LC ofE3 was shown to have closest homology to DPK4 and three substitutions in E3 relative to the germline framework regions were identified.

[0550] We constructed a germlined version ofE3 in which the LC framework regions were altered to include sequences identical to the DPK4 germline framework regions. The germlined E3 antibody was constructed by engineering a nucleic acid encoding the desired sequence. Changes to nucleic acids encoding the E3 LC variable domain were made by PCR and other standard molecular biological techniques and verified by nucleic acid sequencing.

WO 2006/020706 PCT/US2005/028413 [0551] An exemplary germlined light chain variable domain E3 sequence includes:

DIQMTQSPSSLSASVGDRVTITCRASQGIGHYLAWYQQKPGKVPKLLIYTASTLQSG

VPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQFNSYPHTFGQGTRLEIK

(SEQ

ID NO:159) The altered positions are underscored.

[0552] We produced the germlined version of the E3 antibody as both a soluble Fab and as an IgG. The Fab cassette of the positive sFAB-expressing clone was PCR amplified with oligonucleotides, ligated into a mammalian expression vector containing the human IgG4 Fc region and electroporated into XL1 Blue MRF' cells. The prokaryotic ribosomal binding sequence and gene three leader sequence were replaced with a mammalian internal ribosomal entry and heavy chain leader sequences. Reformatted antibody clones were sequenced to confirm accuracy following the cloning procedure. Endotoxin-free DNA was prepared and used for transient transfection studies.

[05531 Example 10 Production and Testing of Germlined Anti Tiel E3 Fab for Binding to Recombinant Tiel-Fc in ELISA [0554] To evaluate if the conversion of any of the somatic mutations in the framework of E3 back to germline residues had any effect on binding activity the soluble Fabs were produced. The soluble expression vector containing the parental E3 Fab and the germlined E3 Fab construct were grown overnight at 30 0 C in 2 xTY broth containing 100 gg/ml ampicillin and 2% glucose and use 4 ml of this overnight culture to inoculate 400 ml of 2xTY broth containing 100 gg/ml ampicillin and 0.1% glucose. Cells were grow at 37°C until an OD 6 0 o of 0.8-1.0, 1mM IPTG was added and the culture was maintained at 30 0 C for 4 hours. The cultures were spun down at 4,000 rpm for 15 min at 4 C. The supernatants were discarded and resuspend the pellets resuspended in 4.8 ml of ice cold TES buffer (0.2 M Tris-HC1, 0.5 mM EDTA, M sucrose, pH 8.0) containing proteases inhibitors (protease inhibitor cocktail tablets [Roche]: dissolve 1 tablet in 1 ml of water and dilute 50-times in TES buffer).

Transfer to 50 ml Falcon tubes and place on ice for 5-10 min. During this incubation, wash the centrifugation bottles with 5.25 ml TES:H 2 0 containing proteases inhibitors and add this to the cells. Incubate for 20 more min on ice. Spin at 3000 g for WO 2006/020706 PCT/US2005/028413 min at 4 0 C and transfer the supernatants into new centrifugation tubes. Resuspend the cell pellets in 6 ml TES containing 15 mM MgSO 4 and proteases inhibitors and incubate on ice for 15 min. Centrifuge at 3000 g for 15 min at 4 0 C. Transfer the supematants into the centrifugation tubes and spin at 8000 g for 20 min at 4°C.

Collect the supematants and dialyze against PBS. The Fabs were purified by metal chelate chromatography. Incubate the dialyzed periplasmic extracts with 1 ml of

TALONT

M Metal Affinity Resin (Clontech) and rotate at room temperature for 2 hours. Transfer the beads into empty gravity column (Poly-Prep chromatography columns, Bio-Rad, Cat. 731-1550). Wash the beads with 5 mM imidazole in PBS and elute the Fabs with 150 mM imidazole in PBS. Dialyze against PBS using dialysis cassettes (SLIDE-A-LYSER T M Dialysis Cassettes, MWCO 10,000, Pierce, cat. no.

66380) and determine the protein concentration from the absorbance at 280 nm assuming that a 1 mg/ml solution has an absorbance of 0.86. The quality of the preparations can be analyzed by reducing and non-reducing SDS-PAGE.

[0555] Wells of an IMMULON T M 2 HB plate coated overnight with 500 ng or ng of purified recombinant human Tiel-Fc target antigen per 100 microliters 0.1 M sodium bicarbonate buffer, pH 8.5. Parental E3, E3 germlined (E3g) or a negative control soluble Fab were loaded into wells at either 5 micrograms or 1 microgram per 100 microliters ofPBST. Recombinant human Tiel-Fc target antigen is dissolved in an appropriate amount of acetic acid and subsequently diluted into 0.1 M sodium bicarbonate buffer, pH 9.6 at final concentrations of 500 ng and 50 ng per 100 microliters. After addition of the target antigen to the wells the microtitre plate is incubated overnight at 4 0 C. The plate is subsequently washed 5 times with PBST and blocked with 1% BSA in PBS at 37 0 C for 2 hours. The plate is again washed plate times with wash buffer, PBST and 100 microliters per well of purified Fab at 5 or 1 micrograms per 100 microliter PBST was added followed by incubation at room temperature for 1 hour. After washing plate 7 times with PBST 100 microliters of a 1:5000 dilution of anti-sFab-HRP in PBST was added (Pierce Product #31414). After washing the wells seven times 100 microliters TMB-H 2 0 2 solution was added to each well and the plate read at 630 nm in an ELISA. Both E3 and germlined E3 bound to the recombinant human Tiel-Fc target antigen by this assay.

WO 2006/020706 PCT/US2005/028413 [05561 Example 11 Production and Testing of Germlined Anti Tiel E3 Fab for Binding to Recombinant Human Tiel in BIAcore [0557] Recombinant purified human Tiel-Fc antigen (Stock 2.45 mg/ml) was biotinylated using the EZ-link Sulfo-NHS-SS-Biotin (Pierce, Cat. 21331). The reaction was performed for 2 hours on ice in 50 mM sodium carbonate buffer, pH 9.6, in the presence of a 5-fold molar excess ofbiotinylating agent and was stopped by the addition of Tris-HC1, pH 7.5 (50 mM final concentration) followed by a 1-hour incubation on ice. Samples were then dialyzed against PBS. The antigen was then diluted 1/100 fold in HBS and was then captured onto a streptavidin chip. This was coated to a density of 830RU (resonance units). All analysis was performed in HBS buffer. The parental Fab E3 and germlined E3 Fab were prepared as described above.

A stock solution of 0.587 mg/ml (11740nM) was diluted 1/587 in HBS BSA to obtain a stock of 20nM and the germlined Fab E3 0.025 mg/ml (500 nM) was diluted 1/25 in HBS BSA to obtain a stock of 20nM. Serial dilutions were made of each Fab preparation to obtain 10nM, 5nM, 2.5nM, and 1.25nM solutions. For the association phase samples were injected at 30Rl/min for 4 minutes using kinject program. This was followed by a 10 minutes dissociation phase, any remaining sample was stripped from the Tiel Fc surface at a flow of 50 utl/min with a single injection of 5 mM NaOH 1M NaCI for 18 seconds. All samples were run and analyzed in duplicate.

[0558] Sensorgrams were analyzed using the simultaneous ka/kd fitting program with 1:1 model in the BIAEVALUATIONTM software 3.1. From the analysis we can see that the germlining of the E3 antibody has had minimal effect on the binding activity of the antibody.

Table 2: Comparison of the binding affinity of parental and germlined E3 Fab E3 Fab Tiel Fc kn (I/Ms) koff KD(1) nM parental Human 3.00E+05 6.10E-04 germlined Human 3.00E+05 1.02E-03 3.4 WO 2006/020706 PCT/US2005/028413 [05591 Example 12 Comparison of Affinity of Germlined Anti Tiel E3 -IgG to Parental Anti Tiel E3 for Binding to Recombinant Human Tiel Using BIAcore [0560] In order to evaluate if the binding behavior had been affected in any way by the conversion of the somatic mutations back to germline residues, the germlined antibody was produced and tested as an IgG. The germlined E3-IgG construct used to transiently transfect HEK293T cells and purified.

[0561] The germlined E3 IgG1 stock solution 0.63 mg/ml was diluted 1/50 in a buffer ofpH4.5 and the parental E3 IgG1 stock solution 0.56 mg/ml (2143-001) was diluted 1/50 in a buffer ofpH 4.5. The IgG were directly coated onto a CM5 chip.

The surface of the chips was activated with a 7 minute pulse of 0.05M NHS/0.2M EDC and the IgG was flowed over until 780RU germlined E3-IgG and 728 non germlined E3 IgG was coated onto the surface. All flow cells were subsequently deactivated with a 7 minute pulse of 1M ethanolamine hydrochloride pH 8.5. All analysis was performed in HBS buffer. Purified recombinant human Tiel Fc was diluted 1/28.7 in HBS to obtain a 400 nM stock solution. Serial dilutions were made to obtain 200nM, 100nM, 50nM and 25 nM Tiel Fc stocks. For analysis of the association phase samples were injected at 30 il/min for 8.3 minutes using kinject program. This was followed by a 40 minutes dissociation phase. Any antigen remaining associated to the surface was stripped from the IgG surface at a flow of gl/min with two injections of 10mM glycine pH 1.5 for 30secods. All samples were run and analyzed in duplicate [0562] Sensorgrams were analyzed using the simultaneous ka/kd fitting program with 1:1 model in the BIAEVALUATIONTM software 3.1. Germlining had minimal impact on the binding activity of the E3 IgG with respect to human Tiel Fc.

Table 3: Comparison of the binding affinity of parental and germlined E3 IgG E3 IgG Tiel Fc kon (1/Ms) kff KD(1) nM parental Human 6.19E+03 3.61E-05 5.83 germlined Human 7.09E+03 3.67E-05 5.17 WO 2006/020706 PCT/US2005/028413 [0563] Example 13 Production and Testing of Germlined Anti Tiel E3 Fab for Binding to Recombinant Mouse Tiel in BIAcore [0564] Mouse Tie 1-Fc antigen (0.5 mg/ml stock) was biotinylated using established procedures and after dilution 1/100 fold in HBS this was then used for capturing to a streptavidin chip. This was coated to a resonance value of 740RU. All analysis was performed in HBS buffer. The parental Fab E3 0.587 mg/ml (11740 nM) was diluted 1/587 in HBS BSA to obtain a stock of 20 nM and the germlined Fab E3 0.025 mg/ml (500 nM) was diluted 1/25 in HBS BSA to obtain a stock of 20 nM. Serial dilutions were made of each Fab preparation to obtain 10 nM, nM, 2.5nM, and 1.25nM. For the association phase samples were injected at for 4 minutes using kinject program. This was followed by a 10 minutes dissociation phase, any remaining sample was stripped from the Tiel Fc surface at a flow of 50 tl/min with a single injection of 50 mM NaOH 1 M NaCI for 18 seconds. All samples were run and analyzed in duplicate.

[0565] Sensorgrams were analyzed using the simultaneous ka/kd fitting program with 1:1 model in the BIAEVALUATIONTM software 3.1. The germlining of the E3 antibody has had minimal effect on the binding activity of the antibody.

Table 4: Comparison of the binding affinity of parental and germlined E3 Fab E3 Fab Tiel Fc kon (1/Ms) koff (11s) KD(1) nM parental Mouse 2,46 E+05 9,50E-04 3,9 germlined Mouse 3,40E+05 1,04E-03 3,1 [05661 Example 14 Comparison of Affinity of Germlined Anti Tiel E3 -gG to Parental Anti Tiel E3 for Binding to Recombinant Mouse Tiel Using BIAcore [0567] In order to evaluate if the binding behavior had been affected in any way by the conversion of the somatic mutations back to germline, the germlined antibody was produced and tested as an IgG. The germlined E3 was reformatted to an IgG as described. This was then used to transiently transfect HEK293T cells using established procedures. The IgG was purified from the culture supernatant using protein A column chromatography using established procedures and the subsequent IgG was then tested for binding activity using surface plasmon resonance (BIAcore).

WO 2006/020706 PCT/US2005/028413 The germlined E3 IgG1 stock solution 0,63 mg/ml (2146-002) was diluted 1/50 in a buffer ofpH 4.5 and the parental E3 IgG1 stock solution 0,56 mg/ml (2143-001) was diluted 1/50 in a buffer ofpH 4.5. The IgG were directly coated via onto a CM5 chip.

The surface of the chips was activated with a 7 minute pulse of 0.05M NHS/0.2M EDC and the IgG was flowed over until 780RU germlined E3-IgG and 728 non germlined E3 IgG was coated onto the surface. All flow cells were subsequently deactivated with a 7 minute pulse of 1M ethanolamine hydrochloride pH8,5. All analysis was performed in HBS buffer. Purified recombinant mouse Tiel Fc was diluted 1/6,5 in HBS to obtain a 400nM stock solution. Serial dilutions were made to obtain 200nM, 100nM, 50nM and 25 nM Tiel Fc stocks. For analysis of the association phase samples were injected at 30l/min for 8,3 minutes using kinject program. This was followed by a 40 minutes dissociation phase. Any antigen remaining associated to the surface was stripped from the IgG surface at a flow of ul/min with two injections of 10mM glycine pHl,5 for 30seconds. All samples were run and analyzed in duplicate [0568] Sensorgrams were analyzed using the simultaneous ka/kd fitting program with 1:1 model in the BIAEVALUATION TM software 3.1. The germlining process had minimal impact on the binding activity of the E3 IgG with respect to mouse Tiel-Fc.

Table 5: Comparison of the binding affinity of parental and germlined E3 IgG E3 IgG Tiel Fc kon (1/Ms) koff KD(1) nM parental Mouse 6.17E+03 9.20E-05 14.9 germlined Mouse 6.00E+03 8.99E-05 [05691 Example 15 Comparison of ICn 0 of Germlined Anti Tiel E3 and Parental Anti Tiel E3 in Tube Formation Assays using HUVEC Cells [0570] Germlined E3 (DX-2220) and its parental antibody (DX-2200) were evaluated in the tube formation assay in a collagen type-I matrix. Human Umbilical vein endothelial cells (HUVEC) (freshly isolated) were obtained by treating human umbilical cord veins with Trypsin-EDTA (lx) (Gibco/Invitrogen) for 20-25 minutes at 37 0 C. The cells were then cultured in a T-25 flask coated with attachment factor WO 2006/020706 PCT/US2005/028413 (Cascade Biologics) in RPMI 1640 medium supplemented with 10 FCS, 0.4 BBE, 1% 1-glutamin, 1% penicillin/streptomycin. Primary cultures were detached with warm Trypsin-EDTA and used when confluent at the second or third passage.

During culturing, the cells were kept in a proliferative state by culturing them in a split ratio 1:2 at an approximate density of the monolayer of about 60-80%. HUVEC monolayers were treated with trypsin/EDTA (500ul/dish) at 37°C for 3 min. Trypsin activity was stopped by adding 3 volumes of complete RPMI medium. The cells were carefully scraped, separated by repeated pipetting, and finally washed with PBS.

HUVECs (passage 2) were seeded in their culture medium (40 x 10 3 /50l/well of a 96-well plate) on a collagen gel (50 gl of collagen I 1.5mg/ml) prepared by mixing volumes of 2mg/ml collagen (Collagen R; Serva, Heidelberg, Germany), 1 volume of 10X MEM, 1.5 volume of NaHC03 (15.6 mg/ml) and 1 volume of NaOH to adjust the pH to 7.4. After lh 30 min., the culture medium was then discarded and the cells were covered with a new layer of collagen (1.5 mg/ml, new preparation, 50pl/well). After polymerization of the gel, culture medium was added to each well in presence or in absence ofE3 antibody (DX-2200) or germlined E3 antibody (DX-2220) (0.1 ng/ml to 100 ng/ml). The total length of the tube network on the culture surface was quantified at 40 x magnification by the METAVUETM Software (Universal Imaging Corporation). Results from triplicate wells were expressed as mean vessel area per field ISEM (relative units). Each assay was performed at least three times. The conclusions are that conversion of the three somatic mutations to germline amino acids in E3 has had little effect on the potency of E3. Both parental E3 (FIGS. 2A and 2B) and germlined E3 (FIGS. 2C and 2D) inhibit tube formation in vitro with an ICso less than 10 ng/ml, i.e. 66 pM.

[0571] Preliminary studies demonstrated that a monovalent Fab version of DX-2240 Fab was unable to inhibit tube formation in HUVECs. Thus, in this assay, bivalency is required to elicit an effect in a cell-based assay.

WO 2006/020706 PCT/US2005/028413 [0572] Example 16 Analysis of Germlined Anti Tiel E3 in Tube Formation Assays With Mouse Endothelial Cells [0573] In order to assess mouse Tiel cross-reactivity and biological activity on mouse Tiel, both E3 and germlined E3 were evaluated for their ability to inhibit tube formation in vitro using mouse endothelial cell line (LEII).

[0574] LEII lung mouse endothelial cell line (ATCC) was cultured in a flask in MEM medium with GLUTAMAX T M (Life Technologies Ltd., Paisley, Scotland) supplemented with 10 FCS, and 1% penicillin/streptomycin. During culturing, the cells were kept in a proliferative state by culturing them in a split ratio at an approximate density of the monolayer of about 80%. LEII monolayers were treated with trypsin/EDTA (500 jl/dish) at 37 0 C for 3 min. Trypsin activity was stopped by adding 3 volumes of complete MEM medium. The cells were carefully scraped, separated by repeated pipetting, and finally washed with PBS.LEII cells were seeded in their culture medium (20-40 X 103/50Rl/well of a 96-well plate) on a basement membrane (BIOCOAT n T Angiogenesis System; Becton Dickinson). After polymerization of the MATRIGELTM (30 min at 37 0 C, 5% CO 2 environment) the endothelial cell suspension resuspended in complete culture medium in the presence of the desired molecules (4.105 cells/ml; 50gl/well) was added to each well. The angiogenesis assay plate was then incubated for 16 to 18 hours at 37 0 C, 5% CO 2 atmosphere. The total length of the tube network was then quantified at 40 X magnification by the METAVUE

T

M Software (Universal Imaging Corporation).

Results from triplicate wells were expressed as mean vessel area per field SEM (relative units). Each assay was performed at least two times. Germlined E3 is a potent inhibitor of tube formation in mouse endothelial cells.

[0575] Example 17 Immunohistochemical Analysis of Mouse Tumor Tissue Sections Using Anti Tiel E3 IgG [0576] We determined if antibody E3 binds to mouse endothelial cells in mouse xenographs. Inmunohistochemistry was performed with biotinylated E3 IgG1 (a,z allotype) antibody and control antibodies anti-CD31 (endothelial cell specific marker) and anti-PCNA (proliferating cell nuclear antigen). Formalin-fixed tumor tissues from a mouse-xenograph containing SW480 cells (ATCC) were tested for the WO 2006/020706 PCT/US2005/028413 binding pattern of the human anti-Tiel antibody E3. 5 tm sections of paraffin embedded tissues were deparaffinized, rehydrated and pretreated with warm the citrate buffer (0.01 M sodium citrate, plH6 at 95 0 C) for 45 min. The slides were cooled down in fresh citrate buffer for 20 min and rinsed with distilled water. The slides were hydrogen peroxide treated, (0.3 H 2 0 2 in PBS), and preincubated with PBS, 5 FCS, 5% heat inactivated human serum (HS) for 1 hour. Between antibody incubations slides were washed 3 times 5 minutes in PBS. Biotinylated antibodies E3 and A2-SV were diluted to a concentration of 10 [ig/ml in PBS, 10 HS and incubated for 1 hour at RT. Slides were then incubated with an avidin-HRP (Dako) for 30 minutes at room temperature. Staining was detected by AEC (Vector Laboratories, Burlingame) and H 2 0 2 The peroxidase reaction was stopped with water and slides were counter-stained with haematoxylin. The tissues were evaluated for their binding reactivity. The staining pattern was consistent with staining of mouse endothelial cell Tiel and also with Tiel expressed by the E3 binds to Tiel expressed by SW480 tumor cells in a mouse xenograft.

[05771 Example 18 E3 Activity in a MATRIGEL T M Plug Assay [0578] The germlined variant of the E3 IgG antibody was evaluated in an in vivo assay for angiogenesis induced by bFGF in MATRIGELTM plugs. Growth factor reduced MATRIGELTM (BD Biosciences, catalog 354230) was supplemented with ng/ml ofbFGF (R&D Systems, catalog #234-FSE). The A2-SV or an IgG4 E3 antibody (10 pg/ml) or PBS was injected subcutaneously into the abdominal area of NMRI nu/nu mice (150 il of Matrigel/plug).

[0579] In the first assay, two mice were injected with MATRIGELTM supplemented with bFGF and soluble VEGFR-1 (10 pg/ml) as a positive control for an angiogenic inhibitor. At day 7 post-implantation mice were anesthetized and perfused through heart with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS). MATRIGELTM plugs and a piece of liver were removed and embedded in paraffin. Sections were cut and stained with hematoxylin and eosin [0580] The staining revealed modification of MATRIGELTM and formation of vessel-like structures in the PBS and A2-SV antibody treated plugs. Even though the WO 2006/020706 PCT/US2005/028413 E3 antibody and soluble VEGFR1 supplemented plugs contained single cells, there were neither modification of the matrix nor organization of the cells observed in these plugs. This results indicates that the germlined E3 antibody inhibits angiogenesis in MATRIGELTM in vivo.

[0581] In a second assay, mice were treated as described above, and then anesthetized eight days post-implantation and injected with fluorescein-conjugated tomato (lycopersicon esculentum) lectin (100 [Lg in 200 jtl of PBS; Vector, catalog #FL-1171) into the tail vein. After five min circulation the animals were perfused through the heart with 10 ml of PBS followed by 10 ml of 4% PFA in PBS.

MATRIGELTM plugs and pieces of kidney and liver were removed and frozen in OCT (Tissue-Tek). Nuclei were visualized on sections by using VECTASHIELDV mounting medium containing DAPI (Vector) and analyzed under fluorescence microscopy.

[0582] Staining of the MATRIGELTM with fluorescein lectin revealed stainpositive material for the PBS and control antibody (A2-SV) containing plugs, but no staining could be detected in the E3 antibody containing plugs. As a control, the blood vessels of the kidney and liver from the same mice showed nice staining with the fluorescent lectin.

[0583] Results from these two experiments suggest that the anti-Tiel antibody E3 can inhibit bFGF-induced angiogenesis in vivo.

[0584] To assess further the potential anti-angiogenic activity of the E3 antibody, a third assay examining the effect ofDX-2210 (E3 antibody with germlined light chain) on bFGF-induced endothelial cell tube formation in MATRIGELTM plugs was performed. Growth factor reduced MATRIGELTM supplemented with HUVECs, bFGF, and DX-2210, A2-SV (negative control IgG), or PBS were injected subcutaneously into the abdominal area ofBalb/c nu/nu mice (150 Rl MATRIGELTM/plug). At day 8 post-implantation, mice were anesthetized and injected with fluorescein-conjugated tomato (Lycopercicon esculentum) lectin into the tail vein. After a five minute circulation period, the MATRIGELTM plugs and liver and kidneys were removed and frozen in OCT media. In order to quantitate the amount of blood vessels in the MATRIGELTM plugs, sections were cut and either stained for endothelial cell content using an anti-CD-31 antibody or analyzed under WO 2006/020706 PCT/US2005/028413 fluorescence microscopy to assess the amount of functional blood vessels (tomato lectin staining) (data not shown). In addition, the amount of blood vessels per unit area was quantitated. These results demonstrated that DX-2210 inhibits bFGFinduced angiogenesis by 70% in the MATRIGELTM assay (FIG. 3).

[05851 Example 19 Evaluating Effects of Ligands on Complex Formation [0586] A candidate protein (for example, E3 or E3b antibody) that binds a complex member, such as Tiel, Tie2, or an angiopoietin is tested for its ability to antagonize formation of a heteromeric complex that includes Tiel, Tie2, and Ang, by inhibiting its formation or disrupting the heteromeric complex once it forms.

[0587] To test the ability of a candidate protein to disrupt complex formation, cells expressing Tiel and Tie2 are treated with Ang for a period of time sufficient to allow binding of Ang to Tiel and/or Tie2. The cells are contacted with the candidate protein for a period of time sufficient to allow disruption of the complex. The cells are treated with a membrane non-permeable cross-linker, such as DTSSP, to chemically cross-link the proteins. Cell lysates are prepared and subjected to immunoprecipitation with an antibody specific to a complex member. The immunoprecipitated proteins are separated by SDS-PAGE electrophoresis and immunoblotted with antibodies specific to the complex members. A positive control immunoprecipitation-immunoblot is also performed in which cells expressing Tiel and Tie2 are treated with Ang but not with the candidate protein or are treated with a nonspecific protein. If treatment with the candidate protein decreases the amount of a complex member- that is not bound by the immunoprecipitating antibody- associated with the immunoprecipitated member as compared to the positive control, the candidate protein is an antagonist of complex formation.

[0588] To determine if a candidate protein inhibits complex formation, a similar experiment is performed, except that the cells expressing Tiel and Tie2 are treated with the candidate protein prior to treatment of the cells with Ang. The cells are incubated for a period of time sufficient to allow complex formation in the absence of candidate protein. As described above, a positive control in which the cells are not treated with a candidate protein or are treated with a nonspecific protein WO 2006/020706 WO 206/00706PCTII§S2005/028413 is performed. The treated cells are then lysed and immunoprecipitations and immunoblots are performed as described above.

[0589] Candidate proteins that antagonize complex formation, by inhibiting complex formation or by disrupting complexes, are then tested for their effects on angiogenesis in an assay described herein.

~O59fli Examule 20 Tie2 Amino Acid Senuence r05901 ExamDle 20: Tie2 Amino Acid Seauence [0591] An exemplary Tie2 amino acid sequence is as follows:

MDSLASLVLC

PHEPITIGRD

FCEGRVRGEA

EDAVIYKNGS

SAFTRLIVRR

CRKACELHTF

ACHPGFYGPD

KIVDLPDHIE

TDHFSVAIFT

PNVIDTG~HNF

IVTLNYLEPR

LLPKSQTTLN

LLNNLHPREQ

THSSAVISWT

GLEPETAYQV

ILGSAGMTCL

LALNRKVKNN

DAAIKRMKEY

AIEYAPHGNL

GMDYLSQKQF

PVRWMAIESL

LPQGYRLEKP

TYLVNTTLYEK

GVSLLLSGTV

FEALMNQHQD

IRIRTMKMRQ

FIHSVPRHEV

CEAQKWGPEC

GRTCKERCSG

CKLRCSCNNG

VSTSGKFNPIC

IHRILPPDSG

AVINISSEPY

TEYELCVQLV

LT WQPIF PS S

YVVRARVNTK

ILDGYSISSI

DIFARNNIGS

TVLaLAFL1IL

PDPTIYPVLD

ASKDDHRDFA

LDFLRKSRVL

IHRDLAARNI

NYSVYTTNSD

LNCDDEVYDL

FTYAGIDCSA

EGANDLILIN

PLEVTQDVTR

QASFLPATLT

PIJILEVHLPH

NHLCTACMNN

QEGCKSYVFC

EMCDRFQGCL

KASGWPLPTN

VWVCSVNTVA

FGDGPIKSKK

RP.GEGGEGHP

EDDFYVEVER

AQGEWSEDLT

TIRYKVQGKN~

SNPAFSHELV

QLKP.ANVQRR

WNDIKFQDVI

GELEVLCKLG

ETDPAFAIAN

LVGENYVAKI

VWSYGVLLWE

MRQCWREKPY

EEAA

SLPLVSDAET

EWAKKVVWKR

MTVDKGDNVl

AQPQIDAGVYS

GVCHEDTGEC

LPDPYGCSCA

CSPGWQGLQC

EEMTLVKPDG

GMVEKPFNIS

LLYKPVNHYE

GPVRRFTTAS

RSVQKSDQQN

AWTLSDILPP

EDQHVDVKIK

TLPESQAPAl

MAQAFQNVRE-

GEGNFGQVLK

HHPNI INLLG

STASTLSSQQ

ADFGLSRGQE

IVSLGGTPYC

ERPSFAQILV

SLTCIASGWR

EKASKINGAY

ISFKKVLIKE

ARYIGGNLFT

ICPPGFMGRT

TGWKGLQCNE

EREGIPRMTP

TVLHPKDFNH

VKVLPKPLNA

AWQHIQVTNE

IGLPPPRGLN

IKVPGNLTSV

QPENIKISNI

NATIIQYQLK

LGGGKMLLIA

EPAVQFNSGT

ARIKKDGLRM

ACEH-RGYLYL

TJLHFAAD VAR

VYVKKTMGRL

GMTCAELYEK

SLNRMLEERK

100 150 200 250 300 350 400 450 S00 550 600 650 700 750 800 850 900 950 1000 1050 1100 1124 (SEQ ID NO: 162) SWISS PROT ACCESSION NUMBER: Q02763 21:- Angi Amino Acid Sequence [0593] An exemplary Angi amino acid sequence is as follows: 1 MTVFLSFAFL AZULTHIGCS NQRRSPESTSG RRYNRIQHGQ CAYTFILPEH DGNCRESTTD 61 QYN~TNALQRD APHVEPDFSS QKLQHLEHVM ENYTQWLQKL ENYIVRNNKS EMAQIQQNAV 121 QNHTATMLEI GTSLLSQTAE QTRKLTDVET QVLNQTSRLE IQLLENSLST YKLEKQLLQQ 181 TNEILKIHEK NSLLEHKILE MEGKHKEELD TLKEEKENLQ GLVTRQTYII QELEKQLNPA 241 TTNNSVLQKQ QLELMDTVHN LVNLCTKEVL LKGGKREEEK PFRDCADVYQ AGFNKSGIYT 301 IYINNMPEPK KVFCNMDVNG GGWTVIQHRE DGSLDFQRGW KEYKMGFGNP SGEYWLGNEF 361 IFAITSQRQY DLRIELMDWE GNRAYSQYDR PHIGNEKQNY RLYLKGHTGT AGKQSSLILE WO 2006/020706 PCT/US2005/028413 421 GADFSTKDAD NDNCMCKCAL MLTGGWWFDA CGPSNLNGMF YTAGQNHGKL NGIKWHYFKG 481 PSYSLRSTTM MIRPLDF (SEQ ID NO:163) NCBI ACCESSION NUMBER: AAM92271; gi: 22203641 [05941 Example 22 Conversion of a Mutation Positioned in the Framework 3 Region of Anti-Tiel E3 Heavy Chain to Germline Residue [0595] In order to limit the risk of potential immunogenicity of the E3 antibody after administration to patients, all non-germline mutations in framework regions were corrected back to germline amino acid residues. The anti-Tiel E03 antibody was isolated from Dyax Fab 200 library. In this library, the HC framework regions are unique and correspond to the DP47 germline segment (V3-23). Since the construction of the synthetic HC-CDR1-CDR2 sublibrary was made through the assembling of overlapping oligonucleotides, followed by some PCR cycles, mutations may have been introduced by one of those 2 steps. Therefore, an analysis was performed which aligned the HC of E03 antibody with the DP47 germline gene sequence. One non-germline mutation positioned in framework region number 3 was identified where a methionine residue has been replaced by a valine residue.

[0596] A strategy was designed to repair this mutation. The introduction of the germlined residue was facilitated by the presence of internal restriction sites in the framework flanking regions of the CDRs. Indeed, the design of the HC-CDR1-CDR2 sublibrary, present in FAB 310 library, was made in such a way that the shuffling of every CDR is allowed by the presence of unique restriction sites in the framework flanking regions. Since the valine residue to be corrected is located in FR3 region, 3' near the Xbal site, a primer was designed containing both the XbaI sequence and the corrected methionine germline residue. The changes were introduced by PCR using the Top XbaI-M forward primer combined with a 3' reverse primer (CJ-lift Nhe REV) annealing in the CH1 region. A PCR fragment of ~180bp was then generated.

The germlining PCR primers were: Top XbaI -M primer: TTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGaTGAAC 3' (SEQ ID NO:717) WO 2006/020706 PCT/US2005/028413 F T I S R D N S K N T L Y L Q M N (SEQ ID NO:718) CJ-lift Nhe REV: GGAGGGTGCTAGCGGGAAGACCG 3' (SEQ ID NO:719) [05971 Example 23 Cloning of Germlined Heavy Chain Tiel E3 [0598] In order to determine if the germlined residue introduced into E3 heavy chain had affected the biological activity of the antibody, a soluble Fab expression vector containing the germlined E3 antibody (termed "E3b" or DX-2220) was constructed. The PCR fragment from Example 22 was digested overnight with U/lggXba restriction enzyme, followed by a 5 hours digestion with 25 U/gg BstEII.

The cleaved PCR product was then purified on a 1% TAE-agarose preparative gel.

Ligation into the similarly-digested phagemid expression vector (pMIDl) containing the Tiel E3 germlined light chain sequence was performed for three hours at room temperature. Five nanograms of the newly-ligated material were electroporated into TG1 bacterial cells. Verification of the correction of the mutation was performed by sequence determination of the heavy chain of 20 randomly picked isolates. The resulting coding construct contained sequences that encode a germlined HC and a germlined LC sequence in a Fab format (termed Fab E3b).

[05991 Example 24 Production and Purification of E3b (DX-2220) [0600] The E3b Fab antibody was reformatted to a human IgG1. This construct was then used to transiently transfect HEK293T cells. Plasmid preparations for transient cell transfections were obtained using the Qiagen filter Plasmid Maxi kit (Qiagen, cat. no. 12263). HEK293T cells (GenHunter Corp., cat. no. Q401) were seeded 24 hours before transfection; 220 x 106 cells were plated per CELLSTACK® culture vessel (CellSTACK®-10 Chamber, Corning, cat. no. 3271). Transfections were carried out using the GeneJuice@ reagent (VWR, cat. no. novg70967-3) following the manufacturer's instructions. 650 micrograms ofplasmid DNA was used per CELLSTACK®. Cells were cultured in DMEM (Invitrogen, cat. no.

31966021) supplemented with 10 "ultra-low IgG" fetal calf serum (Invitrogen, cat.

no. 16250078), at 37 5 C0 2 in a water saturated atmosphere. Conditioned WO 2006/020706 PCT/US2005/028413 media were harvested 72, 144 and 216 hours after transfection, pooled and sterile filtered.

[0601] Cell culture supematants were loaded on a 25-ml rProteinA FF column (GE Healthcare, cat. no. 17-1279-02) equilibrated against PBS containing 0.5 M NaC1. The column was washed with PBS containing 0.5 M NaC1, then with 0.1 M sodium acetate pH 5.0 to remove bovine IgGs and the antibody was eluted with 12.5 mM citric acid. Fractions (5 ml) containing the antibody were neutralized by addition of 150 gl of 1 M Tris-HCI, pH [0602] The E3b antibody was further purified by cation exchange.

The antibody was dialyzed against 50 mM sodium citrate, pH 5.0, and loaded on a HiLoad 26/10 SP Sepharose HP column (GE Healthcare, cat. no. 17-1138-01) equilibrated in the same buffer. The antibody was eluted with 50 mM sodium citrate, pH 5.0, containing 1 M NaC1 (linear gradient on 10 column volumes). Fractions containing the antibody were pooled and dialyzed against PBS. Antibody concentration was calculated from the absorbance at 280 nm, assuming that a protein concentration of 1 mg/ml has an absorbance of 1.36.

[06031 Example 25 Testing of E3b IgG1 Binding to TIE-l/Fc in BIAcore [0604] The germlined E3b IgG1 stock solution (0.56 mg/ml) and the parental E3 IgG1 stock solution (0.41 mg/ml) were diluted 50-fold in 10 mM sodium acetate, pH 4.5. The IgGs were directly coated on a CM5 chip. The surface of the chip was activated with a 7-minute pulse of 0.05 M NHS 0.2 M EDC and the IgG was run over the chip until 823 RU of germlined E3b and 788 RU of parental E3 were coated on the surface. All flow cells were subsequently deactivated with a 7-minute pulse of 1 M ethanolamine hydrochloride, pH 8.5. All further experiments were performed in HBS buffer.

[0605] Purified recombinant human Tiel/Fc was diluted in HBS to final concentrations of 200, 100, 50, 25 and 12.5 nM. Samples were injected at 30 Itl/min for 8.3 minutes using the kinject program. This was followed by a dissociation phase. Any remaining antigen was stripped from the surface with two injections of 10 mM glycine, pH WO 2006/020706 PCT/US2005/028413 [0606] The sensorgrams obtained with this approach are shown below. Visual analysis shows that the dissociation (koff) is extremely slow (only a very small fraction of Tiel/Fc dissociated despite the long dissociation time), which suggests a very tight interaction. Interestingly, the dissociation rates for the IgGs as measured here are much slower that those of the corresponding Fabs (see Example 29 below), indicating that there is a significant increase in the affinity when going from the monovalent Fab to the bivalent IgG (avidity).

[06071 Example 26 Testing ofE3b Fab Binding to Tiel/Fc in BIAcore [0608] To evaluate if the binding behaviour had been affected in any way by the conversion of the somatic mutations back to germline residues, the parental and the germlined E3b antibodies were produced and tested in Biacore as Fab fragments.

Here, by contrast to what was done for the IgGs (see Example 28), and in order to measure a monovalent interaction, the Fabs were run over the antigen directly coated onto the surface.

[0609] Recombinant human Tiel/Fc was coated on a CM5 chip. The surface of the chip was first activated with a 7-minute pulse of 0.05 M NHS 0.2 M EDC, then Tiel/Fc (2 utg/ml in 10 mM sodium acetate, pH 4.0) was run over the chip surface until 750 RUs were coated on the surface. All flow cells were subsequently deactivated with a 7-minute pulse of 1 M ethanolamine hydrochloride, pH 8.5. All further experiments were performed in HBS buffer.

[0610] The parental and the germlined E3b Fabs were prepared. A series of dilution (50, 25, 12.5, 6.25 and 3.125 nM) was prepared in HBS buffer. Samples were injected at 30 dl/min for 5.3 minutes using the KINJECTTM program. This was followed by a 10-minute dissociation phase, and the remaining Fab was stripped from the surface with a single 18-sec injection of 50 mM NaOH 1 M NaC1.

[0611] Sensorgrams were analyzed using the simultaneous ka/kd fitting program from the BIAEVALUATIONTM software 3.1 assuming a 1:1 model. This analysis proved that the germlining of the E3 antibody has little or no effect on the affinity against Tiel/Fc E3 Fab Tiel Fc kon (I/Ms) koff KD (nM) WO 2006/020706 PCT/US2005/028413 Parental Human 8,81e4 1,05e-03 12 germlined (E3b) Human 1.36e5 1,01e-03 7 [06121 Example 27 Testing of E3b IgG for Biological Activity in Tube Formation Assays [0613] The purpose of this study was to determine if the correction of HC mutation back to germline in the parental E3 has any effect on the biological activity.

Human umbilical vein endothelial cells (HUVEC) (freshly isolated) were obtained by treating human umbilical cord veins with Trypsin-EDTA (lx) (Gibco/Invitrogen) for 20-25 minutes at 37 0 C. The cells were then cultured in a T-25 flask coated with attachment factor (Cascade Biologics) in RPMI 1640 medium supplemented with 10 FCS, 0.4 BBE, 1% 1-glutamin, 1% penicillin/streptomycin. Primary cultures were detached with warm Trypsin-EDTA and used when confluent at the second or third passage. During culturing, the cells were kept in a proliferative state by culturing them in a split ratio 1:2 at an approximate density of the monolayer of about 60-80%. HUVEC monolayers were treated with trypsin/EDTA (500 Vl/dish) at 37 0 C for 3 min. Trypsin activity was stopped by adding 3 volumes of complete RPMI medium. The cells were carefully scraped, separated by repeated pipetting, and finally washed with PBS. HUVECs (passage 3) were seeded in their culture medium x 103/50 pl/well of a 96-well plate) on a collagen gel (50Pl of collagen I prepared by mixing 7.5 volumes of 2mg/ml collagen (Collagen R; Serva, Heidelberg, Germany), 1 volume of 10X MEM, 1.5 volume of NaHCO 3 (15.6 mg/ml) and 1 volume ofNaOH to adjust the pH to 7.4. After lh 30 min, the culture medium was then discarded and the cells were covered with a new layer of collagen new preparation, 50l/well). After polymerization of the gel, culture medium was added to each well in presence or in absence of E3b-IgG1 or parental E3 antibody (1 pg/ml to 10 ng/ml). Endothelial tube formation was assessed with an inverted photomicroscope. Microphotographs of the centre of each well at low power were taken with a Nikon camera with the aid ofimaging-capture software.

Tube formation in the microphotographs was quantitatively analysed (total tube length) with METAVUE® software (data not shown). Tube formation by untreated HUVECs in full endothelial cell growth medium was used as control. Results from WO 2006/020706 WO 206/00706PCTII§S2005/028413 triplicate wells were expressed as mean vessel area per field SEM (relative units) (FIG. The conclusions are that E3b-TgGl inhibits tube formation. Correction of HG mutation had no significant effect on biological activity.

[0614] Example 28: Exempla Tiel Binding Seguence [0615] The following are exemplary sequences of immnunoglobulin light chain and heavy chain variable domains: 1. 806C-M0044-A06 1-Variable (AA): QSELTQPPSASGTPGQRVTI SCSGSSSSIGLNPVNWYQQLPGTAPKVVIHSNDQRPS GVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLNGPAFGGGTKLTVL (SEQ ID NO :164) 1-Variable (DNA):

CAGAGCGAATTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACC

ATCTCTTGTTCTGGAAGCAGCTCCAGCATCGGACTTAATCCTGTAAACTGGTACCAGCAGCT

CCCAGGAACGGCCCCCAAAGTAGTCATCCATAGTAATGATCAGCGGCCCTCAGGGGTCCCTG

ACCGATTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTCGCCATCAGTGGACTCCAGTCT

GAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTGAATGGTCCGGCATTCGG

CGGAGGGACCAAGCTGACCGTCCTAG (SEQ ID NO:165) H-Variable (AM): EVQLLESGGGLVQPGGSLPISCAASGFTFS SYVMMWVRQAPGKGLEWVSRIYPSGGITQYAD SVKGRFTI SRDNSKNTLYLQMNSLPAEDTAVYYCARDVYRAFDIWGQGTM~VTVS S (SEQ ID NO:166) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCOGATTCACTTTCTCTTCTTACGTTATGATGTCGGTTCGCCAAGCTCCTG

GTAAzAGGTTTGGAGTGGGTTTCTCGTATCTATCCTTCTGGTGGCATTACTCAGTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCAA-GAGATGTCTACAGGGCTT

TTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 167) 2. 806C-M0044-All L-Variable QD IQNTQS PGTLSLS PGERATLSCRASQSVSS SYLAWYQQKPGQAPRLLIYGASSRATGI PD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPGGTFGQGTKVEIK (SEQ ID NO: 168) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCC-AGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTCGCCACGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC

AGGTTCAGTGGCAGTCGGTCTCGGACAGACTTCACTCTCACCATCAGCA@ACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCCGGGGGGAACGTTCGGCC

AAGOACCAAGQTCGAAATCAAA (SEQ ID NO:169) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (AA):

EVQLLESGGGLVQPGSIRLSCASGFTFSSYKMHWVRQAPGKGLEWVSSIYPSGGYTYA

SVKGRFTT SRDNSKNTLYLQMNSLPAEDTAVYYCARDSEHFHFWGDYYFLEYWGQGTLVTVS S (SEQ ID NO:170) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTDGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTATACTTATTATGCTGAC

TCCGTTAA2AGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTATATTACTGTGCGAGAGATAGCCATCATTTCC

ATTTTTGGGGTGACTATTATTTTCTAGAATACTGGGGCCAGGGAACCCTGGTCACCGTCTCA

AGC (SEQ ID NO:171) 3. 806C-M0044-B04 1-Variable (AA): QDIQMTQSPS SLSASVGDRVTITCRASQS ISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGGGTKVEIK (SEQ ID NO:172) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTC

CATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAATTGGTATCAGCAGAAACCAG

GGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGG

TTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCA-CCTGAA

GA

TTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCCACTTTCGGCGGAGGGACCA

AGGTGGAGATCAAA (SEQ ID NO:173) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYLMFWVRQAPGKGLEWVSYIYPSGGWTMYD

SVKDRFT ISRDNSKNTLYLQMNSLRAEDTAVYYCARQNYYDS

SGYYYRGFDYWGQGTLVTVS

S (SEQ ID NO:174) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACCTTATGTTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTATATCTATCCTTCTGGTGGCTGGACTATGTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTCAGGCAATTACTATGATA

GTAGTGGTTATTACTATCGTGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCA

AGC (SEQ ID NO:17S) 4. 806C-M0044-B05 1-Variable (AA): DIHMTQSPATLSLS PGERATLSCPRASQSVSSYLAWYQQKPGQAPRLLIYDASNPRATGIPARF SGSGSGTDFTLTISSLEPEDPAVYYCQQRSNWPPGITFGGGTKVEIK (SEQ ID NO: 176 L-Variable (DNA):

CACATCCATATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT

CTCCTGCAGGGCCAGTCAGAGTGTTAQCAGCTACTTAGCCTGGTACCAACAGAAACCTQGCC

AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC

WO 2006/020706 WO 206/00706PCTII§S2005/028413

AGTGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT

TGCAGTTTATTACTGTCAGCAGCGTAGCACTGGCCTCCGGGGATACTTTCGGCGAGGGA

CCAAGGTGGAGATCAAAL (SEQ ID NO:177) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYMGWRQAPGKGLEWVSS

IYPSGGWTHYAD

SVKGRFTISRDNSKNTIYLQMNSLRAEDTAVYYCARVLLYFDYWGQGTLVTSS

(SEQ

ID NO:178) H-Variable (DNA):

GAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTQGTTCTTTACGT

CTTTCTTGCGCTGCTTCCGGATTCACTTTCTCTTCTTAAGATGGGTTGGGTTCGCCAAGC

TCCTcGGTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTGGACTCATTATG

CTGACTCCGTTACGTCGCTTCACTATCTCTAGAGACACTCTAAGATACTCTCTACTTO

CAGATGAACAGCTTAGGGCTGAGGACCTGCAGTCTACTATTGTGCAGA(TACTACTACA

CTACTTTGACTACTGGGGCCAGGGACCCTGGTCACCGTCTCAAGC (SEQ TD NO: 179) 806C-M0044-B08 1-Variable (AA): QDIQMTQSPSFLSASVGDRVTISCRASQYIS

IYLNWYQQRPGEAPKLLINAASSLQSGDPSR

FSGSGSGTDFTLTINSLQPDDFATYYCQQYKSYPLTFGEGTKVEIK (SEQ ID NO:180) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTTCCTGTCCGCATCTGTAGGAGACAGAGTCAC

CATCTCTTGCCGGGCAGTCAGTACATCACATATATTTGATTGGTATCAGCAGAGACCAG

GCGAAGCCCCTAAACTCCTGATCAATGCTGCATCCAGTTTGCAJAGTGGGGACCCATCAGG

TTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAACAGCCTGCAGCCTGATGA

TTTCATATCGCAATTAAGTCCCCCTCGGGGAC

AGGTGOAGATCAAA (SEQ ID NO:181) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCASGFTFSAYGMGWJRQAPGKGESVI

SPSGGQTSYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTALYYCAGGDRYGPLHYWGQGTLVTVSS

(SEQ

ID NO:182) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACGGTATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTCTCCTTCTGOTGGCCAGACTTCTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACACTCTAGATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACCGCCTTGTATTACTGTGCGGGAGGGGACAGGTATGGAC

CCTTGCACTACTQGOCCAGGCGAACCCTGGTCACCGTCTCAGC (SEQ ID NO: 183) 6. 806C-M0044-B09 1-Variable (AA): QDI QMTQS PS SLSASVGDRVT ITCQASQDI SNYLNWYQQKPGKAPKLLIYHASNLETGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCLQYKSYPRLFGQGTKVEVK (SEQ ID NO:184) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

WO 2006/020706 WO 206/00706PCTII§S2005/028413

CATCACTTGCCAGGCGAGTCAGGACATTAGCAACTATTTAAATTGGTATCAGCAGAAACCAG

CGAAAGCCCCTAAGCTCCTGATCTACCATGCATCCAATTTGGAAACAGGGGTCCCATCAAGG

TTCAGTGGAAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGA

TTTTGCAACTTATTACTGTCTTCAGTATAAAAGTTACCCTCGATTGTTCGGCCAAGGGACCA

AGGT'GGAAGTCAAA (SEQ ID NO:185) H-Variable CAA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYKMN'WVRQAPGKGLEWVSVIYPSGGWTYYAD

SVKGRFTI SRDNSKNTLhYLQMNSLR1AEDTAVYYCASGYYDSSGYSRFDYWGQGTLVTVSS (SEQ ID NO:186) H-Variable (DNA):

CAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACAAGATGAATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTATCCTTCTGGTGGCTGGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCTGTGTATTACTGTGCGAGTGGTTACTATGATAGTA

GTGGTTACTCCCGATTTGACTACTGGGGCCAGGGAACCCTCGTCACCGTCTCAAGC (SEQ ID NO:187) 7. 8OGC-M0044-BIO L-Variable (AA): QSALTQPASVSGSPGQSITIS CTGTS SDVGSYNLVSWYQQI-PGKAPQLMTYEGSKRPSGLSN RFSGSKSDNTASLTISGLQAEDEADYYCCSYAGSSTLVFGGGTKLTVL (SEQ ID NO: 188) L-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGATGTTGGGAGTTATAACCTTGTCTCCTGGTACCAACAACACC

CACGCAAAGCCCCCCAACTCATGATTTATGAGGGCAGTAAGCGGCCCTCAGGACTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGACAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGA

GGACGAGGCTGATTATTACTGCTGCTCATATGCAGGTAGTAGCACTTTAGTATTCGGCGGAG

GGACCAAGCTGACCGTCCTA (SEQ IDNo:189) H-Variable (AA): EVQLLESCGGLVQPGGSLRLSCAASGFTFSRYKMGWVRQAPGKGLEWVSS

IYPSGGPTYYAD

SVKGRFTISRDNSKNTLYLQMNSLAEDTAMvYYCARSEVGAPDYWGQGTLVTVSS (SEQ ID NO:190) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTCGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTTCGTTACAAGATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCCCTACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCATGTATTACTGTGCGAGAAGCGAAGTGGGAGCCC

CCGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 191) 8. 806C-M0044-B12 L-Variable (AA): QDTQMTQSPSTLSASVGDTVTMTCRASQSI SGWLAWYQQKPGKAPNLLIFKASTLKSGVPSR FRGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSQTFGTKVEIK (SEQ ID NO:192) WO 2006/020706 WO 206/00706PCTII§S2005/028413 L-Variable (DNA):

CAAGAATCCAGATGACCCAGTCTCCTTCCACCCTTTCTGCATCTGTAGGAGACACCGTC

CATGACTTGCCGGCCATCAGAGTATTAGTOGGGTGGTTGGCCTGGTATCAGCAGAAACCAG

GGAAGCCCCTAACCTCCTGATCTTTAAGGCGTCTACTTTAAAGTGGGTCCCTAGG

TTTCSCGGCAGTGOATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGA

TTTCATATCGCAATTAAGTTCCGCTCGCAGAC

AGGTGGAAATCAAA (SEQ ID NO:193) H-Variable

EVQLLESGGGLVQPGGSLRLSCASGFTFSMYKMHVRQAPGKGLEWVSSIYPSGGYTYA

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCATDRWSSGGYGVDFWGQGTLVTVSS (SEQ ID NO:194) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAOCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATGTACAAGATGCATTGGGTTCGCCAAGCTCCTG

OTAAAOGTTTGGAGTGGTTTCTTCT

ATCTATCCTTCTGGTGGCTATACTGTTTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAGAGACACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAGGGCTGAGGACACGG

CCGTGTATTACTGTGCCACAGACCGG

TGGAGCAGTGGCGGGTACGGTGTTGACTTCTGGGGCCAGGGAACCCTGGTCACCGTTCAG

C (SEQ ID NO:195) 9. 806C-M0044-C07 1-Variable (AA): QDIQMTQSPLSLPVTPGEPASI

SCRSSQSLLH~SNGYNYLDWYLQKPGQSPQLLIYLGSNRAS

GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPQFGQGTKVEIK (SEQ ID NO: 196) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTC

CATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGCATTGGT

ACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCC

GGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAATCAGCAG

AGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACACTCCTCAGTTCG

GCCAAGGrGACCAAGGTGGAAATCAAG (SEQ ID NO:197) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSHYDMSWVRQAPGKGLEWVSYIYPSGGPTYYAD SVKGRFTISRDNSKNTLYLQMNSLFAEDTAVYYCARGDWASRFATWGQGTTVTVSS

(SEQ

ID NO:198) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGCCCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACGATATGTCTTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTATATCTATCCTTCTGGTGGCCCTACTTATTATGCTGAC

TCCGTTAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCAAGAGGCGATTGGGCTTCTC

GTTTTGCCACCTGGGGCCAGCGACCACGGTCACCGTCTCAAGC (SEQ ID NO:199) 1.806C-M0044-DOI WO 2006/020706 WO 206/00706PCTII§S2005/028413 L-Variable (AA): QYELTQPPSVSVAPGQTARITCGGNIGIKSVTYQQKPGQAPVLV-VYDDSGRPSGI

PQRFS

GSNSGNTATLTINRVEAGDEADYYCQVWDSGSDHWVFGGGTKLTVL (SEQ ID NO :200) L-Variable (DNA):

CAGTACGAATTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAGGATTAC

CTGTGGGGGAACAACATTCGAATTAAGTGTGACTGGTACCAGCAGAGCCAGGCCAGG

CCCCTGTGCTGGTCGTCTATGATGAT

AGTGGCCGGCCCTCAGGGATCCCTAGCGATTCTCTGGCTCCAACTCTGGQXACACGGCC

CCTGACCATCAACAGGGTCGAAGCCGGGGATGAGGCCGACTATTACTGTCAGGTGTGGGATA

GTGGTAGTGATCATTGGGTGTTCGGCGGACGGACCAAGCTGACCGTCCTA (SEQ ID NO: 201) H-Variable (AA):

EVLEGGVPGLLCAGTSYKGVQPKLWSIPGFRA

SVKGRFT ISRDNSKNTLYLQMNSLRAEDTAVYYCARNFVES

SHYYHDYWGQGTLVTVSS

(SEQ ID NO:202) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACAGATGGGTTGGGTTCGCCAJAGCTCCTG

GTAAAGGTTTGAGTGGTTTCTTCTATCTATCCTTCTGGTGGCTTTACTCGTTATGCTGAC

TCGTAGTGTCCACCAAACATTAATCCCATGAA

GACGTAGGTAGCCGCTTATCGGCGATTGTAAT

GTCATTATTACCATGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO:2 03) 1 i.806C-M0044-E03 1-Variable (AA): QSELTQPPSVSVAPGQTAVITCGGSNIGGKSVHWYQQKSGQAPVLVVFDDRDRPSGI

PERFS

GSNSGNTATLTITRVEVGDEADYYCQVWDSGTDHRVFGGGTRLTAL (SEQ ID NO :204) 1-Variable (DNA):

CAGAGCGAATTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGGCGACGGCCGTGATTAC

CTGTGGGGGGAGCAACATTGGAGGTAAAJAGTTACACTGTACCACCAOAAGTCAGGCCAGG

CCCCTGTGCTGGTCGTCTTTGATGATCGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCT

GGCTCCAACTCCGGGAACACGGCCACCCTGACCATCACCAGGTCGAAGTCGGGGATGAGC

CGACTATTACTGTCAGGTGT2GGGATAGTGGAZACTGATCATCGGGTGTTCGGCGAGGOACCA GGCTGACCGCCCTA (SEQ ID NO:205) H-Variable (AA): EVQLLE SGGGLVQPGGSLRLSCAASGFTFSRYVJMFWVRQAPGKGLEWVSGIYPSGGHTRYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARRGSGGYFDYWGQGTLVTVSS

(SEQ

ID NO:206) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTOGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGTTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTGGCCATACTCGTTATGCTGACTCCGTTAQGTCGCTTCACTATCTC

TAGAGACAACTCTAAGATACTCTCTACTTGCAGATGAACGCTTAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGACGAGGC

WO 2006/020706 WO 206/00706PCTII§S2005/028413 TCGGGGGGCTACTTTc3ACTACTGGCGCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 207) 12.806C-M0044-F03 L-Variable (AA): QSALTQDPAVSVALOQTVRTTCRDRLRSYYSSWYQQKPRQAPV-VMFGRNNRPSGI

PDRFS

GSTSGSTAS-TTTATQADDEADYFCSSRDGSGNFLFGGGTKLTVL (SEQ ID NC:208) L-Variable (DNA):

CAGAGCGCTTTGACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGGCAGACAGTCAGGATCAC

ATGCCGAGGAGACAGACTCAGAAGTTATTATTCAAGTTGOTACCAGCAGAAGCCACGACAGG

CCCCTGTTCTTGTCATGTTTGGTAGAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCT

GGCTCCACCTCAGGAAGCACAGCTTCCTTGACCATCACTGCGACTCAGGCGGACGATGAGGC

TGACTATTTCTGTAGTTCCCGGGACGGCAGTGGTAATTTCCTCTTCGGCOGAGGGACCAAAC

TGACCGTCCTT (SEQ ID NO:209) H-Variable (AA): EVQLLESGGGIJVQPGGSLRLSCAASGFTFSPRYKMIWVRQAPGKGLEWVSS

IYPSGGTTSYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARSDLGSGWYSAEYFQHWGQGTLVTVSS (SEQ ID NO:210) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAAGATGATTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCACTACTTCTTATGCTGAC

TCCGTTAAAOOTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCTGTGTATTACTGTGCGAGAAGCGACCTAGGCAGTG

GCTGGTATAGCGCTGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCAAGC

(SEQ ID NO: 211) 13 .806C-M0044-F06 L-Variable (AA): QDIQMTQSPGTLSLSPGERATLSCPASQSVSGNLLAWYQQKPGQAPRLLIYGAS

SRATGIPD

RFSGSGSGTDFTLTITRLEPEDFAVYFCQQYGGSPPVTFGGGTKVEIK (SEQ ID NO: 212) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCOCAACCTCTTAGCCTGGTATCAGCAGAAAC

CTGGCCAGGCTCCCAGACTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AcACTTCACTCTCACCATCACCAGACTGGAGCCTGAAGATTTTGCAGTGTATTTCTGTCAGC

AGTATGGTGGCTCACCTCCGGTCACT

TTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO 21-3) H-Variable (AA)- EVQLLESGGGLVQPGGSLRLSCAAiSGFTFSSYLMIWVRQAPGKGLEWVSRIYPSGGGTEYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARVTYYYDSSGYQPAFDIWGQGTMVTVS S (SEQ ID NO:214) H-Variable (DNA): WO 2006/020706 WO 206/00706PCTII§S2005/028413

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACCTTATGATTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGTATCTATCCTTCTGGTGGCGGTACTGAGTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCc4TGTATTACTGTGCGAGAGTCACGTATTACTATG ATAGTAGTGGTTATCAACCCGCTTTTGATATCTGGCGCCAAGGGAC2XATGGTCACCGTCTCA AGC (SEQ ID NO: 215) 14.806C-M0044-F09 L-Variable (AA):

QDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPAR

FSGSGSGTDFTLIISSLEPEDFAVYYCQQRSNWPRTFG2QGTKVEIK (SEQ ID NO: 216) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTOGCATCCCAGCCAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCATCATCAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTATTGTCAGCAGCGTAGCAACTGGCCTCGAACGTTCGGCCAAGGGACCA

AGGTGGAAATCAAA (SEQ ID NO:217) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYGMTWVRQAPGKGLEWVSVIGPSGGNTMYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVWGAFDIWGQGTMVTVSS (SEQ ID NO :218) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACGGTATGACTTGGGTTCOCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCGGTCCTTCTGQTGGCAATACTATGTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAGTATGGGGTGCTTTTG

ATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: :219) 15.806C-M0044-G06 L-Variable (AA):

QDIQMTQSPATLSVSPGERATLSCRASQSVYNNLAWYQQKPGQAPRLLIYDASTTATGIPAR

FSGSGSGTDFTLTTSLEPEDFAVYYCQQRSNWPSLTFGGGTKVEIK (SEQ ID NO :220 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAACGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTTACAACAACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCACCACGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCACCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGC

GTAGCAACTGGCCCTCGCTCACTTTC

GGCGGAGGGACCAAGGTGGAGATCAAA (SEQ IDNO.:221) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYKMGWVRQAPGKGLEWVSSIYPSGGWTHYAD

SVKGRFTITSRDNSKNTLYLQMNSLRAEDTAVYYCARVLLHYFDYWGQGTLVTVSS (SEQ ID NO:222) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTGGACTCATTATGCTGAC

TCCGTTAAAGGTCGCTTC'ACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGGACACTGCAGTCTACTATTGTGCAAGAGTACTACTACACTACT

TTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO :223) 16.806C-M0044-G07 1-Variable (AA): QDI QMTQS PSFLSASLGDRVTITCRATQGIGTFLAWYQQKAGRAPKLLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCQQPNSFFGQGTKLEIK (SEQ ID NO:224) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCTTTAGGAGACAGAGTCAC

CATCACTTGTCGGGCCACTCAGGGCATCGGCACTTTTTTAGCCTGGTATCAGCAAALAAGCAG

GGAGAGCCCCTAAACTCCTGATCTATGGTGCTTCCACTTTGCAGAGTGGGGTCCCATCAAGG

TTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATAAGCAGCCTGCAGCCTGAAGA

TTTTGCAACTTATTACTGTCAACAGCCTAATAGTTTTTTTGGGCAGGGGACCAAGCTGGAGA

TCAAA (SEQ ID NO:225) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYKMGWVRQAPGKGLEWVSSIYPSGGWTHYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVLLHYFDYWGQGTLVTVSS (SEQ ID NO:226) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTCATTATOCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAOGGCTGAGGACACTG

CAGTCTACTATTGTGCAAGAGTACTA

CTACACTACTTTGACTACTGGGGCCAGGOAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 227) 17.806C-M0044-G 11 1-Variable (AA): QDTQMTQSPSSVSASVGDRVTITCPASQDI SSWLVWYQQKPOKAPKLLIHDASNLQSQVPSP.

FSGSGSGTDFTLTINSLQPEDFATYYCQQANSFPVTFGGGTKVEIK (SEQ ID NO: 228) 1-Variable (DNA): CAAGACAT CCAGATGAC CCAGT CTC CAT CTT CCGTGTCTGCAT CTGTAGGAGACAGAGT CAC

CATTACTTGTCGGGCCAGTCAGGATATTAGCAGTTGGTTAGTCTGGTATCAGCAGAAACCAG

GGAAAGCCCCTAAGCTCCTGATCCATGATGCATCCAATTTGCAAAGTGGGGTCCCATCAAGG

TTCAGCGGCAGTGcGQTCTGGACAGATTTTACTCTCACCATCAACAGCCTGCAGCCTGAAGA WO 2006/020706 WO 206/00706PCTII§S2005/028413

TTTTGCAACTTACTATTOTCAACAGGCTAACAGTTTCCCGGTCACTTTCGGCGGAGGGACCA

AGGTGGAGATCAAA (SEQ ID NO:229) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYPMLWVRQAPGKGLEWVSSI SPSGGATAYAD SVKGRFTI SRDNSKNTLYLQMNSLFAEDTAVYYCAKGSYSDYGVFESWGQGTJVTVSS (SEQ ID NO:230) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTOCGCTGCTTCCGGATTCACTTTCTCTGCTTACCCTATGCTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTCTCCTTCTGGTGGCGCTACTGCTTATGCTGACTCCGTTAAXGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAAAGGCTCA

TACAGTGATTACGGGGTCTTTGAGTCCTGCCGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID N0:231) 18. 806C-M0044-H03 L-Variable (AA): QRVLTQPPSASGTPGQRVTISCSGSS SNVGSNN VNWYQQLPGQAPKLLIDSNNHRPSGVPDR FSGSKSGTSASLALSGLQSEDEADYYCATWDDNLIAPVFGGGTKLTVL (SEQ ID NO: 232) L-Variable (DNA):

CAGAGGGTCTTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTC

CTOTTCTGGAAGCAGCTCCAATGTCGGAAGTAATAATGTAAACTGGTATCAGCAGCTCCCAG

GACAGGCCCCCAAACTCCTCATCGATAGTAATAATCACCGGCCCTCAGGGGTCCCTGACCGA

TTCTCTGGCTCCAAGTCTGGCACCTCAGCCTCCCTGGCCCTCAGTGGGCTCCAGTCTGAGGA

TGAGGCTGATTATTATTGTGCGACATGGGACGACAACCTGATTGCCCCGGTATTCGGCGGAG

GGACCAAGCTGACCGTCCTA (SEQ ID NO:233) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYRMSWVRQAPGKGLEWVSGIVPSGGWTTYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDNYYDFWSGYYI

SRFGMDVWGQGTTV

TVSS (SEQ ID NO:234) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCGTATGTCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGTATCGTTCCTTCTGGTGGCTGGACTACTTATGCTGAC

TCCGTTATAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACTGCAGTCTACTATTGTGCGAGAGATAACTATTACGATT

TTTGGAGTGGTTATTATATTTCTCGATTCGGTATGGACGTCTGGGGCCAAGGGACCACGGTC

ACCGTCTCAAGC (SEQ ID NO:235) 19 .806C-M0044-H05 1-Variable (AA): QYELTQPASV 'SGS PGQS IT ISCTGSSSDVSGYNYVSWYQHHPGKAPKLMLYDVSNRPSGVSN RFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGGTKLTVL (SEQ ID NO: 236) WO 2006/020706 WO 206/00706PCTII§S2005/028413 1-Variable (DNA):

CAGTACGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGATCCAGCAQ4TQACGTTAGTGGTTATAACTATGTCTCCTGGTACCAACACCACC

CAGGCAAAGCCCCCAAACTCATGCTTTATGATGTCAGTAATCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGA

GOACGAGGCTGATTATTACTGCAOCTCATATACAAGCAGCAGCACTTGGGTGTTCGGCGGAG

GGACCAAGCTGACCGTCCTA (SEQ ID NO:237) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYMMFWVRQAPGKGLjEWVSRIYPSGGWTYYAD SVKGRFT ISRDNSKNTLYLQMNSLRAEDTAVYYCARVTVPLDSGSYYFDYWGQGTLVTVS S (SEQ ID NO:238) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACATGATGTTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTFI'GGAGTGGGTTTCTCGTATCTATCCTTCTGGTGGCTGGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACA1ACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAGTTACGGTACCCCTTG

ATAGTGGGAGCTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID NO:239) 20.806C-M0044-H07 1-Variable (AA): QDT QMTQS PS SISASVGDRVTITCRASQGIRNDIJGWYQQKPGKAPKLLIYAAS SLQSGVPSR FSGSGSGTDFTLTTSSLQPEDFATYYCLQDYNYPWTFGQGTNVETK (SEQ ID NO :240) 1-Variable (DNA):

CAAC;ACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAG

GGAAAGCCCCTAAGCTCCTGATCTAT

GCTGCATCCAGTTTACAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTOGATCTGGCACAGA

TTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCTACAAG

ATTACAATTACCCGTGGACGTTCGGC

CAAGGGACCAA'TGTGGAAATCAAA (SEQ ID NO:241) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAAGFTFSSYIJ MTWVRQAPGKGLEWVSSIYPSGGWTYYAD SVKGRFTI SRDNSKNTLYLQMNSLR1AEDTATYYCAREMYYDFWSGYYRGFDIWGQGTTVTVS S (SEQ ID NO:242) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACCTTATGACTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTOGGTTTCTTCTATCTATCCTTCTG3TCGCTGGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCACATATTACTGTGCGAGAGAGATGTATTACGATT

TTTGGAGTGGTTATTATCGAGGTTTTGATATCTGGGGCCAGGCACCACGOTCACCGTCTCA

AGC (SEQ ID NO: 243) 21.806C-M0044-H09 1-Variable (AA): WO 2006/020706 WO 206/00706PCTII§S2005/028413 QDIQMTQSPSTLSAS TGDRVTTTCRASQRVSTWVAWYQQKPGRAPKLLIYMASRLESGVPSR FSGSGSGTEEPTLTISSLQPDDFATYWCQQYNFYPRTFGQGTKVDIK (SEQ ID NO:244) L-Variable (DNA): CAAGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTATAGGAGACAGAGTCAc

CATCACTTGCCGGGCCAGTCAGCGTGTTAGTACTTGGGTGGCCTGGTATCAGCAGAAACCAG

GGAGAGCCCCAAAA CTCTTGATCTATATGGCGTCTAGGTTAGAAAGTGGGGTCCCATCAAGG

TTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATAAGCAGCCTGCAGCCTGATGA

TTTTGCTACTTATTQGTGCCAACAATATAATTTTTATCCTCGGACGTTCGGCCAAGGGACCA

AGGTGGACATCAAA (SEQ ID NO: 245) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYGMNWVRQAPGKGLEWVSST SPSGGQTPYAD SVKGRFTISRDNSKNTLYLQMN'SLRAEDTAVYYCARDLGGAYIPDSWGQGTLVTVSS (SEQ ID NO:246) ,H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTGGTACGGTATGAATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTCTCCTTC!TGGTGGCCAGACTCCTTAT@CTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGCGAGATCTC

GGTGGGGCCTACATACCTGACTCCTGGGGCCAGGGCACCCTGGTCACCGTCTCAAOC (SEQ ID NO:247) 22. 806C-M0045-A02 L-Variable (AA):

QDIQMTQSPSFLSASVGDRVTITCRASQGISNYLAWYQQEPGKAPKLLIYSASTLQTGVPSR

FSGSGSGTEFTLTISSLQPEDFATYYCQQFNSYPRTFGHiGTKVEFK (SEQ ID NO :248) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCTTCCTTCCTGTCTGCATCTGTGGGAGACAGAGTCAC

CATCACTTGCCGGGCCAGTCAGGCCATTAGCAATTATTTAGCCTGGTATCAGCAAGAACCAG

GGAAAGCCCCTAAGCTCCTCATCTATTCTGCGTCCACTTTGCAAACTGGAGTCCCATCAAGG

TTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACAATCAGCAGCCTGCAGCCTGAGGA

TTTTGCAACTTATTACTGTCAACAGTTTAACAGTTACCCTCGAACGTTCGGCCACGGGACCA

AGGTGGAATTCAAA (SEQ ID NO:249) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYPMMWVRQAPGKGLEWVSVI SPSGGQTSYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGGRLNAFDIWGQGTMVTVSS (SEQ ID NO:250) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTACTTACCCTATGATGTGGGTTCCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTCTCCTTCTGGTGGCCAGACTTCTTATGCTGAC

TCCGTTAlAOGTCGCTTCACTATCTCTAOAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCGTGTATTACTGTACGAGAGGGGGGAGGCTGAATO

CTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO:2 51) WO 2006/020706 WO 206/00706PCTII§S2005/028413 23.806C-M0045-A04 1-Variable (AA): QSALTQDPAVSVAJLGQTVRFTCQGDSLRNYHPSWYQQKPGQAPVLVIYGKNNRPSGI

PDRFS

GSSSGNTASLTITGAQAEDELADYYCNSqRDSSN-HVFGTGTKVTVL (SEQ ID NO: 252) 1-Variable (DNA):

CAGAGCGCTTTGACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGGTTCAC

TTGCCAAGGAGACAGCCTCAGAAATTATCATCCAAGCTGGTACCAGCAGAAGCCAGGACAGG

CCCCTGTACTTGTCATCTATGGTAAAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCT

GGCTCCAGCTCAGGAAACACAGCTTCCTTGACCATCACTGGGGCTCAGGCGGAAGATGAGGC

TGACTATTACTGTAACTCCCGGGACAGCAGTGGTAACCATGTCTTCGGAACTGGGACCAAGG

TCACCGTCCTA (SEQ ID NO:253) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSIYQMGWVRQAPGKGLEWVSRIYPSGGVTKYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARDFGPGDLWSGYYDAFDIWGQGTMVTV SS (SEQ ID NO:254) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATTTACCAGATGGGTT3GGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGTATCTATCCTTCTGGTGGCGTTACTAAGTATGCTGAC

TCCGTTAAAGTCCTTCACTATCTCTAGAGACACTCTAGATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCTGTGTATTACTGTGCCAGAGATTTCGGTCCGGGCG

ATTTATGGGTGTTATTATGATGCTTTTGATATCTGGGGCCAGGGACAJATGGTCACCGTC

TCAZAGC (SEQ ID NO:255) 24.806C-M0045-BOI 1-Variable (AA):

QSALTQPASASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSKRPSGVPD

RFSGSKSATTASLTVSGLQAEDEADYYCSSYAQSNNLIFGGGTKVTVL (SEQ ID NO: 256) 1-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTGCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCACCATCTC

CTCCGACACGGCTGTGTAACAGCCTGACAACC

CAGGCAAAGCCCCCAAACTCATGATT

TATGAGGTCAGTAAGCGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGCTCCAGTCTGCCAC

CACGGCCTCCCTGACCGTCTCTGQGCTCCAGGCTGAGGATGAGGCTGATTATTACTGCAGCT

CATATGCAGGCAGCAACAATTTGATATTCGGCGGGGGGACCA AGGTGACCGTCCTA (SEQ ID NO:257) H-Variable (AA):

EVQLLESGGGLVQPGSLRLSCAASGFTFSSYQMQWVRQAPGKGLEWVSVIYPGGYTYYADS

VKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARJQFYGSSAAFDIWGQGTMVTVS

S

(SEQ ID H-Variable (DNA):

OAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACCAGATGCAGTGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTATCCTGGTGGCTATACTTATTATGCTGACTCC

GTTAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAA

WO 2006/020706 WO 206/00706PCTII§S2005/028413 CAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGcAAGACTCCAGTTCTACGGTTCCT CTGCTGCTTTTGACATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 259) 25.806C-M0045-B03 1-Variable (AA): QDIQMTQSPDTLSLSPGERATLSCRASQS ISRYLAWYQQRPGQAPSLL IYDASERAAGI P2R FSGSGSGTDFTLjTISSLEPEDFAVYYCQQRGNWPLTFGGGTKVDIR (SEQ ID NO: 260) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTATTAGTAGATACTTAGCCTGGTACCAACAAAGACCTG

GCCAGGCTCCCAGCCTCCTCATCTAT

GATGCATCCGAAAGGGCCGCTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTGGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAAC

GTGGCAACTGGCCGCTCACTTTCGGC

GGAGGGACCAAGGTGGACATCAGA (SEQ ID 110:2 61) H-Variable EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYPMIWVRQAPGKGLEWVSVI SPSGGHTSYAD SVKGRFTTSRDNSKNTLYLQMNSLAElTAVYYCARTQYYGcOAFDIWGQGKMVTVSS (SEQ ID NO:262) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACCCTATGATTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTCTCCTTCTGGTGGCCATACTTCTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAATCCAGTACTACGGTG

GGGGTTTTGATATCTGGGGCCAAGGGAAAATGGTCACCGTCTCAAGC (SEQ ID NO: 263) 26.806C-M0045-Bll 1-Variable (AA): QDIQMTQS PATLSLSPQERATLSCRASQSVS SYTAWYQQKPGQAPRLLIYDASNRATGI PAR FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPHTFGGGTKVEIK (SEQ ID NC :264) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGCGTAOCAACTGGCCTCACACTTTCGGCGGAGGGACCA

AGGTGGAGATCAAA (S EQ I D NO: 26 H-Variable (AA): EVQLLESGGGLVQPGtGSLRLSCAASGFTFSPYMLWVRQAPGKGLEWVSVI SPSOGQTFYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARLGAEKGMDVWGQGTTVTVSS (SEQ ID NO:266) H-Variable (DNA): WO 2006/020706 WO 206/00706PCTII§S2005/028413 GA1GTTCAATTGTTAGAGTCTGGTGGCGGcTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCCTTACGGTATGCTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTCTCCTTCTGGTGGCCAGACTTTTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAA.TACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGGCTAGGTGCGGAAAAG

GTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCAAGC (SEQ ID NO :2 67) 27.806C-M0045-C02 L-Variable (AA): QDIQMTQSPATLSVSPGERATLS CRASQSVS SNLAWYQQRPGQAPRLLIYGASSRATGI PDR FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGsSPRTFGQGTKVEIK (SEQ ID NO:2 68) L-,Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAGACCTG

GCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAQA

TTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCTCGGACGTTCGGCCAAGGGACCA

AGGTGGAAATCAAA (SEQ ID NO:2 69) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYVMGAVRQAPGKGLENVS

SIYPSGGYTYYAD

SVKGRFTISRDNSKNTIJYLQMNSIJRAEDTAVYYCAKDSPHCSGGSCYGGYYYYGMDIWGQGT

TVTVSS (SEQ ID NO:270) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTATACTTATTATGCTGACTCCGTTAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATAAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAAAGATTCC

CCGCATTGTAGTGGTGGTAGCTGCTACGGGGGCTACTACTACTACGGTATGGACGTCTGGGG

CCAAGGGACCACGGTCAOCGTCTCAAGC (SEQ ID NO: 271) 28. 806C-M0045-C1II L-Variable (AA): QSELTQPASVSGSPGQS ITI SCTGTNRDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSN RFSGSKSGNTASLTISGLQADDEAEYYCSSYTSSGTRVFGTGTKVTVL (SEQ ID NO: 272) 1-Variable (DNA):

CAGAGCGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTCCGACACGGCTGTGTAACAGCCTGACAACC

CAGQCAAAGCCCCCAACTCATGATTTATGATGTCAGTAJATCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGA

CGACGAGG3CTGAGTATTACTGCAGCTCATATACAJACAGCGGCACTCGAGTCTTCGGAACTG GGACCAAGGTCACCGTCCTA (SEQ ID NO:273) H-Variable (AA): EVQIJIESGGGIJVQPGGSLRLSCAASGFTSHYIMVWVRQAPGKGLEWVS

SIYPSGGVTYYAD

SVKGRPTISRDNSKNTLYLQMNSLRAEDTAVYYCARDVAGAIDYWGQGTLVTVSS

(SEQ

WO 2006/020706 WO 206/00706PCTII§S2005/028413 ID NO:274) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACATTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAJXGGTTTGGAGTGGTTTCTTCT

ATCTATCCTTCTGGTGGCGTTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGATGTT

GCCGGAGCTCTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 275) 29.806C-M0045-C12 L-Variable (AA): QYELTQPASVSGSPGQS ITISCTGTSTDVGGYNYVSWYQKHPGKAPKLMIYDVSNRPSGVSN RFSGSKSGNTASLTISGLQAEDEADYYCSSYTNTITVTFGGGTKJTVL (SEQ ID NO: 276) L-Variable (DNA):

CAGTACGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCACTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAAAAACACC

CAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAACCGGCCCTCTGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACCCCTCCCTGACCATCTCTGGGC!TCCAGGCTGA

GGACGAGGCTGACTATTACTGCAGCTCATATACAALACACCATCACCGTGGTGTTCGGCGGAG

GGACCAAGCTGACCGTCCTA (SEQ ID NO:277) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYWIMHWIRQAPGKGLEWVSSIYSSGGRTHYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTANYYCAHTDS STWYRWYPDLWGRGTLVTVSS (SEQ ID NO:27B) H-Variable (DNA):

GAALTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAAGTACTGGATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATTCTTCTGGTGGCCGTACTCATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GA2ACAGCCTAAGGGCTGAGGACACCGCCATGTATTACTGTGCACACACTGATAGCAGCACCT GGTACCGGTG GTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCAAGC

(SEQ

ID NO:279) 30.806C-M0045-DO 1 1-Variable (AA): QD TQMTQSPSTLSSSVGDRVTITCRASQSVSNWJAWYQQKPGKAPKVLIYKASTLESGVPSR FSCSGSGTEFTLTTSSLQPDDFATYYCQHYHRYSRTFGQGTKV7ETK (SEQ ID NO:2 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTTCATCTGTAGGAGACAGAGTC

CATCACTTGCCGGGCCAGTCAGAGTGTTAGTAACTGGTTGGCCTGGTATCAGCAGAAACCAG

GGAAGCCCCTAAGGTCCTAATCTATAAGGCGTCTACTTTAGAAAGTGGGGTCCCGTCAAGG

TTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGA

TTTTGCAACTTATTACTGCCAACATTATCATCGTTATTCTCGAACGTTCGGCCAAGGGACCA

AGC-TGGAAATCAAA (SEQ ID NO: 281) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYKMTWVRQAPGKGLEWVS

SIYPSGGWTWYAD

SVGFIRNKTYQNLAETAYCRNQGFIGGMTS

(SEQ

ID NO:282) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACAAGATGACTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTGGACTTGGTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGAGT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATAACTGGCAGGGCOf GTGCTTTTGACATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 283) 31. 806C-M0045-D07 1-Variable (AA):

QDIQMTQSPGTLSLSPOERATLSCRASQSVNSNQLAWYQQKPGQAPRLLIYGASNRATGIPA

RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNFWTFGQGTKVEIK CSEQ ID NO; 284) 1-Variable (DNA): CAAGACATCCAG2ATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAACAGCAACCAGTTAGCCTGTACCAGCAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTCTATTACTGTCGC

AGCGTAGCAACTTTTGGACGTTCGGC

CAAGGGACCAAGGTGOAAATCAAA (SEQ ID NO:285) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYLMMWVRQAPGKGLEWVS

SIYPSGGWTYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAMYYCARVAPYDSSGSVNYAFDPWGQGTLVTVS S (SEQ ID NO:286) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCTTATGATGTGGGTTCGCCAAGCTCCTG

GTAAGGTTTGGAGTGGTTTCTTCTATCTATCCTTCTGGTGCTGGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACCGCCATGTATTACTGTGCCAGAGTCGCCCCCTATGATA

GTAGTGGTTCOGTAAATTACGCGTTCGACCCCTGGGGCCAGGGCACCCTGGTCACCGTCTCA

AGC (SEQ ID NO:287) 32.806C-M0045-GO1 1-Variable (AA): QDTQMTQS PSSISASVGDRVTTTCPASQNINTYLNWYQQKPGRAPSLLIYTQSNLRSGVPSR FSGSGYGTDFTLTISGLQPEDFATYYCQQSH-SAPRTFGQGTRVEIK CSEQ ID NO:2 88) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTC

CATCACTTGCCGGGCAAGTCAGAACATTAACATCTATTTGAATTGGTATCAGCAAAGCCG

GGAGAGCCCCTAGCCTCCTGATTTAT

ACTCAATCCAATTTGCGAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATATGGCACAGA

WO 2006/020706 WO 206/00706PCTII§S2005/028413

TTTCACTCTCACCATCAGCGGTCTGCAACCT.UAAGATTTTGCAACTTACTACTGTCAACAGA

GTCACAGTGCCCCCCGGACGTTCGGC

CAGGGGACCAGGGTGGAAATCAAA (SEQ ID NO: 289) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYKVVQAGKGLEWSVYPSGGWTRYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARJEMIDTI

SPGWHFDLNGRGTLVTVSS

(SEQ ID NO:290) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGSTGGTTCTTTACGTCTTTC

TTQCGCTGCTTCCGGATTCACTTTCTCTCATTACAAGATGGTTTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCTGGACTCGTTATGCTGACTCCGTTAGGTCGCTTCCTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAAGAGAAATG

ATTGACACTATTTCGCCCGGCTGGCACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGT

CTCAAGC (SEQ ID NO:291) 33.806C-M0045-GIO L-Variable (AA):

QSELTQDPAVSVALGQTVRTTCQGDSLRSYYASWYQQKPGQAPVLVMYGKNNRPSGIPDRFS

GSSSGNTASLTITGAQAEDEADYYCQSRGSSSGNIYVFGTGTKVTVL (SEQ ID NO: 292 1-Variable (DNA):

CAGAOCGAATTQACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGGATCAC

ATCAGAAACTAAGTTAGCACGTCACGACAGCG

CCCCTGTACTTGTCATGTATGGTAAAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCT

GGCTCCAGTTCAGGAAACACAGCTTCCTTGACCATCACTGGGGCTCAGGCGGAAGATGAGGC

TGACTATTACTGTCAGTCCCGGGGCAGCAGCAGTGGTAACCATTATGTCTTC

GGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:293) H-Variable (AA): EVQLLESGGGLVQPc3GSLRLSCAASGFTFSRYQMMWVRQAPGKGLEWVSS

IYPSGGFTRYAD

SVKGRFTI SRDNSKNILYLQMNSLRAEDTAVYYCAKSYYYGSTYIYSYYGMDVWGQGTTVT VSS (SEQ ID NO:294) H-Variable (DNA): GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGc3TGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCAGATGATGTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTTTACTCGTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAOACAACTCTAAGATATTCTCTACTTGCAGATGACACTTAGGGCTAGACACGG

CCGTATATTACTGTGCGAAATCATAT

TACTATGGGTCOGGGACCTATCATTACTCTTACTACGGTATGGACGTCTGGGGCCAJGGGAC

CACGGTCACCGTCTCAAGC (SEQ ID NO:295) 34. 806C-M 0046-All 1-Variable (AA): QDTQMTQSPGTLSLS PGERATLSCRASQSVSSTYLAWYQQKPGQAPPWE IYGASSRATGI PD RFTGSGSGTDFTLTISRLEPEDFAVYYCQHYGSSPLTFGGGTKVEIK (SEQ ID NO :296 WO 2006/020706 WO 206/00706PCTII§S2005/028413 1-Variable (DNA):

CAAGACATCCAGATCACCCAGTCTCCAGGCACCTTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGTAGCACCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGAC

AGGTTCACTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCACTATGGTAGCTCACCGCTCACTTTCGGCGGAGGGA

CCAAGGTGGAGATCAAA (SEQ ID NO:297) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYRMDWVRQAPGKGLEWVSGIYPSGGHTYYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARTLYLWGSYPTQVAFDIWGQGTMVTVSS

(SEQ ID N'O:298) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTC-ACTTTCTCTCGTTACCGTATGGATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGTATCTATCCTTCTGGTGGCCATACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCACGTATTACTGTGCGAGACTTTACCTTTGGGGGA

GTTATCCCACCCAGGTTGCTTTTGATATCTG3GGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO:299) 35.806C-M0046-B06 1-Variable (AA): QDIQMTQS PATLSVS PGERATLSCRASQSVSSNLJAYQQKPGQAPRLL IYGASTPATGT PAR FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIK (SEQ TD NO :300) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTG

CCCAGCCTCCCAGCCTCCTCATCTATGGTGCATCCACCAGGGCCACTQGTATCCCAGCCAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCGCTCACTTTCGGCGGAGGGACCA

AGGTGGAGATCAAA (SEQ ID NO:301) H-Variable (AA):

EVQLLESGGGTJVQPGGSLRLSCAASGFTFSMYPMLWVRQAPGKGLEWVSSIYPSGGMTYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARQGYYDSSGWTFDYWGQQTLVTVSS (SEQ ID NO:302) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATGTACCCTATGCTTTGGGTTCCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCATGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAOAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTOAGCACACGGCCGTGTATTACTGTGCAGACAXGGTTACTATGATA

GTAGTGGGTGGACCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO:303) 36.806C-M0046-B1O 1-Variable (AA): WO 2006/020706 WO 206/00706PCTII§S2005/028413

QDIQMTQSPATLSLSPGERATLSCRASQSVSSY

4

AWYQQKPGQAPRLLIYDASNUXTGIPAR

FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKTEIK (SEQ ID NO :304) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGC

GTAGCAACTGGCCGCTCACTTTCGGC

GGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:305) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYVMNWVRQAPGKGLEWVSGIYSSGGYIYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTATYYCARRHFNGVGFDLWGQGTMVTVSS (SEQ ID NO:306) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACGTTATGAATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGTATCTATTCTTCTGGTGGCTATATTTATTATGCTGAC

TCCGTTAAAGGTrnCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTQCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCACATATTACTGTGCGAGAAGACATTTCAACGGGG

TTGGTTTTGATCTCTCCAAGGACAATGGTCACCGTCTCAAGC (SEQ IDNO :307) 37.806C-M0046-GI2 L-Variable (AA): QDIQMTQSPGTLSLSPGEPATLSCRASQSVSSSNLAWYQQKPGQAPRLLIYGASTRATGI PA RFSGSGSGTEFTLTISSLQSEDFAVYYCQLYKTFGGGTKVEIK (SEQ ID NO: 308) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCAACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCC

AGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTQCAGTCTGA

AGATTTTGCAGTTTATTACTGTCAGCTGTATAAGACTTTCGGCGGAGGGACCAAGGTGGAGA

TCAAA (SEQ ID NO:309) H-Variable (AA): EVQLLESGGGLVQPGGSLRJS CAASGFTFSNYKMNWVRQAPGKGLEWVSVTYPSQCCTYYAD SX1KGRFTI SRDNSKNTLYLQMNSLPAEDTAVYYCARVGYSSGWFLFYGMDVWGQGTTVTVSS (SEQ ID NO:310) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGDTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACAAGATGAATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGGTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CTGTGTATTACTGTGCGAGAGTCGGG

TATAGCAc3TGGCTGGTTTCTCTTTTACGGTATGGACGTCTGGGGCCAAGOGACCACGGTCAC CGTCTCAAGC (SEQ ID No:311) WO 2006/020706 WO 206/00706PCTII§S2005/028413 38.806C-M0046-H03 1-Variable (AA): QSALTQPRSVSGSPGQSVTISCTGSNTDVGRYNVSWYQQKPGKAPKLI IYDVYKRPSGVPD RFSGSKSGNTASLTISGLQADDEADYYCCSYARASTFSYVFGIGTEVTVL~ (SEQ ID NO: 312) 1-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTCGCTCAGTGTCCGGGTCTCCTGGACAGTCAGTCACCATCTC

CTGCACTGGATCCAATACTGATGTTGGTCGATACAATTTTGTTTCCTGGTACCAACAAAAGC

CAGGCAAAGCCCCCAAACTCATAATTTATGATGTCTATAGCGGCCCTCAGGGGTCCCTGAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGA

CGATGADGCTGATTATTACTGCTGCTCATATGCTCGCGCCTCCACTTTCTCTTATGTCTTCG

GAATTGGGACCGAAGTCACCGTCCTT (SEQ ID NO:313) H-Variable (AA): EVQLLESGLVQPGSLRLSCAASFTFSSYIMVWVRQAPGKGLiEWVSS IYPSGGHTPYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARQTGGYAHFDYWGQGTTJVTVSS (SEQ ID IN.O:314) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGQTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACATTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCCATACTCCTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGA.ATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGACAGACGGGTGGCTACG

CCCACTTTGATTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 315) 39 .806C-M0046-HIO 1-Variable (AA): QDTQMTQS PSSLSASVGDRVTMTCRASQGIGTYLAWYQQKPGIVPKLLIYAASTLQSGVPSR FSGSGSGTDFTLTISSIJQPEDVATYYCQKYNSAPRPFGQGTQVEIK (SEQ ID NO :316) 1-Variable (DNA):

CAAGACATCCAGATGACCCAOTCTCCGTCCTCCCTGTCTGCATCTGTAGDAGACAGAGTCAC

CATGACTTGCCGGGCGAGTCAGGGCATTGGCACTTATTTAGCCTGGTATCAGCAGAAACCAG

GGAA-AGTTCCTAAGCTCCTGATCTATGCTGCGTCCACTTTGCAATCAGGGGTCCCATCTCGG

TTCAGTGGCAGTGGATCTGGGACGDATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGA

TGTTGCAACTTATTACTGTCAAAAGTATAACAGTGCCCCTCGTCCGTTCGGCCAAGGGACCC

AGGTGGAAATCAAA (SEQ ID NO:317) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYVMHWTRQAPGKGLEWVSS IYPSGGWTLYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAPAVGPFDYWGQGTLVTVSS (SEQ ID NO :318) H-Variable (DNA):

GAAGTTCAZTTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACGTTATGCATTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTCTTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGCAGTG

GGACCTTTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 319 WO 2006/020706 WO 206/00706PCTII§S2005/028413 40.806C-M0046-H 11 1-Variable (AA): QYELTQPPSVSGI PGQRVTI SCSGNNSNFGSNTVTWYQQLPGTAPKLLIYSDSRRPSGVPDR FSGSRSDTSASLAISGLQSEDEAEYHCAAWDDSLNGVFGGGTK-TVL (SEQ ID NO :320 1-Variable (DNA):

CAGTACGAATTGATTCAGCCACCCTCAGTGTCTGGGATCCCCGGACAGAGGGTCACCATCTC

TTGTTCTGGAAACAACTCCAACTTCGGAAGTAATACTGTAACCTGGTACCAGCAGCTCCCAG

GAACGGCCCCCAAACTCCTCATCTAT

AGTGATAGTCGGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAGGTCTGACACCTC

AGCCTCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGAGTATCACTGTGCAGCAT

GGGATGACAGCCTAAATGGGGTGTTC

GGCGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO: 321) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYKMEWVRQAPGKGLEWVSVIYPSGGHTNYAD

SVKGRFTI SRDNSKNTLYLQMNSLR-AEDTAVYYCARGYYDILTGYYKYYFDYWGQGTLVTV SS (SEQ ID NO:322) H-Variable (DNA): GAAGTTCAATTGTTAGAGTCTGGTGGCc3GTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAAGATGGAGTGGOTTCGCCAAGCTCCTG

GTAAkAGGTTTGGAGTGGGTTTCTGTTATCTATCCTTCTGGTGGCCATACTAATTATGCTGAC TCCGTTAA-AGGTCGCTTCACTATCTCTAGA4ACAACTCTAAGAATACTCTCTACTTGCAGAT GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTc4TGCGAGAGGAGGCTATTACGATA

TTTTGACTGGTTATTATAAGTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTC

TCAAGC (SEQ ID NO:323) 41.806C-M0047-B03 1-Variable (AA): QD IQMTQSPSPLSASVGDSVTITC1RASQRIGSYLNWYQQNPGKAPKLLIYGASNLESGVPSR FSGRGSGTEFTLTITSLQPEDFATYFCQQTSSVSPLTFGQGTRLDIK (SEQ ID NO :324 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCCCCCTGTCTGCATCTGTAGGAGACAGTGTCAC

CATCACTTGTCGGGCAAGTCAGAGGATTGGCAGCTACTTGAATTGGTATCAGCAGAATCCAG

GCAAAGCCCCAAAACTCCTGATCTAC

GGTGCATCCAATTTGGAAAGTGGGGTCCCATCAAGGTTCAGTGGCCGTGGATCTGGGACAGA

GTTCACACTCACCATCACCAGTCTGCAACCTGAAGATTTTGCAACTTATTTCTGTCAACAGA

CCTCCAGTGTCTCCCCGCTCACCTTC

GGCCAAGGGACACGACTGGACATTAAA (SEQ ID NO: 3 2 H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSSYKMSWVRQAPGKGLEWVSVIYPSGGWTWYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARMMYYYDSSGYL-'ADAFDIWGQGTMVT VSS (SEQ ID NO:326) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGAT3TCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCTATCCTTCTGGTGGCTGGACTTGGTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAATGATGTATTACTATG

ATAGTAGTGGTTACCTAAQGGCTGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACC

GTCTCAAGC (SEQ ID NO:327) 42.806C-M0047-DOI L-Variable (AA): QDIQMTQSPGTLSTS IGDRVTITCRASQSINEWrIAWYQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDPTLTTSRLEPEDFAVYYCQQYGSSPALTFGGGTKVEIK (SEQ ID NO :328 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTCTCTACATCTATAGGAGACAGAGTCAC

CATCACTTGCCGGGCCAGTCAGAGTATTAATGAGTGGTTGCCTGGTTCAGCAGACCAG

GGAALAGCCCCTAAGCTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGG

TTCAGTGGCAGTGGATCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGA

TTTTGCAGTGTATTACTGTCGCAGTATGcGTAGCTCACCCGCGCTCACTTTCGGCGGAGGGA CCAAGGTGGAGATCAAA (SEQ ID NO: 3 29) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTPSAYKMMWVRQAPOKGILEWVS SIYPSGGWTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARSMGYGDAFDIWGQGTMVTVSS (SEQ ID NO:330) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACAAGATGATGTGGGTTCGCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTGGACTTATTATGCTGAC

TCGTAGTGTCCACCAAACATTAATCCCATGAA

GAACAGTTTAAGGGCTGAGGACACCGCCTTGTATTACTGTGCGAGATCAATGGGCTATGGTG

ATGCTTTTGATATCTGGCGCCAAGGGACAATGTCACCGTCTCAJAGC (SEQ IDNO :33 i) 43.806C-M0047-D03 1-Variable (AA): QDIQMTQS PS SLSASVGDRVTITCRASQTIRSYLNWYQQKPGKAPKLLIYAASNLQSGVPSR FSGSGSGTDFTLTISSLQPEDPATYYCQQSYSMSSWTFGQGTNLEI( (SEQ ID NO:332 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

AATCACTTGCCGGGCAAGTCAGACCATTAGAAGCTATTTATTGGTATCAGCAGAAACCAG

GGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCAATTTGCAAAGTGGGGTCCCATCAAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGA

TTTTGCAACTTACTACTGTCAACAGAGTTACAGTATGTCGTCGTGGACTTTTGGCCAGGGGA

CCAACCTGGAGATCAAA (SEQ ID NO:333) H-Variable (AA): WO 2006/020706 WO 206/00706PCTII§S2005/028413 EVQLLESGGGIVQPGGSLRLSCAASGFTFSVYPMAWVRQAPGKGLEWVSWI SPGGKTYYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARGSRKYDKFDYWGQGTLVTVSS (SEQ ID NO:334) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGTTTACCCTATGGCTTGGGTTCGCCAA-GCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTGGATCTCTCCTGGTGGCAAGACTTATTATGCTGACTCC

GTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAA

CAGCTTAAGGGCTGAGGACACAGCCACGTATTACTGTGCGAGAGGGAGCCGCCACTATGATA

AGTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 335) 44.806C-M0047-ElO L-Variable (AA): QSVLTQPASVSGSPGQSITI SCTGTSSDVGGYNYVSWYQQHPGKAPKVMIYDVSNRPSGVSN RFSGSKSGNTASLTISGLLAEDEADYYCSSYTSTATYTLGTGTRVTVV (SEQ ID NO: 336) L-Variable (DNA):

CAGAGCGTCTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCATGACGTTGGTGGTTACACTATGTCTCCTGGTACCAACAACACC

CAGGCAAAGCCCCCAAAGTCATGATTTATGATGTCAGTAATCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCGGGGCTCCTGGCTGA

GGACGAAGCTGATTATTACTGCAGCTCATATACAAGTACAGCCACCTATGTC

CTCGGAACTGGGACCAGGGTCACCGTCGTA (SEQ ID NO:337) H-Variable (AA):

EVQLLESGC-GLVQPGGSLRLSCAASGFTFSHYKMAWVRQAPGKGLEWVSVIYPSGGATYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARALPGGYFDYWGQGTLVTVSS (SEQ ID NO:338) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACAAGATGGCTTGGGTTCGCCAAGCTCCTG

GTAAACGTTTGGAGTGGGTTTCTOTT

ATCTATCCTTCTGGTGc3CGCTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAAGGGCCTTA

CCGGGGGGCTACTTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO :339) 45.806C-M0047-G09 L-Variable (AA): QDIQMTQSPGTLSLSPGERATLACRASQSVSSSYLAWYQQKPGQAPRLLIYGASNRATGI PD RFSGSGSDTDFTLKISRVEAEDVGTYYCMQATFWPYAFGQGTKLEIK (SEQ ID NO :340 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCGCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAACAGGGCCACTGGCATCCCAGACAGATTCAGCGGCAGTGGGTCAGACAC

TGATTTCACACTGAAAATCAGCAGGGTGGAGGCTGAGGATGTTGGGACTTATTACTGCATGC

WO 2006/020706 WO 206/00706PCTII§S2005/028413

AAGCTACATTCTGGCCGTACGCTTTT

GGCCAGGGGACCAAGCTGGAGATCAAA (SEQ ID NO:341) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSWYRMVWVRQAPGKGLEWVSGIYPSGGFTSYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARVYYYDSSGYYFRGGFDPWGQGTLVTV SS (SEQ ID NO:342) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTGGTACCGTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTGGCTTTACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTGTAT

TACTATGATAGTAGTGGTTATTATTTCCGTGGGGGGTTCGACCCCTGGGGCCAGGGCACCCT

GGTCACCGTCTCAAGC (SEQ ID NO:343) 46.806C-M0053-A02 L-Variable (AA): QSVLTQPPSVSGI PGQRVTI SCSGNNSNFGSNTVTWYQQLPGTAPKLLIYSDSRRPSGVPDR FSGSRSDTSASLAISGLQSEDEAEYHCAAWDDSLMGVFGGGTKLTVL (SEQ ID NO: 344 L-Variable (DNA):

CAGAGCGTCTTGACTCAGCCACCCTCAGTGTCTGGGATCCCCGGACAGAGGGTCACCATCTC

TTGTTCTGGAAACAACTCCAACTTCGGAAGTAATACTGTAACCTGGTACCAGCAGCTCCCAG

GAACGGCCCCCAAACTCCTCATCTAT

AGTGATAGTCGGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAGGTCTGACACCTC

AGCCTCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGAGTATCACTGTGCAGCAT

GGGATGACAGCCTAAATGOGGTGTTC

GGCGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO: :345) H-Variable (AA): EVQLLESGGQLVQPGGSLRLSCAASGFTFSQYLMQWVRQAPGKGLEWVSS

TYPSGGATYYAD

SVKGRFT ISRDNSKNTLYLQMNYSLAEDTAVYYCATRKDGYSRSAFDIWGQGTMVTVSS (SEQ ID NO:346) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACCTTATGCAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCGCTACTTATTATCTACTCCGTTAAAGGTCGCTTCACTATCTC

TAcAGACAACTCTAAGAZATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAACAAGGAAG

GATGGCTACAGTCGAAGTGCTTTTOATATCTGOGGCCAAGGGACAATGTCACCGTCTCA-

c (SEQIDNO:347) 47. 806C-M0053-A03 L-Variable (AA): QDIQMTQSPGTLSLSPGE1,ATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQRGNWPRTFGQGTKVEIK (SEQ ID NO: 340 WO 2006/020706 WO 206/00706PCTII§S2005/028413 L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGC

AGCGTGGCAACTGGCCCCGGACGTTC

GGCCAAGGGACCAAGGTOOAAATCAAA (SEQ ID NO: 349) H-Variable (AA): EVQLLESGGGLiVQPGGSLRLS CAASGFTFSHYVMWWVRQAPGKGLEWVSGIYPSGWTVYADS VKGRFTT SPDNSKNTLYLQMNSLPAEDTAVYYCAKDLGGTRAFDYWGQGTLVTVSS (SEQ ID NO:350) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACGTTATGTGGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTTGGACTGTTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTCTAG

AGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTA.AGGGCTGAGGACACGGCCG

TGTATTACTGTGCGAAAGATCTGGGG

GGGACCCGTGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 351) 48.806C- MOOS3-A05 L-Variable (AA): QSELTQPASVSGSPGQSIT ISCTGTS SDDVGGYNYVSWYQQHPGKAPKLLIYDVSDRPSQVS NRFSGSKSGNTASLTISGLLAEDEADYYCGSYRVTSVSRSYVFGTETK (SEQ ID NO: 352) L-Variable (DNA):

CAGAGCGAATTGACTCAGCCTCCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGACGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAAC

ACCCAGGCAAAGCCCCCAAACTCCTG

ATTTATGATGTCAGTGATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGG

CAACACGG0CCTCCCTGACCATCTCTGGGCTCCTGGCTGAGGACGAGGCTGATTATTATTGCG

GCTCATATCGCGTCACCAGCGTCAOC

AGATCCTATGTCTTCGGAACTGAGACCAAG (SEQ ID NO:353) H-Variable (AA):

EVQLLESGGOTJVQPGGSLRLSCAASGFTFSNYPMTWVRQAPGKGLEWVSRIYPSGGYTYYAD

SVKGRFTT SRDNSKNTLYLQMNSLPAEDTAVYYCARGRIAALDYWGQGTLVTVSS

(SEQ

ID NO:354) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACCCTATGACTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCTATCCTTCTGGTGGCTATACTTATTATGCTGACTCCGTTAA

AGGTCGCTTCACTATCTC

TAG-AGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAOGGCTGAOGACACGG

CCGTGTATTACTGTGCGAGGGGTCGT

WO 2006/020706 WO 206/00706PCTII§S2005/028413 ATAGCAGCTCTTGACTACTGGGQCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ TD NO: 355) 49.806C-M0053-A09 L-Variable (AA): QSALTQGPTVSVALGQTVRITCQGDTLRYFSASWYQQKPGQAPVLVIFGANNRPSOT PDRFS GSRSGVTASLTITGAQAEDEAEYYCNSRDGSGNWLFGGGTKLSVL (SEQ ID NO :356) 1-Variable (DNA):

CAGAGCGCTTTGACTCAGGGCCCTACTGTGTCTGTGGCCTTGGGACAGACAGTCAGGATCAC

ATGTCAAGGAQACACCCTCAGATACTTTTCTGCAJAGTTGGTACCAGCAGAAGCCGGGACAGG

CCCCTGTCCTTGTCATCTTTGGGGCA

AACAATCGGCCCTCAGGGATCCCAGACCGGTTCTCTGGCTCCAGGTCAGGAGTCACCGCTTC

CTTGACCATCACTGGGGCTCAGGCGGAAGATGAQOCTGAGTATTACTGTAACTCCCGGGACG

GCAGTGGTAATTGGCTGTTCGGCGGA

GGGACCAAGCTGTCCGTCCTC (SEQ ID NO:357) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASOFTFSRYVHWVRQAPGKGLEWVSVIYPSGGATLYAD

SVKGRFTI SRDNSKUTLYLQMNSLRAEDTAVYYCARGQYSSGWYTEGWFDPWGQGTLVTVSS (SEQ ID NO:358) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGCTACTCTTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGGCCAO

TATAGCAGTGGCTGGTACACGGAGGGCTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTCAC

CGTCTCAAGC (SEQ ID NO:39) 50.806C-M0053-B09 1-Variable (AA): QYELTQPPSASGTPGQRVTIS CSOS SSNIGSNINVNWYQQLPGTAPKLLIYSNDQRPSGVPDR FSGSKSATSASLAISGLQSEDEADYHCAAWDDSLNGPVFGGGTKLTVL (SEQ ID NO: 360) 1-Variable (DNA):

CAGTACGAATTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTC

TTGTTCTGGAAGCAGCTCCAACATCGGAAGTAATAATGTCAACTGGTACCAGCAACTCCCAG

GAACGGCCCCCAAACTCCTCATCTAC

AGTAATGATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGCCACCTC

AGCCTCCCTGGCCATCAGTGCGCTCCAGTCTGAGGATGGCTGATTATCACTGTGCAGCAT

GGGATGACAGCCTGAATOCI2CCOOTC TTCGGCGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO:361) H-Variable (AA): EVQLjLESGCOLVQPGGSLRLSCAASGFTFSRYKMQWVRQAPGKGLEWVSS IYPSGGITYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARGRTTR\FDYWGQGTLVTVSS C SEQ ID NO:362) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (DNA):

GAAGTTCAATTGTTAGACTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAAGATGCAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCATTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGGACGA

GGAACGACGCGc3GCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO:363) 51.806C-M0053-B1 1 L-Variable (AA): QYELTQPPSVSVAPGQTAKILCGGNDIGRKFVNWYQQKPGQAPVLVVFDDSDRPSGI PERPS GSNSGSTATLTISGVEAGDEADYFCQVWDLSSDHNVFGGGTKLTVL (SEQ ID NO :364) L-Variable (DNA):

CAGTACGAATTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCAAGATTCT

CTGTGGGGGAACGACATTGGAGAAA2TTTGTTCACTGGTACCAGCAGAAGCCAGGCCAGG

CCCCTGTGCTGGTCGTCTTTGATGAT

AGCGACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAATTCTGGGAGCACGGCCAC

CCTGACCATCAGCGGGGTCGAACCCGGGGATGAGGCCGACTATTTCTGTCAGGTGTGGGATC

TTAGTAGTGATCATTGGGTGTTCGGC

GGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO:365) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYAMHWVRQAPGKGLEWVSRIGSSGGITSYAD

SVKGRFTI SRDNSKNTLYLQMNSLPAEDTAM'YYCATDYYYDSSGYYYPAFDIWGQGTMVTVS S (SEQ ID NO:366) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGATTACGCTATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCGGTTCTTCTGGTGGCCATACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTQAGGACACCG

CCATGTATTACTGTGCGACTGACTAT

TACTATGATAGTAGTGGTTATTACTACCCTGCTTTTGATATCTGGGGCCAAGGGACAATGGT

CACCGTCTCAAGC (SEQ ID NO:367) 52.806C-M0053-D03 L-Variable (AA): QDIQMTQS PGTLSLSPGERATLSCRASQSVSS SYIAWYQQKPGQAPRLLIYGASSRATGI PD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLFGGGTKVEIK (SEQ ID NO: 368) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAcCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTCGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGC

WO 2006/020706 WO 206/00706PCTII§S2005/028413

AGTATGGTAGCTCACCTCTGTTCGGC

GGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:369) H-Variable (AA): .EVQLTESGGGLVQPGGSLRLSCAASQFTFSRYAMMWVRQAPGKGLEWVSS IYPSGGSTYYAD SVKGRFTISRDNSKNTTJYLQMNSTRAEDTAVYYCARVQGGAGAFDIWGQGTMVTVSS (SEQ ID NO:370) H-Variable (DNA):

GAAGTTCAATTGTTAGAQTCTGGTGQCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGCTATGATGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTCTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAAXCTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTACAG

GGGGGGGCGGGTGCTTTTGATATCTGGGGCCAAGCGACAATGGTCACCGTCTCAAGC (SEQ ID NO:371) 53 .806C-M0053-D06 1-Variable (AA):

QDIQMTQSPSSLSASVGDRVTITCRASQSINTYLNWYQHKPGKAPELLISAASSLQSGVPSR

FSGSGSGTDFTLTISSLRPEDFATYYCQQSHSISTFTFGPGTKVDVK (SEQ ID NO :372 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCTTCCCTGTCTGCATCTGTCGGAGACAGAGTCAC

CATCACTTGCCGGGCAAGTCAGAGCATTAACACCTATTTAAATTGGTATCAGCACAAACCAG

GGAAGGCCCCTGAGCTCCTGATCTCT

GCTGCATCTAGCTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGA

TTTCACTCTCACCATCAGCAGTCTGCGACCTGAAGATTTTGCGACTTACTACTGTCAACAGA

GTCACAGTATATCCACATTCACTTTC

GGCCCTGGGACCAAAGTGGATGTCAAG (SEQ ID NO:373) H-Variable (AA): EVQLIJESGGGLVQPGGSLRLS CAASGFTFSRYKMHWVRQAPGKGFEWVS SIVPSGGWTYYAD SVKGRFTT SRDNSKNTLYLQMNSLRAEDTAVYYCARQMYYYDSSGYWVGRFDIWGQGTTVTV SS (SEQ ID NO:374) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAAGATGCATTGGGTTCCCIAACTCCTG

GTAAAGGTTTTGAGTGGGTTTCTTCT

ATCGTTCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGACAAATG

TATTACTATGATAGTAGTGGTTATTATGTCGGGCGTTTTGATATCTGGGGCCAAGGGACCAC

GGTCACCGTCTCAAGC (SEQ ID NO: 375) 54. 806C-M0053-D12 L-Variable (AA): QDIQMTQSPATLSLS PGEATLSCRSQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPAR WO 2006/020706 WO 206/00706PCTII§S2005/028413 FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPRITFGGGTKVEIK (SEQ ID NO: 376) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTACAGCTACTTAGCCTGGTACCAACAGACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATC!CCAGCCAGGTTCAGTGC(AGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTCTCAGCAGC

GTAGCAACTGGCCTCCCCGGATCACT

TTCGGCGOAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:377) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFS

SYMMFWVRQAPGKGLEWVSRIYPSGGWTYYAD

SVKGRFTI SRDNSKNTILYLQMNSLRAEDTAVYYCARVTVPLDSGSYYFDYWGQGTLVTVSS (SEQ ID NO:378) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACATGATGTTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCCGAGAGTTACC

GTACCCCTTGATAGTGGGAGCTACTACTTTGACTACTGGGCCAGGGACCCTGGTCACCGT

CTCAAGC (SEQ ID rNTm379) 55.806C-M0053-E03 1-Variable (AA):

QDIQMTQSPATLSLSPGEIRATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSATGTPD

RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPQLTFGGGTKVEIK (SEQ ID NO: 380) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAC

CTOCCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGC

AGTATGGTAGCTCACCCCAGCTCACT

TTCGGCGGAGGGACCAAGGTGGAGATCAA A (SEQ IDNO :381) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASFTFSNYKMWWVRQAPGKGLEWVSS

IYPSGGWTQYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDVGGGGFDYWGQGTLVTVSS

(SEQ

ID NO:382) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGQTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACAAGATGTGGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTCAGTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACTG

WO 2006/020706 WO 206/00706PCTII§S2005/028413 CCGTGTATTACTGTGCcGAAAGATGTT GGGGGGGGTGGCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAA.GC (SEQ ID NO: 383) 56.806C-M0053-E04 L-Variable (AA): QDIQMTQS PATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPAR FSGSGSGTEFTLTISSLQSEDFAVYYCLTRVTFGGGTKVELK (SEQ ID NO:3 84) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAQGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

ATTCACT'CTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCTAACAC

GAGTCACTTTCGGCGGAGGGACCAAG

GTTGAGCTCAAG (SEQ ID NO:385) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYKMGWVRQAPGKGLEWVSS IYPSGGWTTYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARDSPLVVPAAIKSGAYYYGMDVWGQGT TVTVSS (SEQ ID NO:386) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACAAGATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGc3TTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTACTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAI\CTCTAAGAATACTCTCTACTTGCAGATGAAICAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGATTCC

CCCCTAGTAGTACCAGCTGCTATTAALGAGCGGGGCCTACTACTACGGTATGGACGTCTGGGG

CCAAGGGACCACGOTCACCGTCTCAAGC (SEQ ID NO:3 87) 57.806C-M0053-E08 1-Variable (AA): QSVLTQPPSASGTPGQRVS TSCSGSSYNTGVYDVYWYQQLPGTAPKLLIYTNNQRPSGVPDR FSGSKSGTSASLSISGLRSEDEADYYCAAWDDSLAGWVFGGGTKVTVL (SEQ ID NO: 388) 1-Variable (DNA):

CAGAGCGTCTTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCAGTATCTC

TTGTTCTGGAAGCAGCTACAACATCGGAGTTTATGATGTATACTGGTACCAGCACTCCCAG

GAACGGCCCCCAAACTCCTCATCTAT

ACCAATAATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTC

AGCCTCCCTGTCCATCAGTOGGCTCCGGTCCGAGGATGAGGCTGATTATTACTGTGCAGCCT

GGGATGACAGCCTGGCTGGTTGGGTG

TTCGGCGGAGGGACCAAGGTGACCGTCCTA (SEQ ID NO:389) H-Variable (AA): WO 2006/020706 WO 206/00706PCTII§S2005/028413

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYMLWVRQAPGKGLEVSVIYPSGGYTYYAD

SVKGRFTISRDNSKNTLYLQNNSLRAEDTAVYYCARGVLRAFDIWGQGTMVTVSS

(SEQ

ID NO:390) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGCTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCTATACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGGGGTA

CTAGACTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 391) 58.806C-M0053-F04 L-Variable (AA):

QDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDTSNRATGIPAR

FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK (SEQ ID NO :392) L-Variable (DNA):

CAAGACATCCAGATGACCCAQTCTCCAGCCACCCTGTCTTTGTCTCCGGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATACATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAc3TCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGC

GTAGCAACTGGCCGATCACCTTCGGC

CAAGGGACACGACTGGAGATTAAA (SEQ IDN1.O :393) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYGMYWVRQAPGKGLEWVSVI

SPSGGYTFIYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARAY8SCWYLDYWGQGTLVTVSS

(SEQ

ID NO:394) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGGTTACGOTATGTATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTCTCCTTCTGGTGGCTATACTCATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAOCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGCGTAT

AGCAGTGGCTGGTACCTTGACTACTGGGGCCAGGGAACCCTCGTCACCGTCTCAAGC

(SEQ

ID NO:39S) 59.806C-M0053-F05 L-Variable (AA): QSLQPLVPQACGNLS VSYQKGSV V 8

YRSIEI

CSNSGNTATLTISGTQAVDEADYYCQAWDRSTAVFGGGTRLTVL (SEQ ID NO :396) L-Variable (DNA):

CAGACTCTTGACTCAGCCACCCTCACTGTCCGTGTCCCCAGGGCAGACADCCCGCATCGC

CTGCTCTGGAGATAATTTGGGGAGTAGATATATTTCCTGGTATCAGCAGAAGTCAGGCCACT

CTCCTGTGGTGGTCCTCTATCAAGAC

WO 2006/020706 WO 206/00706PCTII§S2005/028413 TACAGACGGCCCTCACGGATCCCTGAGCGAATCTCTGGCTCCA2XCTCTGGGAACACAOCCAC

TCTGACCATCAGCGGGACTCAGGCTGTGGATGAGGCGGACTATTATTGTCAGGCGTGGGACA

GAAGCACTGCGGTGTTCGGCGGAGGG

ACCAGGCTGACCGTCCTA (SEQ ID NO:397) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCASGFTFSSYMMFVRQAPGKGLEVSRIYPSGGWTYYAD

SVKGRFTI SRDNSKN\TLYLQMNSLR-AEDTAVYYCARVTVPTJDSGSYYFDYWGQGTLVTVSS (SEQ ID NO:398) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACATGATGTTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTA-AGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTTACG

GTACCCCTTGATAGTGGGAGCTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGT

CTCAAGC (SEQ ID NO:399) 60.806C-M0053-F06 L-Variable (AA): QDIQMTQSPDTLSLSPGERATLSCRASHSVTNNRLAWYQQKPGQgPRLLIYGASNRGI

PA

RFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSHWLYTFGQGTKLEIK (SEQ ID NO :400 L-Variable (DNA):.

CAAGACATCCAGATGACCCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGAGAAAGAGCCAC

CCCCTCGGCGCCGGTCAAACGTACTGACGAAA

CTGGCCAGTCTCCCAGGCTCCTCATC

TATGGTGCATCCAACAGG3GCCGCTGGCATCCCTGCCAGGTTCAGTGGCAGTGGCTCTGGGAC

AGACTTCACTCTCACCATCAGCAGCCTAGAOCCTGAAGATTTTGCAGTTTATTACTGTCAAC

AGCGTAGCCACTGGCTTTACACTTTT

GGCCAGGGGACCAAGCTGGAGATCAAA (SEQ ID NO:401) H-Variable (AA): EVQLLESGGGLVQPCGSLRLSCAASGPTFSSYTMTWVRQAPGKGLEWVSS

IYPSGGQTYYAD

SVKGRFT ISRDNSKNTLYLQMNSLRAEDMAVYYCARKNSGYNNVFDVWGQGTMVTVSS

(SEQ

ID NO:402) H-Variable (DNA): GAATTCAA.TTGTTAGAGTCTGGTGcGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACATTATGATTTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTPCTTCT

ATCTATCCTTCTGGTGGCCAGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACATGG

CTGTGTATTACTGTGCAAGAAAAAAT

GGCTACAATAATGTATTTGATGTCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGc

(SEQ

ID NO:403) 61.806C-M0053-F08 L-Variable WO 2006/020706 WO 206/00706PCTII§S2005/028413 QSALTQPASVSGSPGQS ITI SCTGTSSDVGSYNLVSWYQQHPCKAPKLMIYEGSKRPSGV9N RFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSSTYVFGTGTKVTVL (SEQ ID NO: 404) 1-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTGCCTCCGTGTCTGGCTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGATGTTGGGAGTTATAACCTTGTCTCCTGGTACCAACAGCACC

CAGGCAAAGCCCCCAAACTCATGATT

TATGAGGGCAGTAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAA

CACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCT

CATATGCAGGTAGTAGCACTTATGTC

TTCGGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:405) H-Variable (AA): EVQILESGGGLVQPGGSLRLSCAASGFTFSRYPMLWVRQAPGKGLEWVSS IYPSGGWTSYAD SVKQRFT ISRDNSKNTLYLQMNSLPAEDTAVYYCTTPTHNWNDDPDAFDIWGQGTTVTVSS (SEQ TD NO:406) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCOCTGCTTCCGGATTCACTTTCTCTCGTTACCCTATGCTTTGGGTTCGCCQAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAAAACCAGAATTTCTCAAGAACTAGCGGAAA

CCGTGTATTACTGTACCACCCCTACC

CACAACTGGAACGATGACCCTGATGCTTTTGATATCTGGGGCCAAGGGACCACGGTCACCGT

CTCAA.GC (SEQ ID NO:407) 62. 806C-M0053-G04 1-Variable (AA): QSVLTQPPSVSVAPGQTATITCGGNNI GTKSVHWYQQKPGQAPVFVYDDNDRPSGI PERFSG SNSGNTATMTISRVEAGflEADYYCQVWDPTGDQYVFGSGTKVTVL (SEQ ID NO :408) L-Variable (DNA):

CAGAGCGTCTTGACTCAGCCACCCTCGGTGTCAGTGGCCCCAGGACAGACGGCCACGATTAC

CTGTGGGGGAAACAACATTGGAACTAAI\AGTGTACACTGGTACCAGCAGAAGCCAGGCCAGG

CCCCTGTCTTCOTCTATGATGATAAT

GACCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCCGGGAACACGGCCACCAT

GACCATCAGCAGGGTCGAAGCCGGGGATGAGGCCGACTATTATTGTCAGGTGTGGGATCCTA

CTGGTOATCAGTATOTCTTCGGAACT

GGGACCAAGGTCACCGTCCTA (SEQ ID NO:409) H-Variable (AA):

EVQIJLESGGGLVQPGGSLRLSCAASGFTFSKYKMLWVRQAPGKGLEWVSVIYPSGGYTYYAD

SVKGRFTI SRDNSKNTLYLQMNSJRAEDTAVYYCARVVVPAFYYYYYMDVWGKGTTVTVS

S

(SEQ ID H-Variable (DNA): GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTcGGTGGTTCTTTACGTCTTTC

TTCCTGCTTCCGGATTCACTTTCTCTAAGTACAAGATGCTTTGGGTTCGCAGCTCCTG

GTAAAiGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCTATACTTACTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

WO 2006/020706 WO 206/00706PCTII§S2005/028413 CCGTGTATTACTGTGCGAgAGTAgTA

GTACCAGCTTTCTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACCGT

CTCAAGC (SEQ ID NO:411) 63.806C-M0053-G05 1-Variable (AA): QSELTQPASVSGSPGQS TTTSCTGTSSDVGGYNYPISWYQQHPGKAPKLMIYEVSNRPSGVSN RFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLGGVFGGGTKLTVL (SEQ ID NO: 412) 1-Variable (DNA):

CAGAGCGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAGCACC

CAGGCAAAGCCCCCAAACTCATGATT

TATGAGGTCAGTAATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAA

CACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCT

CATATACAAGCAGCAGCACTCTCGGG

GGGGTATTCGGCGCAGGGACCAAGCTGACCGTCCTA (SEQ ID NO: 413) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYKMDWVRQAPGKGLEWVSS IYPSGGFTYYAD SVKGRFTI SRDNSKNTLYLQMNSLPAEDTAVYYCAREKMATMDYWGQGTLVTVSS (SEQ ID NO:414) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAAGTACAAGATGGATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTTTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAAGAGAGAAG

ATGGCTACAATGGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 415) 64. 806C-M0054-A08 1-Variable (AA): QYELTQPASVSGSPGQS ITI SCTGTSSDVGGCNYVSWYQQHPGKAPQLLIYDVSYRPSGVSN RFSGSKSGNTASLTISGTJQADDEADYYCSSCTSSSTLFGTGTKVTVL (SEQ ID NO :416 1-Variable (DNA):

CAGTACGAATTGACTCAACCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGACGTTGGTGGTTGTAACTATGTCTCCTGGTACCAACAACACC

CAGGCAZAAGCCCCCCAACTCTTGATT

TATGATGTCAGTTATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCAA

CACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGACGACGAGGCTGATTACTACTGCAGCT

CATGTACAAGTAGCAGCACTCTCTTC

GGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:417) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYVMHWVRQAPGKGLEWVSRIYPSGGWTYYAD

SVKGRFTISRDN\SKNTLYLQMNSLRAEDTAVYYCARVAGESNGMDVWGQGTTVTVSS (SEQ WO 2006/020706 WO 206/00706PCTII§S2005/028413 ID NO:418) H-Variable (DNA): GA1AGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGCATTGCGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTGGCT

GGGGAGTCGAACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCAAGC (SEQ ID NO: 419) 65.806C-M0054-B06 L-Variable (AA): QDIQMTQSPSSLSAS IGDRVTVTCRTSQS IDTYLNWYQQKPGQAPNLLIYGASSLESGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQQSYTTSYTFGRGTTLEIQ (SEQ ID NO :420) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCAGCATCTATAGGAGACAGAGTCAC

CGTCACTTGCCGGACAAGTCAGAGCATTGACACCTATTTATTCGTATCAGCAAAAACCAG

GGCAAGCCCCTAACCTCCTGATCTAT

GGTGCATCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGA

TTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGA

GTTACACTACCTCCTACACTTTTGGC

CGGGGGACCACGCTGGAQATCCAA (SEQ ID NO:421) H-Variable (AA): EVQIJLESQGGLVQPGGSIJRLSCAASGFTFS IYKIQWRQAPGKGLEWVSSIYPSGGATYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARQTYYYDS SGYFRNAFDIWGQGTMVTV SS (SEQ ID NO:422) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCOOTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATTTACAAGATGCAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCGCTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAGAATACTCTCTACTTGCAGATGjAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGACAAACG

TATTACTATGATAGTAGTGGTTATTTCCGCAATGCTTTTGATATCTGGGGCCAAGGGACAAT

GGTCACCGTCTCAAGC (SEQ ID NO:423) 66.806C-M0054-B08 1-Variable (AA): QSVL-TQAASVSGS PGQSI TLSCTGATRDVSWYQQHPGKAPKLVLYEVNSRPSDVSDRFSGSM SGNTASLTISGLQAEDEADYYCSSTTSRAPRVIFGGGTKJTVL (SEQ ID NO:424) 1-Variable (DNA):

CAGAGCGTCTTGACTCAGGCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCCTCTC

CTGCACTGGAGCCACCAGG-GACGTCTCCTGGTACCAACAACACCCAGGCAJAGGCCCCCAAAC

TCGTCCTTTATGAAGTCAATAGTCGC

CCCTCAGACGTTTCCGATCGCTTCTCTGGCTCCATGTCTGGCA\CACGGCCTCCCTGACCAT

CTCTGGACTCCAGGCTGAAGACGAGGCTGATTATTACTCCTCCTCAACCACAAGTCOCCCCC

WO 2006/020706 WO 206/00706PCTII§S2005/028413

CTCGCGTGATTTTCGGCGGAGGGACC

AAACTGACCGTCCTA (SEQ ID NO:425) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYRMVWVRQAPGKGLEWVSWIYPSGGWTSYD

SVKGRF'TI SRDNSKNTLYLQMNSLRAEDTAVYYCARSNYYDSAATLDIWGQGTMVTVS

S

(SEQ ID NO:426) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCGTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTGG

ATCTATCCTTCTGGTGGCTGGACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGGTCAAkAT

TACTATGATAGTGCTGCGACTCTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAG

C (SEQ ID NO:427) 67.806C-M0054-C03 1-Variable (AA): QDIQMTQSPSSLSASVGDRVTITCP-ASQTISSYLNWYQQKPGKAPKLLI

SAASTLQSGVPSR

FSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPSFGQGTKVEIK (SEQ ID NO :428) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTC

CATCACTTGCCGGGCAAGTCAGACCATTAGCAGCTATTTAAATTGTATCAGCAAACCAG

GGAAAGCCCCTAAGCTCCTGATCTCT

GCTCCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGA

TTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAGA

GTTACAGTACCCCCTCGTTCGGCCAA

GGGACCAAGGTCGAAATCAAA (SEQ ID NO:429) H-Variable CAA): EVQLLESGGGLVQPGGSLRLSCAASGFTPSHYQMLWVRQAPGKGLEWVS

SIYPSGGWTYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARVGYSSGWYALTSKTFDYWGQGTLV SS (SEQ ID NO:430) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACCAGATGCTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAQTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTGOGGG

TATAGCAGTGGCTGGTACGCGTTGACTTCAAAGACTTTTGACTACTGGGGCCAGGGAACCCT

GOTCACCGTCTCAAGC (SEQ 'ID NO:431) 68.806C-M0054-C07 1-Variable (AA): QDIQMTQSPATLSLSPGD1RAILSCRASHNIDNFLAWYQQKPGQAPRLLIYDASHATGI

PPR

FSGSGSGTDFTLTISSLEPEDFAVYFCQQRTNWL~FGGGTKVEIK (SEQ ID NO :432) 200 WO 2006/020706 WO 206/00706PCTII§S2005/028413 L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCGGGGGATCGAGCCAT

CCTCTCCTGTAOQGCCAGTCACAATATTGACAACTTCTTAGCCTGGTATCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCTCATAGGGCCACTGGCATCCCCCCCCGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAACCTGAAGATTTTGCTGTGTATTTCTGTCAACAAC

GGACCAACTGGCTTTTCGGCGGAGGG

ACCAAGGTGGAGATCAAA (SEQ ID NO:433) H-Variable (AA): EVQLLESGGG-VQPGGSLRLS CAASGFTFSRYPMNWVRQAPGKGLEWVSRIWPSGGSTVYAD SVKGRFTISRDNSKNTLYL~QMNSIRAEDTAVYYCARDSSRYFDVWGRGTLVTVSS

(SEQ

ID NO:434) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCCTATGAATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCTGGCCTTCTGGTGGCTCTACTGTTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGATTCT

TCTCGATACTTCGATGTCTGGGGCCGTGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO :435) 69.806C-M0054-E04 L-Variable (AA): QDIQMTQSPATLSVSPGEPATLSCRASQS

ISSNLAWYQQKPGQAPRLLIYGTSTRATGIPAR

FSGSOSGTEFTLTISSLQSEDFVVYYCQQYKDWPLTFGGGTTVEIK (SEQ ID NO :436) L-Variable (DNA): CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAkGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTATTAGCAGTAATTTAGCCTGGTACCAACAAAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GGTACATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACCGA

GTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGTAGTTTATTACTGTCAGCAGT

ATAA7AGACTGGCCTCTCACTTTCGGC GGAGGGACCACGGTGGAGATCAAG (SEQ ID NO:437) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYKMHWVRQAPGKGLEWVSVIYPSGGVTEYD

SVKGRFTISRDNSKNTLYLQMNSLPAEDTAVYYCARDQYSGHDYWGQGTLVTVSS

(SEQ

ID NO:438) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTQCTTCCGGATTCACTTTCTCTAA

TTACAAGATGCATTGGGTTCGCCAAGCTCCTG

GTAAPAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGTTACTGAGTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGAC2ACTCTAAATACTCTCTACTTGCAGATGACAGCTTAAGGGCTAGOACACGG

CCGTGTATTACTGTGCGAGAGATCAA

TACAGTGGCCATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO :439) WO 2006/020706 WO 206/00706PCTII§S2005/028413 70.806C-M0054-GO 1 1-Variable (AA): QDIQMTQS PGTLSLS PGERATLSCRASQSVSSYAWYQQKPGQAPRLLIYDA\SNRATGIPAR FSGSGSGTDFTLTISSI-EPEDFAVYYCQQRYSWPLTFGGGTKVEIK (SEQ ID NO :440) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGAAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAOCAGC

GTTACAGCTGGCCTCTCACTTTCGGC

GGAGGGACCAAGGTGGAGATCAAG (SEQ ID NO:441) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSEYQMIWVRQAPGKGLEVWVSYIVPSGGFTAYD

SVKGRFTI SRDNSKNTLYLQMNSLPAEDTAVYYCARVNYYGMDVWGQGTTVTVSS

(SEQ

ID NO:442) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGAGTACCAGATGATTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTCGAGTGGGTTTCTTATATCGTTCCTTCTGGTGGCTTTACTGCTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAGTGACTACTACGGTA

TGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCAAGC (SEQ ID NO: 443) 71 .806C-M0054-G05 1-Variable QSALTQPASVSGSPGQS IS ESCTGTNTDVGGYNYVSWYQQH-PGKAPKLMIYDVSNRPSGVSN RFSGSKSCNTASLTISGLQAEDEADYYCSSYTSSSTWVFGGTKLTVL (SEQ ID NO: 444) L-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCAGCATCTC

CTOCACTGGAACCAACACTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAACACC

CAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGA

OCACOAGGCTGATTATTACTGCAGCTCATATACAAGTAGTAGCACTTGGGTGTTCGGCGGAG

GGACCAAGCTGACCGTCCTA (SEQ ID NO:445) H-Variable (AA): EVQLLESGGGLVQPGcGSLRLS CAASGFTFSAYLMEWVRQAPGKGLEWVSGIYPSGGKTYYD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARVNVISVAGTGYYYYGMDVWGQGTTVT VSS (SEQ ID NO:446) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACCTTATGGAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

202 WO 2006/020706 WO 206/00706PCTII§S2005/028413

ATCTATCCTTCTGGTGGCAAGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTGAAC

GTTATATCAGTGGCTGGTACTGGCTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGAC

CACGGTCACCGTCTCAAlC (SEQ ID NO:447) 72.806C-M0054-H 1-Variable (AA): QDIQMTQS PATLSLS PGERATLSCPASQSVS IYLAWYQQKPGQAPRLLIYDASNRATDIPAR FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPITFGLGTRLEIK (SEQ ID NO: 448) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCATCTACTTAGCCTGGTACCAACAGAAACCTG

GTCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGACATCCCADCCAGGTTCAGTGGCAGTQGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAAC

GTAGCAGCTGGCCGATCACCTTCGGC

CTTGGGACACGACTGGAGATTAAA (SEQ ID NO 44 9) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYPMIWVRQAPGKGLEWVSVIS PSGGHTSYAD SVKORFTT SRDNSKNTLYLQMNSLPAEDTAVYYCARIQYYGDAFDTWGQGKMVTVSS (SEQ ID NO:450) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACCCTATGATTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTCTCCTTCTGGTGGCCATACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACACTCTAGATACTCTCTACTTGCAGATGAACAGCTTAGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAATCCAG

TACTACGGTGGGGCTTTTGATATCTGGGGCCAAGGGAAAATGGTCACCGTCTCAAGC (SEQ ID NO:451) 73. BOGC-M0055-A09 1-Variable (AA): QDIQMTQSPSSLSASVGDGVTITCRASQS INDHLNWYQQKPGKAPKVLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPWTFGQGTKVEIK (SEQ ID NO: 452) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTTAGGAGACGGAGTCAC

CATCACTTGCCGGGCAAGTCAGAGCATTAACAACCATTTAAATTGGTATCAGCAGAAACCAG

GGAAAGCCCCTAAGGTCCTGATCTATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGG

TTCAGTGGCAGTOGATCTOGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGA

TTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCGTGGACGTTCGGCCAAGGGACCA

AGGTOGAAATCAAA (SEQ ID NO:4S3) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYRMSWVRQAPGKGLEWVSGIYPSGGGTTYAD

SVKGRFTT SRDNSKNTLYLQMNSLPAEDTAVYYCARPTYYYDSSGYYYSGPIDYWGQGTLVT VSS (SEQ ID NO:454) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAAGTACCGTATGTCTTGGGTTCGCCAXGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGTATCTATCCTTCTGGTGGCGGTACTACTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGACCCACGTATTACTATG

ATAGTAGTGGTTATTACTACTCGGGGCCTATTGACTACTGGGGCCAGGGAACCCTGGTCACC

GTCTCAAGC (SEQ ID NO:455) 74.806C-M0055-B1 1 L-Variable (AA): QYELTQPASVSGSPGQS ITI SCTGTNTDVGGYNLVSWYQQHPGKAPKLI IYEVSNRPSGVSN RFSGSKSGNTASLTISGLQAEDEVDYYCGSYTSSSTHVFGSGTKVTVL (SEQ ID NO: 456) 1-Variable (DNA):

CAGTACGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAACACTGACGTTGGTGGTTATAACCTTGTCTCCTGGTACCAACAGCACC

CAGGCAAAGCCCCCAAACTCATAATT

TATGAGGTCAGTAATCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAA-GTCTGGCAA

CACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGTTGATTATTATTGCGGCT

CATATACAAGCAGCAGTACTCATGTC

TTCGGAAGTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:457) H-Variable (AA):

EVQLLESGGGLVQPQGSLRLSCAASGFTFSAYKMHWVRQAPGKGLEWVSVIYPSGGWITYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARGTAGWFDPWGQGTLVTVSS (SEQ ID NO:458) H-Variable (DNA):

GGTTCAATTGTTAGAGTCTGGTGGCGTCTTGTTCAGCCTGTGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACAAGATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAAGAGGGACT

GCAGCGTGGTTCGACCCTTGGGGCCAGGGAACCCTGGTCACCQTCTCAAGC (SEQ ID NO :459) 75.806C-M0055-Bl2 1-Variable (AA): QSELTQPASVSGS PGQSITI SCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSN RFSGSKSCNTASLTISGLQAEDEADYYCCSYAGSSTYVFGTGTKVTVL (SEQ ID NO: 460) L-Variable (DNA):

CAGAGCGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGATGTTCGGAG3TTATAACCTTGTCTCCTGGTACCAACAGCACC

CAGGCAAAGCCCCCAAACTCATGATTTATGAGGGCAGTAAGCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTQGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGA

WO 2006/020706 WO 206/00706PCTII§S2005/028413

GGACGAGGCTGATTATTACTGCTGCTCATATGCAGGTAGTAGCACTTATGTCTTCGGAACTG

GGACCAAGGTCACCGTCCTA (SEQ ID NO:461) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCASGFTFSNYKTWVRQAPGKGLEWVSSIYPSGGWTYYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAMYYCARQEDGGYGTWGQGTLVTVSS (SEQ ID NO:462) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACAAGATOACTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAOAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGACGACACCG

CCATGTATTACTGTGCGAGACAGGAG

GATGGTGGCTACGGGACTTGGGGCCAGGGAACCCTGGTCACCGTCTCAAQC (SEQ ID NO: 463) 76.806C-M0055-C05 L-Variable (AA): QSVLTQDPAVSVALGQTVRITCQGDSLRSYYATWYQQKPGQAPVLVIYGENNRPSGI PDRFS GSSSGNTGSLTITGAQAEDEADYYCN\SRDTSGSHLLFGGGTKLTVL (SEQ ID NO: 464) ,L-Variable (DNA):

CAGAGCGTCTTGACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGGATCAC

ATGCCAAGGAGACAGCCTCAGAAGCTATTATGCAACCTGGTACCAACAGAAGCCAOGACAGG

CCCCTGTACTTGTCATCTATGGTGAA

AACAAkCCGGCCCTCAGGGATCCCAGACCGATTCTCTGGCTCCAGTTCAGGAAACACAGGTTC

CTTGACCATCACTGGGCTCAGGCGGAAGATGAGGCTGACTATTACTGTAACTCCCGGGACA

CCAGTGGTAGTCATCTATTATTCGGC

GGAGGGACCAAGCTGACCGTCCTG (SEQ ID NO:465) H-Variable (AA): EVQLLESGGGLVQPQGSLRLS CAASGFTFSQYKMLWVRQAPGKGLEWVSS TYPSGGWTSYAD SVKGRFT ISRDNSKNTLYLQMNSLEAEDTAVYYCARASYYDSGGYYRENFQFWGQGTLVTVS S (SEQ ID NO:466) H-Variable (DNA): GAAgTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTArnTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACAAGATGCTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTGGACTTCTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAGCCTCTTACTATGATA

GTGGAGGTTATTACCGAGAAAACTTCCAGTTTTGGGGCCAGGGCACCCTGGTCACCGTCTCA

AGC (SEQ ID NO:467) 77.806C-M0055-C07 L-Variable (AA): QDIQMTQSPSSLSASVGDRVTI I CRASQSIS IYLNWYQQKPGKAPKVLIYDASSLQSGVPSR FSGSGSGTDFSLTITSLQPEDFATYYCQQSYSTPPMYTFGQGTKLEIK (SEQ ID NO: 468) WO 2006/020706 WO 206/00706PCTII§S2005/028413 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCATTTGCCGGGCAAGTCAGAGCATCAGCATCTATTTAAATTGGTATCAGCAGAAACCAG

GCGAAAGCCCCTAAGG4TCCTGATATATGATGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGG

TTCAGTGGCAGTGGATCTGGGACAGATTTCAGTCTCACCATCACCAGTCTGCAACCTGAAGA

TTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTCCCATGTACACTTTTGGCCAGG

GGACCAAGCTGGAGATCAAA (SEQ ID NO:469) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFS SYKNHWVRQAPGKGLEWVSVIYPSGGATYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCAKGLDFWSGPDYWGQGTLVTVSS

(SEQ

ID NO:470) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGCATTGGGTTCGCCAAGCTCCTG

GTIAAGGTTTGGATGOGTTTCTGTTATCTATCCTTCTGGTGGCGCTACTTATTATGCTGAC

TCTGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCACATATTACTGTGCAAAAGGGCTCGATTTTTGGA

GTGGCCCGGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ IDNO :471) 78.806C-M0055-D03 1-Variable (AA): QDI QNTQS PS SLSASVGDRVT ITCWASQDIRTSIJAWYQQKPGKPPKLLI FAASTLQGGVPSR FSGSGSGTEFTLTISGLQPEDFATYYCQHLNGYPLTFGDGTKVEIR (SEQ ID NO :472) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCACTTGCTGGGCCAGTCAGGATATTCGCACTTCTTTAGCCTGGTATCAGCAGAAACCAG

GGAAACCCCCTAAACTCCTCATCTTTGCTGCGTCTACTTTgCAAGGTGGGTCCCATCAAGG

TTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACAATCTCCGGCCTGCAGCCTGAGGA

TTTTGCGACTTATTACTGTCAGCACCTTAATGGTTACCCGCTCACTTTCGGC

GATGGGACCAAGGTGGAGATCAGA (SEQ ID NO :473) H-Variable (AA): EVQLLE SGGGLVQPGGSLRLSCAASGFTFSNYVMQWVRQAPGKGLEWVSVIYPSGGMTNYAD SVKGRFTI SRDNSKNTLYLQMNSLPAEDTATYYCARIRGDTPAFDIWGQGTMVTVSS

(SEQ

ID NO:474) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCOGATTCACTTTCTCTAATTACGTTATGCAQTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCATGACTAATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAOAGACAACTCTAA\GAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTQAGGACACAG

CCACGTATTACTGTGCACGGATACGC

GGTGACACCAGGGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC

(SEQ

ID NO:475) 79 .806C-MOOSS-D06 1-Variable (AA):

QDIQMTQSPGTLSLSPGERATLSCRASQSVSSSYJAWYQQKPGQAPRLLIYGASSRATGIPD

WO 2006/020706 WO 206/00706PCTII§S2005/028413 RFSGSGSGTDFTLTISRLEPEDLAVYYCQLFGSSPRITFGQGTRLEIK (SEQ ID NO: 476) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGCGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCACOCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTGGCAGTATATTACTGTCAGC

TGTTTGGAAGCTCTCCTCGGATCACC

TTCGGCCAGGGGACGCGGCTGGAAATTAAA (SEQ ID NO:477) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYKMWWTRQAPGKGLEWVSVIYPSGGATYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAERDTAVYYCARSSLGCSSTSCYDAFDIWGQGTMVTVS S (SEQ ID NO:478) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAAGTACAAGATGTGGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGCTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGGTCTTCT

CTAGGGTGTAGTAGTACCAGCTGCTATGATGCTTTTGATATCTGGGGCCAAGGGACAATGGT

CACCGTCTCAAGC (SEQ ID NO:479) 80.806C-M0055-D12 1-Variable (AA): QDIQMTQS PSSLSASVGDRVTITCRASQGISNYTJAWYQQKPGKVPKLLIYAASTLQSGVPSR FSGSGSGTDFTLTISSLQPEDVATYYCQKYNSAPWTFGQGTKVEIK (SEQ ID NO :480) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCACTTGCCGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTATCAGCAGAAACCAG

GOAAAGTTCCTAAGCTCCTGATCTAT

GCTGCATCCACTTTGCAATCAGGGGTCCCATCTCGGTTCAGTGGCAGTGGATCTGGGACAGA

TTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAAAGT

ATAACAGTGCCCCCTGGACGTTCGGC

CAAGGGACCAAGGTGGAAATCAAA (SEQ ID NO:481) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYGMWWVRQAPGKGLEWVSS ISSGGST\TYADS VKGRFT ISRDNSKNTLYLQM~NSLRAEDTAVYYCARDLTTVTGNYFDYWGQGTLVTVSS (SEQ ID NO:482) H-Variable (DNA):

GAAGTTCAATTGTTAGAOTCTGGTGGCGGTCTTGTTCAOCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTACTTACGGTATGTGGTGGGTTCGCCAAGCTCCTG

GTAAAGOTTTGGAGTGGGTTTCTTCT

ATCTCTTCTGGTGGCTCTACTGTTTATGCTGACTCCGTTAAAGGTCOCTTCACTATCTCTAG

AGACAACTCTAAGA7ATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGGCCG

TGTATTACTGTGCGAGAGATCTGACT

WO 2006/020706 WO 206/00706PCTII§S2005/028413

ACGGTGACGGGGAACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID NO:483) 81.806C-M0055-E04 L-Variable (AA): QDIQMTQSPGTLSLS PGEPATLSCRASQSVS SSQLAWYQHKRGQPPRLLIYGASSPATGIPD RFSGSGSGTDYILTISRLEPEDFAVYYCQHFGSSPPATFGQGTKVEIK (SEQ lID NO: 484) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTATCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTTCCAGCAGCCAGTTAGCCTGGTACCAGCATAAAC

GTGGCCAGCCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAOGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTACATTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGC

ATTTTGGTAC;TTCACCTCCGGCGACG

TTCGGCCAAGGGACCAAGGTGGAAATCAAA (SEQ ID NO:485) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYKMVWVRQAPGKGLEWVSS IYPSGGVTIYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARDGS 8SGWYNPRRAFDYWGQQTLVTVS S (SEQ ID NO:486) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTQCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGGTTTQGGGTTCGCCAAOCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCGTTACTATTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAACGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGATGGA

AGTAGCAGTGGCTGGTACAATCCCCGTAGGGCCTTTGACTACTGGGGCCAGGGAACCCTGGT

CACCGTCTCAAGC

(SEQ ID NO:487) 82.806C-M0055-E06 1-Variable (AA): QYEITQPPSLSVSPGQTVKITCSAEKLSEKYVAWYQQRPGQSPVMVIYQDSRRPSGI PERFS GSNSGNTATLTISGTQPMDEADYYCQAWFSDSLPFGSGTKVTVL (SEQ ID NO :488) 1-Variable (DNA):

CAGTACGAATTGACTCAGCCACCCTCTCTGTCCGTGTCCCCAGGACAGACAGTCAAGATCAC

CTGCTCTGCAGAGAAGTTGAGTGAGAAATATGTTGCTTOGTATCAACAGAGGCCGCGCCAGT

CCCCTGTCATGGTCATCTATCAAGAT

AGTAGGCGGCCCTCAGGGATCCCTGAGCGATTCTCTGGCTCCAACTCTGGGAACACAGCCAC

TCTOACCATCACCGGACCCAGCCCATGQATGAGGCTGACTACTATTGTCAGGCGTGGTTTA

GCGACAGTCTCCCCTTTGGAAGTGGG

ACCAAGGTCACCGTCCTA (SEQ ID NO:489) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFS KYKMIWVRQAPGKGLEWVS SIYPSGGH-TIYAD SVKGRFTT SRDNSKNTLYLQMNSLRZXEDTAMYYCAREGGGATSFDYWGQGTLVTVSS (SEQ ID NO:490 WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAGTACAAGATGATCTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCCATACTATTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACCG

CCATGTATTACTGTGCGAGAGAGGGC

GGGGGAGCTACCTCCTTTGACTACTGGGGCCAGGGACCCTGGTCACCGTCTCAAjGc (SEQ ID NO: 491) 83.806C-MO055-E L-Variable (AA): QDIQMTQSPATLSLSPGERATLSCRASQSVRTYLGWYQQKHGQAPRLLIYDASNRATGI PAR FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK (SEQ ID NO: 492) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGJGJAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGGACCTATTTAGGCTGGTACCAACAQAAACATG

GCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTACTQTCAGCAGCGTAGCAACTGGCCGCT-ACTTTCGGC3GAGGGACCA AGGTGGAGATCAAA (SEQ ID NO:493) H-Variable (AA): EVQLLESGCGLVQPGGSLRLSCAASGPTPSAYPMFWVRQAPGKGLEWVSVI SPSGGQTSYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAKSFSGJAALDFWCQGTLVTVSS (SEQ ID NO:494) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACCCTATQTTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTCTCCTTCTGGTGGCCAGACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACACTTAA.OGGCTGAGGACACOG

CCGTGTATTACTGTGCGAAATCATTC

TCAGGCTTAGCAGCTCTTGACTTCTGGGGCCAGGGAjACCCTGGTCACCGTCTCAAGC (SEQ ID NO:49S) 84.806C-M0055-E12 L-Variable (AA): QD IQMTQS PGTLSLSPGERATLISCRASQTVSSGSIJAWYQQKPGLAPRLLIYGASRRGTGI PD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSTLPLTFGGGTKVEIK (SEQ ID NO: 496) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGACAGTGAGCAGCGGCTCCTTAGCCTGGTACCAGCAGAAAC

CTGGCCTGGCTCCCAGGCTCCTCATC

TATGGTGCATCCCGTAGGGGCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGAGCCTG~AGATTTTGCAGTGTACTACTGTCAGC

WO 2006/020706 WO 206/00706PCTII§S2005/028413

AGTATGGTAGTACACTCCCGCTCACT

TTCGGCGGAGGGACCAAGGTCGAGATCAAA (SEQ IDNO :497) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYTMYWVRQAPGKGLEWqVSS

IYPSGCWTNYAD

SVGFIRNKTYQNLADAYCRRGKFIGGMTS

(SEQ

ID UO:498) H-Variable (DNA)-.

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACACTATGTATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATTTCTTGGCGATATTCTATCTAAGCCTATTT

TAGAACAACTCTAGAATACTCTCTACTTGCAGATGACAGCTTXAGGGCTGAGGACATGG

CTGTGTATTACTGTGCGAGAGGCCGT

GGGTGAACTTAACGGCAGGCAGTACTTA~

(SEQ

ID NO:499) 85.806C-M0055-FIO 1-Variable (AA): QSELTQPASVSGSPGQSITISCTGTTSDVGGYNYVSWYQQDPGKVPKLI

IYEVYNRPSGVSN

RFSGSKSGNTASLTISGLIRAEIDEADYYCSSKTSSVYVFG'TGTKVTVL (SEQ ID NO.

500) L-Variabie (DNA):

CAGAGCGAATTGACTCAGCCTGCCTCCGTGTCTGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCACCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTATCACAGGACC

CAGGCAAAGTCCCCAAACTCATAATT

TATGAGGTCTATAATCGCCCTCAGGGTTTCAATCGCTTCTCTGGCTCCAGTCTGGA

CACGGCCTCCCTGACCATCTCTGGGCTCCGGGCTOAGGACGAGGCTGATTATTACTGCAGCT

CAAAAACAAGCAGCGTCACTTATGTC

TTTGGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:501) H-Variable (AA): EVQLL2SGGGLVQPGGSLRLS

CAASGFTFSAYVMSWVRQAPGKGLEWVSRIYPSGGGTRYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKEAGGSYFLDYWGQGTLVTVSS

(SEQ

ID NO:502) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGCTTACGTTATGTCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGOTTTCTCGT

AITCTATCCTTCTGGTGGCGGTACTCGTTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAAAACCAGAATTTCTCAAGAACTAGCGGAAG

CCGTGTATTACTGTGCGAAAGAGGCG

GGTGGGAGCTACTTCCTTGACTACTGGGGCCAGGGACCCTGGTCACCGTCTCAAGC

(SEQ

ID NO:503) 86.806C-M0055-G02 L-Variable (AA): WO 2006/020706 WO 206/00706PCTII§S2005/028413 QSELTQPRSVSGSLGQSVTISCTGTTSDVGRYNFVSWYQQYPGRAPKLI

IHDVTRRPSGVSD

RFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSFYVFGSGTQVTVL (SEQ ID NO: 504 L-Variable (DNA):

CAGAGCGAATTGACTCAGCCTCGCTCAGTGTCCGGGTCTCTTGGACAGTCAGTCACCATCTC

CTGCACTGGAACCACCAGTGATGTTGGTCGTTATAACTTTGTCTCCTGOTACCAACAGTATC

CAGGCAGAGCCCCCAAACTCATCATT

CATGATGTCACTCGQCGGCCCTCCGGGGTATCTGATCGCTTCTCTGGCTCCAAGTCCGGCAA

CACGGCCTCCCTGACCATCTCTGGTCTCCAGGCTGAGGATGAGGCTGATTATTACTGCTGCT

CATATGCAGGCAGCTTTTATGTCTTC

GGATCTGGGACCCAGGTCACCGTCTTG (SEQ ID NO:505) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYKMIWVRQAPGKGLEWVSGIYPSGGATGYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTATYYCARDGGDIVVPDYWGQGTLVTVSS

(SEQ

ID NO:506) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGATTTGGGTTCGCCAAGCTCCTG

GTAAQG-TTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTGGCGCTACTGGTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACAG

CCACGTATTACTGTGCGAGAGATGGG

GGGGATATTGTACTGCCTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ

ID NO:507) 87 .806C-M0055-G03 L-Variable (AA):

QYELTQPPSASGTPGQRVTISCSGSSSNIGTNTVYWYQQLPGTAPKLLIYTNVQRPSGVPDR

FSGSKSGTSASLAISGLQSEDEADYYCQSYDGSJSSAVFGGGTQLTVL (SEQ ID NO: 508) L-Variable (DNA):

CAGTACGAATTGACTCAGCCACCCTCAGCGTCTGGGACCCCCOGGGCAGAGGGTCACCATCTC

TTGTTCTGGAAGCAGCTCCAACATCGGAACTAAkTACTGTATACTGGTACCAGCAGCTCCCAG

GAACGGCCCCCAAACTCCTCATCTAT

ACTAATGTCCAGCOGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCACCTC

AGCCTCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGCCAGTCCT

ATGACGGCAGCCTGAGTTCTGCTGTG

TTCGGAGGAGGCACCCAGCTGACCGTCCTC (SEQ ID NO:509) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSKYHMGWVRQAPGKGLEWVS

SIYSSGGITQYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARf3RVGGWSLFNWFDPWGQGTLVTVSS (SEQ ID NO:510) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAAGTACCATATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

WO 2006/020706 WO 206/00706PCTII§S2005/028413 AT ,UTATI' 'U1IU-iUU1U(:,KCA1ACT CA~gTATGCTGACTC CGTTAAAGGTCGCTTCACTAT CT C

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAAGAGGCCGA

GTCGGTGGCTGGTCCCTTTTTAACTGGTTCGACCCCTGGGGCCAGGGCACCCTGGTCACCGT

CTCAAGC (SEQ ID NO:511) 88.806C-M0055-H04 1-Variable (AA):

QDIQMTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNPATGIPAR

FSGSGSGTDFTLTISSLEPEDPAVYYCQQRSNWPRTFGQGTKVETK (SEQ ID NO:5 12) 1L-Variable

(DNA):

CAGCTCGTACATTCGCCCTTTTTTCGGAAACA

CCTCTCCTGCGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCACAGAJXACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGC

GTAGCAACTGGCCTCGGACGTTCGGC

CAAGGGACCAAGGTGGAAATCAAA (SEQ ID NO: 513) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMYWRQAPGKGLEWVSRIVPSGGWTNYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDKGDWYFDLWGRGTLVTVSS

(SEQ

ID NO:514) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACCCTATGTATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCGTTCCTTCTGGTGGCTGGACTAACTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGATAAG

GGGGACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGTCACCGTCTAGC (SEQ ID NO:S 89.80 6C-M0056-AO 1 1-Variable (AA): QDIQMTQSPATLSLSPGERATLSCPASQSVSRYLAWYQQKPGQAPRLLIYDTSNRATGI

PAR

FSGSGSGTDFTLTISSLEPEDFAIYYCQQRSNWPPALhTFGGGTKJEIK (SEQ ID NO: 51G) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTCTGTCTCCAGGGGAGAGAGCCAC

CCCCTCGGCGCGGGTGAGTCTGCGTTACAACT

GCCAGGCTCCCAGGCTCCTCATCTAT

GATACATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAAJTTTATTACTGTCCAGC

GTAGCAACTGGCCTCCGGCGCTCACT

TTCGGCGGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO: :517) H-Variable (AA): EVQjLE SGGGLVQPGGSLRLSCAASGTFSRYAGWVRQAPGKGLEVSWIYPGGITSYAD WO 2006/020706 WO 206/00706PCTII§S2005/028413 SVKGRFT ISRDNSKNTLYLQMNSLRAEDTAMYYCARITYFDTSVIDYWCQGTLVTVS

S

(SEQ ID NO:518) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGCTATGGGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTGG

ATCTATCCTTCTGGTGGCATTACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAC4ATGAACAGCTTAAGGGCTGAQGACACCG

CCATGTATTACTGTGCACGGATTACG

TATTTTGATACCAGCGTTATTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID NO:519) 90.806C-M0056-A06 L-Variable (AA): QSVLTQPASVSGS PGQS ITI SCTGTS SNVGNYNLVSWYQQHPGKAPKLMIYEDNKRPSGVSN RFSVSKSGNTASLTISGLQTEDEAEYYCCSYAOSGTWCFGRRGTRVTV (SEQ ID NO: 520) L-Variable (DNA):

CAGAGCGTCTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTAATQTTGGGAATTATAACCTTGTCTCCTGGTACCAGCAGCACC

CAGGCAAAGCCCCCAAACTCATGATT

TATGAGGACAATAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGTGTCCAAGTCTGGCAA

CACGGCCTCCCTGACAATCTCTGGGCTCCAGACTGAGGACGAGGCTGAATATTACTGCTGCT

CATATGCAGGTAGTGGCACTTGGTGT

TTCGGGCGGAGGGGAACCAGAGTGACCGTC (SEQ ID NO: 521) H-Variable (AA): EVQLLE SGGGLVQPGGSLRLSCAASGFTFSHYPMEWVRQAPGKGLEWVSRTVPSGGWTTYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCASRVVTTYLDYFDYWGQGTLVTVS

S

(SEQ ID N0:522) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACCCTATGGAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCGTTCCTTCTGGTGGCTGGACTACTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGTCGGGTQ

GTAACTACGTACTTAGACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCA.G

C (SEQ ID NO:523) 91 .806C-M005 6-BOB H-Variable (AA): EVQLLESGQLVQPGGSLRLS CAASGFTFSVYVMSWVRQAPGKGLEWVSS IYPSGGGTYYAD SVKGRFTI SRDNS KNTLYLQMNSLR-AEDTATYYCARRKAAAGYLDYWGQGTLVTVS S (SEQ ID NO:524) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGTTTACGTTATGTCTTGGOTTCGCCAAGCTCCTG

WO 2006/020706 WO 206/00706PCTII§S2005/028413

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAICAGCTTAkAGGGCTGAGGACACAGCCACATATTACTGTGCGAGACGAAAAGCAGCAGCAG GTTACCTTGACTACTGGGGCCAQGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO :52 L-Variable (AA): QSALTQPASVSGSPGQS ITI SCTGTS SDIGAYKHVSWYQQHPGKAPKLMIYEVTNRPSGISN RFSGSKSGNTASLTISGLQAEEEADYYCSSYTSRNTWVFGGGTKLTVL (SEQ ID NO: 526) L-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATTTC

CTGCACTGGAACTAGCAGTGACATTGGTGCTTATAAACATGTCTCCTGGTATCAACAACACC

CAGGCAAAGCCCCCAAACTCATGATT

TATGAGGTCACTAATCGGCCCTC-AGGGATTTCTAATCGTTTCTCTGGCTCCAAGTCTGGCAA

CACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGTT

CATATACAAGCCGTAACACTTGGGTA

TTTGGCGGAGGGACCAAGCTGACCGTCCTA (SEQ ID NO:527) 92.806C-M0056-B09 L-Variable (AA): QDIQMTQS PCTLSLS FGERATLSCRASQSVS SSYLAWYQQKPGQAPRLLIYDASSRA-TGI PD RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGRSPSFGPGTKVDIK (SEQ ID NO :528) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGATGCATCCA@TAGGGCCACTGGCATCCCAGACAG3TTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGC

AGTATGGTAGGTCACCCTCTTTCGGC

CCTGGGACCAAAGTGGATATCAAA (SEQ ID NO:529) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYKNSWVRQAPGKGLEWVSS

TYPSGGWTYYAD

SVKGRPTI SRDNSK.NTLYLQMNSLPAEDMAVYYCARDRPGAFDVWGQGTMVTVS S (SEQ ID NO:530) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACAAGATGTCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACATGG

CTGTGTATTACTGTGCAZ\GAGATCG

CCTGGAGCTTTTGATGTTTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO :531) 93.806C-M0056-C03 1-Variable (AA): QDIQMTQS PGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPD WO 2006/020706 WO 206/00706PCTII§S2005/028413 RFSGSGSGTDFTLTISRLEPDDSATYYCQQYNSYPITFGQoTRLETK (SEQ TD NO :532 L-Variable (DNA):

CAAGACAI[CCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGATGATTCTGCAACCTATTACTGCCAAC

AATATAATAGTTATCCGATCACCTTC

GGCCAAGGGACACGACTGGAGATTAAA (SEQ ID NO:533) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYKMWWVRQAPGKGLEWVSVIYPSGGATYYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGIGAVGGFDSWGQGTLVTVSS (SEQ ID NO:534) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACAAGATGTGGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGCTACTTATTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGGGATC

GGAGCAGTGGGCGGGTTTGACTCCTGGGGCCAGGGAACCCTGOTCACCGTCTCAAGC (SEQ ID NO:535) 94.806C-M0056-C04 L-Variable (AA): QDIQMTQS PS SLSASVGDRVTTACRASHDI SDNLNWYQQKPQPAPKVVT SDAFNLEAQVPSR FSGSRSGTYFTFTINSLQPEDVATYYCQQFNNVPYTFGQGTKLEIK (SEQ ID NO: 53 G) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCGCTTGCCGGGCGAGTCACGACATTAGTGACTTTATTGGTATCAGCAAACCAG

OOAGAGCCCCTAAGGTCGTGATCTCCGATGCATTCAATTTGGCAGGGGTCCCATCAAGG

TTCAGTGGAAGTAGATCTGGGACATATTTTACTTTCACCATCAACAGCCTGCAGCCTGAAGA

TGTTGCAACATATTACTGTCAACAATTTAATAATGTCCCGTACACTTTTGGCCAGGGGACCA

AGCTGGAGATCAAA (SEQ ID NO:537) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSHYIMAWVRQAPGKGLEWVSRIYPSGGKTYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARQGGGGRAFDIWGQGTMVTVS S (SEQ ID NO:538) H-Variable (DNA): G2AAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTQGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACATTATGGCTTGGGTTCGCCAAGCTCCTG

GTAAGTTTGGATGGTTTCTCGTATCTATCCTTCTGGTGcCAAOACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCOAGACAGGGTGGTGGTGGGC

GTGCTTTTGATATCTGGGGCCAAGCGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 539 WO 2006/020706 WO 206/00706PCTII§S2005/028413 95.806C-M0056-E08 1-Variable (AA): QSALTQDPAVSVALGQTVKITCQGDSLRNYYASWYQQKPGQAPIVIYGKQNNRPSGI

PDRFS

GSRSGSTASLTITGAQAVDEADYYCSSRDTTNYRMEFGGGTKLTVL (SEQ ID NO: 540) L-Variable (DNA):

CAGAGCGCTTTGACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGATCAC

ATGCCAAGGAGACAGTCTCAGAATTATTATGCAAGCTGGTACCAGCAGAGCCAGGACAGG

CCCCTATAGTTGTCATCTATGGTA,

AACAACCGGCCCTCAGGGATCCCAGACCGTTTCTCTGCTCAGGTCAGQAAGCACAGCTTC

CTTGACCATCACTGGGGCTCAGCGTACATAGGCTGACTATTACTGTAGTTCCCGGACA

CTACTAATTACCGCATGGAATTCGGC

GGAGGGACCAAGCTGACTGTCCTA (SEQ ID N O:S41) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYIMAWVRQAPGKGLEWVSGIYPSGGFTTYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAKIAGGAYHLDYWGQGTJVTVSS

(SEQ

ID NO:542) H-Variable (DNA):

GA.AGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACATTATGGCTTGGGTTCGCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTGGCTTTACTACTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACACTCTAAGATACTCTCTACTTGCAGATGAJCAGCTTAGGGCTGAGGACACGG

CTGTGTATTACTGTGCC;AAAATTGCA

GGGGGAGCCTACCACCTTGATTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ

ID NO:543) 96.806C-M0056-FOI.

1-Variable (AA): QDIQMTQSPATLSLS PGEPATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPAR FSGSGSGTDF'TLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK C SEQ ID NO: 544) L-Variable (DNA):

CAAGACATCCAGATGATCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGJAAOCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAJACCTG

GCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCACAGGGCCACTGGCATCCCAGCCGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGCGTAGCAACTGGCCTCCGGCCCTCACTTTCGGCGGAG

CGACCAAGOTGGAGATCAAA (SEQ ID NO:545) H-Variable (AA):

EVQLLESOGGLVQPGGSLRLSCASGFTFSRYGMEWVRQAPGKGLEWVSSIYPSGGWTYYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGSGRYFDYWGQGTLVTVSS

(SEQ

ID NC:546) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGGTATGGAGTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTCGGTTTCTTCTATCTATCCTTCTGGTGGCTGGACTTATTATGCTGAC

WO 2006/020706 WO 206/00706PCTII§S2005/028413 TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGATi

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGACGGGGTAGTGGCCGGT

ACTTTGACTACTGGGGCCAGGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO :547) 97.806C-M0056-F02 L-Variable (AA):

QSEITQPPSASGSPGQSVTITCTGTSSDVGYYNYVSWYQQHPGKAPKLMIFEVSNRPSGVPD

RFSGSKSGNTASLTVSGLQAEDEAH{YYCSSYAGSDNFVFO8GTKVTVL (SEQ ID NO: 548) L-Variable (DNA):

CAGAGCGAATTGACTCAGCCTCCCTCCGCGTCCGGGTCTCCTGGACAGTCAGTCACCATCAC

CTGCACTGOAACCAGCAGTGACGTTGGTTATTATAACTATGTCTCCTGGTATCAACAACACC

CAGGCAAAGCCCCCAAACTCATGATTTTTGAGGTCAGTAATCGGCCCTCAGGGGTCCCTGAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCCCTGACCGTCTCTGGGCTCCAGGCTGA

CATGAGGCTCATTATTACTGCAOCTCATATGCAGGCAGCGACAATTTTGTCTTCGGAAGTG

GGACCIAAGGTCACCGTCTTA (SEQ ID NO:549) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYVMGWVRQAPGKGLEWVSSIYPSGGYTWYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARQGGGGPAFDIWGQGTTVTVSS (SEQ ID NO:550) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATTTACGTTATGGGTTGGGTTCGCCAAOCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTATACTTGGTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGACAGGGA

GGGCGCTCTTAACGGCAGGCAGTACTTAG (SEQ ID NO:551) 98 .806C-M0056-F1O L-Variable (AA): QSVLTQPASVSGSPGQS ITIS CTGTS SDVGGYNYVSWYQQHPGKAPKLMIYDVSNRPSGVSN RFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLFYVFGTGTKVTVL (SEQ ID NO: 552) L-Variable (DNA):

CAGAGCGTCTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTDOACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAACACC

CAGGCAAAGCCCCCAAACTCATGATTTATGATGTCAGTAATCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGTCTGGCAACACOOCCTCCCTOACCATCTCTOOGCTCCAGGCTGA

GGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGCAGCACTCTCTTTTATGTCTTCG

GAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:553) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYKMMWVRQAPGKQLEWVSYIVPSGGWTYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARVDYYDFWSGYWWSGGYGMDVWGQGTT VTVSS (SEQ ID NO:554) 217 WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAGATGATGTGGGTTCGCCAJAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTATATCGTTCCTTCTGGTGGCTGGACTTATTATGCTGAC

TCCGTTAAGGTCGCTTCACTATCTCTAGAGACACTCTAGATACTCTCTACTTGCGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAOAGTTGACTATTACGATT

TTTGGAGTGGTTATTGGTGTCGGGGGGTACGTATGGCGTCTGGGCCAGGGACCACG

GTCACCGTCTCAAGC (SEQ ID NO:555) 99.806C-M0056-F1 1 L-Variable (AA): QD IQMTQSPSFLSASVGDRVTITCRASQQI

STYLAWYQQKPGKAPKLLIYATSTIJQSGVPSR

FSGSGSGTEFTLAISTLQPEDFATYYCQQLINSYPITFGQGTRLEIK (SEQ ID NO: 556) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCACTTGCCGGGCCAGTCAGGGCATAAGCACTTATTTAGCCTGGTATCAGAAAGCCAG

GGAAAGCCCCTAAGCTCTTGATCTAT

GCTACATCCACTTTGCAAGTGGAGTCCCATCAAGGTTCAGCGCAGTGQGTCTGGGACA

ATTCACTCTCGCAATCAGCACCCTGCACCTGGATTTTGCTTATTACTGTCACA

TCAATAGTTACCCGATCACTTTCGGC

CAAGGGACGCGACTGGAGATTAAA (SEQ ID NO:557) H-Variable (AA):

EVLEGGVPGLLCAOTSYVLVQPKLWSIPGYYA

SVKG-RFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGVLRAFDIWGQGTVTVSS

(SEQ

ID NO:558) H-Variable (DNA): GAAGTTCAATTGTTAGAGTCTGrn2GGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGCTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCTATACTTATTATGCTGACTCCGTTAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGATACTCTCTACTTGCAGATGACAGCTTAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGGGGTA

CTAAGAGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 559) 100. 806C-M0056-G03 1-Variable (AA): QNIQMTQS PATLSLSPGERATLSCRASQS IS SYLAWYQQKPGQVPRLLI YDASNPATGI PAR FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPRTFGQGTKVJEIK (SEQ ID NO :560) 1-Variable (DNA):

CAAAACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAGAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTATTAGCAGTTACTTAGCCTGGTATCAACGAXJCCTG

GCCAGGTTCCCAGGCTCCTCATCTAT

GATGCAT CCAATAGGGCCACTGGCAT CC CAGC CAGGTT CAGTGGCAGTGGGT CTGGGACAGA

CTCCCCCACGAATGGCGAGTTGATTTATTACG

WO 2006/020706 WO 206/00706PCTII§S2005/028413

ATGGTAGTTTACCTCGGACGTTCGGC

CAAGGGACC.AAGGTGGAAATCAAA (SEQ ID NO:5G1) H-Variable (AA):

EVQLLESGGGLVQPGSLRLSCAASFTFSKYMHVQAPGKGLEWSVIYPSGGKTYYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYAEMGGSGWYDYWGQGTLVTVSS

(SEQ

ID NO:562) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAGTACAAGATGCATTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCATCTGGTGGCAAGACTTATTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAGAGACAACTCAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGAAATG

GGTGGTAGTCGCTGGTACACTACTGGGGCCAGGGACCCTGGTCACCGTCTAGC

(SEQ

ID NO:563) 101. 806C-M0056-G04 1-Variable (AA): QD TQMTQSPATLSLSPGARATLSCRASQSVS SYLAWYQQRPGQTPRLLIYGAS

SRATGIPDR

FSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSRHTFGQGTKLEIK (SEQ ID NO: 564) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGCAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAJACAGAGACCTG

GCCAGACTCCCAGGCTCCTCATCTAT

GGTGCATCCAGCAGGGCCACTGGCATCCCAOACAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGT

ATGGTAGCTCACGACACACTTTTGGC

CAGGGGACCAAGCTGGAGATCAAA (SEQ ID NO:565) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCASGFTFSQYRVRQAPGKGLEWVSCIYPSGGWTTYAD

SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATVJAAAAGAFDIWGQGTMVTVSS

(SEQ

ID NO:566) H-Variable (DNA): GAAGTTCAATTGTTAcGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACGTTATGCGTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTGGCTGGACTACTTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAAAACCAGAATTTCTCAAGAACTAGCGGAAG

CCGTGTATTACTGTGCAACAGTGGCA

GCAGCTGCGGGGGCTTTTGATATCTGGGGCCAGGGACATGGTACCGTCTCAAGC

(SEQ

ID NO:567) 102. 806C-M0056-GOS I-Variable (AA): QDIQMTQSPGTLSIJSPGERATLSCRASQSI

SSSYLAWYQQKPGQAPRLLLYGTSNRATGIPD

RFGGGDTTSLPDAYCQYWLFPTVF (SEQ ID NO: 568 WO 2006/020706 WO 206/00706PCTII§S2005/028413 L-Variable (DNA)-.

CAGCTCGTACATTCGCCCTTTTTTCGGAAACA

CCTCTCCTGCAGGGCCAGTCAGAGTATTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCCGGCTCCTCCTC

TATGGTACATCCAACAGGGCCACTCGCATCCCAGACAGGTTCGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGAGACTGGAGCCTGAAGACTTTGCACTTTATTACTGTCAGC

AGCGTTACAAGTGGCCTCTCACTTTC

CCCCCTGGGACCAAGGTGGATTTCAAA (SEQ ID NO:569) H-Variable (AA): E-VQrJLESGGGLVQPGGSLRLSCAASGFTFSHYGMVRQAPGKGLEWVSVI

SPSGGQTNYAD

SVKcGRTI SRDNSKNTTJY1QMNSLAERDTAVYYCAKGQIHGCNTASWGQGTLVTVSS

(SEQ

ID MOZ57O) H-Variable (DNA)-.

GAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTG-CTTTCTCTCATTACGGTATGT(3GTGGGTTCGCCAAGCTCCTG GTAAAGGTiTTGGAGTGGGTTTCTGTT

ATCTCTCCTTCTGGTGGCCAGACTATTATGCTGACTCCGTTAAAGGTCGCTTCCTATCTC

TAAAACCAGAATTTCTCAAGAACTAGCGGAAT

CCGTGTATTACTGTGCCAAAGGGCAA

ATCCACGGTGGTAATCTTGCCTCCTGGCCAGGGAACCCTGGTCACCGTCTCAAGc

(SEQ

ID NO -571) 103. 806C-M0056-G12 L-Variable (AA): QSALTQPASVSGSPGQS ITI SCTGTSSDVGG3YNYVSWYQQHPGKAPKLMISDVSNRPSGVSN RFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTLYVFGTGTKVTVL (SEQ ID NO: 572) L-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGACTAGCAGCGACGTTGGTGGTTATACTATGTCTCCTGGTACCACAGCACC

CAGOCAAAGCCCCCAAACTCATGATT

TCCTTATACGCTAGOTCTACCTTTGTCATTGA

CACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCT

CATATACAAGCACCAGCACTCTGTAT

GTCTTCGGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:573) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYKMNRQAPGKGJEwSVIYPSGGATYYAD SVKGRFTI SRDNSKNTLYLQMNSLP-AEDTAMYYCARVGYS

SSWDPNFDYWGQQTLVTVSS

(SEQ TD NO:574) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTCCGTCGATATTTTATCATATGGTGCACCT

CTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGCTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAAAACCAGAATTTCTCGGAACTAGCGGAAC

CCATGTATTACTGTGCGAGAGTCGGG

WO 2006/020706 WO 206/00706PCTII§S2005/028413 TATAGCAGCAGCTGGGACCCCCACTTTcGACTACTGGrnccAGGGAACCCTGGTCACCGTCTC AAGC (SEQ ID NO:575) 104, 806C-M0056-H04 L-Variable (AA): QDIQMTQSPATLSLSPGERATLSCRAiSQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPD RFSGSGSGTEFTLTISSLQSEDFGVYYCQQYKDWPRTFGQGTKVEIK (SEQ ID NO:576 L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTcGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGGAOTTTATTATTGTCAGC

AGTATAAGGACTGGCCTCGAACGTTC

GGCCAGGGACC1AAGGTGGAAATCAAA (SEQ ID NO:577) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYRMVWVRQAPGKGLEWVSS

IYPSGGPTRYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARWSYYYDSSGYYPVSGPFDIWGQGTMV TVSS (SEQ ID NO:578) H-Variable (DNA):

GAAGTTCAATTGTTAGAQTCTGOTGGCGGTCTTGTTCA.GCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACCGThTGGTTTGGGTTCGCCAAGCTCCTG GT1A-AAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCCCTACTCGTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGATGGTCG

TATTACTATGATAGTAGTGGTTATTACCCCGTGAGTGGGCCTTTTGATATCTGGGGCCAAGG

GACAATGGTCACCGTCTCAAGC (SEQ ID NO:579) 105. 806C-M0056-H12 L-Variable (AA):

QDIQMTQSPGTLSLSPGERATLSCRASQGVRSTYLAWYQQKPGQAPRLLIYGASSRATGIPD

RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSQGFTFGPGTKVDIK (SEQ ID NO: 580) 1-Variable (DNA)-.

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAIGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGGGTGTTAGA~AGTACCTCTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGOAC

AGACTTCACTCTCACCATCAGCAGACTGAGCCTGAAIGATTTTGCAGTGTATTACTGTCAGC

AGTATGGTAGCTCACAGGGTTTCACT

TTCGGCCCTGGGACCAAAGTGGATATCAAA (SEQ ID NO:581) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSMYKMHWVRQAPGKGLEWVSVIYPSGGITAYD

SVKGRFTI SRDNSKNTLYLQMNSTARADDTAVYYCTREVMGPSDYWCQGTLVTVSS

(SEQ

ID NO:582) WO 2006/020706 WO 206/00706PCTII§S2005/028413 H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATGTACAAGATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCATTACTGCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAOAATACTCTCTACTTGCAGATGAACAGCrTTAAGGGCTGATGACACAG

CCGTGTATTACTGTACTAGAGAGGTT

ATGGGACCATCTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 583) 106. 806C-M0057-B05 1-Variable (AA): QDIQMTQS PATIJSVSPGERATLSCRSSQSLSNNLAWYQQKPGQAPRLLIYGASTRATGIPA- FSGSGSGTEFTLTISSLQSEDFATYYCQQANSFPRTFGQGTKLEIK (SEQ ID NO: 584) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGTCCAGTCAGAGTCTTAGCAACAACTTAGCCTGGTACCAGCAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GGTGCATCCACCAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

GTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAACTTACTATTGTCAACAGG

CTAACAGTTTCCCTCGAACTTTTGGC

CAGGGGACCAAGCTGGAGATCAAA (SEQ ID NO:585) H-Variable (AA): EVQJIJESGGGLVQPGGSIJRLS CAASGFTFSKYVMHWVRQAPGKGLEWVSS IYPSGGWTYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCATSTTYSSRPFDYWGQGTLJTVSS (SEQ ID NO:586) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAAGTACGTTATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGACCTCTACG

ACTTATAGCAGCAGGCCCTTTGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID NO:587) 107. 806C-M0057-H07 1-Variable (AA): QDIQMTQSPSSLSASVGDRVAITCRASQS IDTYLNWYQHKPGKAPKLLIYAASKLEDGVPSR FSGSGTGTDFTLTIRSLQPEDFASYFCQQSYSSPGITFGPGTKVEIK (SEQ ID NO :588 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAC-AGTCGC

CATCACTTGCCGCGCAAGTCAc3AGCATCGACACCTATTTAAATTGGTATCAGCACAAACCAG

GCAAAGCCCCTAAACTCCTGATCTAT

GCTGCATCCAAGTTGGAAGACGGGGTCCCATCAAGATTCAGTGGCAGTGGAACTGGGACAGA

TTTCACTCTCACCATCAGTCTCACCTGAAATTTTGCAGTTATTTCTGTCACAGA

WO 2006/020706 WO 206/00706PCTII§S2005/028413 GCTACTCTAG3TCCAGGGATCACTTTC GGCCCTQGGACCAAGGTGGAGATCAAA (SEQ ID No..589) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYPMMWVRQAPGKGLEWVSVIYSSGGYTYYAD

SVKGRFTI SRINSKNTLYLQMNSLRAEDTAVYYCARVSRGIYYAMDVWGQGTTVTVSS (SEQ ID NO:590) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTQOTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCCTATGATGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATTCTTCTGGTGGCTATACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGTATCT

CGCGGGATCTACTACGCTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCAAGC

(SEQ ID NO:591) 108. 806C-M0058-A09 L-Varlable (AA): QDIQMTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGI PD RFSGSGSGTDFTLTISRLEPEDFVVYYCQQYGRSRYTFGQGTKLEIK (SEQ ID NO :592 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGOCTCCCAGGCTCCTCATC

TATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGTAGTGTATTACTGTCAGC

AGTATGGTAGGTCACGGTACACTTTT

GGCCAGGGGACCAA GCTGGAGATCAAA (SEQ ID NO: 593) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSNYKMHWVRQAPOKGLEWVSS IYPSGGPTHYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAREGYS SGWYIHWYFDLWGRGTLVTVSS (SEQ ID NC:594) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACAAGATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCCCTACTCATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAkGGGCTGAGGACACGGCCGTGTATTACTG-TGCGAGAGAAGGGTATAGCAGTG

GCTGGTACATTCACTGGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCAAGC

(SEQ ID No:595) 109. 806C-M0058-D04 1-Variable (AA):

QDIQMTQSPSSLSASVGDRVAITCRASQSIDTYLNWYQQKPGKAPKLLIYDASNLETGVPSR

FSGSGSGTHFTFTISSLQPEDFATYYCQQADSFPITFGQGTRLEIK (SEQ ID NO: 596) WO 2006/020706 WO 206/00706PCTII§S2005/028413 L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCGC

CATCACTTGCCGCGCAAGTCAGAGCATCGACACCTATTTAAATTGTATCAGCAGAAACCAG

GGAAAGCCCCT.AAGCTCCTGATCTAC

GATGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACACA

CTTTACCTTCACCATCAGCAGCCTGCAGCCTGAA~GATTTTGCAACTTACTATTGTCAGCAOG

CTGACAGTTTCCCGATCACCTTCGGC

CAAGGGACACGACTGGAGATTAAA (SEQ ID NO:597) H-Variable (AA): EVQLLESGGGLVQPGGELRLSCAASGFTFSSYFMTWVRQAPGKGLEWVSGI

SPSGGITSYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAKGSYSDYGVFNSWGQGTLVTVSS (SEQ ID NO:598) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACTTTATGACTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTc3GAGTGGGTTTCTGGT

ATCTCTCCTTCTGGTGGCATTACTTCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAAAGGCTCA

TACAGTGATTACGGGGTCTTTAATTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID NO:599) 110. 806C-M0058-E09 L-Variable (AA): QDIQMTQSPATLSVSPGERATLSCRASQS ISSSLAWYQQKPGQAPRLLIYDASNRATGIPAR FSGSGSGTDFTILTISSLEPEDFAVYYCQQRSNWPLTFGGGTKVEIK (SEQ ID NO: 600) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTL3CAGGGCCAGTCAGAGTATTAGCAGCAGCTTAGCCTGGTACCAGCAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTOAAGATTTTGCAGTTTATTACTGTCAGCAGC

GTAGCAACTGGCCGCTCACTTTCGGC

cGGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:601) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASOFTFSNYVMAWVRQAPGKGLEWVSVIYPSGGATYYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCTRLAVTHFDYWGQGTLVTVSS

(SEQ

ID NO:602) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTAATTACGTTATGGCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGCTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTACGAGACTGGCG

GTTACTCACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 603) WO 2006/020706 WO 206/00706PCT/US20051028413 111, 806C-M0058-F03 1-Variable (AA): QDTQMTQSPSTLSASVGDRVTTTCRASQGI SNYLAWYQQKPGKVPICLLIYGASNLQSOVSSR FSGSGSATDFTLTISSLQPEDFATYYCQQFNSYPLTFGGGTKVEIK (SEQ ID NO: 604) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCAC

CATCACTTGCCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGTATCAACAGAAACCAG

GGAAAGTTCCTAAACTCCTGATCTAT

GGTGCATCTAATTTGCAGTCAGGGGTCTCATCGCGGTTCAQTGCCAGTGGATCTGCGACAGA

TTTCACCCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGT

TTAATAGTTACCCTCTGACTTTCGGC

GGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:605) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSDYGMAWVRQAPGKGLEWVSVI SPSGGQTAYAD SVKGRFTISRDNSKNTLYLQMN~SLRAEDTAVYYCATVRWFGAFDYWGQGTLVTVSS

(SEQ

ID NO:G06) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGATTACGGTATGGCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTCTCCTTCTGGTGGCCAGACTGCTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACOG

CTGTGTATTACTGTGCCACAGTTAGA

TGGTTCGGGGCATTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 607) 112. 806C-M0058-G03 1-Variable (AA): QD IQMTQSPGTLSLS PGEPATLSCRASQSVTS SFLSWYQHRPGQAPRLLIYATSTRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQHYH-TSPPTYTFGQGTKLEIK (SEQ ID NO: 608) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACGCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAAAGTGTGACCAGCAGCTTCTTATCCTGGTACCAGCACAGAC

CTGGCCAGGCTCCCAGGCTCCTCATCTATGCTACATCCACCAGGGCCA~CAGGCATCCCAGAC

AGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACTATCAGCAGACTGGAGCCTGA

AGATTTTGCAGTGTATTACTGTCAGCACTATCATACCTCACCTCCCACTTACACTTTTGGCC

AGGGGACCAAGCTGGAGATCAAA (SEQ ID NO:609) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSLYLMYWVRQAPGKGLEWVSVIYPSGGWTYYAD

SVKGRFTISRDNSKNTLYLQMNSLRPAEDTAMYYCARGYYYGMDVWGQGTTVTVSS

(SEQ

ID NO:610) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCTTTACCTTATGTATTGGGTTCGCCAAGCTCCTG

WO 2006/020706 WO 206/00706PCT/US20051028413

ATCTATCCTTCTGGTGGCTGGACTTATTATGCTGACTCCGTTAGGTCCTTCACTATCTC

TAAAACCAGAATTTCTCAAGAACTAGCGGAAC

CCATGTATTACTGTGCGAGAGGCTAC

TACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCAAGC (SEQ ID NO :611) 113. 806C-M0058-HO1 L-Variable (AA):

QSALTQPPSVSVAPGETAEITCGGE\IGSKSVHWYQQKPGQAPVLVIYYDNDRPSGIPERFS

GSNFGSTATLTISRVEAGDEADYYCQVWDSGSEH-YVFGTETKVTVLGQ (SEQ ID NO: 612) 1-Variable (DNA): CAGAGCGCTTTGACTCAGCCACCCTCAGTCTCAGTGGCCCCArnGGAGACGGCCGAAATTAC

CTGTGGGGGCGAGAACATTGGAAGTAJ\AAGTGTCCATTGGTACCAGCAGAAGCCAGGCCAGG

CCCCAGTGCTGGTCA TCTATTATGATAACGACCGCCCCTCAGGGATCCCTGAGCGATTCTCT

GGCTCCAACTTTGGGAGCACGGCCACCCTGACCATCAGCAGGTCGAACCGGGGATGAGQC

CGACTATTACTGTCAGGTCTGGGATAGTGGCAGTGAGCACTATGTCTTCGGAACTGAGACCA

AGGTCACCGTCCTAGGTCAG (SEQ ID NO:613) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSGYIMMVRQAPGKGLEWVSSIYPSGGITYYAD

SVKGRFTISRDNSKNTLYLQMNSTJRAEDTAVYYCARWYYGMDVWGQGTTVTVSS C SEQ ID NC:6 14) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTGGTTACATTATGATGTGGGTTCGCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCCATACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGATGGTAT

TACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCAAGC (SEQ ID NO: 615) 114. 806C-M0059-A02 1-Variable (AA): QSALTQPASVSGSPGQSITISCTGTNSDVGGYNYVSWYQQHPQKAPKLI

IFDVTNRPSQVSN

RFSGSKAGNTASLTISGLQAEDEADYYCSSYSSTSPRPGGGTKLTVL (SEQ ID NO: 616 L-Variable (DNA): CAGAGCGCTTTGACTCAGCCTGCCTCCTcGTCAQGGTCTCCTGGACAGTCGATCACCATTTC

CTGCACTGGAACCAACAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAGCACC

CAGGCAAAGCCCCCAAACTCATAATTTTTGATGTCACTAATCGGCCCTCAGGGGTTTCTAAT

CGCTTCTCTGGCTCCAAGGCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAAGCTGA

GGACGAGGCTGATTATTACTGCAGCTCATATTCAAGTACCAGCCCTCGCTTCGGCGGAGGGA

CCAAGCTGACCGTCCTG (SEQ ID NO:G17) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSMYQMQWVRQAPGKGLEWVSRIYPSGGWTVYAD WO 2006/020706 WO 206/00706PCT/US2005/028413 SVKGRFTT SRDNSKNTLYLQMNSLRAEDTAVYYCTRITYDSSGYYDYWGQGTLVTVSS (SEQ ID NO:618) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATGTACCAGATGCAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGTATCTATCCTTCTGGTGGCTGGACTGTTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACAGCCGTGTATTACTGTACACGGATCACOTATGATAGTA

GTGGTTATTACGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 619) 115. 806C-M0059-A06 L-Variable (AA): QDIQMTQSPSSLSASVGDRVAITCRASQS IDTYLNWYQHKPGKAPKLLIYAASKLEDOVPSR FSGSGTGTDFTLTIRSLQPEDFASYFCQQSYSSPGITFGPGTKVEIK (SEQ ID NO: 620 L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTOTGGGAGACAGAGTCGC

CATCACTTGCCGCGCAAGTCAGAGCATCGACACCTATTTAAATTGGTATCAGCACAAACCAG

GGAAAGCCCCTAAACTCCTGATCTATGCTGCATCCAAGTTGGAAGACGGGGTCCCATCAAGA

TTCAGTGGCAGTGGAACTGGGACAGATTTCACTCTCACCATCAGAAGTCTGCAACCTGAAGA

TTTTGCAAGTTATTTCTGTCAACAGAGCTACTCTAGTCCAGGGATCACTTTCGGCCCTGGGA

CCAAGGTGGAGATCAAA (SEQ ID NO: 621) H-Variable (AA): EVQLLESGGGLVQPOGSLRLS CAASGFTES PYKMIWVRQAPGKGLEWVSGIYPSGGWTYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAYIYYCARLLPALRGAVMDVWGQGTT VTVS S (SEQ ID NO:622) H-Variable (DNA): CAAGTTCAATTGTTAGAGTCTGG0TGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCCTTACAAGATGATTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGTATCTATCCTTCTGGTGGCTGGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACCGCCATGTATTACTGTGCGAGACTGTTACCAGCCTTGC

GGGGAGCCGTGATGGACGTCTQGOCCAAGGOACCACGGTCACCGTCTCAAOC (SEQ ID NO :623) 116. 806C-M0060-B02 1-Variable (AA):

QSVLTQDPTVSVATJGQTVRITCRGDRLRSYYSSWYQQKPRQAPVLVMFGP-NNRPSGIPDRFS

GSTSGSTASLTITATQADDEADYFCSSRDGSGNFLFGGGTKLTVL (SEQ ID NO: 624) 1-Variable (DNA):

CAGAGCGTCTTGACTCAGGACCCTACTGTGTCTGTGGCCTTGGGGCAGACAGTCAGGATCAC

ATGCCGAGGAGACAOACTCAC-A AGTTATTATTCAAGTTGGTACCAGCAGAAGCCACGACAGG

CCCCTGTTCTTGTCATGTTTGGTAGAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCT

GGCTCCACCTCAGGAAGCACAGCTTCCTTCACCATCACTGCGACTCAGGCGGACGATGAOGC

TGACTATTTCTGTAGTTCCCGGGACGGCAGTGGTAATTTCCTCTTCGGCGGAGGGACCAAAC

TGACCGTCCTT (SEQ ID WO 2006/020706 WO 206/00706PCT/US2005!028413 H-Variable

EVLEGGVPGLLCAGTSYPHVOPKLWSIPGIRA

SVKGRFT:SRDNSNTLYLQMNSLPJAEDTALYYCARQRGSWHDSWGQGTLVTVSS

(SEQ

ID NYO:626) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATTTACCCTATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCATTACTCGTTATGCTGACTCCGTTAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATG~r-GCTTAGGGCTGAGGACACCG

CCTTGTATTACTGTGCGAGACAACGG

GGCAGTGGCTGGCATCACTCCTGGGGCCAGGACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 627) 117. 806C-M0060-HOI L-Variable (AA):

QDIQMTQSPATLSLSPGERATLSCRASQSVSSYLWYQQKPGQAPRLLIYDASNPSATGIPAR

FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPVTFGQGTRLEIK (SEQ ID NO: 628) 1-Variable (DNA):

CAAQACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCGGGGAJAAGAGCC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCACAGACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAGATTTTGCAGTTTATTACTGTCAGCAGC

OTAGCAACTGGCCGGTCACCTTCGGC

CAAGGGACACGACTCGAGATTAAA (SEQ ID NO:629) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSYYPMVWVRQAPGKGLERWJ8VTVSGGFTAYAD SVKGRFTI SRDNSKNTLYLQMNSLREDTAMYYCARK.PGNAFDIWGQGTMVTVSS

(SEQ

ID NO:630) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTATTACCCTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTTATCGTTCCTTCTGGTDGCTTTACTGCTTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTA.AGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACCGCCATGTATTACTGTGCGAGAAAGCGACCTGGAAATG

CTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 631) 118. 806C-M0061-A03 L-Variable (AA): QDI QNTQSPSFLSASVGDSVAITCPASQDI

SRFLAWYQQRPGKAPKLLIFSASTLQSGVPSR

FSGSGSGTEFTLTINALQPEDFATYYCQQLSRYSTFGQGTTLEIK (SEQ ID NO: 632) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTTCCTGTCTGCATCTGTAGGAGACGTGTCGC

CATCACTTGCCGGGCCAGTCAGACATTATCGTTTTTTAGCCTGGTATCAQAAAACCAG

GGAAAGCCCCTAAACTCCTGATTTTT

WO 2006/020706 WO 206/00706PCT/US2005!028413

TCTGCTTCCACTTTACAAAGTGGGGTCCCATCCAGGTTCAGCGGCAGTGGATCTGGGACAGA

ATTTACTCTCACAATCAACGCCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAAC

TTAGTCGTTATTCGACGTTCGGCCAAGGCACCAAACTGGAAATCAAA (SEQ ID NO: 633 H-Variable (AA): EVQLLE9GCGLVQPGGSLRLSCAASGFTFSYYKMWVRQAPGKGLEWVSSISPGGTHYADS VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGPVSSGGDYWGQGTLVTVSS (SEQ ID NO:634) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTATTACAAGATGTGGTGGGTTCGCCAAGCTCCTG

GTA-AAGGTTTGGAGTGGGTTTCTTCTATCTCTCCTGGTGGCTGGACTCATTATGCTGACTCC

GTTAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAA

CAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCTAGAGGCCCTGTCAGTAGTGGTG

GGGACTACTGGGGCCAOOGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 635) 119. 806C-M0061-C05 1-Variable (AA): QDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGI PAR FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK (SEQ ID NO: 636 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGC

GTAGCAACTGGCCTCCOCTCACTTTC

GGCGGAGGGACCAAGGTGGAGATCAAA (SEQ IID NO:637) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSQYVNMWVRQAPGKGLEWVSS IYPSGOQTYYAD SVKGRFT ISRDNSKNTLYLQMNSLRAEDTAVYYCAKIAGGAYHLDYWOQGTLVTVS S (SEQ ID NO:638) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAOTACGTTATGATGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCCAGACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAOCGCTGAGGACACGGCCGTGTATTACTGTGCGAAATTGCAGGGGGAGCCT

ACCACCTTGATTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 639 120. 806C-M0061-C06 1-Variable (AA): QYELTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLTI FDVTKRPSGVSD RFSGSKSDNTASLTISGLQAEDEADYYCGSYTSSGSRVFGTGTKVTVL (SEQ in NO: 640) WO 2006/020706 WO 206/00706PCT/US2005!028413 L-Variable (DNA):

CAGTACGAATTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

CTGCACTGGAACCAGCAGTGACGTTGGTGGTTATACTATGTCTCCTGGTACCAJACACACC

CACGCAAAGCCCCCAAACTCACGATT

TTTGATGTCACTAAACGGCCCTCAGGGGTTTCTGATCGCTTCTCTGGCTCCAGTCTGAA

TACGGCCTCCCTGACCATCTCTGGGCTCCAGQCTGAGACGAGCTGATTATTACTGCGGCT

CATATACAAGCAGCGGCTCTCGGGTC

TTCGGAACTGGGACCAAGGTCACCGTCCTC (SEQ ID NO:641) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCASGFTFSRYVGWJRQAPGKGLEW7SRIYPSGGFTYYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRIREGYFDYWGQGTLVTVSS

(SEQ

ID NO:642) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGGGTTGGGTTCGCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGTATCTATCCTTCTGGTGGCTTTACTTATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAGATACTCTCTACTTCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTACGAGGATAAGGGAGGGTACT

TTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 643) 121. 806C-M0061-F07 L-Variable (AA):

QDQTSSLAVDVICAQITYNYQPKPLIASLDVS

FSGSGTGTDFTLTIRSLQPEDFASYFCQQSYSSPGITFGPGTKVEIK (SEQ ID NO: 644 L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTOGAGACAGAGTCGC

CATCACTTGCCGCGCAAGTCAGAGCATCGACACCTATTTATTGGTATC-'GCAGAAACCAG

GGAGCCAATCGTTTCGATCATGAGCGGCCTAG

TTCAGTGGCAGTGGAACTGGGACAGATTTCACTCTCACCATCAGAGTCTGCAACCTGAAGA

TTTTGCAAGTTATTTCTGTCAACAGAGCTACTCTAGTCCAGGGATCACTTTCGGCCCTGGGA

CCAAGGTGGAGATCAAA (SEQ ID NO:645) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSVTWVXRQAPGKGLEWVSSIYPSGGFTAYAD

SVTGRFTI SRDNSKTLYLQMNSLRADTAYYCAKSTYYYEGSGYYFDIWGQTMpJTVS S (SEQ ID NO:646) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGOTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACGTTATGACTTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCTATCTATCCTTCTGGTGGCTTTACTGCTTATGCTGAC

TCGTCGTGTCCACCAAACATTAATCCCATGAA

GAZCAGCTTAAGGGCTGAGGACACCGCCATGTATTACTGTGCGATCGACT

TATTACTATGAGGGTAGTGGTTATTACCGCGCTTTTGATATCTGGGCCCAGGGACATGGT

CACCGTCTCAAGC (SEQ ID NO:647) 122. 806C-M0061-GI2 WO 2006/020706 WO 206/00706PCT/US2005!028413 1-Variable (AA):

QDIQMTQSPATIJSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASNRATGIPA

RFSGSGSGTDFTLTISGIEPEDFWVYYCQKYGSSSLTFGGGTKVEIK (SEQ ID NO: 648 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTCTATCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAAC

CTGGCCAGGCTCCCAGGCTCCTCATC

TATGGTGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGAC

AGACTTCACTCTCACCATCAGTGGCCTc3GAGCCTGAAGATTTTGTAGTGTATTACTGTCAGA

AGTATGGTAGTTCATCGCTCACTTTC

GGCGGAGGGACCAAGGTGGAGATCAAA (SEQ ID NO:649) H-Variable (AA): EVQIJLESGGGLVQPGGSLRLSCAASOFTFSQYKMWWVRQAPGKGLEWVSVIYPSGGVTYYAfl SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAISYSPVGAFDIWGQGTMVTVSS (SEQ ID NO:650) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCAGTACAAGATGTGGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCGTTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACACCTTAAGCTGACOACACGG

CCGTGTATTACTGTGCGATCTCGTAT

AGTCCCGTGGGGCTTTTGATATCTGGOGCCAAGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO:651) 123. 806C-M0061-H09 L-Variable (AA): QSALTQPPSVSGSPGQSVTI SCTGTSSDVOSYNRVSWYRQPPGTAPKVT IYDTNNRPSGVPD RFSGSRSGDTAYLTISGLQVEDEADYYCSSFTSSSTYIFGTGTKVTVL (SEQ ID NO: 652) 1-Variable (DNA):

CAGAGCGCTTTGACTCAGCCTCCCTCCGTGTCCGGGTCTCCTGGACAGTCAQTCACCATTTC

CTGCACTGGAACCAGCAGTGACGTTGGTAGTTATAACCGTGTCTCCTGGTACCGGCAGCCCC

CAGGCACAGCCCCCAAAGTCATCATT

TATGACATCAJATTCGGCCCTCAOCTGTCCCTGATCGCTTCTCTGGGTCCAGGTCTGGCGA

CACGGCCTACCTGACCATCTCTGGGCTCCAGGTGGAGGACGAGGCTGATTATTACTGTAGCT

CATTTACAAGCAGCAGCACCTATATC

TTCGGAACTGGGACCAAGGTCACCGTCCTG (SEQ ID NO: 653) H-Variable (AA): EVQLLESGGGLVQPGGSLRJSCAASGFTFSVYKM7 TRQAPKGLEVSVYPSGGYTDYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQLPMSYFDYWGQGTLVTVSS (SEQ ID NO:654) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

WO 2006/020706 WO 206/00706PCT/US2005!028413 TTGCGCTGCTTCCGGATTCACTTTCTCTGTTTACAA GATGTATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGACTGGGTTTCTGTTATCTATCCTTCTGGTGGCTATACTGATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGCGGCAGCTGCCCATGTCGT

ACTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 655) 124. 806C-M0062-A12 1-Variable (AA); QDIQMTQSPLSLPVTPGEPASMS CRS SQSLLQSNGYNYLDWYLQKPGQSPQLLIYLGSNRAS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTWTFGQGTKVEIK (SEQ ID NO: 656) 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTC

CATGTCCTGCAGGTCTAGTCAGAGCCTCCTGCAALAGTAATGGATACAACTATTTGGATTGGT

ACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCC

GGQGTCCCTQACAGGTTCA3TGGCAGTGGATCAGc4CACAGATTTTACACTGAAAATCAGCAG

AGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCTCTACAAACTTGGACGTTCG

GCCAAGGGACCAAGGTGGAAATCAAA (SEQ ID NO:657) H-Variable (AA):

EVQLLESGQQLVQPGGSLRLSCAASGFTFSRYVMVWVRQAPGKGLEWVSRIYPSGGFTNYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARDKTAHMDVWQKGTTVTVSS

(SEQ

ID NO:658) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCGCGTATCTATCCTTCTGGTGGCTTTACTAATTATGCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATAAGACAGCCCACA

TGGACGTCTGGGGCAAAGGGACCACGGTCACCCTCTCAAGC (SEQ ID NO: 659) 125. 806C-M0062-B05 L-Variable (AA):

QDIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPAR

FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSWPPLTFGGGTKVEIK (SEQ ID NO :660 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGG

TTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCA-ICAGCAGCCTAGAGCCTGAAGA

TTTTGCAGTTTATTACTGTCAGCAGCGTAGCAGCTGGCCTCCGCTCACTTTCGGCGGAGGGA

CCA2AOGTGGAGATCAAG (SEQ TD NO:661) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTF9RYKMNWVRQAPGKGLEWVSSIYPSGGWTNYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARGGRYGDYVRHWGQGTLVTVSS

(SEQ

ID NO:662) WO 2006/020706 WO 206/00706PCT/US2005!028413 H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAAGATGAATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCTGGACTAATTATGCTGAC'TCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCCAGAGGGGG

AGATACGGTGACTACGTGCGTCACTOGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ

ID NO:GG3) 126. 806C-M0062-B07 L-Variable (AA):

QDIQMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQHKPGQAPRLLIYGASIRATGIPAR

FSGSGSGTEFTLTISSLQSEDFGVYYCQQYKDWPRTFGQGTKVEIK (SEQ ID NO: 664) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCAC

TCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCACAAACCTG

GCCAGGCTCCCAGGCTCCTCATCTAT

GGTGCATCCATCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

GTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGGAGTTTATTATTGTCAGCAGT

ATAAGGACTGGCCTCGAACGTTCGGC

CAAGGGACCAAGGTGGAAATCAAA (SEQ ID NO:-.6 H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYRMAWVRQAPGKGLEWVS SIYPSGGVTYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARDLS IAAAGTAYWGQGTLVTVSS (SEQ ID NO:666) Hl-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCGTATGGCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTCT

ATCTATCCTTCTGGTGGCGTTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGATACTCTCTACTTGCAATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCAAGAGATCTT

AGTATAGCAGCAGCTGGTACTGCCTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC

(SEQ ID NO:667) 127. 806C-M0062-C08 L-Variable (AA): QDI QMTQSPGTLSLS PGERATLS CRASQSFVGSRNLAWYQQKPGQPPRLLIYGAFNRATGIP GRFSGSGSGTDFTLTISRJEPEDFAVYYCQQYGTSPRTFGGGTKTEIK (SEQ ID NO: 668) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCAGGCACGCTGTCTTTGTCTCCAGGGGA.AAGAGCCAC

CCTCTCCTGCAGGGCCAGTCAGAGTTTTGTCGGCAGCAGAAACTTAGCCTGGTACCAGCAAA

AACCTGGCCAGCCTCCCAGGCTCCTCATCTATGGTGCATTCAACACCCCCACTGGCATCCCA

GGCAGGTTTAGTGGCAGTGGCTCTGGGACAGACTTCACTCTCACCATLCAGCAGACTGGAGCC

TGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTACGTCACCTCGGACTTTCGGCGGAG

GGACCAAAGTGGAGATCAAA (SEQ ID NO:669) WO 2006/020706 WO 206/00706PCT/US2005!028413 H-Variable (AA): EVQLLESGGOLVQPCQSLRLSCAASGFTFSRYVMQWVRQAPOKGLEWFSS IYPSGGATIYAD SVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRGIPGYFDSWGQGTLVTVSS (SEQ ID NO:670) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACGTTATGCAGTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGTTTTCTTCT

ATCTATCCTTCTGOTGGCGCTACTATTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAAGGGA

ATTCCGGGCTACTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 671) 128. 806C-M0062-D04 L-Variable (AA):

QDIQMTQSPLSLSASIGDRVTITCRASQSISTYLNWYQQKPGKAPKLILIYATSTLQSGVPSR

FSGSGSGTEFILTISGLQPEDFATYYCQQFNFYPLTLGGGTRVEIKRT (SEQ ID NO: 672) L-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCACTCTCCCTGTCTQCATCTATAGGAGACAGAOTCAC

CATCACTTGCCGGGCAPAGTCAGAGCATTAGCACCTATTTATTGGTATCAGCAGAAGCCAG

GGAAAGCCCCTAAACTCCTGATCTAT

GCAACTTCCACTTTACAGAGTGGGGTCCCATCAAGGTTCAGCOGCAGTGGATCTGGOACAGA

ATTCATTCTCACAATCAGCGGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAACAGT

TTAATTTTTATCCTCTCACTCTCGGC

GGAGGGACCAGGGTGGAGATCAAACOAACT (SEQ ID NO: 673) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYGMVWVRQAPGKGLEWVSSI SPSGGNTGYAD SVKGRFTTSRDNSKNTLYLQMNSLPAEDTAVYYCARGNGGFDSWGQGTLVTVSS (SEQ ID NO: 674) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTTCTTACGGTATGGTTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGCGTTTCTTCT

ATCTCTCCTTCTGGTGGCATACTGGTTATGCTGACTCCGTTAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGACAGCTTAAGGOCTGAGGACACGG

CCGTCTATTACTGTGCAAGAGGAAAT

GGTGGCTTTGACTCCTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 675) 129. 806C-M0062-E02 L-Variable (AA): QSVLTQPASVSGSPGQSITI SCTGTSSDVGSYNLVSWYQQHPGKAPKLMIYEGSKRPSGVSN RFSGSKSGNTASLTI SGLQAEDEADYYCCSYAGSSTYVFGTGTKVTVL (SEQ ID NO: 676) 234 WO 2006/020706 WO 206/00706PCT/US2005!028413 L-Variable ('DNA):

CAGAGCGTCTTGACTCACCTGCCTCCGTGTCTGTCTCCTGGAAGTCGTCACCATCTC

CTGCACTGGAACCAGCAGTGATGTTGGGAGTTATAACCTTGTCTCCTGGTACCACAGCACC

CAGGCAAAGCCCCCAAACTCATGATT

TATGAGGGCAGTAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTGCTGCCGTCTGGCAA

CACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCTGCT

CATATGCAGGTAGTAGCACTTATGTC

TTCGGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:677) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMSWVRQAPGKGLEWVSVIYPSGGWTGYD

SKGRFTIRDNSKNTLYLQMNSLRAEDTAVYYCARGVATTSF'DYGQGTLVTVSS C SEQ ID NO:678) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCATTACGTTATGTCTTGGSTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGTT

ATCTATCCTTCTGGTGGCTGGACTGGTTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGCCAGGACACGG

CCGTGTATTACTGTGCGAGAGGGGTG

GCAACTACTAGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGc (SEQ ID NO: 679) 130. 806C-M0062-E03 L-Variable (AA):

QDIQMTQSPATLSLSPGERATLSCASQSVSSYLAWAYQQKPGQAPRLLIYDASNATGIPAR

FSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPRSITFGQGTRLEIK (SEQ ID NO: 680) L-Variable (DNA):

CAAGACATCCACATGACCCAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGAAAGAGCCAC

CCTCTCCTGCAGGGCCAGCAGAGTGTTAGCAGCTACTTAGCCTGGTACCCGACCTG

CCCAGGCTCCCAGGCTCCTCATCTAT

GATGCATCCA1ACAGQGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGA

CTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAOGCG

GTACCAACTGGCCTCGATCGATCACC

TTCGGCCAAGGGACACGACTGGAGATTAAA (SEQ ID NO: 681) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYLMRWVRQAPGKGLEW1VSGIYPSGGITAYAD SVKORFTT SRDNSKNTLYLQMNSLRAEDTAVYYCARASGSYYNYYFDYWGQGTLVTVSS (SEQ ID NO:682) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGDTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACCTTATGCGTTGGGTTCGCCAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTGGT

ATCTATCCTTCTGGTGGCATTACTGCTTATGCTGACTCCGTTAAAGTCGCTTCACTATCTC

TAGAGACAACTCTAAGA1ATACTCTCTACTTGCAGATGAACADCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGCTTCG

GGGAGTTATTATJAATTACTACTTTGACTACTGGGGCCAGGCACCCTGGTCACCGTCTAG

C (SEQ ID NO:683) WO 2006/020706 WO 206/00706PCT/US2005!028413 131. 806C-M0062-Ell L-Variable (AA): QDIQMTQS PS SLSASVGDRVAITCRASQS IDTYLNWYQHKPGKAPKLLIYA4SKLEDGVPSR FSGSGTGTDFTLTIRSLQP8IDFASYFCQQSYSSPGITFGPGTKVEIK (SEQ ID NO:684 1-Variable (DNA):

CAAGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCGC

CATCACTTGCCGCGCAAGTCAGAGCATCGACACCTATTTAAATTGGTATCAGCACAAACCAG

OOAAAGCCCCTAAACTCCTGATCTAT

GCTGCATCCAAGTTGGAAGACGGGGTCCCATCAAGATTCAGTGGCAGTGGAXCTGGGACAGA

TTTCACTCTCACCATCAGAAGTCTGCAACCTGAAGATTTTGCAAGTTATTTCTGTCAACAGA

GCTACTCTAGTCCAGGGATCACTTTC

GGCCCTGGGACCAAGGTGGAGATCAAA (SEQ ID NO:685) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSAYVMHWTVRQAPGKGLENVSRIYPSGGITYYAD SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCARGILTGPNYWGQGTLVTVS S (SEQ ID NO:686) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTOCTTCCGGATTCACTTTCTCTGCTTACQTTATGCATTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTCGT

ATCTATCCTTCTGGTGGCATTACTTATTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGGGATT

TTGACTGGCCCAAACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NTO: 687) 132. 806C-M0062-FIO I-Variable (AA): QSALTQS PSASASLGASVKLTCSLS SGHSSYAIAWHQQQPEKGPQYLMKVNSDGSHTKGDGI PDRFSGSSSGAERYLTTSSTJQSEDEADYYCQTWGTGSWVFGGGTKLTVL (SEQ ID NO: 688) 1-Variable (DNA):

CAGAGCGCTTTGACTCAATCGCCCTCTGCCTCTGCCTCCCTGGGAGCCTCGGTCAAGCTCAC

CTGCAGTCTGAGCAGTGGGCACAGCAGCTACGCCATCGCATGGCATCAGCAGCAGCCAGAGA

AGGGCCCCCAGTACTTAATGAAGGTTAACAGTGATGGCAGCCACACCAAGGOGGGACGGGATC

CCTGATCGCTTCTCAGGCTCCAGCTCTGGGGCTGAGCGCTACCTCACCATCTCCAGCCTCCA

OTCTGAGGATGAGGCTGACTATTACTGTCAGACCTGGGGCACTGGCTCTTQGGTGTTCGGCG

GAGGGACCAAGCTGACCGTCCTA (SEQ ID NO:689) H-Variable (AA):

EVQLLESGGGLVQPGGSLRLSCAASGFTFSRYKMSWVRQAPGKGLEWVSYIYPSGGHTEYAD

SVKGRFTI SRDNSKNTLYLQMNSLRAEDTAVYYCAREREGTPDYWGQGTLVTVSS (SEQ ID NO:690) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

WO 2006/020706 WO 206/00706PCT/US2005!028413

TTGCGCTGCTTCCGGATTCACTTTCTCTCGTTACAAGATGTCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTAT

ATCTATCCTTCTGGTGGCCATACTGAGTATGCTGACTCCGTTAAAGGTCGCTTCACTATCTC

TAGAGACAACTCTAAGAATACTCTCTACTTGCAGATGAACAGCTTAAGGGCTGAGGACACGG

CCGTGTATTACTGTGCGAGAGAAAGG

GAAGGGACCCCTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 691) 133. 806C-M0062-G06 1-Variable (AA): QSVLTQPASVSGSPGQSITI SCTGTSSDDVGGYNYVSWYQQIIGKAPKLLIYDVINRPSOVS NRFSGSKSGNTASLTISGLQAEDEADYYCSSYASSGARVFGTGTKVTVL (SEQ ID NO: 692) 1-Variable (DNA):

CAGAGCGTCTTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTC

C-TGCACTGGAACCAGCAGTGACGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAAC

ACCCAGGCAAAGCCCCCAAACTCCTG

ATTTATGATGTCATTAATCGGCCCTCAGGAGTTTCTAATCGCTTCTCTGGGTCCAGTCTGG

CAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCA

GCTCATATGCAAGCAGCGGCGCTCGA

GTCTTCGGAACTGGGACCAAGGTCACCGTCCTA (SEQ ID NO:693) H-Variable (AA): EVQLLESGGGLVQPGGSLRLSCAASGFTFS

IYPMIWVRQAPGKGLEWVSVIYPSGGHTRYAD

SVKGRFTISRDNSKNTLYLQMNSLPAEDTAVYYCTRRVYS

SGSAYFDLWGRGTLVTVSS

(SEQ ID NSO:694) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGOTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATTTACCCTATGATTTGGTTCGCCAAGCTCCTG

GTAPAGGTTTGGAGTGGGTTTCTGTTATCTATCCTTCTGGTGGCCATACTCGTTATQCTGAC

TCCGTTAAAGGTCGCTTCACTATCTCTAOAGACAACTCTAA

GAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTOAGGACACAGCCGOTATTACTGTACGACACGGGTATATAQTAGTG

GTTCTGCCGTACTTCGATCTCTGGGGCCGTGGCACCCTGGTCACCGTCTCAAGC (SEQ ID NO: 695) 134. 806C-M0062-HOI 1-Variable (AA): QDIQMTQSPSTLSASVGDRVTITCRASQSVAGLLAW9FQQKPGKAPKLLISKAS

ILETGVPSR

FSGSGSGTEFTLjTITSLQPDDFATYYCQQYSFNSGTFGQGTRVEMK (SEQ ID NO :696) 1-Variable (DNA):

CAAOACATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTGGGAGACAGAGTCAC

CATCACCTGCCGGGCCAGCCAGAGTOTTGCTGGCTTGTTGOCCTGGTTTCACAGACC-GO

GCAAAGCCCCTAACTCCTCATCTCTAAGGCGTCTATTTTAGAGACTGGGGTCCCATAGG

TTCAGCGGCAOTGGATCTGGGACAGAATTCACTCTCACCATCACCAGCCTGCAGCCTGATGA

TTTCGCAACTTATTACTGCCACAATATAGTTTCAATTCTGGGACATTCGGCAGGACCA

GGGTGGAAA\TGAAA (SEQ ID NO:697) H-Variable (AA): EVQLLESGGGLVQPGGSLRLS CAASGFTFSMYKMAWVRQAPGKGLEWVSYIYPSGGYTYYAD WO 2006/020706 WO 206/00706PCT/US2005!028413 SVKGRFTISRDNSKNTLYLQMNSLRAEDTALYYCARVRDSAFDIWGQGTMVTVSS (SEQ ID NO:698) H-Variable (DNA):

GAAGTTCAATTGTTAGAGTCTGGTGGCGGTCTTGTTCAGCCTGGTGGTTCTTTACGTCTTTC

TTGCGCTGCTTCCGGATTCACTTTCTCTATGTACAAGATGGCTTGGGTTCGCCAAGCTCCTG

GTAAAGGTTTGGAGTGGGTTTCTTATATCTATCCTTCTGGTGGCTATACTTATTATGCTGAC

TCCGTTAAAGTCCTTCACTATCTCTAGAGACAACTCTAAGAATACTCTCTACTTGCAGAT

GAACAGCTTAAGGGCTGAGGACACCGCCTTGTATTACTGTGCGAGAGTAAGGGATTCCGCTT

TTGATATCTGGGGCCAAiGGGACAATGGTCACCGTCTCAAGC (SEQ ID NO: 699) W06161 Example 29: Exemplpa Tiel Antibodies [06171 Tables 5 (FIG. 3 7) and 6 (Fig. 3 8) list CDR regions of exemplary light and heavy chain variable regions which are listed herein. FIG. 39 (Table 9) list properties of some of the exemplary antibodies [0618] Some antibodies described herein include related variable domains.

The same variable domain can function with a different partner variable domain. For example, M0044-G06 and M0044-B05 share a HC variable domain, but have different LC variable domains, as do M0044-G07 and M0044-B05. Other antibodies that have the same HC variable domain include: HC 54(M0053-D12) and 19(M0044- HOS); HG 59(M40053-F05) and 19(M0044-H05); HG 72(M0054-11) and 25(M0045- B03); and BC 98(M0056-F1 1) and 57(M0053-E08). Some antibodies that have the same LC variable domain include: LC 1 14(M\0059-A06) and 106(M0057-H07); LC 130(M0062-Ell) and 106(M0057-H07); and LC 115(M0060-B02) and 12(M0044- F03). Some antibodies have the same GDR3. For example, the CDR3 sequence, QGGGGRAFDI, is present in MOOS 6-C04 and M0056-1702. The CDR3 sequence JAGGAYIILDY is present in M005 6-E08 and M006 1-C05.

[0619] In some cases, an antibody can include a non-gerinline residue. One or more of such non-germline residues can be modified, to restore the gerinline residue. Exemplary non-gerinline residues include: L45F (see, M0053-D06); V48F (see, M0062-C08); delta S53 (see, e.g.,M0045-B30l; M0047-D03; M0055- D12; M0061-A03); delta G54 (see, e.g.,M0053-A03); T571 (see, e.g.,M0046-B1O1); (see, e.g.,M0056-H-12); T87M (see, e.g. ,M0053-F06; M0055-E12; M0056- B08); V89L (see, e.g.,M0044-B308; M0047-DO1; M0060-1302; M0062-1101); V89M (see, e.g.,M0044-B 10; M0045-C12; M0045-D07; M0053-111; M0055-B12; M0055- E06; M0056-AO 1; M0056-G1 2; M0058-G03; M0059-A06; M0060-1101; M0061- WO 2006/020706 WO 206/00706PCT/US2005!028413 F07); V89T (see, e.g.,M0044-H07; M0046-All1; M0046-BlO; M0047-D03; M0055- C07; M0055-D03; M0055-G02); A93T (see, e.g.,M0045-A02; M0053-FO8; M0056- H12; M0058-E09; M0059-A02; M0061-C06; M0062-G06); and T107K (see, e.g. ,M0045-B 03).

[0.6201 Examle 30: Sequence of DX-2220 Antibody [0621] DX-2220 is a full length, IgGi, germlined human anti-Tiel antibody EAb The sequence of DX-2220 is as follows: DX-2220 Light Chain Amino Acid Seqiuence:

DIQMTQSPSSLSASVGDRVTLTCRASQGIGHYLAWYQQKPGKVPKLLI

YTASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQFNSYPTHT

FGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV

QWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYA

CEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:700) DX-2220 Heavy Chain Amino Acid Sequence:

EVQLLESGGGLVQPGGSLRLSCAASGFTFSMYGMVWVRQAPGKGLE

WVSVISPSGGNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV

YYCARAPRGYSYGYYYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSG

GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV

VTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

LLGGPS VFLFPPKPKDTLMISRTPE VTC V VVD VSHEDPE VKFN WY VDG

VEVHNAKTKPR.EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA

LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDI

AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS

CSVMHEALIJNIYTQKSLSLSPGK (SEQ ID NO:701) An explar9y DX-2220 Light Chain Nucleotide Seqjuence: ggcgtgcactctgacatccagatgacccagtctccatcctccctgtctgcatctgtaggagacagagtca ccatcacttgccgggcgagtcagggcattggccattatttagcctggtatcagcagaaaccagggaaagt tcctaagctcctgatctatactgcatccactttgcaatcaggggtcccatctcggttcagtggcagtgga WO 2006/020706 WO 206/00706PCTII§S2005/028413 agtftaatagttaccctcacaccttcggccaagggacacgactggagattaaacgaactgtggctgcacc atctgtcttcatcttcccgccatctgatgagcagttgaaatctggaactgcctctgttgtgtgcctgctg aataacttetatcccagagaggccaaagtacagtggaaggtggataacgccctccaatcgggtaactccc aggagagtgtcacagagc-aggacagcaaggacagcacctacagcctcagcagcaccctgacgctgagcaa agcagactacgagaaacacaaagtctacgcctgcgaagtcacccatcagggcctgagctcgcccgtcaca aagagcttcaacaggggagagtgttaataa (SEQ ID) NO:702) An exemnplary DX-2220 Heavy Chain Nucleotide Sequence: gagtatgtggcgtggttgtactggtctagct cttgcgctgcttccggattcactttctctatgtacggtatggmtgggttcgccaagctcctggtaaagg tttggagtgaggtttctgttatctctccttctggtggcaatactggtatgctgactccgttaaggcgc ttcactatctctagagacaactctaagaatactctctacttgcagatgaacagcutaagggctgaggaca ctgcagtctactafttgcgagagcccacgtggatacagctatggtactactactggggccagggaac cctggtcaccgtctcaagcgcctccaccaagggcccatcggtcttcccgctagcaccctcctccaagagc acctctgggggcacagcggccctgggctgcctggtcaaggactacttccccgaaccgtgagt~cgt ggaactcaggcgccctgaccagcggcgtccacaccttcccggctgtcctacagtcctccggactctactc cctcag~cagcgtagtgaccgtgccctccagcagcttgggcacccagacctacatctgcaacgtgaatac aagcccagcaacaccaaggtggacaagaaagttgagcccaaatcttggacaaaactcacacatgcccac cgtgcccagcacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaaggacaccct catgatctcccggaccectgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtaag ttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaaca gcctcgggtacteccgcteacgatgtatgagatcat caaggtctccaacaaagccctcccagccccatcgagaaaaccatctccaaagccaaagggcagccccga gaaccacaggtgtacaccctgcccccatccgggatgagctgaccaagaaccaggtcagcctgacctgcc tggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaacta caagaccacgcctcccgtgctggactccgacggctccttcttcctctacagcaagctcaccgtggacaag agcaggtggcagcaggggaaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgc agaagagcctctccctgtctccgggtaaatga (SEQ ID NO:703) WO 2006/020706 PCT/US2005/028413 [06221 Example 31 DX-2220 Slows Colorectal Cancer Xenograft Tumor Progression in Nude Mice [0623] Mice (nu/nu) were implanted subcutaneously with 5 x 106 SW-480 (colorectal cancer) cells. After 12 days, when tumors reached approximately 100-200 mg, the mice were separated into 5 groups and treated with the following agents (or left untreated): 1- Untreated 2- Vehicle (PBS) 3- Cisplatin (4mg/kg/, IV, q2d x 5 times) 4- A2-SV (negative control antibody 10 mg/kg, IP, q2d x 14 times) DX-2220 (anti-Tie-1 antibody 10 mg/kg, IP, q2d x 14 times) [0624] Throughout the study, the length and width of any tumors that developed were measured in millimeters using calibrated vernier calipers, where L is the longer of the two dimensions. When applicable, tumor weight in milligrams was calculated by using the formula associated with a prolate ellipsoid: M (L x

W

2 Table 7 shows the average weights (in mg) of the tumors for each of the groups. A2-SV is an isotype matched (IgG1) negative control antibody that binds strepavidin.

Table 7: Tumor Weight (mg) Days after Group 1 Group 2 Group 3 Group 4 Group Cell Injection Untreated Vehicle Cisplatin A2-SV DX-2220 57 95 48 111 112 9 88 117 69 120 137 12 118 139 137 149 139 153 203 185 159 145 19 202 309 207 308 186 22 316 431 235 350 224 26 403 532 310 405 292 28 449 587 363 526 328 [0625] The results from the animal study shown in Table 7 are depicted graphically in FIG. 5. DX-2220 slowed tumor progression by 44% when compared to WO 2006/020706 PCT/US2005/028413 vehicle (PBS)-treated control animals. In addition, DX-2220 was as efficacious as the chemotherapeutic control (cisplatin).

[06261 Example 32: Production and Testing of Germlined Anti Tiel E3 Fab and IgG for Binding to Human and Mouse Tiel in BIACore [0627] Expression and Purification. Fabs were produced in the E. coli strain, TG1, using an expression vector containing a PelB leader sequence for secretion into the periplasm. Under the conditions used for induction (overnight incubation at in the presence of 1 mM IPTG), the majority of the secreted Fab was localized in the culture medium rather than the periplasm. The secreted Fab was recovered by adding protein A resin to the clarified culture medium. This protein A resin was then packed into a column to facilitate washing, with PBS, and elution with 50 mM sodium phosphate, 150 mM NaC1, pH 2.5. The pH was brought to approximately neutral by addition of one half volume of 1 M HEPES before buffer exchange into PBS The concentration of the purified germlined E3 (DX-2220) Fab was determined using

OD

2 80 1.4 1.0 mg/ml.

[0628] The IgG was produced transiently in HEK293T cells using either LIPOFECTAMINETM 2000 or GENEJUICETM as the transfection reagent. Antibody could be produced from cells harvested at 72, 144, and 216 hours post transfection.

Purification of the IgG from the conditioned culture media essentially followed the same protocol outlined above for the Fab purification. The concentration of the purified IgG was determined using OD 280 1.4 1.0 mg/ml.

[0629] For preclinical animal studies, IgG were purified using a two-step purification procedure, initially with protein A chromatography subsequently followed by ion exchange chromatography (IEX). Purified IgGs were subjected to biochemical analyses to assess endotoxin levels, leached protein A, DNA content, and host cell proteins.

[0630] Biochemical Analysis [0631] Affinity analysis of the Fab and IgGs was performed using surface plasmon resonance using a BIAcore 3000 instrument. For this analysis both dimeric (Tiel-Fc fusion protein) and monomeric (Tiel-HIS) versions of the extracellular WO 2006/020706 PCT/US2005/028413 domain of the Tiel were used. The sensor chips used in these experiments were (dextran-coated) which allow immobilization of proteins to the chip via standard amine coupling chemistries. The concentration of flowed antibody was determined using a surface plasmon resonance based method. Using a high-density protein A sensor chip, under mass transport limited conditions, the response signal is dependent only on the concentration of the antibody in the sample under test. This approach allows a precise determination of the antibody concentration, a parameter important for accurate determination of the KD.

[0632] 470 RUs of Tiel HIS protein were coated on a CM5 sensor chip and 100, and 500 nM of the Fab flowed over the chip at four different flow rates 50 and 80 al/s), rates in which the system is not mass transport limited. Kinetic data was typically determined using a range of analyte concentrations and three different chip coating densities. The data from the lowest coating density that gave a good signal was typically chosen, this was often in a range from 50-100 RUs. Using such low coating densities allowed the sensor curves to be fit using BIAEVALUATIONTM 3.0 software to a 1:1 model, often even when using a bivalent analyte (IgG or Tiel-Fc fusion protein). For bivalent analytes, when fit to a 1:1 model was not possible, the curves were fit using a 2:1 model. The generated data is shown in Table 8.

Table 8: Kinetic data for binding of DX-2220 Fab and IgG to human Tiel-Fe fusion protein Fab Human Tiel-Fc Kon Kofi(l/s) KD (nM) (I/Ms) Fab Parental 8.26E+03 4.47E-05 5.4 Fab Germlined 9.30E+03 4.41E-05 4.7 IgG Parental 6.19E+03 3.61E-05 5.8 IgG Germlined 7.09E+03 3.67E-05 5.2 [0633] The anti-Tiel antibodies described here bind to both human and mouse Tiel molecules. The binding of the anti-Tiel Fab to mouse Tiel-Fc fusion protein was compared with the binding of the anti-Tiel Fab to human Tiel-Fc fusion protein.

In both of these experiments the Tiel-Fe fusion protein was immobilized on the sensor chip and the anti Tie-1 Fab served as the analyte. Under these experimental WO 2006/020706 PCT/US2005!028413 conditions the anti-TieI Fab has very similar KD nM) values for both the human and mouse Tiel-Fc fusion proteins (Table Under conditions that are likely to mimic those used in the animal efficacy experiments, i.e. Tiel-Fc immobilized to the sensor chip and anti-Tiel used as the analyte, the measured KD was 0.2 nM.

This greater than 10 fold increase in affinity represents an avidity effect that results from a bivalent molecule (anti-Tie1) binding to a multivalent surface (immobilized Tiel-Fe).

[0634] Example 33: Sequence of DX-2240: Germlined F Allotyped E3 Antibody [0635] DX-2240 (Light, heavy variable, constant). Variable region: DIQMTQSPSSLSASVGrRVTITCRASQGIGHYLAWYQQKPGKVPKLLIYTAS

TLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQQFNSYPHTFGQGTRLETK

Light constant:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS

QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTIQGLSSPVTKSFNRGEC

SEQ ID NO 724 light chain (variable constant) [06361 DX-2240 Heavy variable:

EVQLLESGGGLVQPGGSLRLSCAASGFTFSMYGMVWVRQAPGKGLEWVSVIS

PSGGNTGYADSVKGRFTISRDNSKTLYLQMNSLREDTAVYYCARAPRGYSYGYYY

WGQGTLVTVSS

Heavy constant (CHi, Hinge, CH2, CH3):

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT

FPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTC

PPCPAPELLGCPSVFLFPPKPKDTLMTSRTPEVTCVVVDVSHEDPEVKFNWYVDGVE

VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAP IEKT ISKAK GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP SDAVEWESNGQPENNYKTTPPV

LDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO:723 heavy chain (variable constant) WO 2006/020706 PCT/US2005/028413 [0637] The light chain can optionally further include the following signal sequence: Light signal sequence: MGWSCIILFLVATATGVHS (SEQ ID NO:729).

The heavy chain can optionally further include the following signal sequence MGWSCIILFLVATATGAHS (SEQ ID NO:730) [06381 Example 34: Characterization ofDX-2240 from a GS-CHO Cell Line [0639] The anti-Tiel antibody DX-2240 (light and heavy chain germlined and f-allotype) antibodies was produced in HEK293T cells. A stable CHO cell line expressing DX-2240 was generated. Using standard molecular biology cloning techniques, the light and heavy chains from DX-2240 was inserted into glutamine synthase (GS) vector system available from Lonza Group Ltd. CH (see, Clark et al. (2004) BioProcess International 2(4):48-52; Barnes et al. (2002) Biotech Bioeng.

81(6):631-639). The single vector constructs containing the light and heavy chains respectively, were then combined to create a single, double gene vector. This DNA construct was then used to generate stable CHO cell lines, grown under MSX selection pressure. One of these clones was then expanded and a single 40L stirred bioreactor seeded and run over the course of 12 days. Following the completion of this run, 36 liters of clarified CHO culture supernatant was loaded onto a 200ml Protein A XK50 column. The column was first washed with PBS pH 7.4, followed by a PBS+0.4M NaC1 pH7.4 wash, and then with a final wash of PBS pH 7.4 prior to the low pH elutions. DX-2240 IgG1 was eluted first with 0.1M NaCitrate pH followed by the same buffer at pH 3.0. A sharp protein peak eluted at pH 3.0. The pH elution contained a predominant peak representing DX-2240, with a low level of contaminants eluting shortly thereafter. A high degree of purity of DX-2240 was obtained.

[06401 Example 35: Sequence Optimization of Nucleic Acid Encoding DX- 2240 Antibody [0641] To improve expression of DX-2240 in CHO cells, a synthetic gene with optimized codons and sequences was engineered. The strategies include codon optimization, CpG island and splice site analysis. An optimized DX-2240 sequence WO 2006/020706 WO 206/00706PCTII§S2005/028413 nas ueen syritnesizeci anct retormaited into the glutamine, synthase (GS) vector system.

The exemplary codon optimized sequence is as follows: [0642] DX-2240-heavy chain (SEQ ID NO:725) signal sequence

ATGGGCTGGTCCTGTATCATCCTGTTTCTGGTGGCCACCGCCACCGGCGCTCACTCT

GAGGTGCAGCTGCTGGAGTCTGGCGGCGGACTGGTGCAGCCTGGCGGCTCTCTGAGA

CTGTCTTGTGCCGCCTCCGGCTTCACCTTCTCC ATGTACGGCATGGTG TGGGTGAGGCAG GCCCCTGGCAAGGGCCTGGAGTGGGTGTCC GTGATCTCTCCTTCTGGCGGCAATACCGGC TACGCCGACTCTGTGAAGGGC CGGTTCACCATCTCCCGGGACAACTCCAAGAACACCCTG TACCTGCAGATGAACTCCCTQAciAGCCGAGGATACCGCCGTGTACTACTGTGCCAGA GCC CCTAGAGGCTACTCCTACGGCTACTACTAC TQOQQCCAGGGCACCCTGGTGACCGTGTCC TCTGCTTCTACCAAGGGCCCTTCCGTGTTTCCTCT GGCCCCTTCCTCCAAGTCTACCTCT

GGCGGCACCGCCGCTCTGGGCTGCCTGGTGAAGGACTACTTCCCTGAGCCCGTGACAGTG

TCCTGGAACTCTGGCGCCCTGACCTCCGGCGTGCACACCTTCCCTGCTGTGCTGCAGTCC

TCCGGCCTGTACTCTCTGTCCTCCGTGGTGACAGTGCCTTCCTCTTCTCTGGGCACCCAG

ACCTACATCTGTAACGTGAACCACAAGCCCTCCAACACCAAGGTGGACAAGCGGGTGGAG

CCTAAGTCCTGTGACAAGACCCACACCTGCCCTCCTTGTCCTGCCCCTGAGCTGCTGiGC

GGACCTTCTGTGTTCCTGTTCCCCCCCAAGCCTAAGGACACCCTGATGATCTCCAGGACC

CCTGAGGTGACCTGTGTGGTGGTGGACGTGTCTCACGAGGATCCCGAGGTGAAGTTCAAC

TGGTACGTGGACGGCGTGGAGGTGCACACGCCAJAGACCIAGCCTAGGGAGGAGCAGTAC

AACTCCACCTACCGGGTGGTGTCTGTGCTGAkCCGTGCTGCACCAGGATTGGCTGAACGGC

AAGGAGTACAAGTGTAAGGTGTCCAACAAGGCCCTGCCTGCCCCTATCGXJXJGACCATC

TCCAAGGCCAAGGGCCAGCCTAGAGAGCCTCAGGTGTACACCCTGCCTCCTTCCAGGGAG

GAGATGACCAGAACCAGTGTCCCTGACCTGTCTGGTGAAGGGCTTCTACCCTTCCGAT

ATCGCCGTGGAGTciciAGTCTA2-TGCCAGCCCGAGAACAACTACAGACCACCCCTCCT

GTGCTGGACTCTGACGGCTCCTTCTTCCTGTACTCCAAGCTGACCGTGGACAAGTCCAGA

TGGCAGCAGGGCAACGTGTTCTCCTGCTCCGTGATGCACGAGGCCCTGCACAATCACTAC

ACCCAGAAGTCCCTGTCTCTGTCCCCCGGCAAGTGATGAGAATTC

DX-2240 Light chain (SEQ ID NO:726): Signal sequence

ATGGGCTGGTCCTGTATCATCCTGTTTCTGGTGGCCACCGCCACCGGCGTGCACTCT

GACATCCAGATGACCCAGTCCCCTTCCTCTCTGTCTGCCTCTGTGGGCGACAGAGTGACCATC

ACCTGTAGAGCCTCTCAGGGCATCGGCCACTACCTGGCCTGGTATCAGCAGAAGCCTGGCAAGGTGCCC

AAGCTGCTGATCTACACCGCCTCCACCCTGCAGTCTGGCGTGCCTTCCAGATTCTCCGGCTCTGGCTCT

GGCACCCATTTCACCCTGACCATCTCCTCCCTGCAGCCTCACGATGTGGCCACCTACTACTGC

246 WO 2006/020706 PCT/US2005/028413 CAGCAGTTCAACTCCTACCCCCACACC TTCGGCCAGGGCACCAGACTGGAGATCAAG

AGAACCGTGGCCGCTCCTTCCGTGTTCATCTTCCCCCCTTCCGACGAGCAGCTGAAGTCTGGCACCGCC

TCTGTGGTGTGTCTGCTGAACAACTTCTACCCCCGGGAGGCCAAGGTGCAGTGGAAGGTGGACAACGCC

CTGCAGTCCGGCAATTCCCAGGAGTCTGTGACCGAGCAGGACTCCAAGGACAGCACCTACTCCCTGTCC

TCTACCCTGACCCTGTCCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGTGAGGTGACCCACCAG

GGCCTGTCCTCTCCTGTGACCAAGTCCTTCAACCGGGGCGAGTGCTGATGAGAATTC

[0643] Example 36: Pharmacokinetic and Biodistribution Studies in Mice [0644] The in vivo pharmacokinetics and stability of DX-2240 (produced in HEK293T cells) was determined by iodinating the protein on available tyrosine residues and measuring plasma clearance and stability in mice after a single intravenous dose. Samples were radio-iodinated by the indirect method using the IODO-GENT" reagent (method from Pierce, and described by Chizzonite et al.

((1991)J. Immunol. 147:1548; (1992) J. Immunol. 148: 3117). Samples were incubated with the 1 25 I-NaI solution for 9 min at which time tyrosine (10 mg/mL, a saturated solution) was added to quench the reaction. After about 15 min a 5 tl aliquot was removed as a standard for counting. For each labeling reaction, the 1 25 I-labeled material (approx. 0.6 mL) was purified using a single 5 mL D-salt 1800 polyacrylamide column (Pierce). Columns were washed with 25 mM Tris, 0.4 M NaCI, pH 7.5 containing 2.5% HSA to block nonspecific sites then extensively with the same buffer minus the HSA. Samples were applied in and columns were eluted with a series of 0.3 mL aliquots. Recovery of applied activity in all protein fractions was 75% and the total recovery of applied activity was 90%. The fractions containing peak levels of labeled protein were pooled for animal injections. To prepare the injectate, the pool was diluted with Tris buffer (pH so that the 100 pl injection volume contained about 10 ptg of labeled material.

[0645] Solutions containing the radio-labeled compounds were administered to all mice by injection into the tail vein. At predetermined times post-administration animals were sacrificed and blood samples were taken for analyses. Time points tested after injection of radio-labeled compounds were: approximately 0, 7, 15, 30 and minutes, 4h, 8h, 16h, 24h, 48h and 72h after injection. Four animals were sacrificed for each time point. At sacrifice, 0.5 mL aliquots of blood were collected into anticoagulant (0.02 mL EDTA) tubes. Plasma was separated from cells by WO 2006/020706 PCT/US2005/028413 centrifugation and the plasma fraction was divided into two aliquots, one frozen and one stored at 4 0 C for immediate analysis. [0646] Analyses included gamma counting of all samples. In this single dose i.v. study, DX-2240 exhibited a relatively short-half life in mice of less than 5 hours. Analysis of the biodistribution of DX- 2240 in these mice revealed some accumulation of this antibody, at 30 minutes, in the lungs (12.85% ID/g), spleen (7.44% ID/g), kidney (8.34% ID/g), liver (5.42% ID/g) and heart (4.04% ID/g). DX-2240, due to its interaction with Tiel on the surface of endothelial cells, may accumulate in areas of high vascularization such as the lung.

Therefore, multiple administrations of DX-2240 may be required to achieve an effective steady-state level of this antibody in the serum of mice. ELISA on ocular bleeds following three every other day dosings, as well as terminal bleed samples from tumor-bearing mice treated with DX-2220, were performed. In each case, levels of DX-2220 in the serum averaged 500 gg/ml, suggesting that despite a short serum half-life in mice, an effective steady-state level of this antibody can be achieved following just three doses of DX-2220.

[0647] In addition, SEC-HPLC analysis of plasma samples to assess the in vivo stability of DX-2240 was performed. Instability of DX-2240 in mouse could have contributed to the fast clearance of this compound from the serum. SEC-HPLC analysis was performed for two plasma samples at time points at 0 min, 30 min, min, 24h and 72h. The analysis of the radio-labeled DX-2240 showed that this compound is stable in vivo both to degradation and to interactions with plasma components. Therefore, the relatively rapid half-life of DX-2240 in mice is not due to degradation of this compound.

r06481 Example 37 DX-2220 Slows Lung Cancer Xenograft Tumor Progression in Nude Mice [0649] The effect of DX-2220 on tumor growth in mice bearing human lung cancer xenografts was tested. For these studies, LNM35 cells were injected subcutaneously in the lateral thorax of athymic nude mice. Four days after tumor cell implantation, treatment was initiated with DX-2220 or A2-SV (negative control antibody) at a dosage of 20 mg/kg, three times a week. Tumor sizes were measured at day 6, 8 and 10 post antibody treatment.

WO 2006/020706 PCT/US2005/028413 [UO3uj AS snown im rgure o, DX-2220 significantly slowed tumor progression in this mouse xenograft model (p=0.037). In addition, mice treated with DX-2220 did not exhibit any significant loss in body weight. These data coupled demonstrate that DX-2220 possesses significant tumor growth inhibitory activity in vivo.

[06511 Example 38: DX-2220 Slows Tumor Progression in Nude Mice In addition to the in vivo studies presented above, four additional mouse xenografts studies were performed. These studies were conducted either according to the protocols used in the SW-480 or LNM35 study. The results from these studies are listed below.

LLC (mouse lung carcinoma) 20% inhibition day 14 after start of treatment PC-3 (human prostate cancer) 24% inhibition day 28 after start of treatment #3 (human lung carcinoma) 30% inhibition day 21 after start of treatment Colo205 (human colorectal cancer) no effect [0652] These results suggest that the E3 anti-Tiel antibody has an effect on a variety of tumor types, indicating broad therapeutic applicability.

[06531 Example 39: Immunohistochemical Analysis of Normal Tissues [0654] A series of immunohistochemical analyses on a series of nonmalignant normal human tissues to assess potential areas ofimmunoreactivity of the E3 anti-Tiel antibody was performed. Antibody titration experiments were conducted on both cryostat and paraformaldehyde fixed sections of select normal human tissues with biotinylated DX-2220 and an IgG isotype control antibody to determine the preferred tissue preservation conditions as well as optimal concentration of the antibody that would result in minimal background and maximal detection of signal. A concentration of 20 pg/ml for the primary antibody was selected WO 2006/020706 PCT/US2005/028413 for the study with biotinylated DX-2220 and the biotinylated IgG isotype control antibody used as the primary antibodies, and the principal detection system consisting of Streptavidin HRP with DAB as the chromagen. Tissues also were stained with the positive control antibodies (anti-CD31 and anti-vimentin) to ensure that the tissue antigens were preserved and accessible for immunohistochemical analysis. Only tissues that were positive for CD31 and vimentin staining were selected for the remainder of the study. The negative control consisted of performing the entire immunohistochemical procedure on adjacent sections in the absence of primary antibody. Slides were imaged with a DVC 1310C digital camera coupled to a Nikon microscope.

[0655] The negative control (no primary antibody) slides showed occasional faint background staining within renal tubular epithelium and occasional granulocytes, but was uniformly negative in all other cell types, including the positive control cell line (HMEC, Human Microvascular Endothelial Cells) and positive control colon cancer. The IgG isotype control antibody showed faint background staining of granulocytes, macrophages, adrenal cortex, renal tubular epithelium, fallopian tube epithelium, hepatocytes, Leydig cells, and thyroid. The positive control cell line (HMEC) and positive control colon cancer sample showed either no staining or background staining.

[0656] DX-2220 demonstrated moderate membrane staining within the HMEC cell line, and staining of macrophages, some carcinoma cells, and endothelial cells within the colon cancer positive control samples. Within normal tissues, the antibody showed faint to moderate staining of macrophages, microglia in the brain, squamous epithelium of the cervix, faint staining of skeletal muscle, islets of Langerhans, and placental endothelium. These observations are consistent with low level expression of Tiel in some endothelial, hematopoietic and epithelial tissues, as anticipated from previous reports. The islets of Langerhans staining were unexpected and should be investigated further. Most other faint staining was similar to that seen with the IgG isotype control. If the background from the IgG isotype control is subtracted from the analysis of DX-2220, the majority of tissues were negative, including adrenal, bladder, blood, bone marrow, neurons, breast, colon, endothelium, eye, fallopian tube, heart, kidney, liver, lung, lymphocytes, ovary, exocrine pancreas, WO 2006/020706 PCT/US2005/028413 pituitary, prostate, skin, spinal cord, spleen, seminiferous epithelium of the testis, thymic lymphocytes, ureter, and uterus.

r06571 Example 40: Platelet Studies [0658] It has been reported that Tiel is expressed on platelets (Tsiamis et al.

(2000) J Vasc. Res. 37(6):437). The possibility of platelet immunoreactivity with the E3 anti-Tiel antibody was investigated by FACs analysis and immunoprecipitation studies. DX-2200 did not show significant binding to platelets, nor did it immunoprecipitate Tiel from platelet extracts. In addition, the effect of DX-2200 and DX-2210 on platelet agglutination and aggregation was investigated. Ristocetin, a cofactor that induces platelet agglutination by mediating the binding ofvon Willebrand factor (vWF) to platelet membrane glycoprotein GPIb (CD42), was used as a positive control for platelet agglutination. Antibodies to CD9 were used as a positive control to activate platelets and induce platelet aggregation, with kinetics and extent comparable to physiological agonists such as thrombin (reference). Neither the DX-2200 nor its light chain germlined variant DX-2210 induced platelet agglutination or aggregation.

[06591 Example 41: Chord Blood Stem Cell Studies [0660] To evaluate the binding characteristics to blood progenitor cells (stem cells), FACS analysis with the anti-Tiel antibody (or the appropriate negative control antibody) on G-CSF mobilized peripheral blood cells and with bone marrow cells was performed. Briefly, cells were blocked with 10% heat-inactivated human AB serum/ 2% mouse serum. Binding was initiated with biotinylated DX-2220 or biotinylated A2 negative control antibody. After washing the cells, primary antibodies were detected using FITC-labeled streptavidin. Following an additional 30 minute incubation period, remaining erythrocytes were lysed, and the resulting cell pellet after centrifugation was resuspended in PBS prior to FACS analysis. Data acquisition was performed on a FACSCantoTM (Becton-Dickinson) using FacsDivaTM software.

Active gating on SSC/CD45 was used. Progenitor cells were gated on CD45 CD34 cells and were acquired automatically with at least 100,000 CD45 CD34 counted.

WO 2006/020706 PCT/US2005/028413 [0661] While the expression of Tiel has been reported on certain hematopoietic malignancies, this experiment demonstrated that neither the negative control IgG A02, nor the E3 anti-Tiel antibody DX-2220, positively stained CD45 CD34 blood progenitor cells. This finding supports the hypothesis that targeting Tiel with E3 should have no deleterious effects on stem cells, unlike certain chemotherapeutic agents.

[06621 Example 42: In Vitro Hematopoiesis Studies: [0663] The effect of anti-Tiel antibodies (DX-2220 and DX-2240) on human myeloid and erythroid progenitors was evaluated using methylcellulose-based in vitro colony assays and megakaryocyte progenitors using collagen-based in vitro assays.

Neither DX-2220 nor DX-2240 inhibited colony formation in the particular conditions of this in vitro assay at concentrations up to 100 ptg/ml.

[0664] The effect of the E3 anti-Tiel antibody DX-2240 on the recovery of the mouse hematopoietic system using an in vivo myeloablation model was evaluated.

Mice were injected with 5-FU on day 0 and then received either DX-2240 or a negative control antibody. At various time points following injection (days 2, 4, 6, 8, 12 and 14), 4 mice were sacrificed from control and treated groups and peripheral blood and femurs were harvested. The peripheral blood and femoral cells were analyzed to determine the following: Total nucleated cells per femur Frequency of bone marrow colony forming cells for both myeloid and erythroid progenitors Total hematopoietic CFC per femur Total megakaryocytic CFC per femur Total white blood cell count and differential analysis of mature cells [0665] DX-2240 had no effect on the recovery of the mouse hematopoietic system following 5-FU administration. This supports the in vitro findings that DX-2240 possesses no hematological toxicities under these assay conditions. Thus, it is particularly useful as a therapeutic as it will not interfere with 252 WO 2006/020706 PCT/US2005/028413 IIUlluxil UliitiupuitLI UIi unIuus required to maintain red cell and lymphocyte production.

[0666] The anti-Tiel antibody was also evaluated for its effect on implanted tumors. Tumor cells were injected subcutaneously into the abdominal region of mice (Balb/C nu/nu female mice, 5-6 weeks old). The following tumor cells were tested: a lung carcinoma (mouse syngeneic Lewis lung carcinoma human lung carcinoma LNM35; an aggressive human colon carcinoma clone (SW480R).

Treatments with anti-Tiel antibody were initiated 4-6 days post-implantation. The anti-Tiel antibodies or a control antibody (the A2 anti-streptavidin antibody) were administered intraperitoneally at 20 mg/kg every second day. Tumor volume was measured every second day and calculated as 0.5 x height x width x depth.

[0667] The E3 anti-Tie antibody (also termed DX-2240) inhibits primary tumor growth of LLC (about a 20% effect, p 0.078; ANOVA, single factor test) and In one study, this anti-Tiel antibody inhibited primary tumor growth by (most responsive). (Doubling of the antibody dose with administration only twice a week rather than every second day resulted in only a modest effect on primary tumor growth). The SW480R tumor was not responsive to the antibody treatment under these conditions. As described in Example 34, the antibody was effective for inhibiting tumor growth of SW480 cells rather than the derivative SW480R cells).

[0668] Histological analysis of tumor sections from the experiment in which inhibition was observed indicated that blood vessels in anti-Tiel antibody treated tumors have a distinct morphology even though blood vessel density may not be altered. In anti-Tie antibody treated tumors, the vessels form septa-like structures in between lobuli of tumor cells. These tumors also have more necrosis than control antibody treated tumors. The distribution of smooth muscle cells (as detected by antismooth muscle actin antibody staining) was also altered. The lymphatic vessels in anti-Tiel antibody treated tumors were also more dispersed, somewhat dilated and in several instances composed of adjacent lumina clustered together in a string. These observations indicate that this anti-Tie antibody has a distinctive effect on tumor necrosis and vessel organization within the tumor.

06691 Example 43: Evaluating Combination Theranies 43 Evaluatin n [0670] An animal model can be used to evaluate combination therapies. For example, the combinations (provided intraperitoneally) can be tested for ability to modulate tumor growth in female NCr nu/nu mice with xenografts of HT29, COL0205, or PC3. The following are some exemplary test regimes: Compound Dose for HT29 and Schedule COL0205 xenografts PBS 0.2ml/20g Q2Dx14;D4 DX-2230 10 mg/kg/inj Q2Dx14;D4 DX-2230 avastin 10 mg/kg/inj; 2.5 Q2Dx14;D4, Q3Dx3;D3 mg/kg/inj avastin 2.5 mg/kg/inj Q3Dx3;D4 A2-SV (control) 10 mg/kg/inj Q2Dx14;D4 [0671] Another regime is as follows: Compound Dose for PC3 xenografts Schedule PBS 0.2ml/20g Q2Dxl4;D4 DX-2230 10 mg/kg/inj Q2Dx14;D4 DX-2230 10 mg/kg/inj; Q2Dxl4;D4, QDxl;D4 cyclophosphamide 150 mg/kg/inj cyclophosphamide 150 mg/kg/inj QDxl;D4 A2-SV (control) 10 mg/kg/inj Q2Dx14;D4 [0672] A2-SV is the control anti-streptavidin antibody. Twelve animals can be used in each group. Clinical signs, mean group weights are evaluated every day.

Individual body weights and tumor burden are evaluated twice weekly. At study termination, tissue samples can be obtained from tumors, liver, lung, spleen, heart, axial node, kidney, and uterus.

254 r [0672a] The foregoing embodiments are illustrative only of the principles of the Sinvention, and various modifications and changes will readily occur to those skilled in

(N

the art. The invention is capable of being practiced and carried out in various ways and in other embodiments. It is also to be understood that the terminology employed herein is for the purpose of description and should not be regarded as limiting.

00 [0672b] The term "comprise" and variants of the term such as "comprises" or 0 "comprising" are used herein to denote the inclusion of a stated integer or stated integers but not to exclude any other integer or any other integers, unless in the tt context or usage an exclusive interpretation of the term is required.

C [0672c] Any reference to publications cited in this specification is not an admission that the disclosures constitute common general knowledge in Australia.

Other embodiments are within the following claims: [Text continues on page 255] 254a

Claims

2. The method according to claim 1, wherein the heavy chain immunoglobulin variable domain sequence comprises i) a HC CDR1 that includes (AGSIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ ID NO: 118); ii) a HC CDR2 that includes (SEQ ID NO: 160); and iii) a HC CDR3 that includes A-P-R-G-Y-S-Y-G-Y-Y-Y (SEQ ID NO:727). 255
3. The method according to claim 1, wherein the light chain immunoglobulin Svariable domain sequence comprises: i) a LC CDRI that includes R-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN)- S(STIRH)-XI-(SYWNH)-(LV)-(ASN) (SEQ ID NO:132), wherein Xl can be serine or absent; ii) a LC CDR2 that includes Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)- (LWRH)-(TIY) (SEQ ID NO:161); and 00 Siii) a LC CDR3 that includes Q-Q-F-N-S-Y-P-H (SEQ ID NO:728). In
4. The method according to claim 1, wherein the amino acid sequences of the HC variable domain sequence comprises CDRI, CDR2, and CDR3 sequences from the E3 clone, and the LC variable domain sequence comprises CDR1, CDR2, and CDR3 sequences from the E3 clone. The method according to claim 1, wherein the protein comprises the HC and/or LC immunoglobulin variable domains of the E3 antibody, (ii) HC and/or LC immunoglobulin variable domain sequences that are at least 85% identical to the HC and LC immunoglobulin variable domains of the E3 antibody, respectively, or (iii) HC and/or LC immunoglobulin variable domain sequences that are encoded by a nucleic acid that hybridizes with high stringency to a nucleic acid encoding a HC or LC variable domain of E3, respectively.
6. The method according to any one of claims 1-5, wherein the protein is a Fab.
7. The method according to any one of claims 1-6, wherein the protein is an IgG.
8. The method according to claim 1, wherein the protein competes with E3, G2, p- Al, p-AlO, p-Bl, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-AlO, s-HI, s-A2, s- B2, s-B9, s-C10, s-C2, s-C7, s-D 1, s-E11, s-Gl0, or s-H4 for binding to Tiel or binds to an epitope that overlaps an epitope that is recognized by E3, G2, p- Al, p-AlO, p-Bl, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-HI, s-A2, s- B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-El s-G10, or s-H4or that has at least one, two or three residues in common with an epitope that is recognized by E3, 256 G2, p-Al, p-A10, p-B1, p-B3, p-C6, p-D12, p-F3, p-F4, p-G3, s-A10, s-H1, s- r A2, s-B2, s-B9, s-C10, s-C2, s-C7, s-D11, s-E11, s-G10, or s-H4.
9. The method according to any one of claims 1-8, wherein the protein has one or more of the following properties: at least one of the variable domain sequences comprising at least two CDR of the E3 antibody; ,1 at least one of the variable domain sequences comprising CDR sequences C N at least 85% identical, in sum, to the CDRs of the corresponding variable domain of the E3 antibody, at least one of the variable domains is at least 85% identical to the corresponding immunoglobulin variable domains of the E3 antibody, the protein competes with E3 for binding to Tiel or binds to an epitope that overlaps the epitope bound by E3 on Tiel, and the protein comprises a domain that is encoded by a nucleic acid that hybridizes with high stringency to a nucleic acid encoding a HC or LC variable domain of E3 or E3b. The method according to any one of claims 1-8, wherein the antibody comprises the variable domains of E3.
11. The method according to any one of claims 1-10, wherein the subject has a vasculature-dependent cancer or tumor.
12. The method according to claim 11, wherein the tumor is a solid tumor.
13. The method according to any one of claims 1-12, wherein the second therapy is a chemotherapeutic.
14. The method according to any one of claims 1-12, wherein the second therapy comprises administering an agent that antagonizes signaling through a VEGF pathway. The method according to claim 14, wherein the agent that antagonizes signaling through a VEGF pathway is bevacizumab. O (N
16. The method according to claiml3, wherein the chemotherapeutic agent is Sleucovorin, and/or irinotecan.
17. A method of providing a post-operative adjuvant therapy to a subject who has 00 I had surgery to remove a tumor, the method comprising administering to the 00 C" subject an isolated protein comprising a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence Swherein the protein binds to Tiel ectodomain and the heavy chain immunoglobulin variable domain sequence comprises one or more of the following properties: i) a HC CDR1 that includes (AGSIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ ID NO:118); ii) a HC CDR2 that includes (GSV)-I-(SY)-P-S-G-G-(WNQ)-T-(GY) (SEQ ID NO:160); and iii) a HC CDR3 that includes A-P-R-G-Y-S-Y-G-Y-Y-Y (SEQ ID NO:727); and/or the light chain immunoglobulin variable domain sequence comprises one or more of the following properties: i) a LC CDRI that includes R-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN)- (STIRH)-X1-(SYWNH)-(LV)-(ASN) (SEQ ID NO:132), wherein X1 can be serine or absent; ii) a LC CDR2 that includes Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)- (LWRH)-(TIY) (SEQ ID NO:161); and iii) a LC CDR3 that includes Q-Q-F-N-S-Y-P-H (SEQ ID NO:728).
18. The method according to claim 17, wherein the Tie binding protein comprises a heavy chain variable domain sequence that is at least 90% identical to Sthe heavy chain variable domain of the E3 antibody and a light chain variable domain sequence that is at least 90% identical to the light chain variable domain of the E3 antibody; a heavy chain variable domain sequence and a light chain variable domain 00 sequence that form an antigen binding site that competes with E3 for 00 'I binding to Tiel; or 00 one, two, or three, of the CDRs of the heavy chain variable domain of the E3 antibody, and one, two, or three of the CDRs of the light chain variable Sdomain of the E3 antibody.
19. The method according to claim 17, wherein the Tie binding protein is to be administered within 48 hours of surgery. The method according to claim 17, wherein the Tie binding protein is to be administered before and after surgery. 259